


**CUMULATIVE  
SUPPLEMENT 8**  
August 2024



**APPROVED  
DRUG PRODUCTS**

**WITH  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**44th EDITION**

**Department of Health and Human Services**

Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy

2024

Prepared By  
Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**44<sup>th</sup> EDITION**

**Cumulative Supplement 8  
August 2024**

**CONTENTS**

*PAGE*

**Contents**

1.0	INTRODUCTION.....	v
1.1	HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2	CUMULATIVE SUPPLEMENT CONTENT.....	vi
1.3	APPLICANT NAME CHANGES.....	vii
1.4	LEVOTHYROXINE SODIUM.....	ix
1.5	AVAILABILITY OF THE EDITION.....	x
1.6	REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	xi
1.7	CUMULATIVE SUPPLEMENT LEGEND.....	xii
<b>DRUG PRODUCT LISTS</b>		
	Prescription Drug Product List .....	1-1
	OTC Drug Product List .....	2-1
	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List .....	3-1
	Orphan Products Designations and Approvals List .....	4-1
	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution .....	5-1
<b>PATENT AND EXCLUSIVITY INFORMATION ADDENDUM</b>		
A.	Patent and Exclusivity Lists .....	A-1
B.	Patent and Exclusivity Terms .....	B-1

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**44<sup>th</sup> EDITION**

**CUMULATIVE SUPPLEMENT 8  
August 2024**

**1.0 INTRODUCTION**

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug

Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

## 1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

## 1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
  - Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOB/PRA) of any changes or corrections. The DOB/PRA can be contacted by email at [orangebook@fda.hhs.gov](mailto:orangebook@fda.hhs.gov).

### 1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME (NEW ABBREVIATED NAME)</u>
AKORN OPERATING CO LLC (AKORN)	EPIC PHARMA LLC (EPIC PHARMA LLC)
AKORN OPERATING CO LLC (AKORN)	SCIEGEN PHARMACEUTICALS INC (SCIEGEN PHARMS INC)
CADILA HEALTHCARE LTD (CADILA)	ZYDUS LIFESCIENCES LTD (ZYDUS LIFESCIENCES)
GLAXOSMITHKLINE (GLAXOSMITHKLINE)	HALEON US HOLDINGS LLC (HALEON US HOLDINGS)
GLAXOSMITHKLINE CONSUMER HEALTHCARE (GLAXOSMITHKLINE CONS)	HALEON US HOLDINGS LLC (HALEON US HOLDINGS)
GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS US LLC (GLAXOSMITHKLINE)	HALEON US HOLDINGS LLC (HALEON US HOLDINGS)

GLENMARK GENERICS INC USA (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS INC USA (GLENMARK PHARMS INC)
GLENMARK GENERICS LIMITED (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS LTD (GLENMARK PHARMS LTD)
GLENMARK GENERICS LTD (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS INC USA (GLENMARK PHARMS INC)
GLENMARK GENERICS LTD (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS LTD (GLENMARK PHARMS LTD)
GLENMARK GENERICS LTD INDIA (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS LTD (GLENMARK PHARMS LTD)
GLENMARK PHARMACEUTICALS SA (GLENMARK PHARMS)	GLENMARK SPECIALTY SA (GLENMARK SPECLT)
GLENMARK PHARMACEUTICALS SA SWITZERLAND (GLENMARK PHARMS SA)	GLENMARK SPECIALTY SA (GLENMARK SPECLT)
LUPIN LTD (LUPIN LTD)	CHARTWELL RX SCIENCES LLC (CHARTWELL RX)
MYLAN LABORATORIES LTD (MYLAN LABS LTD)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
MYLAN LABORATORIES LTD (MYLAN LABS LTD)	XIROMED LLC (XIROMED)
MYLAN PHARMACEUTICALS INC (MYLAN)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
MYLAN PHARMACEUTICALS INC (MYLAN)	NATCO PHARMA LTD (NATCO)
MYLAN PHARMACEUTICALS INC (MYLAN)	NATCO PHARMA LTD (NATCO PHARMA)
MYLAN PHARMACEUTICALS INC (MYLAN)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
MYLAN PHARMACEUTICALS INC (MYLAN PHARMS INC)	NATCO PHARMA LTD (NATCO PHARMA)
MYLAN PHARMACEUTICALS INC (MYLAN PHARMS INC)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
MYLAN TECHNOLOGIES INC (MYLAN TECHNOLOGIES)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
PAR PHARMACEUTICAL (PAR PHARM)	ENDO OPERATIONS LTD (ENDO OPERATIONS)

PAR PHARMACEUTICAL INC (PAR PHARM)	ENDO OPERATIONS LTD (ENDO OPERATIONS)
PAR PHARMACEUTICAL INC (PAR PHARM INC)	ENDO OPERATIONS LTD (ENDO OPERATIONS)
PAR STERILE PRODUCTS LLC (PAR STERILE PRODUCTS)	ENDO OPERATIONS LTD (ENDO OPERATIONS)
SAPTALIS PHARMACEUTICALS LLC (SAPTALIS PHARMS)	SCIEGEN PHARMACEUTICALS INC (SCIEGEN PHARMS INC)
TARO PHARMACEUTICALS USA INC (TARO)	TARO PHARMACEUTICALS INC (TARO)
VERTICE PHARMA MANAGEMENT CORP (VERTICE)	ENCUBE ETHICALS PRIVATE LTD (ENCUBE)
ZYDUS WORLDWIDE DMCC (ZYDUS)	ZYDUS LIFESCIENCES GLOBAL FZE (ZYDUS LIFESCIENCES)

#### 1.4 LEVOTHYROXINE SODIUM<sup>1</sup>

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.<sup>2</sup>

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered

<sup>1</sup> In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

<sup>2</sup> Please consult the Active Section of the Orange Book for information on other strengths.



therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	-
AB4	LEVOTHYROXINE SODIUM <sup>3</sup>	MYLAN	0.3MG	A076187	-	RS

## 1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data

<sup>3</sup> Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,  
Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,  
<https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

## 1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

### DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

### DEFINITIONS

#### Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

#### New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST  
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES</u> <u>COUNTED</u>	<u>DEC</u> <u>2023</u>	<u>MAR</u> <u>2024</u>	<u>JUN</u> <u>2024</u>	<u>SEP</u> <u>2024</u>	<u>DEC</u> <u>2024</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	23099 (12.1%)	23058 (12.2%)	23182 (11.9%)		
MULTISOURCE	20315 (87.9%)	20256 (87.8%)	20419 (88.1%)		
THERAPEUTICALLY EQUIVALENT	20252 (87.7%)	20198 (87.6%)	20332 (87.7%)		
NOT THERAPEUTICALLY EQUIVALENT	63 (0.3%)	58 (0.3%)	87 (0.4%)		
EXCEPTIONS <sup>4</sup>	46 (0.2%)	46 (0.2%)	47 (0.2%)		
NEW MOLECULAR ENTITIES APPROVED	32	18	14		
NUMBER OF APPLICANTS	1214	1219	1214		

## 1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval

<sup>4</sup> Amino acid containing products of varying composition (see Introduction, page xx of the List).

CAHN <sup>5</sup>	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

---

<sup>5</sup> The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL		ABACAVIR SULFATE AND LAMIVUDINE					
AB	!	CIPLA	EQ 600MG BASE;300MG	A091144	001	Mar 28, 2017	Jan CHRS
TABLET, FOR SUSPENSION;ORAL		ABACAVIR SULFATE AND LAMIVUDINE					
>D>	+	@ MYLAN LABS LTD	EQ 60MG BASE;30MG	N204311	001	Dec 22, 2023	Aug CAHN
	+	@	EQ 60MG BASE;30MG	N204311	001	Dec 22, 2023	Jan DISC
>A>	+	@ NORVIUM BIOSCIENCE	EQ 60MG BASE;30MG	N204311	001	Dec 22, 2023	Aug CAHN

ABIRATERONE ACETATE

TABLET;ORAL		ABIRATERONE ACETATE					
AB		MSN	500MG	A210686	002	Apr 24, 2024	Apr NEWA

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL		ACAMPROSATE CALCIUM						
>D>	AB	!	GLENMARK PHARMS LTD	333MG	A202229	001	Jul 16, 2013	Aug DISC
>A>		@		333MG	A202229	001	Jul 16, 2013	Aug DISC
>D>	AB		ZYDUS PHARMS	333MG	A205995	001	May 26, 2017	Aug CHRS
>A>	AB	!		333MG	A205995	001	May 26, 2017	Aug CHRS

ACETAMINOPHEN; BUTALBITAL

TABLET;ORAL		BUTALBITAL AND ACETAMINOPHEN					
AA		QUAGEN	300MG;50MG	A214305	001	Feb 01, 2024	Jan NEWA
AA			325MG;50MG	A214291	001	Jan 18, 2024	Jan NEWA

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL		BUTALBITAL, ACETAMINOPHEN AND CAFFEINE						
		@	KEY THERAP	300MG;50MG;40MG	A206615	001	Aug 04, 2017	May DISC
AA				300MG;50MG;40MG	A206615	001	Aug 04, 2017	Apr CAHN
AA		QUAGEN		300MG;50MG;40MG	A214288	001	Feb 08, 2024	Jan NEWA
AA				325MG;50MG;40MG	A216376	001	Mar 12, 2024	Mar NEWA
AA		SENORES PHARMS		300MG;50MG;40MG	A214087	001	Aug 13, 2021	Feb CAHN
AA				325MG;50MG;40MG	A214087	002	Aug 13, 2021	Feb CAHN
TABLET;ORAL		BUTALBITAL, ACETAMINOPHEN AND CAFFEINE						
AA		QUAGEN		325MG;50MG;40MG	A214287	001	Jan 18, 2024	Jan NEWA

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL		BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE						
		@	NOSTRUM LABS INC	325MG;50MG;40MG;30MG	A075929	001	Apr 22, 2002	May DISC

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE;ORAL		TREZIX						
		@	KEY THERAP	320.5MG;30MG;16MG	A204785	001	Nov 26, 2014	May DISC
				320.5MG;30MG;16MG	A204785	001	Nov 26, 2014	Apr CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL		ACETAMINOPHEN AND CODEINE PHOSPHATE						
		@	AKORN	120MG/5ML;12MG/5ML	A040119	001	Apr 26, 1996	Feb DISC
		@	PAI HOLDINGS	120MG/5ML;12MG/5ML	A040119	001	Apr 26, 1996	May CAHN
TABLET;ORAL		ACETAMINOPHEN AND CODEINE PHOSPHATE						
AA	!	SPECGX LLC		300MG;60MG	A040419	003	May 31, 2001	Apr CHRS
AA		STRIDES PHARMA		300MG;15MG	A089990	001	Sep 30, 1988	Apr CMFD
AA				300MG;30MG	A089805	001	Sep 30, 1988	Apr CMFD
AA				300MG;60MG	A089828	001	Sep 30, 1988	Apr CMFD
		@	SUN PHARM INDS LTD	300MG;30MG	A085868	001		Jan DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

## TABLET; ORAL

## HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	@	AMNEAL PHARMS	300MG;10MG	A207137	001	Nov 29, 2016	Jul	DISC
	@	AMNEAL PHARMS NY	300MG;5MG	A206869	001	Jun 23, 2017	Jul	DISC
	@	ELITE LABS INC	325MG;2.5MG	A209924	001	Nov 16, 2018	Jun	CAHN
	@		325MG;5MG	A209924	002	Nov 16, 2018	Jun	CAHN
	@		325MG;7.5MG	A209924	003	Nov 16, 2018	Jun	CAHN
	@		325MG;10MG	A209924	004	Nov 16, 2018	Jun	CAHN
	@	ENDO OPERATIONS	300MG;5MG	A090415	001	Jan 24, 2011	May	CAHN
	@		300MG;7.5MG	A090415	002	Jan 24, 2011	May	CAHN
	@		300MG;10MG	A090415	003	Jan 24, 2011	May	CAHN
AA		GRANULES	325MG;5MG	A211729	001	Jan 03, 2020	Jul	CMFD
AA			325MG;7.5MG	A211729	002	Jan 03, 2020	Jul	CMFD
AA			325MG;10MG	A211729	003	Jan 03, 2020	Jul	CMFD
	@	PRINSTON INC	325MG;5MG	A214928	001	Dec 30, 2021	Mar	DISC
	@		325MG;7.5MG	A214928	002	Dec 30, 2021	Mar	DISC
	@		325MG;10MG	A214928	003	Dec 30, 2021	Mar	DISC

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

## SOLUTION; ORAL

## OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN

	@	ENDO OPERATIONS	325MG/5ML;5MG/5ML	A203573	001	Dec 18, 2014	May	CAHN
--	---	-----------------	-------------------	---------	-----	--------------	-----	------

## TABLET; ORAL

## OXYCODONE AND ACETAMINOPHEN

>D>	@	ELITE LABS INC	325MG;5MG	A209385	001	Jul 02, 2018	Aug	CMFD
>A>	AA		325MG;5MG	A209385	001	Jul 02, 2018	Aug	CMFD
	@		325MG;5MG	A209385	001	Jul 02, 2018	Jun	CAHN
>D>	@		325MG;7.5MG	A209385	002	Jul 02, 2018	Aug	CMFD
>A>	AA		325MG;7.5MG	A209385	002	Jul 02, 2018	Aug	CMFD
	@		325MG;7.5MG	A209385	002	Jul 02, 2018	Jun	CAHN
>D>	@		325MG;10MG	A209385	003	Jul 02, 2018	Aug	CMFD
>A>	AA		325MG;10MG	A209385	003	Jul 02, 2018	Aug	CMFD
	@		325MG;10MG	A209385	003	Jul 02, 2018	Jun	CAHN
	@	ENDO OPERATIONS	325MG;2.5MG	A090733	001	Jul 11, 2013	May	CAHN
	@		325MG;5MG	A040105	001	Jul 30, 1996	May	CAHN
	@		325MG;7.5MG	A090734	001	Jul 11, 2013	May	CAHN
	@		325MG;10MG	A090734	002	Jul 11, 2013	May	CAHN
AA		GRANULES	325MG;2.5MG	A211708	001	Oct 31, 2019	Jul	CMFD
AA			325MG;5MG	A211708	002	Oct 31, 2019	Jul	CMFD
AA			325MG;7.5MG	A211708	003	Oct 31, 2019	Jul	CMFD
AA			325MG;10MG	A211708	004	Oct 31, 2019	Jul	CMFD
		PERCOCET						
AA	!	ENDO OPERATIONS	325MG;2.5MG	A040330	001	Jun 25, 1999	Apr	CAHN
AA	!		325MG;5MG	A040330	002	Jun 25, 1999	Apr	CAHN
	+	@	325MG;5MG	A085106	002		May	CAHN
AA	!		325MG;7.5MG	A040330	003	Nov 23, 2001	Apr	CAHN
AA	!		325MG;10MG	A040330	004	Nov 23, 2001	Apr	CAHN

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

## TABLET; ORAL

## TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

>D>	AB	SUN PHARM INDS INC	325MG;37.5MG	A077184	001	Dec 16, 2005	Aug	DISC
>A>	@		325MG;37.5MG	A077184	001	Dec 16, 2005	Aug	DISC

ACETAZOLAMIDE

## TABLET; ORAL

## ACETAZOLAMIDE

	@	AJANTA PHARMA LTD	125MG	A211151	001	Sep 11, 2023	Feb	DISC
	@		250MG	A211151	002	Sep 11, 2023	Feb	DISC
AB		EPIC PHARMA LLC	125MG	A218023	001	May 14, 2024	May	NEWA
AB			250MG	A218023	002	May 14, 2024	May	NEWA
BX		EYWA PHARMA	125MG	A211556	001	Oct 18, 2019	Jun	CTEC
BX			250MG	A211556	002	Oct 18, 2019	Jun	CTEC
BX		HIBROW HLTHCARE	125MG	A211556	001	Oct 18, 2019	Jul	CAHN
BX			250MG	A211556	002	Oct 18, 2019	Jul	CAHN
	@	TORRENT	125MG	A213706	001	Jan 26, 2024	Jan	DISC
AB			125MG	A213706	001	Jan 26, 2024	Jan	NEWA
	@		250MG	A213706	002	Jan 26, 2024	Jan	DISC
AB			250MG	A213706	002	Jan 26, 2024	Jan	NEWA

<u>ACETAZOLAMIDE SODIUM</u>							
INJECTABLE; INJECTION							
ACETAZOLAMIDE SODIUM							
	@ ENDO OPERATIONS	EQ 500MG BASE/VIAL	A205358	001	Jun 20, 2017	May	CAHN
<u>ACETIC ACID, GLACIAL</u>							
SOLUTION/DROPS; OTIC							
VOSOL							
	+ @ HIKMA	2%	N012179	001		Apr	CRLD
	@	2%	N012179	001		Apr	DISC
<u>ACETYLCYSTEINE</u>							
INJECTABLE; INTRAVENOUS							
ACETYLCYSTEINE							
AP	SOMERSET THERAPS LLC	6GM/30ML (200MG/ML)	A218397	001	Jun 07, 2024	May	NEWA
SOLUTION; INHALATION, ORAL							
ACETYLCYSTEINE							
	@ EXELA PHARMA	20%	A205643	001	Nov 01, 2023	Feb	DISC
<u>ACETYLCYSTEINE LYSINE</u>							
FOR SOLUTION; ORAL							
LEGUBETI							
	+ @ GALEPHAR	EQ 500MG BASE/PACKET	N215040	001	Feb 13, 2024	Jun	DISC
	+	EQ 500MG BASE/PACKET	N215040	001	Feb 13, 2024	Feb	NEWA
	+ @	EQ 2.5GM BASE/PACKET	N215040	002	Feb 13, 2024	Jun	DISC
	+	EQ 2.5GM BASE/PACKET	N215040	002	Feb 13, 2024	Feb	NEWA
<u>ACITRETIN</u>							
CAPSULE; ORAL							
ACITRETIN							
AB	ALEMBIC	10MG	A217774	001	Aug 05, 2024	Jul	NEWA
AB		17.5MG	A217774	002	Aug 05, 2024	Jul	NEWA
AB		25MG	A217774	003	Aug 05, 2024	Jul	NEWA
<u>ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE</u>							
CAPSULE; ORAL							
SEMPREX-D							
	+ @ ENDO OPERATIONS	8MG; 60MG	N019806	001	Mar 25, 1994	May	CAHN
<u>ACYCLOVIR</u>							
CREAM; TOPICAL							
ACYCLOVIR							
AB	TARO	5%	A205470	001	Jun 12, 2024	Jul	CAHN
AB		5%	A205470	001	Jun 12, 2024	May	NEWA
OINTMENT; TOPICAL							
ACYCLOVIR							
	@ COSETTE	5%	A205591	001	Nov 13, 2017	Mar	DISC
SUSPENSION; ORAL							
ACYCLOVIR							
	@ HIKMA	200MG/5ML	A077026	001	Jun 07, 2005	Mar	DISC
	@ VISTAPHARM LLC	200MG/5ML	A213951	001	Jan 11, 2021	Mar	CAHN
<u>ACYCLOVIR SODIUM</u>							
INJECTABLE; INJECTION							
ACYCLOVIR SODIUM							
AP	DDREG PHARMA	EQ 50MG BASE/ML	A215404	001	Jun 25, 2024	Jun	NEWA
AP	FRESENIUS KABI USA	EQ 50MG BASE/ML	A215404	001	Jun 25, 2024	Jul	CAHN
	@ NORVIUM BIOSCIENCE	EQ 500MG BASE/VIAL	A203927	001	Mar 29, 2017	Jun	CAHN
	@	EQ 1GM BASE/VIAL	A203927	002	Mar 29, 2017	Jun	CAHN
<u>ADAPALENE</u>							
LOTION; TOPICAL							
DIFFERIN							
	+ @ GALDERMA LABS LP	0.1%	N022502	001	Mar 17, 2010	May	DISC

ADEFOVIR DIPIVOXIL

	TABLET; ORAL								
	ADEFOVIR DIPIVOXIL								
AB	! SIGMAPHARM LABS LLC	10MG		A202051	001	Aug 29, 2013	Jun	CHRS	
	HEPSERA								
	+ @ GILEAD	10MG		N021449	001	Sep 20, 2002	Jun	DISC	

ADENOSINE

	SOLUTION; INTRAVENOUS								
	ADENOSINE								
	@ HOSPIRA	60MG/20ML (3MG/ML)		A203883	001	Mar 24, 2014	Feb	DISC	
	@	90MG/30ML (3MG/ML)		A203883	002	Mar 24, 2014	Feb	DISC	

ALBENDAZOLE

	TABLET; ORAL								
	ALBENDAZOLE								
>A> AB	ALEMBIC	200MG		A215652	001	Sep 04, 2024	Aug	NEWA	

ALBUTEROL SULFATE

	AEROSOL, METERED; INHALATION								
	ALBUTEROL SULFATE								
AB2	ARMSTRONG PHARMS	EQ 0.09MG BASE/INH		A212447	001	May 21, 2024	May	NEWA	
	POWDER, METERED; INHALATION								
	PROAIR DIGIHALER								
	+ @ TEVA BRANDED PHARM	EQ 0.09MG BASE/INH		N205636	002	Dec 21, 2018	Jun	DISC	
	SOLUTION; INHALATION								
	ACCUNEB								
	+ @ NORVIUM BIOSCIENCE	EQ 0.021% BASE		N020949	002	Apr 30, 2001	Jul	CAHN	
	+ @	EQ 0.042% BASE		N020949	001	Apr 30, 2001	Jul	CAHN	
	ALBUTEROL SULFATE								
AN	LEXENPHARM	EQ 0.021% BASE		A215571	001	May 03, 2024	Apr	NEWA	
AN		EQ 0.042% BASE		A215571	002	May 03, 2024	Apr	NEWA	
AN	LUOXIN AUROVITAS	EQ 0.021% BASE		A211888	001	Apr 20, 2020	Jun	CMFD	
AN		EQ 0.042% BASE		A211888	002	Apr 20, 2020	Jun	CMFD	
	@ NORVIUM BIOSCIENCE	EQ 0.083% BASE		A072652	001	Feb 21, 1992	Jun	CAHN	
	@ WATSON LABS	EQ 0.021% BASE		A077772	001	Sep 25, 2007	Jun	DISC	
	@	EQ 0.042% BASE		A077772	002	Sep 25, 2007	Jun	DISC	
	SYRUP; ORAL								
	ALBUTEROL SULFATE								
	@ HIKMA	EQ 2MG BASE/5ML		A074749	001	Jan 30, 1998	Mar	DISC	
	TABLET; ORAL								
	ALBUTEROL SULFATE								
BX	AIZANT	EQ 2MG BASE		A210948	001	Mar 15, 2019	Jun	CTEC	
BX		EQ 4MG BASE		A210948	002	Mar 15, 2019	Jun	CTEC	

ALBUTEROL SULFATE; BUDESONIDE

	AEROSOL, METERED; INHALATION								
	AIRSUPRA								
	+! ASTRAZENECA	EQ 0.09MG BASE/INH; 0.08MG/INH		N214070	001	Jan 10, 2023	Jan	CPOT	

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

	SOLUTION; INHALATION								
	DUONEB								
	+ @ NORVIUM BIOSCIENCE	EQ 0.083% BASE; 0.017%		N020950	001	Mar 21, 2001	Jul	CAHN	

ALCOHOL

	SOLUTION; INTRA-ARTERIAL								
	ABLYSINOL								
	+ @ BPI LABS	99% (1ML)		N207987	001	Jun 21, 2018	Jun	DISC	

ALENDRONATE SODIUM

	TABLET; ORAL								
	ALENDRONATE SODIUM								
AB	IPCA LABS LTD	EQ 10MG BASE		A206387	001	Jun 04, 2024	May	NEWA	
AB		EQ 35MG BASE		A206387	002	Jun 04, 2024	May	NEWA	
AB		EQ 40MG BASE		A206387	003	Jun 04, 2024	May	NEWA	
AB		EQ 70MG BASE		A206387	004	Jun 04, 2024	May	NEWA	



ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL  
ALFUZOSIN HYDROCHLORIDE

@ NORVIUM BIOSCIENCE 10MG A079014 001 Jul 18, 2011 Jun CAHN

ALISKIREN HEMIFUMARATE

TABLET;ORAL  
ALISKIREN HEMIFUMARATE

AB ENDO OPERATIONS EQ 150MG BASE A206665 001 Mar 22, 2019 Apr CAHN  
AB EQ 300MG BASE A206665 002 Mar 22, 2019 Apr CAHN

ALLOPURINOL

TABLET;ORAL  
ALLOPURINOL

AB ENDO OPERATIONS 100MG A075798 001 Jun 27, 2003 Apr CAHN  
AB 300MG A075798 002 Jun 27, 2003 Apr CAHN  
AB HARMAN FINOCHEM 200MG A214443 003 Jun 17, 2024 Jun NFTG  
@ LUPIN LTD 100MG A211807 001 Dec 14, 2023 Apr DISC  
@ 300MG A211807 002 Dec 14, 2023 Apr DISC  
ZYLOPRIM  
AB + CASPER PHARMA LLC 200MG N016084 003 Aug 04, 2022 Jun CFTG

ALOSETRON HYDROCHLORIDE

TABLET;ORAL  
ALOSETRON HYDROCHLORIDE

@ ENDO OPERATIONS EQ 0.5MG BASE A206113 001 Feb 23, 2018 May CAHN  
@ EQ 1MG BASE A206113 002 Feb 23, 2018 May CAHN

ALPELISIB

GRANULES;ORAL  
VIJOICE

+! NOVARTIS 50MG/PACKET N218466 001 Apr 24, 2024 Apr NEWA

ALPRAZOLAM

TABLET;ORAL  
ALPRAZOLAM

AB CHARTWELL RX 0.25MG A207507 001 Jul 09, 2018 Mar CAHN  
AB 0.5MG A207507 002 Jul 09, 2018 Mar CAHN  
AB 1MG A207507 003 Jul 09, 2018 Mar CAHN  
AB 2MG A207507 004 Jul 09, 2018 Mar CAHN

TABLET, EXTENDED RELEASE;ORAL  
ALPRAZOLAM

@ ANCHEN PHARMS 0.5MG A078469 001 Sep 29, 2011 Mar DISC  
@ 1MG A078469 002 Sep 29, 2011 Mar DISC  
@ 2MG A078469 003 Sep 29, 2011 Mar DISC  
@ 3MG A078469 004 Sep 29, 2011 Mar DISC  
@ ENDO OPERATIONS 0.5MG A078442 001 Oct 15, 2007 May CAHN  
@ 0.5MG A078469 001 Sep 29, 2011 May CAHN  
@ 1MG A078442 002 Oct 15, 2007 May CAHN  
@ 1MG A078469 002 Sep 29, 2011 May CAHN  
@ 2MG A078442 003 Oct 15, 2007 May CAHN  
@ 2MG A078469 003 Sep 29, 2011 May CAHN  
@ 3MG A078442 004 Oct 15, 2007 May CAHN  
@ 3MG A078469 004 Sep 29, 2011 May CAHN

TABLET, ORALLY DISINTEGRATING;ORAL  
ALPRAZOLAM

AB ENDO OPERATIONS 0.25MG A078088 001 Jan 09, 2009 Apr CAHN  
AB 0.5MG A078088 002 Jan 09, 2009 Apr CAHN  
AB ! 1MG A078088 003 Jan 09, 2009 Apr CAHN  
AB 2MG A078088 004 Jan 09, 2009 Apr CAHN

ALPROSTADIL

INJECTABLE; INJECTION  
EDEX

@ ENDO OPERATIONS 0.005MG/VIAL N020649 001 Jun 12, 1997 Apr CAHN  
AP + 0.01MG/VIAL N020649 002 Jun 12, 1997 Apr CAHN  
+! 0.01MG/VIAL N020649 005 Jul 30, 1998 Apr CAHN  
AP + 0.02MG/VIAL N020649 003 Jun 12, 1997 Apr CAHN  
+! 0.02MG/VIAL N020649 006 Jul 30, 1998 Apr CAHN  
AP +! 0.04MG/VIAL N020649 004 Jun 12, 1997 Apr CAHN  
+! 0.04MG/VIAL N020649 007 Jul 30, 1998 Apr CAHN

SUPPOSITORY; URETHRAL  
MUSE

+ @	MYLAN SPECIALITY LP	0.25MG	N020700	002	Nov 19, 1996	Jun	DISC
+ @		0.5MG	N020700	003	Nov 19, 1996	Jun	DISC
+ @		1MG	N020700	004	Nov 19, 1996	Jun	DISC

AMANTADINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL  
AMANTADINE HYDROCHLORIDE

>A>	AB	ZYDUS	EQ 68.5MG BASE	A214897	001	Aug 26, 2024	Aug	NFTG
		GOCOVRI						
>D>		+ ADAMAS OPERATIONS	EQ 68.5MG BASE	N208944	001	Aug 24, 2017	Aug	CAHN
>D>		+!	EQ 137MG BASE	N208944	002	Aug 24, 2017	Aug	CAHN
>A>	AB	+ SUPERNUS PHARMS	EQ 68.5MG BASE	N208944	001	Aug 24, 2017	Aug	NFTG
>A>		+!	EQ 137MG BASE	N208944	002	Aug 24, 2017	Aug	CAHN

SYRUP; ORAL

AMANTADINE HYDROCHLORIDE

>A>		@ CHARTWELL RX	50MG/5ML	A076352	001	Sep 10, 2004	Aug	CAHN
		@ ENDO OPERATIONS	50MG/5ML	A077992	001	Dec 12, 2006	May	CAHN
>D>		@ GENUS	50MG/5ML	A076352	001	Sep 10, 2004	Aug	CAHN
		@	50MG/5ML	A076352	001	Sep 10, 2004	Jan	CAHN

TABLET, EXTENDED RELEASE; ORAL

OSMOLEX ER

>D>		+ @ ADAMAS OPERATIONS	EQ 129MG BASE	N209410	001	Feb 16, 2018	Aug	CAHN
		+ @	EQ 129MG BASE	N209410	001	Feb 16, 2018	Apr	DISC
>D>		+ @	EQ 161MG BASE	N209410	004	Apr 22, 2020	Aug	CAHN
>D>		+ @	EQ 193MG BASE	N209410	002	Feb 16, 2018	Aug	CAHN
		+ @	EQ 193MG BASE	N209410	002	Feb 16, 2018	Apr	DISC
>D>		+ @	EQ 258MG BASE	N209410	003	Feb 16, 2018	Aug	CAHN
>A>		+ @ SUPERNUS PHARMS	EQ 129MG BASE	N209410	001	Feb 16, 2018	Aug	CAHN
>A>		+ @	EQ 161MG BASE	N209410	004	Apr 22, 2020	Aug	CAHN
>A>		+ @	EQ 193MG BASE	N209410	002	Feb 16, 2018	Aug	CAHN
>A>		+ @	EQ 258MG BASE	N209410	003	Feb 16, 2018	Aug	CAHN

AMBRISENTAN

TABLET; ORAL

AMBRISENTAN

		@ ENDO OPERATIONS	5MG	A209509	001	Apr 10, 2019	May	CAHN
		@	10MG	A209509	002	Apr 10, 2019	May	CAHN
		@ PAR PHARM INC	5MG	A209509	001	Apr 10, 2019	Apr	DISC
		@	10MG	A209509	002	Apr 10, 2019	Apr	DISC

AMCINONIDE

LOTION; TOPICAL

AMCINONIDE

!		GENUS	0.1%	A076329	001	Nov 06, 2002	Jan	CAHN
---	--	-------	------	---------	-----	--------------	-----	------

OINTMENT; TOPICAL

AMCINONIDE

AB	!	GENUS	0.1%	A076096	001	Nov 19, 2002	Jan	CAHN
----	---	-------	------	---------	-----	--------------	-----	------

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

AP		QILU	EQ 250MG BASE/ML	A218146	001	Mar 19, 2024	Mar	NEWA
----	--	------	------------------	---------	-----	--------------	-----	------

AMILORIDE HYDROCHLORIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE

AB	!	ENDO OPERATIONS	5MG	A070346	001	Jan 22, 1986	Apr	CAHN
----	---	-----------------	-----	---------	-----	--------------	-----	------

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

CLINIMIX 8/14 SULFITE FREE IN DEXTROSE 14% IN PLASTIC CONTAINER

		BAXTER HLTHCARE	8%;14GM/100ML	N020734	019	Apr 13, 2021	Apr	NEWA
--	--	-----------------	---------------	---------	-----	--------------	-----	------

AMINOCAPROIC ACID

SOLUTION;ORAL

AMICAR

	+ @ HIKMA	0.25GM/ML		N015230	002			Mar	DISC
	AMINOCAPROIC ACID								
AA	!	TULEX PHARMS INC	0.25GM/ML	A212494	001	Aug 11, 2020		Mar	CHRS
	@	VISTAPHARM LLC	0.25GM/ML	A212814	001	Feb 26, 2020		Mar	CAHN

TABLET;ORAL

AMICAR

	+ @ HIKMA	500MG		N015197	001			Mar	DISC
	+ @	1GM		N015197	002	Jun 24, 2004		Mar	DISC

AMIODARONE HYDROCHLORIDE

INJECTABLE;INJECTION

AMIODARONE HYDROCHLORIDE

	@	HOSPIRA	50MG/ML	A203884	001	Nov 25, 2013		May	DISC
>A>	AP	ZHEJIANG POLY PHARM	50MG/ML	A218253	001	Sep 11, 2024		Aug	NEWA

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB		AIPING PHARM INC	10MG	A212654	002	Sep 29, 2021		May	CMFD
AB			25MG	A212654	001	Apr 07, 2020		May	CMFD
AB			50MG	A212654	003	Sep 29, 2021		May	CMFD
AB			75MG	A212654	004	Sep 29, 2021		May	CMFD
AB			100MG	A212654	005	Sep 29, 2021		May	CMFD
AB			150MG	A212654	006	Sep 29, 2021		May	CMFD
>A>	AB	CENTAUR PHARMS PVT	10MG	A216243	001	Jun 06, 2022		Aug	CAHN
>A>	AB		25MG	A216243	002	Jun 06, 2022		Aug	CAHN
>A>	AB		50MG	A216243	003	Jun 06, 2022		Aug	CAHN
>A>	AB		75MG	A216243	004	Jun 06, 2022		Aug	CAHN
>A>	AB		100MG	A216243	005	Jun 06, 2022		Aug	CAHN
>A>	AB		150MG	A216243	006	Jun 06, 2022		Aug	CAHN
>D>	AB	CHEMISTRY HLTH	10MG	A216243	001	Jun 06, 2022		Aug	CAHN
>D>	AB		25MG	A216243	002	Jun 06, 2022		Aug	CAHN
>D>	AB		50MG	A216243	003	Jun 06, 2022		Aug	CAHN
>D>	AB		75MG	A216243	004	Jun 06, 2022		Aug	CAHN
>D>	AB		100MG	A216243	005	Jun 06, 2022		Aug	CAHN
>D>	AB		150MG	A216243	006	Jun 06, 2022		Aug	CAHN
	@	ENDO OPERATIONS	10MG	A040218	001	Sep 11, 1997		May	CAHN
	@		25MG	A040218	002	Sep 11, 1997		May	CAHN
	@		50MG	A040218	003	Sep 11, 1997		May	CAHN
	@		75MG	A040218	004	Sep 11, 1997		May	CAHN
	@		100MG	A040218	005	Sep 11, 1997		May	CAHN
	@		150MG	A040218	006	Sep 11, 1997		May	CAHN

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

	@	AIPING PHARM INC	EQ 2.5MG BASE	A077759	001	Jul 09, 2007		Feb	CAHN
	@		EQ 5MG BASE	A077759	002	Jul 09, 2007		Feb	CAHN
	@		EQ 10MG BASE	A077759	003	Jul 09, 2007		Feb	CAHN
BX		LUPIN	EQ 2.5MG BASE	A078043	001	Jul 12, 2007		Jun	CTEC
BX			EQ 5MG BASE	A078043	002	Jul 12, 2007		Jun	CTEC
BX			EQ 10MG BASE	A078043	003	Jul 12, 2007		Jun	CTEC
	@	SUN PHARM INDS LTD	EQ 2.5MG BASE	A077974	001	Jul 09, 2007		Jan	DISC
	@		EQ 5MG BASE	A077974	002	Jul 09, 2007		Jan	DISC
	@		EQ 10MG BASE	A077974	003	Jul 09, 2007		Jan	DISC

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

	@	AMNEAL	EQ 2.5MG BASE;10MG	A077215	001	Dec 07, 2018		Apr	CAHN
	@		EQ 5MG BASE;10MG	A077215	002	Dec 07, 2018		Apr	CAHN
	@		EQ 5MG BASE;20MG	A077215	003	Dec 07, 2018		Apr	CAHN
	@		EQ 10MG BASE;20MG	A077215	004	Dec 07, 2018		Apr	CAHN

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

AB	SCIEGEN PHARMS INC	EQ 5MG BASE;20MG	A209010	001	Dec 03, 2018	Feb	CMFD
AB		EQ 5MG BASE;40MG	A209010	002	Dec 03, 2018	Feb	CMFD
AB		EQ 10MG BASE;20MG	A209010	003	Dec 03, 2018	Feb	CMFD
AB		EQ 10MG BASE;40MG	A209010	004	Dec 03, 2018	Feb	CMFD

AMOXAPINE

TABLET; ORAL

AMOXAPINE

	@ CHARTWELL RX	25MG	A072879	002	Jun 28, 1991	Jun	CMS1
	@	50MG	A072879	003	Jun 28, 1991	Jun	CMS1
	@	100MG	A072879	004	Jun 28, 1991	Jun	CMS1

AMOXICILLIN

FOR SUSPENSION; ORAL

AMOXICILLIN

AB	CHARTWELL RX	400MG/5ML	A065319	002	Jun 18, 2007	May	CAHN
	@ DAVA PHARMS INC	125MG/5ML	A062927	001	Nov 25, 1988	Mar	DISC
	@	250MG/5ML	A062927	002	Nov 25, 1988	Mar	DISC
	@ ENDO OPERATIONS	125MG/5ML	A062927	001	Nov 25, 1988	May	CAHN
	@	250MG/5ML	A062927	002	Nov 25, 1988	May	CAHN

AMOXIL

AB	+ US ANTIBIOTICS	400MG/5ML	N050760	002	Apr 15, 1999	Apr	CMFD
----	------------------	-----------	---------	-----	--------------	-----	------

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	CIPLA	250MG/5ML;EQ 62.5MG BASE/5ML	A065431	001	Nov 25, 2008	Jul	CAHN
AB		600MG/5ML;EQ 42.9MG BASE/5ML	A065420	001	Dec 02, 2013	Jul	CAHN

TABLET, CHEWABLE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

	@ CHARTWELL RX	200MG;EQ 28.5MG BASE	A065065	001	Apr 18, 2002	Jul	CAHN
	@	400MG;EQ 57MG BASE	A065065	002	Apr 18, 2002	Jul	CAHN

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

ADDERALL XR 10

AB1	+ TAKEDA PHARMS USA	2.5MG;2.5MG;2.5MG;2.5MG	N021303	001	Oct 11, 2001	Jan	CTEC
-----	---------------------	-------------------------	---------	-----	--------------	-----	------

ADDERALL XR 15

AB1	+ TAKEDA PHARMS USA	3.75MG;3.75MG;3.75MG;3.75MG	N021303	006	May 22, 2002	Jan	CTEC
-----	---------------------	-----------------------------	---------	-----	--------------	-----	------

ADDERALL XR 20

AB1	+ TAKEDA PHARMS USA	5MG;5MG;5MG;5MG	N021303	002	Oct 11, 2001	Jan	CTEC
-----	---------------------	-----------------	---------	-----	--------------	-----	------

ADDERALL XR 25

AB1	+ TAKEDA PHARMS USA	6.25MG;6.25MG;6.25MG;6.25MG	N021303	004	May 22, 2002	Jan	CTEC
-----	---------------------	-----------------------------	---------	-----	--------------	-----	------

ADDERALL XR 30

AB1	+! TAKEDA PHARMS USA	7.5MG;7.5MG;7.5MG;7.5MG	N021303	003	Oct 11, 2001	Jan	CTEC
-----	----------------------	-------------------------	---------	-----	--------------	-----	------

ADDERALL XR 5

AB1	+ TAKEDA PHARMS USA	1.25MG;1.25MG;1.25MG;1.25MG	N021303	005	May 22, 2002	Jan	CTEC
-----	---------------------	-----------------------------	---------	-----	--------------	-----	------

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB1	ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A077302	001	Jun 22, 2012	Jan	CTEC
-----	-------------------	-----------------------------	---------	-----	--------------	-----	------

AB1		2.5MG;2.5MG;2.5MG;2.5MG	A077302	002	Jun 22, 2012	Jan	CTEC
-----	--	-------------------------	---------	-----	--------------	-----	------

AB1		3.75MG;3.75MG;3.75MG;3.75MG	A077302	003	Jun 22, 2012	Jan	CTEC
-----	--	-----------------------------	---------	-----	--------------	-----	------

AB1		5MG;5MG;5MG;5MG	A077302	004	Jun 22, 2012	Jan	CTEC
-----	--	-----------------	---------	-----	--------------	-----	------

AB1		6.25MG;6.25MG;6.25MG;6.25MG	A077302	005	Jun 22, 2012	Jan	CTEC
-----	--	-----------------------------	---------	-----	--------------	-----	------

AB1		7.5MG;7.5MG;7.5MG;7.5MG	A077302	006	Jun 22, 2012	Jan	CTEC
-----	--	-------------------------	---------	-----	--------------	-----	------

AB1	ANI PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A205401	001	Jan 22, 2019	Jan	CTEC
-----	------------	-----------------------------	---------	-----	--------------	-----	------

AB1		2.5MG;2.5MG;2.5MG;2.5MG	A205401	002	Jan 22, 2019	Jan	CTEC
-----	--	-------------------------	---------	-----	--------------	-----	------

AB1		3.75MG;3.75MG;3.75MG;3.75MG	A205401	003	Jan 22, 2019	Jan	CTEC
-----	--	-----------------------------	---------	-----	--------------	-----	------

AB1		5MG;5MG;5MG;5MG	A205401	004	Jan 22, 2019	Jan	CTEC
-----	--	-----------------	---------	-----	--------------	-----	------

AB1		6.25MG;6.25MG;6.25MG;6.25MG	A205401	005	Jan 22, 2019	Jan	CTEC
-----	--	-----------------------------	---------	-----	--------------	-----	------

AB1		7.5MG;7.5MG;7.5MG;7.5MG	A205401	006	Jan 22, 2019	Jan	CTEC
-----	--	-------------------------	---------	-----	--------------	-----	------

AB1	ASCENT PHARMS INC	1.25MG;1.25MG;1.25MG;1.25MG	A214959	001	Sep 29, 2021	Jan	CTEC
-----	-------------------	-----------------------------	---------	-----	--------------	-----	------

AB1		2.5MG;2.5MG;2.5MG;2.5MG	A214959	002	Sep 29, 2021	Jan	CTEC
-----	--	-------------------------	---------	-----	--------------	-----	------

AB1		3.75MG;3.75MG;3.75MG;3.75MG	A214959	003	Sep 29, 2021	Jan	CTEC
-----	--	-----------------------------	---------	-----	--------------	-----	------

AB1		5MG;5MG;5MG;5MG	A214959	004	Sep 29, 2021	Jan	CTEC
-----	--	-----------------	---------	-----	--------------	-----	------

AB1		6.25MG;6.25MG;6.25MG;6.25MG	A214959	005	Sep 29, 2021	Jan	CTEC
-----	--	-----------------------------	---------	-----	--------------	-----	------

AB1		7.5MG;7.5MG;7.5MG;7.5MG	A214959	006	Sep 29, 2021	Jan	CTEC
-----	--	-------------------------	---------	-----	--------------	-----	------

AB1	ELITE LABS INC	1.25MG;1.25MG;1.25MG;1.25MG	A212037	001	Dec 11, 2019	Jan	CTEC
-----	----------------	-----------------------------	---------	-----	--------------	-----	------

AB1		2.5MG;2.5MG;2.5MG;2.5MG	A212037	002	Dec 11, 2019	Jan	CTEC
-----	--	-------------------------	---------	-----	--------------	-----	------

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE									
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A212037	003	Dec 11, 2019	Jan	CTEC		
AB1		5MG; 5MG; 5MG; 5MG	A212037	004	Dec 11, 2019	Jan	CTEC		
AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A212037	005	Dec 11, 2019	Jan	CTEC		
AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A212037	006	Dec 11, 2019	Jan	CTEC		
	@ ENDO OPERATIONS	1.25MG; 1.25MG; 1.25MG; 1.25MG	A206159	001	May 31, 2019	May	CAHN		
	@	2.5MG; 2.5MG; 2.5MG; 2.5MG	A206159	002	May 31, 2019	May	CAHN		
	@	3.75MG; 3.75MG; 3.75MG; 3.75MG	A206159	003	May 31, 2019	May	CAHN		
	@	5MG; 5MG; 5MG; 5MG	A206159	004	May 31, 2019	May	CAHN		
	@	6.25MG; 6.25MG; 6.25MG; 6.25MG	A206159	005	May 31, 2019	May	CAHN		
	@	7.5MG; 7.5MG; 7.5MG; 7.5MG	A206159	006	May 31, 2019	May	CAHN		
AB1	GRANULES	1.25MG; 1.25MG; 1.25MG; 1.25MG	A217027	001	Jan 23, 2023	Jan	CTEC		
AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A217027	002	Jan 23, 2023	Jan	CTEC		
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A217027	003	Jan 23, 2023	Jan	CTEC		
AB1		5MG; 5MG; 5MG; 5MG	A217027	004	Jan 23, 2023	Jan	CTEC		
AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A217027	005	Jan 23, 2023	Jan	CTEC		
AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A217027	006	Jan 23, 2023	Jan	CTEC		
AB1	IMPAX LABS	1.25MG; 1.25MG; 1.25MG; 1.25MG	A076852	001	Feb 16, 2016	Jan	CTEC		
AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A076852	002	Feb 16, 2016	Jan	CTEC		
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A076852	003	Feb 16, 2016	Jan	CTEC		
AB1		5MG; 5MG; 5MG; 5MG	A076852	004	Feb 16, 2016	Jan	CTEC		
AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A076852	005	Feb 16, 2016	Jan	CTEC		
AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A076852	006	Feb 16, 2016	Jan	CTEC		
AB1	LANNETT CO INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A214403	001	Nov 26, 2021	Jan	CTEC		
AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A214403	002	Nov 26, 2021	Jan	CTEC		
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A214403	003	Nov 26, 2021	Jan	CTEC		
AB1		5MG; 5MG; 5MG; 5MG	A214403	004	Nov 26, 2021	Jan	CTEC		
AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A214403	005	Nov 26, 2021	Jan	CTEC		
AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A214403	006	Nov 26, 2021	Jan	CTEC		
AB1	RHODES PHARMS	1.25MG; 1.25MG; 1.25MG; 1.25MG	A210651	001	May 17, 2019	Jan	CTEC		
AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A210651	002	May 17, 2019	Jan	CTEC		
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A210651	003	May 17, 2019	Jan	CTEC		
AB1		5MG; 5MG; 5MG; 5MG	A210651	004	May 17, 2019	Jan	CTEC		
AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A210651	005	May 17, 2019	Jan	CTEC		
AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A210651	006	May 17, 2019	Jan	CTEC		
AB1	SPECGX LLC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A211547	001	Apr 22, 2019	Jan	CTEC		
AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A211547	002	Apr 22, 2019	Jan	CTEC		
AB2		3.125MG; 3.125MG; 3.125MG; 3.125MG	A211546	001	Aug 31, 2023	Jan	CTEC		
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A211547	003	Apr 22, 2019	Jan	CTEC		
AB1		5MG; 5MG; 5MG; 5MG	A211547	004	Apr 22, 2019	Jan	CTEC		
AB2		6.25MG; 6.25MG; 6.25MG; 6.25MG	A211546	002	Aug 31, 2023	Jan	CTEC		
AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A211547	005	Apr 22, 2019	Jan	CTEC		
AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A211547	006	Apr 22, 2019	Jan	CTEC		
AB2		9.375MG; 9.375MG; 9.375MG; 9.375MG	A211546	003	Aug 31, 2023	Jan	CTEC		
AB2		12.5MG; 12.5MG; 12.5MG; 12.5MG	A211546	004	Aug 31, 2023	Jan	CTEC		
AB2	SUN PHARM INDS INC	3.125MG; 3.125MG; 3.125MG; 3.125MG	A215997	001	Sep 27, 2023	Jan	CTEC		
AB2		6.25MG; 6.25MG; 6.25MG; 6.25MG	A215997	002	Sep 27, 2023	Jan	CTEC		
AB2		9.375MG; 9.375MG; 9.375MG; 9.375MG	A215997	003	Sep 27, 2023	Jan	CTEC		
AB2		12.5MG; 12.5MG; 12.5MG; 12.5MG	A215997	004	Sep 27, 2023	Jan	CTEC		
	@ SUN PHARM INDUSTRIES	1.25MG; 1.25MG; 1.25MG; 1.25MG	A211715	001	May 17, 2019	Jul	DISC		
AB1		1.25MG; 1.25MG; 1.25MG; 1.25MG	A211715	001	May 17, 2019	Jan	CTEC		
	@	2.5MG; 2.5MG; 2.5MG; 2.5MG	A211715	002	May 17, 2019	Jul	DISC		
AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A211715	002	May 17, 2019	Jan	CTEC		
	@	3.75MG; 3.75MG; 3.75MG; 3.75MG	A211715	003	May 17, 2019	Jul	DISC		
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A211715	003	May 17, 2019	Jan	CTEC		
	@	5MG; 5MG; 5MG; 5MG	A211715	004	May 17, 2019	Jul	DISC		
AB1		5MG; 5MG; 5MG; 5MG	A211715	004	May 17, 2019	Jan	CTEC		
	@	6.25MG; 6.25MG; 6.25MG; 6.25MG	A211715	005	May 17, 2019	Jul	DISC		
AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A211715	005	May 17, 2019	Jan	CTEC		
	@	7.5MG; 7.5MG; 7.5MG; 7.5MG	A211715	006	May 17, 2019	Jul	DISC		
AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A211715	006	May 17, 2019	Jan	CTEC		
AB2	TEVA PHARMS USA	3.125MG; 3.125MG; 3.125MG; 3.125MG	A210876	001	Jan 31, 2022	Jan	CTEC		
AB2		6.25MG; 6.25MG; 6.25MG; 6.25MG	A210876	002	Jan 31, 2022	Jan	CTEC		
AB2		9.375MG; 9.375MG; 9.375MG; 9.375MG	A210876	003	Jan 31, 2022	Jan	CTEC		
AB2		12.5MG; 12.5MG; 12.5MG; 12.5MG	A210876	004	Jan 31, 2022	Jan	CTEC		
	MYDAYIS								
AB2	+ TAKEDA PHARMS USA	3.125MG; 3.125MG; 3.125MG; 3.125MG	N022063	001	Jun 20, 2017	Jan	CTEC		
AB2	+	6.25MG; 6.25MG; 6.25MG; 6.25MG	N022063	002	Jun 20, 2017	Jan	CTEC		
AB2	+	9.375MG; 9.375MG; 9.375MG; 9.375MG	N022063	003	Jun 20, 2017	Jan	CTEC		
AB2	+!	12.5MG; 12.5MG; 12.5MG; 12.5MG	N022063	004	Jun 20, 2017	Jan	CTEC		

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE

AA	SENORES PHARMS	5MG	A212901	001	May 22, 2020	Feb	CAHN
AA		10MG	A212901	002	May 22, 2020	Feb	CAHN
	@ SUN PHARM INDS INC	5MG	A214574	001	Jan 27, 2021	Mar	DISC
	@	10MG	A214574	002	Jan 27, 2021	Mar	DISC
	EVEKEO						
AA	AZURITY	5MG	A200166	001	Aug 09, 2012	Mar	CAHN
AA	!	10MG	A200166	002	Aug 09, 2012	Mar	CAHN
	TABLET, ORALLY DISINTEGRATING;ORAL						
	EVEKEO ODT						
	+ @ AZURITY	5MG	N209905	001	Jan 30, 2019	Apr	DISC
	+ @	10MG	N209905	002	Jan 30, 2019	Apr	DISC
	+ @	15MG	N209905	003	Jan 30, 2019	Apr	DISC
	+ @	20MG	N209905	004	Jan 30, 2019	Apr	DISC

AMPICILLIN/AMPICILLIN TRIHYDRATE

FOR SUSPENSION;ORAL

AMPICILLIN TRIHYDRATE

	@ ENDO OPERATIONS	EQ 125MG BASE/5ML	A062982	001	Feb 10, 1989	May	CAHN
	@	EQ 250MG BASE/5ML	A062982	002	Feb 10, 1989	May	CAHN

APIXABAN

TABLET;ORAL

APIXABAN

	@ APOTEX	2.5MG	A210091	001	Feb 16, 2024	May	DISC
AB		2.5MG	A210091	001	Feb 16, 2024	Feb	NEWA
	@	5MG	A210091	002	Feb 16, 2024	May	DISC
AB		5MG	A210091	002	Feb 16, 2024	Feb	NEWA

APREMILAST

TABLET;ORAL

APREMILAST

AB	MANKIND PHARMA	10MG	A211734	001	Feb 07, 2024	Jan	NEWA
AB		20MG	A211734	002	Feb 07, 2024	Jan	NEWA
AB		30MG	A211734	003	Feb 07, 2024	Jan	NEWA

APROCITENTAN

TABLET;ORAL

TRYVIO

	+! IDORSIA	12.5MG	N217686	001	Mar 19, 2024	Mar	NEWA
--	------------	--------	---------	-----	--------------	-----	------

ARFORMOTEROL TARTRATE

SOLUTION;INHALATION

ARFORMOTEROL TARTRATE

>A>	AN	AIPING PHARM INC	EQ 0.015MG BASE/2ML	A214901	001	Apr 02, 2024	Aug	CAHN
	AN	CF PHARMTECH	EQ 0.015MG BASE/2ML	A216303	001	May 17, 2024	May	NEWA
	AN	DR REDDYS	EQ 0.015MG BASE/2ML	A215032	001	Jun 03, 2024	May	NEWA
>D>	AN	PHARMAMAX	EQ 0.015MG BASE/2ML	A214901	001	Apr 02, 2024	Aug	CAHN
	AN		EQ 0.015MG BASE/2ML	A214901	001	Apr 02, 2024	Mar	NEWA
	AN	WILSHIRE PHARMS INC	EQ 0.015MG BASE/2ML	A216815	001	Nov 25, 2022	Jul	CAHN

ARIPIPRAZOLE

FILM;ORAL

OPIPZA

	+ XIAMEN LP PHARM CO	2MG	N216655	001	Jul 22, 2024	Jul	NEWA
	+	5MG	N216655	002	Jul 22, 2024	Jul	NEWA
	+!	10MG	N216655	003	Jul 22, 2024	Jul	NEWA

TABLET;ORAL

ARIPIPRAZOLE

>D>	AB	BRECKENRIDGE	2MG	A091279	001	Jan 09, 2017	Aug	DISC
>A>	@		2MG	A091279	001	Jan 09, 2017	Aug	DISC
>D>	AB		5MG	A091279	002	Jan 09, 2017	Aug	DISC
>A>	@		5MG	A091279	002	Jan 09, 2017	Aug	DISC
>D>	AB		10MG	A091279	003	Jan 09, 2017	Aug	DISC
>A>	@		10MG	A091279	003	Jan 09, 2017	Aug	DISC
>D>	AB		15MG	A091279	004	Jan 09, 2017	Aug	DISC
>A>	@		15MG	A091279	004	Jan 09, 2017	Aug	DISC
>D>	AB		20MG	A091279	005	Jan 09, 2017	Aug	DISC
>A>	@		20MG	A091279	005	Jan 09, 2017	Aug	DISC

TABLET;ORAL  
 ARIPIPIRAZOLE

>D>	AB		30MG	A091279	006	Jan 09, 2017	Aug DISC
>A>	@		30MG	A091279	006	Jan 09, 2017	Aug DISC
	AB	LUPIN	2MG	A205589	001	Mar 18, 2024	Mar NEWA
	AB		5MG	A205589	002	Mar 18, 2024	Mar NEWA
	AB		10MG	A205589	003	Mar 18, 2024	Mar NEWA
	AB		15MG	A205589	004	Mar 18, 2024	Mar NEWA
	AB		20MG	A205589	005	Mar 18, 2024	Mar NEWA
	AB		30MG	A205589	006	Mar 18, 2024	Mar NEWA

ARIPIPIRAZOLE LAUROXIL

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR  
 ARISTADA INITIO KIT

+	ALKERMES INC	675MG/2.4ML (281.25MG/ML)	N209830	001	Jun 29, 2018	Jan CPOT
---	--------------	---------------------------	---------	-----	--------------	----------

ASCIMINIB HYDROCHLORIDE

TABLET;ORAL  
 SCEMBLIX

+	NOVARTIS	EQ 100MG BASE	N215358	003	Apr 18, 2024	Apr NEWA
---	----------	---------------	---------	-----	--------------	----------

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION;ORAL

AA	TARO	4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM	A207498	001	Jun 28, 2024	Jun NEWA
----	------	---	---------	-----	--------------	----------

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL  
 LANORINAL

AA	!	SANDOZ	325MG;50MG;40MG	A086996	002	Oct 11, 1985	Jan CAHN
----	---	--------	-----------------	---------	-----	--------------	----------

ASPIRIN; CARISOPRODOL

TABLET;ORAL  
 CARISOPRODOL AND ASPIRIN

>A>	@	GENUS	325MG;200MG	A040116	001	Apr 25, 1996	Aug CAHN
>D>	@	SANDOZ	325MG;200MG	A040116	001	Apr 25, 1996	Aug CAHN

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE;ORAL  
 ASPIRIN AND DIPYRIDAMOLE

AB		ENDO OPERATIONS	25MG;200MG	A207944	001	Jan 18, 2017	Apr CAHN
----	--	-----------------	------------	---------	-----	--------------	----------

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL  
 PERCODAN

AA	+	!	ENDO OPERATIONS	325MG;4.8355MG	N007337	007	Aug 05, 2005	May CAHN
----	---	---	-----------------	----------------	---------	-----	--------------	----------

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET;ORAL  
 PERCODAN

	@	ENDO OPERATIONS	325MG;4.5MG;0.38MG	N007337	006		May CAHN
	@	ENDO OPERATIONS	325MG;2.25MG;0.19MG	N007337	005		May CAHN

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL  
 ATOMOXETINE HYDROCHLORIDE

AB		APOTEX	EQ 10MG BASE	A078983	001	May 30, 2017	Mar CPOT
AB			EQ 18MG BASE	A078983	002	May 30, 2017	Mar CPOT
AB			EQ 25MG BASE	A078983	003	May 30, 2017	Mar CPOT
AB			EQ 40MG BASE	A078983	004	May 30, 2017	Mar CPOT
AB			EQ 60MG BASE	A078983	005	May 30, 2017	Mar CPOT
AB			EQ 80MG BASE	A078983	006	May 30, 2017	Mar CPOT
AB			EQ 100MG BASE	A078983	007	May 30, 2017	Mar CPOT
AB		AUROBINDO PHARMA	EQ 10MG BASE	A079016	001	May 30, 2017	Mar CPOT
AB			EQ 18MG BASE	A079016	002	May 30, 2017	Mar CPOT
AB			EQ 25MG BASE	A079016	003	May 30, 2017	Mar CPOT
AB			EQ 40MG BASE	A079016	004	May 30, 2017	Mar CPOT
AB			EQ 60MG BASE	A079016	005	May 30, 2017	Mar CPOT
AB			EQ 80MG BASE	A079016	006	May 30, 2017	Mar CPOT

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB		EQ 100MG BASE	A079016	007	May 30, 2017	Mar	CPOT
AB	DR REDDYS	EQ 10MG BASE	A090609	001	Feb 23, 2018	Mar	CPOT
AB		EQ 18MG BASE	A090609	002	Feb 23, 2018	Mar	CPOT
AB		EQ 25MG BASE	A090609	003	Feb 23, 2018	Mar	CPOT
AB		EQ 40MG BASE	A090609	004	Feb 23, 2018	Mar	CPOT
AB		EQ 60MG BASE	A090609	005	Feb 23, 2018	Mar	CPOT
AB		EQ 80MG BASE	A090609	006	Feb 23, 2018	Mar	CPOT
AB		EQ 100MG BASE	A090609	007	Feb 23, 2018	Mar	CPOT
AB	GLENMARK PHARMS LTD	EQ 10MG BASE	A079019	001	May 30, 2017	Mar	CPOT
AB		EQ 18MG BASE	A079019	002	May 30, 2017	Mar	CPOT
AB		EQ 25MG BASE	A079019	003	May 30, 2017	Mar	CPOT
AB		EQ 40MG BASE	A079019	004	May 30, 2017	Mar	CPOT
AB		EQ 60MG BASE	A079019	005	May 30, 2017	Mar	CPOT
AB		EQ 80MG BASE	A079019	006	May 30, 2017	Mar	CPOT
AB		EQ 100MG BASE	A079019	007	May 30, 2017	Mar	CPOT
AB	HETERO LABS LTD V	EQ 10MG BASE	A202682	001	Mar 11, 2021	Mar	CPOT
AB		EQ 18MG BASE	A202682	002	Mar 11, 2021	Mar	CPOT
AB		EQ 25MG BASE	A202682	003	Mar 11, 2021	Mar	CPOT
AB		EQ 40MG BASE	A202682	004	Mar 11, 2021	Mar	CPOT
AB		EQ 60MG BASE	A202682	005	Mar 11, 2021	Mar	CPOT
AB		EQ 80MG BASE	A202682	006	Mar 11, 2021	Mar	CPOT
AB		EQ 100MG BASE	A202682	007	Mar 11, 2021	Mar	CPOT
>D>	@ STRIDES PHARMA	EQ 10MG BASE	A079021	001	Feb 18, 2021	Aug	CMFD
>A>	AB	EQ 10MG BASE	A079021	001	Feb 18, 2021	Aug	CMFD
	@	EQ 10MG BASE	A079021	001	Feb 18, 2021	Mar	CPOT
>D>	@	EQ 18MG BASE	A079021	002	Feb 18, 2021	Aug	CMFD
>A>	AB	EQ 18MG BASE	A079021	002	Feb 18, 2021	Aug	CMFD
	@	EQ 18MG BASE	A079021	002	Feb 18, 2021	Mar	CPOT
>D>	@	EQ 25MG BASE	A079021	003	Feb 18, 2021	Aug	CMFD
>A>	AB	EQ 25MG BASE	A079021	003	Feb 18, 2021	Aug	CMFD
	@	EQ 25MG BASE	A079021	003	Feb 18, 2021	Mar	CPOT
>D>	@	EQ 40MG BASE	A079021	004	Feb 18, 2021	Aug	CMFD
>A>	AB	EQ 40MG BASE	A079021	004	Feb 18, 2021	Aug	CMFD
	@	EQ 40MG BASE	A079021	004	Feb 18, 2021	Mar	CPOT
>D>	@	EQ 60MG BASE	A079021	005	Feb 18, 2021	Aug	CMFD
>A>	AB	EQ 60MG BASE	A079021	005	Feb 18, 2021	Aug	CMFD
	@	EQ 60MG BASE	A079021	005	Feb 18, 2021	Mar	CPOT
>D>	@	EQ 80MG BASE	A079021	006	Feb 18, 2021	Aug	CMFD
>A>	AB	EQ 80MG BASE	A079021	006	Feb 18, 2021	Aug	CMFD
	@	EQ 80MG BASE	A079021	006	Feb 18, 2021	Mar	CPOT
>D>	@	EQ 100MG BASE	A079021	007	Feb 18, 2021	Aug	CMFD
>A>	AB	EQ 100MG BASE	A079021	007	Feb 18, 2021	Aug	CMFD
	@	EQ 100MG BASE	A079021	007	Feb 18, 2021	Mar	CPOT
AB	TEVA PHARMS USA	EQ 10MG BASE	A079022	001	May 30, 2017	Mar	CPOT
AB		EQ 18MG BASE	A079022	002	May 30, 2017	Mar	CPOT
AB		EQ 25MG BASE	A079022	003	May 30, 2017	Mar	CPOT
AB		EQ 40MG BASE	A079022	004	May 30, 2017	Mar	CPOT
AB		EQ 60MG BASE	A079022	005	May 30, 2017	Mar	CPOT
AB		EQ 80MG BASE	A079022	006	May 30, 2017	Mar	CPOT
AB		EQ 100MG BASE	A079022	007	May 30, 2017	Mar	CPOT
AB	ZYDUS PHARMS USA INC	EQ 10MG BASE	A079017	007	Apr 05, 2023	Mar	CPOT
AB		EQ 18MG BASE	A079017	001	Sep 16, 2010	Mar	CPOT
AB		18MG	A079017	001	Sep 16, 2010	Jan	CMS1
AB		EQ 25MG BASE	A079017	002	Sep 16, 2010	Mar	CPOT
AB		25MG	A079017	002	Sep 16, 2010	Jan	CMS1
AB		EQ 40MG BASE	A079017	003	Sep 16, 2010	Mar	CPOT
AB		40MG	A079017	003	Sep 16, 2010	Jan	CMS1
AB		EQ 60MG BASE	A079017	004	Sep 16, 2010	Mar	CPOT
AB		60MG	A079017	004	Sep 16, 2010	Jan	CMS1
AB		EQ 80MG BASE	A079017	005	Sep 16, 2010	Mar	CPOT
AB		80MG	A079017	005	Sep 16, 2010	Jan	CMS1
AB		EQ 100MG BASE	A079017	006	Sep 16, 2010	Mar	CPOT
AB		100MG	A079017	006	Sep 16, 2010	Jan	CMS1
	STRATTERA						
	@ LILLY	EQ 5MG BASE	N021411	001	Nov 26, 2002	Mar	CPOT
AB	+	EQ 10MG BASE	N021411	002	Nov 26, 2002	Mar	CPOT
AB	+	EQ 18MG BASE	N021411	003	Nov 26, 2002	Mar	CPOT
AB	+	EQ 25MG BASE	N021411	004	Nov 26, 2002	Mar	CPOT
AB	+	EQ 40MG BASE	N021411	005	Nov 26, 2002	Mar	CPOT
AB	+	EQ 60MG BASE	N021411	006	Nov 26, 2002	Mar	CPOT
AB	+	EQ 80MG BASE	N021411	007	Feb 14, 2005	Mar	CPOT
AB	+	EQ 100MG BASE	N021411	008	Feb 14, 2005	Mar	CPOT



ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

>D>	AB	ACI	EQ 10MG BASE	A217634	001	Dec 21, 2023	Aug	DISC
>A>		@	EQ 10MG BASE	A217634	001	Dec 21, 2023	Aug	DISC
>D>	AB		EQ 20MG BASE	A217634	002	Dec 21, 2023	Aug	DISC
>A>		@	EQ 20MG BASE	A217634	002	Dec 21, 2023	Aug	DISC
>D>	AB		EQ 40MG BASE	A217634	003	Dec 21, 2023	Aug	DISC
>A>		@	EQ 40MG BASE	A217634	003	Dec 21, 2023	Aug	DISC
>D>	AB		EQ 80MG BASE	A217634	004	Dec 21, 2023	Aug	DISC
>A>		@	EQ 80MG BASE	A217634	004	Dec 21, 2023	Aug	DISC
	AB	ANBISON LAB	EQ 10MG BASE	A211886	001	Jan 25, 2024	Jan	NEWA
	AB		EQ 20MG BASE	A211886	002	Jan 25, 2024	Jan	NEWA
	AB		EQ 40MG BASE	A211886	003	Jan 25, 2024	Jan	NEWA
	AB		EQ 80MG BASE	A211886	004	Jan 25, 2024	Jan	NEWA
	AB	AUROBINDO PHARMA LTD	EQ 10MG BASE	A217118	001	Feb 13, 2024	Feb	NEWA
	AB		EQ 20MG BASE	A217118	002	Feb 13, 2024	Feb	NEWA
	AB		EQ 40MG BASE	A217118	003	Feb 13, 2024	Feb	NEWA
	AB		EQ 80MG BASE	A217118	004	Feb 13, 2024	Feb	NEWA
		@ CADILA PHARMS LTD	EQ 10MG BASE	A212103	001	Oct 16, 2023	Apr	DISC
		@	EQ 20MG BASE	A212103	002	Oct 16, 2023	Apr	DISC
		@	EQ 40MG BASE	A212103	003	Oct 16, 2023	Apr	DISC
		@	EQ 80MG BASE	A212103	004	Oct 16, 2023	Apr	DISC
		@ INVAGEN PHARMS	EQ 10MG BASE	A204846	001	Jan 09, 2017	Mar	DISC
		@	EQ 20MG BASE	A204846	002	Jan 09, 2017	Mar	DISC
		@	EQ 40MG BASE	A204846	003	Jan 09, 2017	Mar	DISC
		@	EQ 80MG BASE	A204846	004	Jan 09, 2017	Mar	DISC
	AB	LAURUS	EQ 10MG BASE	A214513	001	Jan 22, 2024	Jan	NEWA
	AB		EQ 20MG BASE	A214513	002	Jan 22, 2024	Jan	NEWA
	AB		EQ 40MG BASE	A214513	003	Jan 22, 2024	Jan	NEWA
	AB		EQ 80MG BASE	A214513	004	Jan 22, 2024	Jan	NEWA
>D>	BX	LUPIN LTD	EQ 10MG BASE	A204991	001	Mar 06, 2019	Aug	DISC
>A>		@	EQ 10MG BASE	A204991	001	Mar 06, 2019	Aug	DISC
	BX		EQ 10MG BASE	A204991	001	Mar 06, 2019	Jun	CTEC
>D>	BX		EQ 20MG BASE	A204991	002	Mar 06, 2019	Aug	DISC
>A>		@	EQ 20MG BASE	A204991	002	Mar 06, 2019	Aug	DISC
	BX		EQ 20MG BASE	A204991	002	Mar 06, 2019	Jun	CTEC
>D>	BX		EQ 40MG BASE	A204991	003	Mar 06, 2019	Aug	DISC
>A>		@	EQ 40MG BASE	A204991	003	Mar 06, 2019	Aug	DISC
	BX		EQ 40MG BASE	A204991	003	Mar 06, 2019	Jun	CTEC
>D>	BX		EQ 80MG BASE	A204991	004	Mar 06, 2019	Aug	DISC
>A>		@	EQ 80MG BASE	A204991	004	Mar 06, 2019	Aug	DISC
	BX		EQ 80MG BASE	A204991	004	Mar 06, 2019	Jun	CTEC
	AB	MACLEODS PHARMS LTD	EQ 10MG BASE	A208480	001	Jun 03, 2024	May	NEWA
	AB		EQ 20MG BASE	A208480	002	Jun 03, 2024	May	NEWA
	AB		EQ 40MG BASE	A208480	003	Jun 03, 2024	May	NEWA
	AB		EQ 80MG BASE	A208480	004	Jun 03, 2024	May	NEWA
	AB	SHANDONG XINHUA	EQ 10MG BASE	A211886	001	Jan 25, 2024	Mar	CAHN
	AB		EQ 20MG BASE	A211886	002	Jan 25, 2024	Mar	CAHN
	AB		EQ 40MG BASE	A211886	003	Jan 25, 2024	Mar	CAHN
	AB		EQ 80MG BASE	A211886	004	Jan 25, 2024	Mar	CAHN
	BX	UMEDICA	EQ 10MG BASE	A213853	001	Aug 19, 2020	Jun	CTEC
	BX		EQ 20MG BASE	A213853	002	Aug 19, 2020	Jun	CTEC
	BX		EQ 40MG BASE	A213853	003	Aug 19, 2020	Jun	CTEC
	BX		EQ 80MG BASE	A213853	004	Aug 19, 2020	Jun	CTEC

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

@	NORVIUM BIOSCIENCE	10MG/ML	A206096	001	Jun 22, 2017	Jun	CAHN
@	NORVIUM BIOSCIENCE	10MG/ML	A206001	001	Apr 07, 2017	Jun	CAHN

ATROPINE SULFATE

SOLUTION; INTRAVENOUS

ATROPINE SULFATE

AP	SOMERSET THERAPS LLC	0.4MG/ML (0.4MG/ML)	A215969	001	Jul 03, 2024	Jun	NEWA
AP		1MG/ML (1MG/ML)	A215969	002	Jul 03, 2024	Jun	NEWA

SOLUTION/DROPS; OPHTHALMIC

ATROPINE SULFATE

AT1	!	AMNEAL	1%	A214752	001	Jul 14, 2022	Apr	CTEC
AT1		APOTEX	1%	A215624	001	Nov 26, 2021	Apr	CTEC

SOLUTION/DROPS;OPHTHALMIC							
ATROPINE SULFATE							
AT1	MANKIND PHARMA	1%	A218148	001	Jan 08, 2024	Apr	CTEC
AT1	+ RISING	1%	N206289	001	Jul 18, 2014	Apr	CTEC
AT2	SOMERSET	1%	A217791	001	Apr 29, 2024	Apr	NFTG
AT1	SOMERSET THERAPS LLC	1%	A215618	001	Jul 01, 2024	Jun	NEWA
ISOPTO ATROPINE							
AT2	+! ALCON LABS INC	1%	N208151	001	Dec 01, 2016	Apr	CFTG
<u>ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE</u>							
TABLET;ORAL							
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE							
	@ ANI PHARMS	0.025MG;2.5MG	A086727	001		Mar	DISC
	@ MYLAN	0.025MG;2.5MG	A085762	001		Apr	DISC
<u>ATROPINE SULFATE; EDROPHONIUM CHLORIDE</u>							
INJECTABLE;INJECTION							
ENLON-PLUS							
	@ NORVIUM BIOSCIENCE	0.14MG/ML;10MG/ML	N019677	001	Nov 06, 1991	Jul	CAHN
	+ @	0.14MG/ML;10MG/ML	N019678	001	Nov 06, 1991	Jul	CAHN
<u>AVACINCAPTAD PEGOL SODIUM</u>							
SOLUTION;INTRAVITREAL							
IZERVAY							
	+! ASTELLAS	EQ 2MG BASE/0.1ML (EQ 2MG BASE/0.1ML)	N217225	001	Aug 04, 2023	Jan	CAHN
<u>AVANAFIL</u>							
TABLET;ORAL							
AVANAFIL							
AB	HETERO LABS LTD V	50MG	A209266	001	Jun 14, 2024	Jun	NFTG
AB		100MG	A209266	002	Jun 14, 2024	Jun	NFTG
AB		200MG	A209266	003	Jun 14, 2024	Jun	NFTG
STENDRA							
AB	+ METUCHEN PHARMS	50MG	N202276	001	Apr 27, 2012	Jun	CFTG
AB	+	100MG	N202276	002	Apr 27, 2012	Jun	CFTG
AB	+!	200MG	N202276	003	Apr 27, 2012	Jun	CFTG
<u>AZACITIDINE</u>							
POWDER;INTRAVENOUS, SUBCUTANEOUS							
AZACITIDINE							
AP	MSN LABS PVT LTD	100MG/VIAL	A212580	001	May 16, 2024	May	NEWA
<u>AZELAIC ACID</u>							
GEL;TOPICAL							
AZELAIC ACID							
AB	TARO	15%	A210549	001	Aug 23, 2019	Apr	CAHN
<u>AZELASTINE HYDROCHLORIDE</u>							
SOLUTION/DROPS;OPHTHALMIC							
OPTIVAR							
	+ @ NORVIUM BIOSCIENCE	0.05%	N021127	001	May 22, 2000	Jul	CAHN
SPRAY, METERED;NASAL							
ASTELIN							
	+ @ NORVIUM BIOSCIENCE	0.137MG/SPRAY	N020114	001	Nov 01, 1996	Jul	CAHN
AZELASTINE HYDROCHLORIDE							
	@ HIKMA	0.137MG/SPRAY	A091444	001	Oct 24, 2014	Mar	DISC
<u>AZITHROMYCIN</u>							
INJECTABLE;INJECTION							
AZITHROMYCIN							
	@ NORVIUM BIOSCIENCE	EQ 500MG BASE/VIAL	A065506	001	Mar 24, 2009	Jun	CAHN
	@ SUN PHARM INDS LTD	EQ 500MG BASE/VIAL	A090923	001	Apr 02, 2013	May	DISC
TABLET;ORAL							
AZITHROMYCIN							
	@ EXTROVIS	EQ 500MG BASE	A065366	001	May 30, 2007	Jul	CAHN
	@ YUNG SHIN PHARM	EQ 250MG BASE	A211317	001	Jul 26, 2022	Feb	DISC

BACLOFEN

INJECTABLE; INTRATHECAL

BACLOFEN

@ ACIC PHARMS 0.5MG/ML A216309 001 Aug 10, 2023 Jan DISC  
 @ 2MG/ML A216309 002 Aug 10, 2023 Jan DISC

TABLET; ORAL

BACLOFEN

>A> AB ANDAS 5 HOLDING 5MG A212378 003 Apr 30, 2021 Aug CAHN  
 >A> AB 10MG A212378 001 Oct 09, 2020 Aug CAHN  
 >A> AB 20MG A212378 002 Oct 09, 2020 Aug CAHN  
 AB ENDO OPERATIONS 10MG A077068 002 Aug 30, 2005 Apr CAHN  
 AB 20MG A077068 001 Aug 30, 2005 Apr CAHN  
 BX EYWA 5MG A211555 003 Nov 30, 2021 Jul CAHN  
 BX 10MG A211555 001 Feb 01, 2019 Jul CAHN  
 BX 20MG A211555 002 Feb 01, 2019 Jul CAHN  
 BX EYWA PHARMA 5MG A211555 003 Nov 30, 2021 Jun CTEC  
 BX 10MG A211555 001 Feb 01, 2019 Jun CTEC  
 BX 20MG A211555 002 Feb 01, 2019 Jun CTEC  
 @ IMPAX 5MG A077971 003 Jul 07, 2021 Mar DISC  
 @ 10MG A077971 001 Oct 26, 2007 Mar DISC  
 @ 20MG A077971 002 Oct 26, 2007 Mar DISC  
 >D> AB INNOGENIX 5MG A212378 003 Apr 30, 2021 Aug CAHN  
 >D> AB 10MG A212378 001 Oct 09, 2020 Aug CAHN  
 >D> AB 20MG A212378 002 Oct 09, 2020 Aug CAHN  
 @ NORVIUM BIOSCIENCE 20MG A077121 002 Jul 29, 2005 Jul CAHN  
 AB RUBICON 15MG A209102 004 Feb 05, 2024 Feb CTEC  
 15MG A209102 004 Feb 05, 2024 Jan NEWA

BALSALAZIDE DISODIUM

CAPSULE; ORAL

BALSALAZIDE DISODIUM

AB ZYDUS LIFESCIENCES 750MG A217592 001 Jun 08, 2023 Mar CAHN

BARICITINIB

TABLET; ORAL

BARICITINIB

>D> AB AUROBINDO PHARMA LTD 1MG A217542 001 Jul 22, 2024 Aug DISC  
 >A> @ 1MG A217542 001 Jul 22, 2024 Aug DISC  
 AB 1MG A217542 001 Jul 22, 2024 Jul NFTG  
 >D> AB 2MG A217542 002 Jul 22, 2024 Aug DISC  
 >A> @ 2MG A217542 002 Jul 22, 2024 Aug DISC  
 AB 2MG A217542 002 Jul 22, 2024 Jul NFTG  
 OLUMIANT  
 >D> AB + ELI LILLY AND CO 1MG N207924 002 Oct 08, 2019 Aug CTEC  
 >A> + 1MG N207924 002 Oct 08, 2019 Aug CTEC  
 AB + 1MG N207924 002 Oct 08, 2019 Jul CFTG  
 >D> AB + 2MG N207924 001 May 31, 2018 Aug CTEC  
 >A> + 2MG N207924 001 May 31, 2018 Aug CTEC  
 AB + 2MG N207924 001 May 31, 2018 Jul CFTG

BENDAMUSTINE HYDROCHLORIDE

POWDER; IV (INFUSION)

BENDAMUSTINE HYDROCHLORIDE

AP MEITHEAL 25MG/VIAL A211001 001 Jun 05, 2023 Jun CAHN  
 AP 100MG/VIAL A211001 002 Jun 05, 2023 Jun CAHN  
 @ NORVIUM BIOSCIENCE 25MG/VIAL A204104 001 Apr 28, 2023 Jun CAHN  
 @ 100MG/VIAL A204104 002 Apr 28, 2023 Jun CAHN

SOLUTION; INTRAVENOUS

VIVIMUSTA

+! AZURITY 100MG/4ML (25MG/ML) N212209 001 Dec 07, 2022 Jul CAHN

BENZGALANTAMINE GLUCONATE

TABLET, DELAYED RELEASE; ORAL

ZUNVEYL

+! ALPHA COGNITION EQ 5MG BASE N218549 001 Jul 26, 2024 Jul NEWA  
 + EQ 10MG BASE N218549 002 Jul 26, 2024 Jul NEWA  
 + EQ 15MG BASE N218549 003 Jul 26, 2024 Jul NEWA

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

>A>	AB	PADAGIS ISRAEL	3.75%;EQ 1.2% BASE	A209610	001	Aug 20, 2024	Aug NEWA
-----	----	----------------	--------------------	---------	-----	--------------	----------

BENZTROPINE MESYLATE

TABLET;ORAL

BENZTROPINE MESYLATE

>D>		@ AIPING PHARM INC	0.5MG	A040103	001	Dec 12, 1996	Aug CMFD
>A>	AA		0.5MG	A040103	001	Dec 12, 1996	Aug CMFD
>D>		@	1MG	A040103	002	Dec 12, 1996	Aug CMFD
>A>	AA		1MG	A040103	002	Dec 12, 1996	Aug CMFD
>D>		@	2MG	A040103	003	Dec 12, 1996	Aug CMFD
>A>	AA		2MG	A040103	003	Dec 12, 1996	Aug CMFD
	AA	ENDO OPERATIONS	0.5MG	A040715	001	Aug 27, 2007	Apr CAHN
	AA		1MG	A040715	002	Aug 27, 2007	Apr CAHN
	AA		2MG	A040715	003	Aug 27, 2007	Apr CAHN
		@ INVAGEN PHARMS	0.5MG	A090294	001	Mar 29, 2010	Mar DISC
		@	1MG	A090294	002	Mar 29, 2010	Mar DISC
		@	2MG	A090294	003	Mar 29, 2010	Mar DISC
	AA	! NUVO PHARM	0.5MG	A204713	001	Apr 14, 2015	Jul CAHN
	AA	!	1MG	A204713	002	Apr 14, 2015	Jul CAHN
	AA	!	2MG	A204713	003	Apr 14, 2015	Jul CAHN

BEPOTASTINE BESILATE

SOLUTION/DROPS;OPHTHALMIC

BEPOTASTINE BESILATE

>A>	AT	SOMERSET THERAPS LLC	1.5%	A217770	001	Aug 14, 2024	Aug NEWA
-----	----	----------------------	------	---------	-----	--------------	----------

BERDAZIMER SODIUM

GEL;TOPICAL

ZELSUVMI

		+! LNHC	EQ 10.3% BASE	N217424	001	Jan 05, 2024	Jan NEWA
--	--	---------	---------------	---------	-----	--------------	----------

BETAMETHASONE DIPROPIONATE

LOTION, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

@	HIKMA	EQ 0.05% BASE	A208849	001	Oct 11, 2019	Mar DISC
---	-------	---------------	---------	-----	--------------	----------

OINTMENT, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

AB		AUROBINDO PHARMA LTD	EQ 0.05% BASE	A218289	001	Apr 10, 2024	Mar NEWA
		@ PADAGIS US	EQ 0.05% BASE	A206118	001	Nov 09, 2017	Jan CAHN

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM;TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB	!	TARO	EQ 0.05% BASE;1%	A075673	001	May 29, 2001	Apr CAHN
----	---	------	------------------	---------	-----	--------------	----------

BETAMETHASONE VALERATE

AEROSOL, FOAM;TOPICAL

BETAMETHASONE VALERATE

>A>	AB	ALEMBIC	0.12%	A215832	001	Aug 22, 2024	Aug NEWA
-----	----	---------	-------	---------	-----	--------------	----------

LOTION;TOPICAL

BETAMETHASONE VALERATE

>D>	AB	ANIMA	EQ 0.1% BASE	A070052	001	Jul 31, 1985	Aug CAHN
>A>	AB	KANCHAN HLTHCARE	EQ 0.1% BASE	A070052	001	Jul 31, 1985	Aug CAHN

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

>D>		@ AKORN	EQ 0.5% BASE	A075386	001	Jun 30, 2000	Aug CAHN
>A>		@ SAPTALIS PHARMS	EQ 0.5% BASE	A075386	001	Jun 30, 2000	Aug CAHN

BEXAROTENE

CAPSULE;ORAL

BEXAROTENE

>A>	AB	ASCENT PHARMS INC	75MG	A208628	001	Sep 06, 2024	Aug NEWA
-----	----	-------------------	------	---------	-----	--------------	----------

BICALUTAMIDE

	TABLET; ORAL						
	BICALUTAMIDE						
AB	CHARTWELL RX	50MG		A091011	001	Jun 10, 2015	Jan CAHN
	@ RISING	50MG		A079185	001	Jul 06, 2009	Feb CAHN

BIMATOPROST

	SOLUTION/DROPS; TOPICAL						
	BIMATOPROST						
	@ HIKMA	0.03%		A203051	001	Oct 09, 2018	Mar DISC

BIRCH TRITERPENES

	GEL; TOPICAL						
	FILSUEVZ						
	+! CHIESI	10%		N215064	001	Dec 18, 2023	Jan CAHN

BISOPROLOL FUMARATE

	TABLET; ORAL						
	BISOPROLOL FUMARATE						
AB	HARMAN FINOCHEM	5MG		A217617	001	Jan 18, 2024	Jan NEWA
AB		10MG		A217617	002	Jan 18, 2024	Jan NEWA

BIVALIRUDIN

	INJECTABLE; INTRAVENOUS						
	BIVALIRUDIN						
>D> AP	HOSPIRA	250MG/VIAL		A090811	001	Jul 14, 2015	Aug DISC
>A>	@	250MG/VIAL		A090811	001	Jul 14, 2015	Aug DISC
	@	250MG/VIAL		A090816	001	Jul 14, 2015	May DISC

BLEOMYCIN SULFATE

	INJECTABLE; INJECTION						
	BLEOMYCIN SULFATE						
	@ TEVA PHARMS USA	EQ 15 UNITS BASE/VIAL		A065033	001	Jun 27, 2000	Jan DISC
	@	EQ 30 UNITS BASE/VIAL		A065033	002	Jun 27, 2000	Jan DISC

BORTEZOMIB

	INJECTABLE; INTRAVENOUS, SUBCUTANEOUS						
	BORTEZOMIB						
AP	HETERO LABS LTD VI	3.5MG/VIAL		A212204	001	May 03, 2024	Apr NEWA
	@ NORVIUM BIOSCIENCE	3.5MG/VIAL		A205160	001	Oct 31, 2022	Jun CAHN
AP	RELIANCE LIFE SCI	3.5MG/VIAL		A211898	001	Oct 11, 2022	May CAHN
	SOLUTION; INTRAVENOUS, SUBCUTANEOUS						
	BORTEZOMIB						
>A>	+! SHILPA	3.5MG/1.4ML (2.5MG/ML)		N212782	001	Aug 26, 2024	Aug NEWA

BOSENTAN

	TABLET; ORAL						
	BOSENTAN						
	@ ENDO OPERATIONS	62.5MG		A205699	001	Apr 26, 2019	Apr CAHN
	@	125MG		A205699	002	Apr 26, 2019	Apr CAHN

BREMELANOTIDE ACETATE

	SOLUTION; SUBCUTANEOUS						
	VYLEESI (AUTOINJECTOR)						
	+! COSETTE	EQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML)		N210557	001	Jun 21, 2019	Apr CAHN

BRIMONIDINE TARTRATE

	SOLUTION/DROPS; OPHTHALMIC						
	BRIMONIDINE TARTRATE						
>A> AB	LUPIN LTD	0.1%		A213215	001	Aug 26, 2024	Aug NEWA
AB	SANDOZ	0.1%		A203172	001	Mar 04, 2024	Feb NEWA
>A> AB	SOMERSET THERAPS LLC	0.1%		A216906	001	Aug 09, 2024	Aug NEWA
AT	UPSHER SMITH LABS	0.15%		A216772	001	Jun 12, 2024	May NEWA

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

	SOLUTION/DROPS; OPHTHALMIC						
	BRIMONIDINE TARTRATE AND TIMOLOL MALEATE						
AB	GLENMARK PHARMS LTD	0.2%;EQ 0.5% BASE		A214987	001	May 16, 2024	May NEWA
>A> AB	SOMERSET	0.2%;EQ 0.5% BASE		A216114	001	Sep 10, 2024	Aug NEWA

BROMFENAC SODIUMSOLUTION/DROPS;OPHTHALMIC  
BROMFENAC SODIUM

AB	ALEMBIC	EQ 0.07% ACID	A214340	001	Jul 08, 2024	Jun	NEWA
AB	AMNEAL	EQ 0.07% ACID	A210962	001	Jul 29, 2024	Jul	NEWA
AB	APOTEX	EQ 0.07% ACID	A207334	001	Jul 08, 2024	Jun	NEWA
AB	LUPIN LTD	EQ 0.075% ACID	A211239	001	Feb 02, 2024	Jan	NFTG
	BROMSITE						
AB	+! SUN PHARM	EQ 0.075% ACID	N206911	001	Apr 08, 2016	Jan	CFTG

BUDESONIDEAEROSOL, FOAM;RECTAL  
BUDESONIDE

AB	! PADAGIS ISRAEL	2MG/ACTUATION	A215328	001	Apr 12, 2023	Jun	CHRS
	UCERIS						
AB	+ SALIX	2MG/ACTUATION	N205613	001	Oct 07, 2014	Jun	CHRS
	POWDER, METERED;INHALATION						
	PULMICORT FLEXHALER						
	+ CHEPLAPHARM	0.08MG/INH	N021949	001	Jul 12, 2006	Jun	CAHN
	+!	0.16MG/INH	N021949	002	Jul 12, 2006	Jun	CAHN
	SUSPENSION;INHALATION						
	BUDESONIDE						
	@ EUGIA PHARMA	0.5MG/2ML	A216667	001	Nov 29, 2023	May	DISC
	SUSPENSION;ORAL						
	EOHILIA						
	+! TAKEDA PHARMS USA	2MG/10ML	N213976	001	Feb 09, 2024	Feb	NEWA

BUMETANIDEINJECTABLE;INJECTION  
BUMETANIDE

	@ HOSPIRA	0.25MG/ML	A074332	001	Oct 31, 1994	May	DISC
	TABLET;ORAL						
	BUMETANIDE						
AB	RISING	0.5MG	A212019	001	Dec 12, 2019	Jun	CTEC
AB		1MG	A212019	002	Dec 12, 2019	Jun	CTEC
AB		2MG	A212019	003	Dec 12, 2019	Jun	CTEC

BUPIVACAINEINJECTABLE, LIPOSOMAL;INJECTION  
BUPIVACAINE LIPOSOME

AP	HENGRUI PHARMA	133MG/10ML (13.3MG/ML)	A214348	001	Jul 01, 2024	Jun	NFTG
AP		266MG/20ML (13.3MG/ML)	A214348	002	Jul 01, 2024	Jun	NFTG
	EXPAREL						
AP	+! PACIRA PHARMS INC	133MG/10ML (13.3MG/ML)	N022496	001	Oct 28, 2011	Jun	CFTG
AP	+!	266MG/20ML (13.3MG/ML)	N022496	002	Oct 28, 2011	Jun	CFTG
>A>	SOLUTION;INFILTRATION						
>A>	POSIMIR						
>A>	+! INNOCOLL	660MG/5ML (132MG/ML)	N204803	001	Feb 01, 2021	Aug	CDFR
>D>	SOLUTION, EXTENDED RELEASE;INFILTRATION						
>D>	POSIMIR						
>D>	+! INNOCOLL	660MG/5ML (132MG/ML)	N204803	001	Feb 01, 2021	Aug	CDFR

BUPIVACAINE HYDROCHLORIDEINJECTABLE;INJECTION  
BUPIVACAINE HYDROCHLORIDE

AP	ASPIRO	0.25%	A217821	001	Mar 27, 2024	Mar	NEWA
AP		0.5%	A217821	002	Mar 27, 2024	Mar	NEWA
AP		0.75%	A217821	003	Mar 27, 2024	Mar	NEWA
AP	MEITHEAL	0.25%	A216039	001	Jun 23, 2023	Jun	CAHN
AP		0.25%	A216040	001	Dec 27, 2023	Jun	CAHN
AP		0.5%	A216039	002	Jun 23, 2023	Jun	CAHN
AP		0.5%	A216040	002	Dec 27, 2023	Jun	CAHN
AP		0.75%	A216040	003	Dec 27, 2023	Jun	CAHN

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATEINJECTABLE;INJECTION  
VIVACAINE

!	SEPTODONT	0.5%;0.0091MG/ML	A077250	001	Sep 27, 2006	Jan	CTNA
---	-----------	------------------	---------	-----	--------------	-----	------

BUPRENORPHINE HYDROCHLORIDE

IMPLANT; IMPLANTATION  
PROBUPHINE

+ @ REACK PHARMS EQ 80MG BASE/IMPLANT N204442 001 May 26, 2016 Apr CAHN

INJECTABLE; INJECTION

BUPRENORPHINE HYDROCHLORIDE

@ AM REGENT EQ 0.3MG BASE/ML A078331 001 Mar 27, 2007 Jan DISC

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

@ NORVIUM BIOSCIENCE EQ 2MG BASE A201066 001 Mar 06, 2015 Jun CAHN

@ EQ 8MG BASE A201066 002 Mar 06, 2015 Jun CAHN

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

AB AUROBINDO PHARMA USA 75MG A075491 001 Apr 17, 2000 Apr CMFD

AB 100MG A075491 002 Apr 17, 2000 Apr CMFD

@ INVAGEN PHARMS 75MG A207389 001 Sep 18, 2017 Mar DISC

@ 100MG A207389 002 Sep 18, 2017 Mar DISC

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

@ ANCHEN PHARMS 100MG A091459 001 Jun 09, 2011 Feb DISC

@ 150MG A091459 002 Jun 09, 2011 Feb DISC

@ 150MG A091520 001 Jun 09, 2011 Feb DISC

@ 200MG A091459 003 Jun 09, 2011 Feb DISC

@ ENDO OPERATIONS 100MG A091459 001 Jun 09, 2011 May CAHN

@ 150MG A077284 001 Dec 14, 2006 May CAHN

@ 150MG A091459 002 Jun 09, 2011 May CAHN

@ 150MG A091520 001 Jun 09, 2011 May CAHN

@ 200MG A091459 003 Jun 09, 2011 May CAHN

@ 300MG A077284 002 Dec 14, 2006 May CAHN

@ INVAGEN PHARMS 100MG A206674 001 Feb 09, 2016 Mar DISC

@ 150MG A206556 001 Aug 26, 2016 Mar DISC

@ 150MG A206674 002 Feb 09, 2016 Mar DISC

@ 200MG A206674 003 Feb 09, 2016 Mar DISC

@ 300MG A206556 002 Aug 26, 2016 Mar DISC

@ RISING 150MG A090941 001 May 03, 2010 Feb CAHN

@ SUN PHARM 150MG A078866 002 Apr 06, 2010 Jul DISC

@ 200MG A078866 003 Apr 06, 2010 May DISC

AB3 TWI PHARMS 150MG A210081 001 Nov 03, 2017 Mar CAHN

AB3 300MG A210081 002 Nov 03, 2017 Mar CAHN

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

AB AIPING PHARM INC 5MG A202087 001 Dec 16, 2015 Jan CAHN

AB 10MG A202087 002 Dec 16, 2015 Jan CAHN

AB 15MG A202087 003 Dec 16, 2015 Jan CAHN

AB 30MG A202087 004 Dec 16, 2015 Jan CAHN

@ AMNEAL PHARMS CO 5MG A208829 001 May 24, 2017 Mar DISC

@ 7.5MG A208829 002 May 24, 2017 Mar DISC

@ 10MG A208829 003 May 24, 2017 Mar DISC

@ 15MG A208829 004 May 24, 2017 Mar DISC

@ 30MG A208829 005 May 24, 2017 Mar DISC

BUSULFAN

INJECTABLE; INJECTION

BUSULFAN

AP EUGIA PHARMA 6MG/ML A215102 001 Jun 25, 2024 Jun NEWA

@ NORVIUM BIOSCIENCE 6MG/ML A205184 001 Jul 13, 2018 Jun CAHN

>A> AP PRINSTON INC 6MG/ML A215235 001 Sep 11, 2024 Aug NEWA

BUTABARBITAL SODIUM

TABLET; ORAL

BUTISOL SODIUM

@ NORVIUM BIOSCIENCE 15MG N000793 002 Jun CAHN

+ @ 30MG N000793 004 Jun CAHN

@ 50MG N000793 003 Jun CAHN

@ 100MG N000793 005 Jun CAHN

CABAZITAXEL

SOLUTION; INTRAVENOUS  
CABAZITAXEL

+ @ ACCORD HLTHCARE 60MG/3ML (20MG/ML) N207949 001 Dec 29, 2021 Jun DISC

CABERGOLINE

TABLET; ORAL  
CABERGOLINE

AB @ NORVIUM BIOSCIENCE 0.5MG A202947 001 Dec 02, 2013 Jun CAHN  
AB SKG PHARMA 0.5MG A218618 001 Jun 26, 2024 Jun NEWA  
>A> AB WELDING 0.5MG A218109 001 Sep 09, 2024 Aug NEWA

CALCIPOTRIENE

SOLUTION; TOPICAL  
CALCIPOTRIENE

@ HIKMA 0.005% A077579 001 Nov 19, 2009 Mar DISC

CALCITONIN SALMON

INJECTABLE; INJECTION  
CALCITONIN-SALMON

AP DR REDDYS 200 IU/ML A215715 001 Apr 11, 2024 Apr NEWA  
SPRAY, METERED; NASAL  
CALCITONIN-SALMON  
AB ! APOTEX INC 200 IU/SPRAY A076396 001 Nov 17, 2008 Jul CTEC  
AB ENDO OPERATIONS 200 IU/SPRAY A076979 001 Jun 08, 2009 Jul CMFD  
@ 200 IU/SPRAY A076979 001 Jun 08, 2009 May CAHN  
MIACALCIN  
+ @ NORVIUM BIOSCIENCE 200 IU/SPRAY N020313 002 Aug 17, 1995 Jul CAHN

CALCIUM ACETATE

CAPSULE; ORAL  
CALCIUM ACETATE

AB ! INVAGEN PHARMS 667MG A203135 001 Feb 07, 2013 Apr CHRS  
PHOSLO GELCAPS  
+ @ FRESENIUS MEDCL 667MG N021160 003 Apr 02, 2001 Apr DISC

CALCIUM CHLORIDE

INJECTABLE; INJECTION  
CALCIUM CHLORIDE

AP AMNEAL 100MG/ML A217524 001 Jul 08, 2024 Jun NEWA

CALCIUM GLUCONATE

SOLUTION; INTRAVENOUS  
CALCIUM GLUCONATE

AP AMNEAL 1GM/10ML (100MG/ML) A216611 001 May 10, 2024 May NEWA  
AP 5GM/50ML (100MG/ML) A216611 002 May 10, 2024 May NEWA  
AP 10GM/100ML (100MG/ML) A216611 003 May 10, 2024 May NEWA  
AP NIVAGEN PHARMS INC 10GM/100ML (100MG/ML) A213071 003 Apr 30, 2024 Apr NEWA

CAPECITABINE

TABLET; ORAL  
CAPECITABINE

AB HETERO LABS LTD V 150MG A210203 001 Mar 05, 2024 Feb NEWA  
AB 500MG A210203 002 Mar 05, 2024 Feb NEWA

CAPREOMYCIN SULFATE

INJECTABLE; INJECTION  
CAPREOMYCIN SULFATE

@ NORVIUM BIOSCIENCE EQ 1GM BASE/VIAL A202634 001 Nov 27, 2017 Jun CAHN

CAPTOPRIL

TABLET; ORAL  
CAPTOPRIL

>A> AB ANDAS 5 HOLDING 12.5MG A074677 004 May 30, 1997 Aug CAHN  
>A> AB 25MG A074677 002 May 30, 1997 Aug CAHN  
>A> AB 50MG A074677 001 May 30, 1997 Aug CAHN  
>A> AB 100MG A074677 003 May 30, 1997 Aug CAHN  
>D> AB INNOGENIX 12.5MG A074677 004 May 30, 1997 Aug CAHN  
AB 12.5MG A074677 004 May 30, 1997 Mar CAHN  
>D> AB 25MG A074677 002 May 30, 1997 Aug CAHN  
AB 25MG A074677 002 May 30, 1997 Mar CAHN



TABLET; ORAL  
CAPTOPRIL

>D>	AB		50MG	A 074677	001	May 30, 1997	Aug CAHN
	AB		50MG	A 074677	001	May 30, 1997	Mar CAHN
>D>	AB		100MG	A 074677	003	May 30, 1997	Aug CAHN
	AB		100MG	A 074677	003	May 30, 1997	Mar CAHN
	AB	STASON PHARMS	12.5MG	A 074677	004	May 30, 1997	Feb CAHN
	AB		25MG	A 074677	002	May 30, 1997	Feb CAHN
	AB		50MG	A 074677	001	May 30, 1997	Feb CAHN
	AB		100MG	A 074677	003	May 30, 1997	Feb CAHN

CARBAMAZEPINE

TABLET; ORAL  
CARBAMAZEPINE

AB		BIONPHARMA	200MG	A 218221	001	Feb 16, 2024	Feb NEWA
BX		UMEDICA	100MG	A 207798	001	Apr 15, 2020	Jun CTEC
BX			200MG	A 207798	002	Apr 15, 2020	Jun CTEC

TABLET, EXTENDED RELEASE; ORAL  
CARBAMAZEPINE

		@ AMNEAL PHARMS	100MG	A 212704	001	Sep 22, 2023	Feb DISC
		@	200MG	A 212704	002	Sep 22, 2023	Feb DISC
		@	400MG	A 212704	003	Sep 22, 2023	Feb DISC
		@ APOTEX	100MG	A 213159	001	Mar 08, 2024	May DISC
AB		@	100MG	A 213159	001	Mar 08, 2024	Mar NEWA
		@	200MG	A 213159	002	Mar 08, 2024	May DISC
AB		@	200MG	A 213159	002	Mar 08, 2024	Mar NEWA
		@	400MG	A 213159	003	Mar 08, 2024	May DISC
AB		@	400MG	A 213159	003	Mar 08, 2024	Mar NEWA

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL  
CARBIDOPA, LEVODOPA AND ENTACAPONE

		@ NORVIUM BIOSCIENCE	12.5MG; 200MG; 50MG	A 203424	001	Aug 13, 2020	Jun CAHN
		@	18.75MG; 200MG; 75MG	A 203424	002	Aug 13, 2020	Jun CAHN
		@	25MG; 200MG; 100MG	A 203424	003	Aug 13, 2020	Jun CAHN
		@	31.25MG; 200MG; 125MG	A 203424	004	Aug 13, 2020	Jun CAHN
		@	37.5MG; 200MG; 150MG	A 203424	005	Aug 13, 2020	Jun CAHN
		@	50MG; 200MG; 200MG	A 203424	006	Aug 13, 2020	Jun CAHN

CARBIDOPA; LEVODOPA

CAPSULE, EXTENDED RELEASE; ORAL  
CREXONT

>A>	+	IMPAX	35MG; 140MG	N 217186	001	Aug 07, 2024	Aug NEWA
>A>	+		52.5MG; 210MG	N 217186	002	Aug 07, 2024	Aug NEWA
>A>	+		70MG; 280MG	N 217186	003	Aug 07, 2024	Aug NEWA
>A>	+	!	87.5MG; 350MG	N 217186	004	Aug 07, 2024	Aug NEWA
		RYTARY					
	+	IMPAX	23.75MG; 95MG	N 203312	001	Jan 07, 2015	May CAHN
	+		36.25MG; 145MG	N 203312	002	Jan 07, 2015	May CAHN
	+		48.75MG; 195MG	N 203312	003	Jan 07, 2015	May CAHN
	+	!	61.25MG; 245MG	N 203312	004	Jan 07, 2015	May CAHN

TABLET, EXTENDED RELEASE; ORAL  
CARBIDOPA AND LEVODOPA

AB		RUBICON	25MG; 100MG	A 217482	001	Jun 04, 2024	May NEWA
AB			50MG; 200MG	A 217482	002	Jun 04, 2024	May NEWA

CARBINOXAMINE MALEATE

SOLUTION; ORAL  
CARBINOXAMINE MALEATE

		@ ENDO OPERATIONS	4MG/5ML	A 040814	001	Feb 26, 2008	May CAHN
--	--	-------------------	---------	----------	-----	--------------	----------

TABLET; ORAL  
CARBINOXAMINE MALEATE

		@ INVAGEN PHARMS	4MG	A 090435	001	Apr 15, 2010	Mar DISC
--	--	------------------	-----	----------	-----	--------------	----------

CARBOPLATIN

INJECTABLE; INTRAVENOUS  
CARBOPLATIN

		@ NORVIUM BIOSCIENCE	50MG/5ML (10MG/ML)	A 077998	001	Apr 24, 2007	Jul CAHN
		@	150MG/15ML (10MG/ML)	A 077998	002	Apr 24, 2007	Jul CAHN
		@	450MG/45ML (10MG/ML)	A 077998	003	Apr 24, 2007	Jul CAHN

CARBOPROST TROMETHAMINE

INJECTABLE; INJECTION  
CARBOPROST TROMETHAMINE

	@ ANI PHARMS	EQ 0.25MG BASE/ML	A215901	001	Jan 25, 2024	Jul	DISC	
AP		EQ 0.25MG BASE/ML	A215901	001	Jan 25, 2024	Jan	NEWA	
AP	MICRO LABS	EQ 0.25MG BASE/ML	A218013	001	Apr 03, 2024	Mar	NEWA	
>D>	AP	STERISCIENCE	EQ 0.25MG BASE/ML	A216897	001	Jul 25, 2023	Aug	CAHN
>A>	AP	STERISCIENCE SPECCLTS	EQ 0.25MG BASE/ML	A216897	001	Jul 25, 2023	Aug	CAHN

CARISOPRODOL

TABLET; ORAL  
CARISOPRODOL

>A>	@ ALLIED	350MG	A211789	001	Oct 20, 2021	Aug	CAHN
>D>	@ MLV	350MG	A211789	001	Oct 20, 2021	Aug	CAHN
	@	350MG	A211789	001	Oct 20, 2021	Jul	DISC

CARMUSTINE

INJECTABLE; INJECTION  
CARMUSTINE

@ NORVIUM BIOSCIENCE 100MG/VIAL

A215368 001 Mar 03, 2023 Jun CAHN

POWDER; INTRAVENOUS  
CARMUSTINE

+ @ ACCORD HLTHCARE 50MG/VIAL  
+ @ 300MG/VIAL

N215000 001 May 16, 2022 May DISC  
N215000 002 May 16, 2022 May DISC

CARVEDILOL

TABLET; ORAL  
CARVEDILOL

>D>	@ ACI	3.125MG	A078786	001	Dec 22, 2009	Aug	CAHN
>D>	@	6.25MG	A078786	002	Dec 22, 2009	Aug	CAHN
>D>	@	12.5MG	A078786	003	Dec 22, 2009	Aug	CAHN
>D>	@	25MG	A078786	004	Dec 22, 2009	Aug	CAHN
>A>	@ MLV	3.125MG	A078786	001	Dec 22, 2009	Aug	CAHN
>A>	@	6.25MG	A078786	002	Dec 22, 2009	Aug	CAHN
>A>	@	12.5MG	A078786	003	Dec 22, 2009	Aug	CAHN
>A>	@	25MG	A078786	004	Dec 22, 2009	Aug	CAHN
	@ MYLAN	3.125MG	A077316	001	Sep 05, 2007	Apr	DISC
	@ SUN PHARM INDS LTD	3.125MG	A076989	001	Sep 05, 2007	Jan	DISC
	@	6.25MG	A076989	002	Sep 05, 2007	Jan	DISC
	@	12.5MG	A076989	003	Sep 05, 2007	Jan	DISC
	@	25MG	A076989	004	Sep 05, 2007	Jan	DISC
	COREG						
AB	+ WAYLIS THERAP	3.125MG	N020297	004	May 29, 1997	Apr	CAHN
AB	+	6.25MG	N020297	003	Sep 14, 1995	Apr	CAHN
AB	+!	12.5MG	N020297	002	Sep 14, 1995	Apr	CAHN
AB	+	25MG	N020297	001	Sep 14, 1995	Apr	CAHN

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL  
COREG CR

AB	+ WAYLIS THERAP	10MG	N022012	001	Oct 20, 2006	Apr	CAHN
AB	+	20MG	N022012	002	Oct 20, 2006	Apr	CAHN
AB	+!	40MG	N022012	003	Oct 20, 2006	Apr	CAHN
AB	+	80MG	N022012	004	Oct 20, 2006	Apr	CAHN

CASPOFUNGIN ACETATE

POWDER; INTRAVENOUS  
CASPOFUNGIN ACETATE

AP	AREVA PHARMS	50MG/VIAL	A211263	001	Oct 01, 2021	Mar	CAHN
AP		70MG/VIAL	A211263	002	Oct 01, 2021	Mar	CAHN

CEFAZOLIN SODIUM

INJECTABLE; INJECTION  
CEFAZOLIN SODIUM

QILU EQ 3GM BASE/VIAL

A203661 003 Jan 24, 2024 Jan NEWA

SOLUTION; INTRAVENOUS  
CEFAZOLIN IN DEXTROSE

+! BAXTER HLTHCARE CORP EQ 1GM BASE/50ML (EQ 20MG BASE/ML)  
+! EQ 2GM BASE/100ML (EQ 20MG BASE/ML)  
+! EQ 3GM BASE/150ML (EQ 20MG

N207131 002 Feb 01, 2021 May CTNA  
N207131 001 Aug 07, 2015 May CTNA  
N207131 003 May 31, 2024 May NEWA

SOLUTION; INTRAVENOUS  
CEFAZOLIN IN DEXTROSE

BASE/ML)

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER

	+	!	B BRAUN	EQ 1GM BASE/VIAL	N050821	001	May 06, 2010	Jul	CHRS
	+			EQ 1GM BASE/VIAL	N050821	001	May 06, 2010	Jul	CRLD
	+	!		EQ 2GM BASE/VIAL	N050821	002	May 06, 2010	Jul	CHRS
	+			EQ 2GM BASE/VIAL	N050821	002	May 06, 2010	Jul	CRLD
			CEFEPIME HYDROCHLORIDE						
			@ CHARTWELL RX	EQ 500MG BASE/VIAL	A090291	001	Dec 21, 2010	Jun	CAHN
			@	EQ 1GM BASE/VIAL	A090291	002	Dec 21, 2010	Jun	CAHN
			@	EQ 2GM BASE/VIAL	A090291	003	Dec 21, 2010	Jun	CAHN
AP			HIKMA	EQ 1GM BASE/VIAL	A214402	001	May 22, 2024	May	NEWA
AP				EQ 2GM BASE/VIAL	A214402	002	May 22, 2024	May	NEWA

POWDER; INTRAVENOUS

CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER

! SAMSON MEDCL EQ 100GM BASE A209408 001 Aug 21, 2018 Apr CHRS

CEFEPIME HYDROCHLORIDE; ENMETAZOBACTAM

POWDER; INTRAVENOUS

EXBLIFEP

	+	@	ALLECRA THERAPS	EQ 2GM BASE/VIAL; 0.5GM/VIAL	N216165	001	Feb 22, 2024	May	DISC
	+	!		EQ 2GM BASE/VIAL; 0.5GM/VIAL	N216165	001	Feb 22, 2024	Feb	NEWA

CEFIXIME

FOR SUSPENSION; ORAL

CEFIXIME

		@	CHARTWELL RX	100MG/5ML	A206144	001	Nov 17, 2017	Jul	CAHN
		@		200MG/5ML	A206144	002	Nov 17, 2017	Jul	CAHN

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CLAFORAN

	+	@	STERIMAX	EQ 500MG BASE/VIAL	N050547	001		Jan	CAHN
	+	@		EQ 1GM BASE/VIAL	N050547	002		Jan	CAHN
	+	@		EQ 2GM BASE/VIAL	N050547	003		Jan	CAHN
	+	@		EQ 10GM BASE/VIAL	N050547	004	Dec 29, 1983	Jan	CAHN
			CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER						
		@	STERIMAX	EQ 20MG BASE/ML	N050596	002	May 20, 1985	Jan	CAHN
		@		EQ 40MG BASE/ML	N050596	004	May 20, 1985	Jan	CAHN
			CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
		@	STERIMAX	EQ 20MG BASE/ML	N050596	001	May 20, 1985	Jan	CAHN
		@		EQ 40MG BASE/ML	N050596	003	May 20, 1985	Jan	CAHN

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

CEFOTAN

AP	+		PAI HOLDINGS PHARM	EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Feb	CMFD
AP	+			EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Feb	CMFD
			CEFOTETAN						
AP	!		FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A065374	001	Aug 09, 2007	Feb	CTEC
AP	!			EQ 2GM BASE/VIAL	A065374	002	Aug 09, 2007	Feb	CTEC

CEFOXITIN SODIUM

INJECTABLE; INJECTION

MEFOXIN

		@	NORVIUM BIOSCIENCE	EQ 1GM BASE/VIAL	A062757	001	Jan 08, 1987	Jul	CAHN
	+	@		EQ 1GM BASE/VIAL	N050517	001		Jul	CAHN
		@		EQ 2GM BASE/VIAL	A062757	002	Jan 08, 1987	Jul	CAHN
	+	@		EQ 2GM BASE/VIAL	N050517	002		Jul	CAHN
	+	@		EQ 10GM BASE/VIAL	N050517	003		Jul	CAHN
			MEFOXIN IN PLASTIC CONTAINER						
		@	NORVIUM BIOSCIENCE	EQ 20MG BASE/ML	A063182	001	Jan 25, 1993	Jul	CAHN
		@		EQ 40MG BASE/ML	A063182	002	Jan 25, 1993	Jul	CAHN

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL  
 CEFPODOXIME PROXETIL  
 @ CHARTWELL RX EQ 50MG BASE/5ML  
 @ EQ 100MG BASE/5ML

A 090031 001 Jan 14, 2009 Jul CAHN  
 A 090031 002 Jan 14, 2009 Jul CAHN

CEFPROZIL

TABLET; ORAL  
 CEFPROZIL

AB ALKEM LABS LTD 250MG A 090857 001 Apr 09, 2024 Mar NEWA  
 AB 500MG A 090857 002 Apr 09, 2024 Mar NEWA

>D> CEFTOBIPROLE MEDOCARIL SODIUM

>D> POWDER; INTRAVENOUS  
 >D> ZEVTERA

>D> +! BASILEA PHARM ALLSCH 667MG/VIAL N218275 001 Apr 03, 2024 Aug DISC  
 >A> + @ 667MG/VIAL N218275 001 Apr 03, 2024 Aug DISC  
 +! 667MG/VIAL N218275 001 Apr 03, 2024 Apr NEWA

CEFTRIAZONE SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS  
 CEFTRIAZONE

AP @ DEVA HOLDING AS EQ 250MG BASE/VIAL A 210197 001 Jan 12, 2024 Jul DISC  
 EQ 250MG BASE/VIAL A 210197 001 Jan 12, 2024 Jan NEWA  
 @ EQ 500MG BASE/VIAL A 210197 002 Jan 12, 2024 Jul DISC  
 AP EQ 500MG BASE/VIAL A 210197 002 Jan 12, 2024 Jan NEWA  
 @ EQ 1GM BASE/VIAL A 210197 003 Jan 12, 2024 Jul DISC  
 AP EQ 1GM BASE/VIAL A 210197 003 Jan 12, 2024 Jan NEWA  
 @ EQ 2GM BASE/VIAL A 210197 004 Jan 12, 2024 Jul DISC  
 AP EQ 2GM BASE/VIAL A 210197 004 Jan 12, 2024 Jan NEWA

CELECOXIB

SOLUTION; ORAL  
 ELYXYB

+! SCILEX PHARMS 25MG/ML N212157 001 May 05, 2020 Jun CAHN

CETIRIZINE HYDROCHLORIDE

SOLUTION; ORAL  
 CETIRIZINE HYDROCHLORIDE

AA @ ACTAVIS MID ATLANTIC 5MG/5ML A 078617 001 Feb 02, 2010 Feb CDFR  
 AA AMNEAL PHARMS 5MG/5ML A 090766 001 Oct 07, 2009 Feb CDFR  
 AA APOZEAL PHARMS 5MG/5ML A 078870 001 Apr 27, 2009 Jul CMFD  
 @ 5MG/5ML A 078870 001 Apr 27, 2009 Feb CDFR  
 AA @ AUROBINDO PHARMA LTD 5MG/5ML A 090751 001 Dec 16, 2009 Feb CDFR  
 AA BAJAJ 5MG/5ML A 090191 001 Nov 12, 2009 Feb CDFR  
 AA BIONPHARMA 5MG/5ML A 078488 001 Oct 06, 2008 Feb CDFR  
 AA CHARTWELL MOLECULAR 5MG/5ML A 078876 001 May 11, 2012 Feb CDFR  
 @ LANNETT CO INC 5MG/5ML A 078496 001 Sep 25, 2009 Feb CDFR  
 AA ! PADAGIS US 5MG/5ML A 078398 001 Jun 17, 2008 Feb CDFR  
 AA PHARM ASSOC 5MG/5ML A 078412 001 Jun 18, 2008 Feb CDFR  
 @ RANBAXY LABS LTD 5MG/5ML A 077472 001 Jun 18, 2008 Feb CDFR  
 AA TARO 5MG/5ML A 076601 001 Jun 20, 2008 Feb CDFR  
 @ TEVA PHARMS 5MG/5ML A 077279 001 May 27, 2008 Mar DISC  
 AA 5MG/5ML A 077279 001 May 27, 2008 Feb CDFR  
 @ WOCKHARDT 5MG/5ML A 078757 001 Aug 28, 2009 Feb CDFR  
 ZYRTEC  
 @ J AND J CONSUMER INC 5MG/5ML N 020346 001 Sep 27, 1996 Feb CDFR  
 SYRUP; ORAL  
 CETIRIZINE HYDROCHLORIDE  
 AA PHARM ASSOC 5MG/5ML A 078412 001 Jun 18, 2008 Jan CMFD

CETRORELIX ACETATE

POWDER; SUBCUTANEOUS  
 CETRORELIX ACETATE

AP GLAND EQ 0.25MG BASE/VIAL A 218150 001 Apr 25, 2024 Apr NEWA  
 AP LIVZON GRP EQ 0.25MG BASE/VIAL A 214540 001 Apr 24, 2024 Apr NEWA  
 AP QILU EQ 0.25MG BASE/VIAL A 217776 001 Apr 16, 2024 Apr NEWA

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

CHLORAMPHENICOL SODIUM SUCCINATE

@ FRESENIUS KABI USA EQ 1GM BASE/VIAL

A062365 001 Aug 25, 1982 Feb DISC

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE

AB WINDER LABS LLC 5MG; 2.5MG

A212344 001 Jul 08, 2024 Jun NEWA

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

>D> @ SAPTALIS PHARMS 0.12%

A074356 001 May 07, 1996 Aug CAHN

@ 0.12%

A074356 001 May 07, 1996 Jun CAHN

>A> @ SCIEGEN PHARMS INC 0.12%

A074356 001 May 07, 1996 Aug CAHN

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION

CHLOROTHIAZIDE SODIUM

@ RK PHARMA EQ 500MG BASE/VIAL

A202493 001 Jun 18, 2014 Mar DISC

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHLORPROMAZINE HYDROCHLORIDE

AP DR REDDYS 25MG/ML

A080365 001 Apr CMFD

AP +! HIKMA 25MG/ML

A083329 001 Jun CAHN

AP ZYDUS PHARMS 25MG/ML

A217275 001 Mar 13, 2024 Mar NEWA

SYRUP; ORAL

SONAZINE

@ CHARTWELL RX 10MG/5ML

A083040 001 May CAHN

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

@ CHARTWELL RX 10MG

A080439 001 Jul CAHN

@ 25MG

A080439 002 Jul CAHN

@ 50MG

A080439 003 Jul CAHN

@ 100MG

A080439 004 Jul CAHN

@ 200MG

A080439 005 Jul CAHN

AB ZAMEER PHARMS 10MG

A212630 001 Nov 29, 2021 Feb CAHN

AB 25MG

A212630 002 Nov 29, 2021 Feb CAHN

AB 50MG

A212630 003 Nov 29, 2021 Feb CAHN

AB 100MG

A212630 004 Nov 29, 2021 Feb CAHN

AB 200MG

A212630 005 Nov 29, 2021 Feb CAHN

>D> AB ZYDUS 10MG

A213368 001 Jan 17, 2020 Aug CAHN

>D> AB 25MG

A213368 002 Jan 17, 2020 Aug CAHN

>D> AB 50MG

A213368 003 Jan 17, 2020 Aug CAHN

>D> AB 100MG

A213368 004 Jan 17, 2020 Aug CAHN

>D> AB 200MG

A213368 005 Jan 17, 2020 Aug CAHN

>A> AB ZYDUS LIFESCIENCES 10MG

A213368 001 Jan 17, 2020 Aug CAHN

>A> AB 25MG

A213368 002 Jan 17, 2020 Aug CAHN

>A> AB 50MG

A213368 003 Jan 17, 2020 Aug CAHN

>A> AB 100MG

A213368 004 Jan 17, 2020 Aug CAHN

>A> AB 200MG

A213368 005 Jan 17, 2020 Aug CAHN

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

>D> @ APTAPHARMA INC 375MG

A212053 001 Sep 14, 2020 Aug CAHN

@ 375MG

A212053 001 Sep 14, 2020 Apr DISC

>D> @ 750MG

A212053 002 Sep 14, 2020 Aug CAHN

@ 750MG

A212053 002 Sep 14, 2020 Apr DISC

AB ENDO OPERATIONS 375MG

A212743 002 Apr 29, 2021 Apr CAHN

AB 750MG

A212743 001 Nov 02, 2020 Apr CAHN

>D> AA GRAVITI PHARMS 250MG

A216925 001 Aug 09, 2023 Aug CAHN

AA HAVIX 500MG

A210961 001 Jan 22, 2024 Jan NEWA

>A> @ I3 PHARMS 375MG

A212053 001 Sep 14, 2020 Aug CAHN

>A> @ 750MG

A212053 002 Sep 14, 2020 Aug CAHN

>A> AA RISING 250MG

A216925 001 Aug 09, 2023 Aug CAHN

AA SENORES PHARMS 250MG

A215158 001 Jul 29, 2021 Feb CAHN

AA 500MG

A210961 001 Jan 22, 2024 Feb CAHN

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE LIGHT

AB	ENDO OPERATIONS	EQ 4GM RESIN/PACKET	A077203	001	Aug 26, 2005	May	CAHN
AB		EQ 4GM RESIN/SCOOPFUL	A077203	002	Aug 26, 2005	May	CAHN

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACID

	@ ANCHEN PHARMS	EQ 45MG FENOFIBRIC ACID	A201573	002	Jul 18, 2013	Mar	DISC	
	@	EQ 135MG FENOFIBRIC ACID	A201573	001	Jul 18, 2013	Mar	DISC	
	@ ENDO OPERATIONS	EQ 45MG FENOFIBRIC ACID	A201573	002	Jul 18, 2013	May	CAHN	
	@	EQ 135MG FENOFIBRIC ACID	A201573	001	Jul 18, 2013	May	CAHN	
>D>	AB	GRAVITI PHARMS	EQ 45MG FENOFIBRIC ACID	A211626	001	Jul 18, 2019	Aug	CAHN
>D>	AB		EQ 135MG FENOFIBRIC ACID	A211626	002	Jul 18, 2019	Aug	CAHN
>D>	AB	MACLEODS PHARMS LTD	EQ 45MG FENOFIBRIC ACID	A207796	001	Feb 08, 2024	Aug	DISC
>A>	@	EQ 45MG FENOFIBRIC ACID	A207796	001	Feb 08, 2024	Aug	DISC	
	AB		EQ 45MG FENOFIBRIC ACID	A207796	001	Feb 08, 2024	Feb	NEWA
>D>	AB		EQ 135MG FENOFIBRIC ACID	A207796	002	Feb 08, 2024	Aug	DISC
>A>	@	EQ 135MG FENOFIBRIC ACID	A207796	002	Feb 08, 2024	Aug	DISC	
	AB		EQ 135MG FENOFIBRIC ACID	A207796	002	Feb 08, 2024	Feb	NEWA
>A>	AB	RISING	EQ 45MG FENOFIBRIC ACID	A211626	001	Jul 18, 2019	Aug	CAHN
>A>	AB		EQ 135MG FENOFIBRIC ACID	A211626	002	Jul 18, 2019	Aug	CAHN
>D>	AB	TWI PHARMS	EQ 45MG FENOFIBRIC ACID	A210469	001	Jul 05, 2019	Aug	DISC
>A>	@	EQ 45MG FENOFIBRIC ACID	A210469	001	Jul 05, 2019	Aug	DISC	
	AB		EQ 45MG FENOFIBRIC ACID	A210469	001	Jul 05, 2019	Mar	CAHN
>D>	AB		EQ 135MG FENOFIBRIC ACID	A210469	002	Jul 05, 2019	Aug	DISC
>A>	@	EQ 135MG FENOFIBRIC ACID	A210469	002	Jul 05, 2019	Aug	DISC	
	AB		EQ 135MG FENOFIBRIC ACID	A210469	002	Jul 05, 2019	Mar	CAHN

CICLESONIDE

AEROSOL, METERED; NASAL

ZETONNA

>D>								
>D>	+!	COVIS	0.037MG/INH	N202129	001	Jan 20, 2012	Aug	DISC
>A>	+ @		0.037MG/INH	N202129	001	Jan 20, 2012	Aug	DISC

CICLOPIROX

CREAM; TOPICAL

CICLOPIROX

AB	TARO	0.77%	A076790	001	Apr 12, 2005	Jan	CAHN
	@ COSETTE	8%	A078233	001	Sep 18, 2007	Jul	DISC
	@ HIKMA	8%	A078270	001	Sep 18, 2007	Mar	DISC

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

@ RISING

50MG

A077323 002 Apr 20, 2006 Feb CAHN

@

100MG

A077323 001 Apr 20, 2006 Feb CAHN

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE

@ COSETTE

EQ 300MG BASE/2ML

A074296 001 Mar 28, 1997 Jun CAHN

@ ENDO OPERATIONS

EQ 300MG BASE/2ML

A074005 001 Aug 31, 1994 May CAHN

@

EQ 300MG BASE/2ML

A074428 001 Apr 25, 1996 May CAHN

SOLUTION; ORAL

CIMETIDINE HYDROCHLORIDE

@ PAI HOLDINGS PHARM

EQ 300MG BASE/5ML

A074664 001 Oct 28, 1997 Feb DISC

@ PHARM ASSOC

EQ 300MG BASE/5ML

A074553 001 Jan 27, 1997 Feb DISC

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CIPROFLOXACIN HYDROCHLORIDE

@ THE J MOLNER

EQ 0.3% BASE

A076754 001 Jun 09, 2004 Jun CAHN

SOLUTION/DROPS; OTIC

CETRAXAL

+! KEY THERAP

EQ 0.2% BASE

N021918 001 May 01, 2009 Apr CAHN

## TABLET; ORAL

## CIPROFLOXACIN HYDROCHLORIDE

AB	AIPING PHARM INC	EQ 250MG BASE	A076593	002	Jun 09, 2004	Apr	CMFD
AB		EQ 500MG BASE	A076593	003	Jun 09, 2004	Apr	CMFD
AB		EQ 750MG BASE	A076593	004	Jun 09, 2004	Apr	CMFD

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

## TABLET, EXTENDED RELEASE; ORAL

## CIPROFLOXACIN EXTENDED RELEASE

	@ ANCHEN PHARMS	212.6MG;EQ 287.5MG BASE	A078166	002	Nov 27, 2007	Mar	DISC
	@	425.2MG;EQ 574.9MG BASE	A078166	001	Nov 27, 2007	Mar	DISC
	! DR REDDYS LABS LTD	425.2MG;EQ 574.9MG BASE	A077701	001	Mar 26, 2007	Mar	CTEC
AB	!	425.2MG;EQ 574.9MG BASE	A077701	001	Mar 26, 2007	Mar	CHRS
	@ ENDO OPERATIONS	212.6MG;EQ 287.5MG BASE	A078166	002	Nov 27, 2007	May	CAHN
	@	425.2MG;EQ 574.9MG BASE	A078166	001	Nov 27, 2007	May	CAHN

CIPROFLOXACIN; DEXAMETHASONE

## SUSPENSION/DROPS; OTIC

## CIPROFLOXACIN; DEXAMETHASONE

AB	AMNEAL	0.3%;0.1%	A216501	001	Mar 22, 2024	Mar	NEWA
----	--------	-----------	---------	-----	--------------	-----	------

CISATRACURIUM BESYLATE

## INJECTABLE; INJECTION

## CISATRACURIUM BESYLATE

	@ CAPLIN	EQ 2MG BASE/ML	A217725	001	Jun 09, 2023	Apr	DISC
	@	EQ 10MG BASE/ML	A217725	002	Jun 09, 2023	Apr	DISC
AP	HAINAN POLY	EQ 2MG BASE/ML	A216538	001	Mar 08, 2024	Mar	NEWA
AP	! MEITHEAL	EQ 2MG BASE/ML	A211668	001	Apr 25, 2019	Apr	CHRS
AP	!	EQ 2MG BASE/ML	A211669	001	Apr 25, 2019	Apr	CHRS
AP	!	EQ 10MG BASE/ML	A211668	002	Apr 25, 2019	Apr	CHRS
AP	PIRAMAL CRITICAL	EQ 2MG BASE/ML	A215516	003	Dec 14, 2022	Mar	CMS1
	CISATRACURIUM BESYLATE PRESERVATIVE FREE						
>A>	AP HAINAN POLY	EQ 2MG BASE/ML	A216539	001	Aug 27, 2024	Aug	NEWA
>A>	AP	EQ 10MG BASE/ML	A216539	002	Aug 27, 2024	Aug	NEWA
	NIMBEX						
	+ @ ABBVIE	EQ 2MG BASE/ML	N020551	001	Dec 15, 1995	Apr	DISC
	NIMBEX PRESERVATIVE FREE						
	+ @ ABBVIE	EQ 2MG BASE/ML	N020551	003	Dec 15, 1995	Apr	DISC
	+ @	EQ 10MG BASE/ML	N020551	002	Dec 15, 1995	Apr	DISC

CISPLATIN

## INJECTABLE; INJECTION

## CISPLATIN

AP	QILU	1MG/ML	A218868	001	May 10, 2024	May	NEWA
----	------	--------	---------	-----	--------------	-----	------

CITALOPRAM HYDROBROMIDE

## TABLET; ORAL

## CITALOPRAM HYDROBROMIDE

AB	APOTEX	EQ 10MG BASE	A077046	001	Nov 24, 2004	Jan	CAHN
AB		EQ 20MG BASE	A077046	002	Nov 24, 2004	Jan	CAHN
AB		EQ 40MG BASE	A077046	003	Nov 24, 2004	Jan	CAHN
>A>	@ CHARTWELL RX	EQ 10MG BASE	A077040	001	Aug 17, 2005	Aug	CAHN
>A>	@	EQ 20MG BASE	A077040	002	Aug 17, 2005	Aug	CAHN
>A>	@	EQ 40MG BASE	A077040	003	Aug 17, 2005	Aug	CAHN
	@ COSETTE	EQ 10MG BASE	A077048	001	Nov 16, 2004	Apr	DISC
	@	EQ 20MG BASE	A077048	002	Nov 16, 2004	Apr	DISC
	@	EQ 40MG BASE	A077048	003	Nov 16, 2004	Apr	DISC
>D>	@ FOSUN PHARMA	EQ 10MG BASE	A077040	001	Aug 17, 2005	Aug	CAHN
>D>	@	EQ 20MG BASE	A077040	002	Aug 17, 2005	Aug	CAHN
>D>	@	EQ 40MG BASE	A077040	003	Aug 17, 2005	Aug	CAHN
	@ TARO	EQ 10MG BASE	A077278	001	Mar 22, 2006	Jan	CAHN
	@	EQ 20MG BASE	A077278	002	Mar 22, 2006	Jan	CAHN
	@	EQ 40MG BASE	A077278	003	Mar 22, 2006	Jan	CAHN

CLADRIBINE

## INJECTABLE; INJECTION

## CLADRIBINE

	@ NORVIUM BIOSCIENCE	1MG/ML	A200510	001	Oct 06, 2011	Jun	CAHN
--	----------------------	--------	---------	-----	--------------	-----	------

CLEMASTINE FUMARATE

SYRUP;ORAL

CLEMASTINE FUMARATE

>D>	!	GENUS	EQ 0.5MG BASE/5ML	A 073399	001	Jun 30, 1994	Aug CTEC
>A>	AA	!	EQ 0.5MG BASE/5ML	A 073399	001	Jun 30, 1994	Aug CTEC
		@ NEW HEIGHTS	EQ 0.5MG BASE/5ML	A 074884	001	Dec 17, 1997	Jan CAHN
>D>		@ NEW HEIGHTSRX	EQ 0.5MG BASE/5ML	A 074884	001	Dec 17, 1997	Aug CMFD
>A>	AA		EQ 0.5MG BASE/5ML	A 074884	001	Dec 17, 1997	Aug CMFD
		@	EQ 0.5MG BASE/5ML	A 074884	001	Dec 17, 1997	Jul CAHN

TABLET;ORAL

CLEMASTINE FUMARATE

	@	OMNIVIUM PHARMS	2.68MG	A 073459	001	Oct 31, 1993	Jun CAHN
--	---	-----------------	--------	----------	-----	--------------	----------

CLINDAMYCIN HYDROCHLORIDE

CAPSULE;ORAL

CLINDAMYCIN HYDROCHLORIDE

	@	COSETTE	EQ 150MG BASE	A 063029	001	Sep 20, 1989	Apr DISC
	@		EQ 300MG BASE	A 063029	002	Aug 05, 2005	Apr DISC

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

	@	EXTROVIS	EQ 75MG BASE/5ML	A 203063	001	May 25, 2016	Jun CAHN
--	---	----------	------------------	----------	-----	--------------	----------

CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE

AB1		ALEMBIC	EQ 1% BASE	A 212466	001	Apr 02, 2024	Mar NEWA
	@	AMNEAL	EQ 1% BASE	A 215219	001	Nov 03, 2022	Feb DISC

GEL;VAGINAL

XACIATO

	+	ORGANON LLC	EQ 2% BASE	N 215650	001	Dec 07, 2021	Jan CAHN
--	---	-------------	------------	----------	-----	--------------	----------

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

	@	ENDO OPERATIONS	EQ 1% BASE	A 203343	001	May 29, 2015	Apr CAHN
--	---	-----------------	------------	----------	-----	--------------	----------

CLOBAZAM

TABLET;ORAL

CLOBAZAM

	@	BRECKENRIDGE	20MG	A 209308	002	Oct 22, 2018	Jan DISC
--	---	--------------	------	----------	-----	--------------	----------

CLOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

CLOBETASOL PROPIONATE

AB2		TARO	0.05%	A 208563	001	Mar 14, 2024	Mar NEWA
-----	--	------	-------	----------	-----	--------------	----------

CREAM;TOPICAL

CLOBETASOL PROPIONATE

	@	COSETTE	0.05%	A 074139	001	Aug 03, 1994	Apr DISC
--	---	---------	-------	----------	-----	--------------	----------

CORMAX

	@	HIKMA	0.05%	A 074220	001	May 16, 1997	Mar DISC
--	---	-------	-------	----------	-----	--------------	----------

GEL;TOPICAL

EMBELINE

	@	HIKMA	0.05%	A 076141	001	Apr 12, 2002	Mar DISC
--	---	-------	-------	----------	-----	--------------	----------

OINTMENT;TOPICAL

EMBELINE

	@	HIKMA	0.05%	A 074221	001	Mar 31, 1995	Mar DISC
--	---	-------	-------	----------	-----	--------------	----------

SHAMPOO;TOPICAL

CLOBETASOL PROPIONATE

	@	HIKMA	0.05%	A 209871	001	Oct 27, 2017	Mar DISC
--	---	-------	-------	----------	-----	--------------	----------

SOLUTION;TOPICAL

CLOBETASOL PROPIONATE

	@	COSETTE	0.05%	A 074331	001	Dec 15, 1995	Apr DISC
--	---	---------	-------	----------	-----	--------------	----------

AT		ENCUBE	0.05%	A 076977	001	Aug 05, 2005	May CMFD
----	--	--------	-------	----------	-----	--------------	----------

EMBELINE

	@	HIKMA	0.05%	A 074222	001	Dec 06, 1995	Mar DISC
--	---	-------	-------	----------	-----	--------------	----------

SUSPENSION/DROPS;OPHTHALMIC

CLOBETASOL PROPIONATE

	+	EYENOVIA	0.05%	N 218158	001	Mar 04, 2024	May CAHN
--	---	----------	-------	----------	-----	--------------	----------

	+	FORMOSA	0.05%	N 218158	001	Mar 04, 2024	Mar NEWA
--	---	---------	-------	----------	-----	--------------	----------



CLOCORTOLONE PIVALATE

CREAM;TOPICAL  
CLODERM

AB	+!	LEGACY PHARMA	0.1%	N017765	001			Apr	CAHN
----	----	---------------	------	---------	-----	--	--	-----	------

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL  
CLOMIPRAMINE HYDROCHLORIDE

AB		CHARTWELL RX	25MG	A074364	001	Mar 29, 1996	Mar	CAHN
AB			50MG	A074364	002	Mar 29, 1996	Mar	CAHN
AB			75MG	A074364	003	Mar 29, 1996	Mar	CAHN
	@	MYLAN	25MG	A074947	001	Apr 30, 1998	May	DISC
	@		50MG	A074947	002	Apr 30, 1998	May	DISC
	@		75MG	A074947	003	Apr 30, 1998	May	DISC
	@	RK PHARMA	25MG	A213221	001	Jun 22, 2020	Mar	DISC
	@		50MG	A213221	002	Jun 22, 2020	Mar	DISC
	@		75MG	A213221	003	Jun 22, 2020	Mar	DISC

CLONAZEPAM

TABLET, ORALLY DISINTEGRATING;ORAL  
CLONAZEPAM

AB		ENDO OPERATIONS	0.125MG	A077171	001	Aug 03, 2005	Apr	CAHN
AB			0.25MG	A077171	002	Aug 03, 2005	Apr	CAHN
AB			0.5MG	A077171	003	Aug 03, 2005	Apr	CAHN
AB	!		1MG	A077171	004	Aug 03, 2005	Apr	CAHN
AB			2MG	A077171	005	Aug 03, 2005	Apr	CAHN

CLONIDINE HYDROCHLORIDE

SUSPENSION, EXTENDED RELEASE;ORAL  
ONYDA XR

+!		TRIS PHARMA INC	0.1MG/ML	N217645	001	May 24, 2024	May	NEWA
----	--	-----------------	----------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE;ORAL  
CLONIDINE HYDROCHLORIDE

@		ANCHEN PHARMS	0.1MG	A202984	001	Sep 30, 2013	Mar	DISC
@		BLUEPHARMA INDUSTRIA	0.1MG	A211433	001	Oct 12, 2018	Jan	CAHN
@		ENDO OPERATIONS	0.1MG	A202983	001	Apr 02, 2014	May	CAHN
@			0.1MG	A202984	001	Sep 30, 2013	May	CAHN
@			0.2MG	A202983	002	Apr 02, 2014	May	CAHN
@			0.2MG	A202984	002	Sep 30, 2013	May	CAHN
@		SOMERSET THERAPS LLC	0.1MG	A211433	001	Oct 12, 2018	May	CAHN

CLOPIDOGREL BISULFATE

TABLET;ORAL  
CLOPIDOGREL BISULFATE

@		ACCORD HLTHCARE	EQ 75MG BASE	A202925	001	Mar 27, 2013	May	DISC
@			EQ 300MG BASE	A202925	002	Mar 27, 2013	May	DISC
AB		DR REDDYS LABS LTD	EQ 75MG BASE	A091023	002	Aug 05, 2024	Jul	NEWA

CLOTTRIMAZOLE

SOLUTION;TOPICAL  
CLOTTRIMAZOLE

>D>	AT	TASMAN PHARMA	1%	A212281	001	Jul 25, 2019	Aug	CAHN
>A>	AT	TRUPHARMA	1%	A212281	001	Jul 25, 2019	Aug	CAHN

TROCHE/LOZENGE;ORAL  
CLOTTRIMAZOLE

AB		THINQ PHARM-CRO PVT	10MG	A215641	001	Feb 29, 2024	Feb	NEWA
----	--	---------------------	------	---------	-----	--------------	-----	------

CLOZAPINE

TABLET;ORAL  
CLOZARIL

>D>	AB	+	HERITAGE LIFE	50MG	N019758	003	May 20, 2019	Aug	DISC
>A>		+	@	50MG	N019758	003	May 20, 2019	Aug	DISC
>D>	AB	+		200MG	N019758	004	May 20, 2019	Aug	DISC
>A>		+	@	200MG	N019758	004	May 20, 2019	Aug	DISC

TABLET, ORALLY DISINTEGRATING;ORAL  
CLOZAPINE

AB		BARR LABS INC	150MG	A090308	004	Nov 25, 2015	Jun	CMS1
AB			200MG	A090308	005	Nov 25, 2015	Jun	CMS1

COBICISTATTABLET; ORAL  
COBICISTAT

AB	MYLAN LABS LTD	150MG	A209986	001	Feb 07, 2024	Jan	NFTG
	TYBOST						
AB	+! GILEAD SCIENCES INC	150MG	N203094	001	Sep 24, 2014	Jan	CFTG

COCAINE HYDROCHLORIDESOLUTION; NASAL  
GOPRELTO

+!	NODEN PHARMA	4%	N209963	001	Dec 14, 2017	Jan	CAHN
----	--------------	----	---------	-----	--------------	-----	------

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

AA	!	GENUS	10MG/5ML; 5MG/5ML; 6.25MG/5ML	A040660	001	Dec 07, 2006	Apr	CAHN
		@ HIKMA	10MG/5ML; 5MG/5ML; 6.25MG/5ML	A040674	001	Dec 23, 2014	Mar	DISC

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

@	HIKMA	10MG/5ML; 6.25MG/5ML	A040151	001	Aug 26, 1997	Mar	DISC
---	-------	----------------------	---------	-----	--------------	-----	------

COLCHICINECAPSULE; ORAL  
COLCHICINE

AB	ANNORA PHARMA	0.6MG	A217620	001	Apr 29, 2024	Apr	NEWA
AB	AUROBINDO PHARMA LTD	0.6MG	A215463	001	Apr 29, 2024	Apr	NEWA
AB	GRANULES	0.6MG	A210757	001	Apr 29, 2024	Apr	NEWA

TABLET; ORAL

COLCHICINE

AB	!	ENDO OPERATIONS	0.6MG	A203976	001	Aug 12, 2021	May	CHRS
		@ MYLAN	0.6MG	A209470	001	Sep 16, 2019	Apr	DISC
		COLCRYS						
		+ @ TAKEDA PHARMS USA	0.6MG	N022352	001	Jul 29, 2009	May	DISC

COLESEVELAM HYDROCHLORIDEFOR SUSPENSION; ORAL  
COLESEVELAM HYDROCHLORIDE

@	IMPAX	3.75GM/PACKET	A212886	001	Jan 18, 2023	May	DISC
---	-------	---------------	---------	-----	--------------	-----	------

COLESTIPOL HYDROCHLORIDEGRANULE; ORAL  
FLAVORED COLESTID

+ @	PFIZER	5GM/PACKET	N017563	001		Jun	DISC
+ @		5GM/SCOOPFUL	N017563	002		Jun	DISC

TABLET; ORAL

COLESTIPOL HYDROCHLORIDE

>A>	AB	EDENBRIDGE PHARMS	1GM	A217667	001	Aug 16, 2024	Aug	NEWA
-----	----	-------------------	-----	---------	-----	--------------	-----	------

COLISTIMETHATE SODIUMINJECTABLE; INJECTION  
COLISTIMETHATE SODIUM

AP	ADRASTEIA PHARMA	EQ 150MG BASE/VIAL	A064216	001	Feb 26, 1999	Jul	CAHN
----	------------------	--------------------	---------	-----	--------------	-----	------

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDESUSPENSION/DROPS; OTIC  
COLY-MYCIN S

+!	ENDO OPERATIONS	EQ 3MG BASE/ML; 10MG/ML; EQ 3.3MG BASE/ML; 0.5MG/ML	N050356	001		Apr	CAHN
----	-----------------	---	---------	-----	--	-----	------

COPPERSYSTEM; INTRAUTERINE  
PARAGARD T 380A

+!	COOPERSURGICAL	309MG/COPPER	N018680	001	Nov 15, 1984	Jun	CDFR
----	----------------	--------------	---------	-----	--------------	-----	------

CORTICOTROPIN

INJECTABLE; INJECTION  
ACTHAR GEL (AUTOINJECTOR)

+!	MALLINCKRODT ARD	40 UNITS/0.5ML	N008372	003	Feb 29, 2024	Mar	NEWA
+!		80 UNITS/ML	N008372	004	Feb 29, 2024	Mar	NEWA

COSYNTROPIN

INJECTABLE; INJECTION  
COSYNTROPIN

@	MYLAN INSTITUTIONAL	0.25MG/VIAL	A090574	001	Dec 17, 2009	May	DISC
---	---------------------	-------------	---------	-----	--------------	-----	------

CUPRIC CHLORIDE

INJECTABLE; INJECTION  
CUPRIC CHLORIDE

AP	RK PHARMA	EQ 0.4MG COPPER/ML	A217626	001	Apr 30, 2024	May	CAHN
AP	SOMERSET	EQ 0.4MG COPPER/ML	A216113	001	Apr 30, 2024	Apr	NEWA
AP	STIRA	EQ 0.4MG COPPER/ML	A217626	001	Apr 30, 2024	Apr	NEWA

CUPRIC SULFATE

INJECTABLE; INJECTION  
CUPRIC SULFATE

>D>	!	AM REGENT	EQ 0.4MG COPPER/ML	A216324	001	Dec 16, 2022	Aug	CTEC
>A>	AP	!	EQ 0.4MG COPPER/ML	A216324	001	Dec 16, 2022	Aug	CTEC
>A>	AP	APOTEX CORP	EQ 0.4MG COPPER/ML	A218745	001	Aug 19, 2024	Aug	NEWA

CYANOCOBALAMIN

GEL, METERED; NASAL  
NASCOBAL

@	ENDO OPERATIONS	0.5MG/INH	N019722	001	Nov 05, 1996	May	CAHN
---	-----------------	-----------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION  
CYANOCOBALAMIN

AP	@	EUGIA PHARMA	1MG/ML	A213874	001	Dec 08, 2020	Jun	DISC
		MANKIND PHARMA	1MG/ML	A217839	001	Jul 10, 2024	Jun	NEWA

SPRAY, METERED; NASAL  
CALOMIST

@	ENDO OPERATIONS	25MCG/SPRAY	N022102	001	Jul 27, 2007	May	CAHN
---	-----------------	-------------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION  
CYANOCOBALAMIN

AB	!	PADAGIS ISRAEL	0.5MG/SPRAY	A212458	001	Sep 09, 2020	Jul	CHRS
----	---	----------------	-------------	---------	-----	--------------	-----	------

NASCOBAL

+ @ ENDO OPERATIONS

AB	+	!	0.5MG/SPRAY	N021642	001	Jan 31, 2005	Jul	DISC
----	---	---	-------------	---------	-----	--------------	-----	------

NASCOBAL

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL  
CYCLOBENZAPRINE HYDROCHLORIDE

AB		MACLEODS PHARMS LTD	15MG	A207314	001	Jul 22, 2024	Jul	NEWA
AB			30MG	A207314	002	Jul 22, 2024	Jul	NEWA
>A>	AB	NOVAST LABS	15MG	A214732	001	Aug 27, 2024	Aug	NEWA
>A>	AB		30MG	A214732	002	Aug 27, 2024	Aug	NEWA

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

@	AIPING PHARM INC	5MG	A072854	002	Feb 03, 2006	Jun	CAHN
---	------------------	-----	---------	-----	--------------	-----	------

@		10MG	A072854	001	Nov 19, 1991	Jun	CAHN
---	--	------	---------	-----	--------------	-----	------

CYCLOPHOSPHAMIDE

CAPSULE; ORAL

CYCLOPHOSPHAMIDE

>D>	AB	ANIMA	25MG	A209872	001	May 07, 2018	Aug	CAHN
>D>	AB		50MG	A209872	002	May 07, 2018	Aug	CAHN
>A>	AB	KANCHAN HLTHCARE	25MG	A209872	001	May 07, 2018	Aug	CAHN
>A>	AB		50MG	A209872	002	May 07, 2018	Aug	CAHN

INJECTABLE; INJECTION

CYCLOPHOSPHAMIDE

AP		HIKMA	500MG/VIAL	A216958	001	Dec 18, 2023	Jan	CAHN
----	--	-------	------------	---------	-----	--------------	-----	------

AP			1GM/VIAL	A216958	002	Dec 18, 2023	Jan	CAHN
----	--	--	----------	---------	-----	--------------	-----	------

AP			2GM/VIAL	A216958	003	Dec 18, 2023	Jan	CAHN
----	--	--	----------	---------	-----	--------------	-----	------

SOLUTION; INTRAVENOUS

CYCLOPHOSPHAMIDE

+	!	AVYXA HOLDINGS	500MG/ML (500MG/ML)	N210852	001	Jun 07, 2023	Jun	CAHN
---	---	----------------	---------------------	---------	-----	--------------	-----	------

+	!		1GM/2ML (500MG/ML)	N210852	002	Jun 07, 2023	Jun	CAHN
---	---	--	--------------------	---------	-----	--------------	-----	------

SOLUTION; INTRAVENOUS  
CYCLOPHOSPHAMIDE

	+		2GM/4ML (500MG/ML)	N210852	003	Jun 07, 2023	Jun	CAHN
	+	@ BAXTER HLTHCARE CORP	500MG/2.5ML (200MG/ML)	N217651	001	Jun 28, 2023	Jan	CAHN
	+	@	1GM/5ML (200MG/ML)	N217651	002	Jun 28, 2023	Jan	CAHN
	+	DR REDDYS	500MG/2.5ML (200MG/ML)	N212501	001	Jul 30, 2020	Jun	CAHN
	+		1GM/5ML (200MG/ML)	N212501	002	Jul 30, 2020	Jun	CAHN
	+		2GM/10ML (200MG/ML)	N212501	003	Nov 19, 2021	Jun	CAHN

CYCLOSPORINE

EMULSION; OPTHALMIC  
CYCLOSPORINE

AB		DEVA HOLDING AS	0.05%	A209811	001	May 21, 2024	May	NEWA
AB		SAPTALIS PHARMS	0.05%	A211943	001	Jul 05, 2024	Jun	NEWA
		@ TEVA PHARMS USA INC	0.05%	A203880	001	Dec 14, 2023	Jun	DISC

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

CYPROHEPTADINE HYDROCHLORIDE

	@	PATRIN	2MG/5ML	A204823	001	Dec 27, 2016	Apr	DISC
	@	PHARM ASSOC	2MG/5ML	A091295	001	Mar 28, 2013	Feb	DISC

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

>A>	@	CHARTWELL RX	4MG	A086808	001		Aug	CAHN
>D>	@	FOSUN PHARMA	4MG	A086808	001		Aug	CAHN

CYSTEINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

ELCYS

	+	@ EXELA PHARMA	2500MG/50ML (50MG/ML)	N210660	002	Dec 04, 2023	Jan	DISC
--	---	----------------	-----------------------	---------	-----	--------------	-----	------

DABIGATRAN ETEXILATE MESYLATE

CAPSULE; ORAL

DABIGATRAN ETEXILATE MESYLATE

AB		ALEMBIC	EQ 75MG BASE	A215233	001	Jun 14, 2024	Jun	NEWA
>A>	AB		EQ 110MG BASE	A215233	003	Aug 12, 2024	Aug	NEWA
	AB		EQ 150MG BASE	A215233	002	Jun 14, 2024	Jun	NEWA
>A>	AB	ALKEM LABS LTD	EQ 110MG BASE	A208040	003	Sep 11, 2024	Aug	NEWA
>A>	AB	HETERO LABS LTD III	EQ 110MG BASE	A207961	003	Aug 13, 2024	Aug	NEWA
	AB	MSN	EQ 75MG BASE	A213879	001	May 22, 2024	May	NEWA
>A>	AB		EQ 110MG BASE	A213879	003	Aug 12, 2024	Aug	NEWA
	AB		EQ 150MG BASE	A213879	002	May 22, 2024	May	NEWA

DACTINOMYCIN

INJECTABLE; INJECTION

COSMEGEN

	+	@ RECORDATI RARE	0.5MG/VIAL	N050682	001		Jan	DISC
AP	!	EUGIA PHARMA	0.5MG/VIAL	A203385	001	Nov 09, 2017	Jan	CHRS

DALFAMPRIDINE

TABLET, EXTENDED RELEASE; ORAL

AMPYRA

AB	+	MERZ PHARMS GMBH	10MG	N022250	001	Jan 22, 2010	Jul	CAHN
----	---	------------------	------	---------	-----	--------------	-----	------

DANICOPAN

TABLET; ORAL

VOYDEYA

	+	ALEXION PHARMS INC	50MG	N218037	001	Mar 29, 2024	Mar	NEWA
	+		100MG	N218037	002	Mar 29, 2024	Mar	NEWA

DAPIPRAZOLE HYDROCHLORIDE

SOLUTION/DROPS; OPTHALMIC

DAPIPRAZOLE HYDROCHLORIDE

>A>	@	BARADAINA LLC	0.5%	A204902	001	May 30, 2019	Aug	CAHN
>D>	@	WOODWARD	0.5%	A204902	001	May 30, 2019	Aug	CAHN

DAPRODUSTAT

TABLET; ORAL

JESDUVROQ

+ @	GLAXOSMITHKLINE	1MG	N216951	001	Feb 01, 2023	May	DISC
+ @		2MG	N216951	002	Feb 01, 2023	May	DISC
+ @		4MG	N216951	003	Feb 01, 2023	May	DISC
+ @		6MG	N216951	004	Feb 01, 2023	May	DISC
+ @		8MG	N216951	005	Feb 01, 2023	May	DISC

DAPSONE

GEL; TOPICAL

DAPSONE

>A>	AB	ACRUX DDS	7.5%	A213636	001	Aug 26, 2024	Aug	NEWA
		@ PADAGIS ISRAEL	5%	A215087	001	Oct 31, 2023	Jan	DISC
		@	7.5%	A212657	001	Nov 01, 2023	Jan	DISC
	AB	TARO	5%	A209506	001	Oct 16, 2017	Jun	CAHN
	AB	ZYDUS	7.5%	A214019	001	May 08, 2024	Apr	NEWA
	AB	ZYDUS LIFESCIENCES	7.5%	A214019	001	May 08, 2024	May	CAHN

DAPTOMYCIN

POWDER; INTRAVENOUS

DAPTOMYCIN

>A>	AP	BIOCON PHARMA	500MG/VIAL	A217215	001	Aug 29, 2024	Aug	NEWA
	AP	FRESENIUS KABI USA	350MG/VIAL	A213396	001	Aug 01, 2024	Jul	NEWA

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

DARIFENACIN HYDROBROMIDE

		@ ENDO OPERATIONS	EQ 7.5MG BASE	A091190	001	Mar 13, 2015	May	CAHN
		@	EQ 15MG BASE	A091190	002	Mar 13, 2015	May	CAHN

DARUNAVIR

TABLET; ORAL

DARUNAVIR

	AB	ZYDUS LIFESCIENCES	600MG	A214085	001	Dec 13, 2023	May	CAHN
	AB		800MG	A214085	002	Dec 13, 2023	May	CAHN

DASATINIB

TABLET; ORAL

DASATINIB

>D>		@ APOTEX	20MG	A202103	001	Jun 10, 2016	Aug	CMFD
>A>	AB		20MG	A202103	001	Jun 10, 2016	Aug	CMFD
>D>		@	50MG	A202103	002	Jun 10, 2016	Aug	CMFD
>A>	AB		50MG	A202103	002	Jun 10, 2016	Aug	CMFD
>D>		@	70MG	A202103	003	Jun 10, 2016	Aug	CMFD
>A>	AB		70MG	A202103	003	Jun 10, 2016	Aug	CMFD
>D>		@	80MG	A203180	001	Nov 23, 2021	Aug	CMFD
>A>	AB		80MG	A203180	001	Nov 23, 2021	Aug	CMFD
>D>		@	100MG	A202103	004	Jun 10, 2016	Aug	CMFD
>A>	AB		100MG	A202103	004	Jun 10, 2016	Aug	CMFD
>D>		@	140MG	A203180	002	Nov 23, 2021	Aug	CMFD
>A>	AB		140MG	A203180	002	Nov 23, 2021	Aug	CMFD
		SPRYCEL						
>D>		+ BRISTOL MYERS SQUIBB	20MG	N021986	001	Jun 28, 2006	Aug	CTEC
>A>	AB		20MG	N021986	001	Jun 28, 2006	Aug	CTEC
>D>		+	50MG	N021986	002	Jun 28, 2006	Aug	CTEC
>A>	AB		50MG	N021986	002	Jun 28, 2006	Aug	CTEC
>D>		+	70MG	N021986	003	Jun 28, 2006	Aug	CTEC
>A>	AB		70MG	N021986	003	Jun 28, 2006	Aug	CTEC
>D>		+	80MG	N021986	005	Oct 28, 2010	Aug	CTEC
>A>	AB		80MG	N021986	005	Oct 28, 2010	Aug	CTEC
>D>		+!	100MG	N021986	004	May 30, 2008	Aug	CTEC
>A>	AB		100MG	N021986	004	May 30, 2008	Aug	CTEC
>D>		+	140MG	N021986	006	Oct 28, 2010	Aug	CTEC
>A>	AB		140MG	N021986	006	Oct 28, 2010	Aug	CTEC

DECITABINEINJECTABLE; INTRAVENOUS  
DECITABINE

AP HETERO LABS LTD VI 50MG/VIAL A215355 001 May 10, 2024 May NEWA

DEFERASIROXGRANULE; ORAL  
DEFERASIROX

>D>	AB	MYLAN	90MG	A213146	001	May 03, 2024	Aug DISC
>A>		@	90MG	A213146	001	May 03, 2024	Aug DISC
	AB		90MG	A213146	001	May 03, 2024	Apr NEWA
>D>	AB		180MG	A213146	002	May 03, 2024	Aug DISC
>A>		@	180MG	A213146	002	May 03, 2024	Aug DISC
	AB		180MG	A213146	002	May 03, 2024	Apr NEWA
>D>	AB		360MG	A213146	003	May 03, 2024	Aug DISC
>A>		@	360MG	A213146	003	May 03, 2024	Aug DISC
	AB		360MG	A213146	003	May 03, 2024	Apr NEWA

TABLET, FOR SUSPENSION; ORAL  
DEFERASIROX

AB	GLENMARK SPECLT	125MG	A209433	001	Jan 06, 2020	May CAHN
AB		250MG	A209433	002	Jan 06, 2020	May CAHN
AB		500MG	A209433	003	Jan 06, 2020	May CAHN
AB	TEVA PHARMS USA	125MG	A207124	001	Sep 23, 2022	Jul CMFD
AB		250MG	A207124	002	Sep 23, 2022	Jul CMFD
AB		500MG	A207124	003	Sep 23, 2022	Jul CMFD

DEFLAZACORTSUSPENSION; ORAL  
DEFLAZACORT

AB TRIS PHARMA INC 22.75MG/ML A217813 001 Apr 25, 2024 Apr NFTG

AB +! PTC THERAP 22.75MG/ML N208685 001 Feb 09, 2017 Apr CFTG

TABLET; ORAL  
DEFLAZACORT

AB	AUROBINDO PHARMA LTD	6MG	A217123	001	Feb 09, 2024	Feb NFTG
AB		18MG	A217123	002	Feb 09, 2024	Feb NFTG
AB		30MG	A217123	003	Feb 09, 2024	Feb NFTG
AB		36MG	A217123	004	Feb 09, 2024	Feb NFTG
	EMFLAZA					
AB	+ PTC THERAP	6MG	N208684	001	Feb 09, 2017	Feb CFTG
AB	+	18MG	N208684	002	Feb 09, 2017	Feb CFTG
AB	+	30MG	N208684	003	Feb 09, 2017	Feb CFTG
AB	+!	36MG	N208684	004	Feb 09, 2017	Feb CFTG

DEOXYCHOLIC ACIDSOLUTION; SUBCUTANEOUS  
DEOXYCHOLIC ACID

AP WILSHIRE PHARMS INC 20MG/2ML (10MG/ML) A212296 001 Apr 02, 2021 Jul CAHN

AP +! ABBVIE 20MG/2ML (10MG/ML) N206333 001 Apr 29, 2015 Jan CAHN

DESIPRAMINE HYDROCHLORIDETABLET; ORAL  
DESIPRAMINE HYDROCHLORIDE

AB	CHARTWELL RX	10MG	A072103	002	May 24, 1988	Mar CAHN
AB		25MG	A072103	003	May 24, 1988	Mar CAHN
AB		50MG	A072103	004	May 24, 1988	Mar CAHN
AB		75MG	A072103	005	Jun 20, 1988	Mar CAHN
AB		100MG	A072103	001	Jun 20, 1988	Mar CAHN
AB		150MG	A072103	006	Jun 20, 1988	Mar CAHN

DESLORATADINETABLET; ORAL  
DESLORATADINE  
@ CHARTWELL RX

5MG A078364 001 Dec 03, 2010 Jan CAHN

DESMOPRESSIN ACETATE

		TABLET; ORAL							
		DESMOPRESSIN ACETATE							
		@ ACTAVIS LABS FL INC	0.1MG	A076470	001	Jul 01, 2005	Feb	DISC	
		@	0.2MG	A076470	002	Jul 01, 2005	Feb	DISC	
AB		AUROBINDO PHARMA	0.1MG	A213095	001	Mar 21, 2024	Mar	NEWA	
AB			0.2MG	A213095	002	Mar 21, 2024	Mar	NEWA	

DESOGESTREL; ETHINYL ESTRADIOL

		TABLET; ORAL-28							
		DESOGESTREL AND ETHINYL ESTRADIOL							
AB		NAARI PTE LTD	0.15MG;0.03MG	A207067	001	Sep 13, 2018	Apr	CMFD	
		@ XIROMED	0.15MG;0.03MG	A202085	001	May 20, 2015	Apr	CAHN	
		EMOQUETTE							
		@ ENDO OPERATIONS	0.15MG;0.03MG	A076675	001	Feb 25, 2011	May	CAHN	
		KIMIDESS							
>D>	AB	ENDO OPERATIONS	0.15MG,N/A;0.02MG,0.01MG	A076681	001	Apr 30, 2015	Aug	DISC	
>A>		@	0.15MG,N/A;0.02MG,0.01MG	A076681	001	Apr 30, 2015	Aug	DISC	
	AB		0.15MG,N/A;0.02MG,0.01MG	A076681	001	Apr 30, 2015	May	CAHN	

DESONIDE

		OINTMENT; TOPICAL							
		DESONIDE							
		@ HIKMA	0.05%	A208836	001	Mar 27, 2017	Mar	DISC	

DESOXIMETASONE

		CREAM; TOPICAL							
		DESOXIMETASONE							
		@ COSETTE	0.25%	A209595	001	Mar 04, 2020	Mar	DISC	
		OINTMENT; TOPICAL							
		DESOXIMETASONE							
		@ COSETTE	0.25%	A206740	001	Dec 23, 2016	Apr	DISC	

DESVENLAFAXINE SUCCINATE

		TABLET, EXTENDED RELEASE; ORAL							
		DESVENLAFAXINE SUCCINATE							
		@ NORVIUM BIOSCIENCE	EQ 50MG BASE	A204095	001	Jun 29, 2015	Jun	CAHN	
		@	EQ 100MG BASE	A204095	002	Jun 29, 2015	Jun	CAHN	

DEURUXOLITINIB PHOSPHATE

		TABLET; ORAL							
		LEQSELVI							
		+! SUN PHARM INDS INC	EQ 8MG BASE	N217900	001	Jul 25, 2024	Jul	NEWA	

DEUTETRABENAZINE

		TABLET, EXTENDED RELEASE; ORAL							
		AUSTEDO XR							
		+ TEVA	18MG	N216354	008	Jul 01, 2024	Jul	NEWA	
		+	30MG	N216354	004	May 29, 2024	May	NEWA	
		+	36MG	N216354	005	May 29, 2024	May	NEWA	
		+	42MG	N216354	006	May 29, 2024	May	NEWA	
			48MG	N216354	007	May 29, 2024	May	NEWA	

DEXAMETHASONE

		ELIXIR; ORAL							
		DEXAMETHASONE							
>D>	AA	! ANIMA	0.5MG/5ML	A084754	001		Aug	CAHN	
>A>	AA	! KANCHAN HLTHCARE	0.5MG/5ML	A084754	001		Aug	CAHN	
		TABLET; ORAL							
		DEXAMETHASONE							
		@ KEY THERAP	1.5MG	A088237	001	Apr 28, 1983	May	DISC	
BP			1.5MG	A088237	001	Apr 28, 1983	Apr	CAHN	
		@ PANGEA	0.25MG	A088149	001	Apr 28, 1983	Jan	CAHN	
AB		ZYDUS LIFESCIENCES	0.5MG	A216282	001	Feb 07, 2024	Mar	CAHN	
AB			0.75MG	A216282	002	Feb 07, 2024	Mar	CAHN	
AB			1MG	A216284	001	May 09, 2024	May	CAHN	
AB			1.5MG	A216282	003	Feb 07, 2024	Mar	CAHN	
AB			2MG	A216283	001	Feb 07, 2024	Mar	CAHN	
AB			4MG	A216282	004	Feb 07, 2024	Mar	CAHN	
AB			6MG	A216282	005	Feb 07, 2024	Mar	CAHN	
AB		ZYDUS PHARMS	0.5MG	A216282	001	Feb 07, 2024	Jan	NEWA	

## TABLET; ORAL

DEXAMETHASONE							
AB		0.75MG	A216282	002	Feb 07, 2024	Jan	NEWA
AB		1MG	A216284	001	May 09, 2024	May	NEWA
AB		1.5MG	A216282	003	Feb 07, 2024	Jan	NEWA
AB		2MG	A216283	001	Feb 07, 2024	Jan	NEWA
AB		4MG	A216282	004	Feb 07, 2024	Jan	NEWA
AB		6MG	A216282	005	Feb 07, 2024	Jan	NEWA

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION		DEXAMETHASONE SODIUM PHOSPHATE					
	@	GENEYORK PHARMS	EQ 4MG PHOSPHATE/ML	A214890	002	Jul 28, 2023	Jul CMS1
	@		EQ 10MG PHOSPHATE/ML	A214890	001	Jul 07, 2023	Feb DISC
AP		HIKMA	EQ 4MG PHOSPHATE/ML	A084282	001		Jun CAHN
	@		EQ 4MG PHOSPHATE/ML	A211451	001	Aug 01, 2023	Jul DISC
AP	!		EQ 10MG PHOSPHATE/ML	A087702	001	Sep 07, 1982	Jun CAHN
AP		MICRO LABS	EQ 10MG PHOSPHATE/ML	A217797	001	Mar 27, 2024	Mar NEWA

DEXCHLORPHENIRAMINE MALEATE

SYRUP; ORAL		DEXCHLORPHENIRAMINE MALEATE					
	+	@ PAI HOLDINGS PHARM	2MG/5ML	A088251	001	Mar 23, 1984	Mar DISC
		POLMON					
	!	CAPELLON PHARMS LLC	2MG/5ML	A202520	001	Jul 16, 2018	Mar CTEC
AA	!		2MG/5ML	A202520	001	Jul 16, 2018	Mar CHRS

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE; ORAL		DEXLANSOPRAZOLE					
AB		MYLAN	30MG	A205205	001	Jan 19, 2024	Jan NEWA
AB			60MG	A205205	002	Jan 19, 2024	Jan NEWA

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION		DEXMEDETOMIDINE HYDROCHLORIDE					
	@	WILSHIRE PHARMS INC	EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	A212791	003	May 08, 2020	Jul CAHN
AP			EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A212791	001	Dec 04, 2019	Jul CAHN
AP			EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A212791	002	Dec 04, 2019	Jul CAHN

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL		DEXEDRINE					
>D>	AB	+	IMPAX LABS INC	5MG	N017078	001	Aug CTNA
>D>	AB	+		10MG	N017078	002	Aug CTNA
>D>	AB	+	!	15MG	N017078	003	Aug CTNA
>A>	DEXEDRINE SPANSULE						
>A>	AB	+	IMPAX LABS INC	5MG	N017078	001	Aug CTNA
>A>	AB	+		10MG	N017078	002	Aug CTNA
>A>	AB	+	!	15MG	N017078	003	Aug CTNA
DEXTROAMPHETAMINE SULFATE							
	@	NORVIUM BIOSCIENCE	5MG	A206735	001	Jan 27, 2016	Jun CAHN
	@		10MG	A206735	002	Jan 27, 2016	Jun CAHN
	@		15MG	A206735	003	Jan 27, 2016	Jun CAHN

## TABLET; ORAL

DEXTROAMPHETAMINE SULFATE							
AA		AZURITY	2.5MG	A090533	001	Oct 25, 2011	Mar CAHN
AA			5MG	A090533	002	Oct 25, 2011	Mar CAHN
AA			7.5MG	A090533	003	Oct 25, 2011	Mar CAHN
AA			10MG	A090533	004	Oct 25, 2011	Mar CAHN
AA			15MG	A090533	005	Oct 25, 2011	Mar CAHN
AA			20MG	A090533	006	Oct 25, 2011	Mar CAHN
AA			30MG	A090533	007	Oct 25, 2011	Mar CAHN
	@	TRIS PHARMA INC	5MG	A206095	001	Aug 18, 2022	Jan DISC
	@		10MG	A206095	002	Aug 18, 2022	Jan DISC



DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE

CAPSULE; ORAL

DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE

>A> AB HETERO LABS LTD III 20MG;10MG A218426 001 Aug 28, 2024 Aug NEWA

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 5%

AP AM REGENT 50MG/ML A217263 001 Apr 08, 2024 Apr CTNA  
 AP 50MG/ML A217263 001 Apr 08, 2024 Mar NEWA

DIAZEPAM

FILM; BUCCAL

LIBERVANT

+ AQUESTIVE 5MG N218623 001 Apr 26, 2024 Apr NEWA  
 + 7.5MG N218623 002 Apr 26, 2024 Apr NEWA  
 + 10MG N218623 003 Apr 26, 2024 Apr NEWA  
 + 12.5MG N218623 004 Apr 26, 2024 Apr NEWA  
 +! 15MG N218623 005 Apr 26, 2024 Apr NEWA

INJECTABLE; INJECTION

DIAZEPAM

AP ALEMBIC 10MG/2ML (5MG/ML) A218450 001 Apr 25, 2024 Apr NEWA  
 AP DR REDDYS 10MG/2ML (5MG/ML) A218422 001 Jul 18, 2024 Jul NEWA  
 @ HIKMA 5MG/ML (5MG/ML) A070311 002 Dec 16, 1985 Jan NEWA  
 @ 10MG/2ML (5MG/ML) A070311 003 Dec 16, 1985 Jan NEWA  
 AP 50MG/10ML (5MG/ML) A070311 001 Dec 16, 1985 Jan CPOT

TABLET; ORAL

DIAZEPAM

@ ENDO OPERATIONS 2MG A070228 002 Sep 26, 1985 May CAHN  
 @ 5MG A070228 003 Sep 26, 1985 May CAHN  
 @ 10MG A070228 001 Sep 26, 1985 May CAHN  
 >A> AB NUVO PHARM 2MG A070464 002 Sep 10, 2024 Aug NEWA  
 >A> AB 5MG A070464 003 Sep 10, 2024 Aug NEWA

DICHLORPHENAMIDE

TABLET; ORAL

ORMALVI

AB TORRENT 50MG A215924 001 Dec 29, 2022 Feb CTNA

DICLOFENAC POTASSIUM

FOR SOLUTION; ORAL

DICLOFENAC POTASSIUM

AB ENDO OPERATIONS 50MG A202964 001 May 02, 2016 May CAHN  
 AB TARO 50MG A218011 001 Jun 14, 2024 Jun NEWA

DICLOFENAC SODIUM

SOLUTION; TOPICAL

DICLOFENAC SODIUM

AB ! LUPIN PHARMS 2% A208021 001 Sep 20, 2022 Mar CHRS

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM AND MISOPROSTOL

@ SANDOZ 50MG;0.2MG A200158 001 May 09, 2013 Jul DISC  
 @ 75MG;0.2MG A200158 002 May 09, 2013 Jul DISC

DICLOXACILLIN SODIUM

CAPSULE; ORAL

DICLOXACILLIN SODIUM

@ CHARTWELL RX EQ 125MG BASE A061454 002 Jul CAHN  
 @ EQ 250MG BASE A061454 001 Jul CAHN  
 @ EQ 500MG BASE A061454 003 Jul CAHN

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

DICYCLOMINE HYDROCHLORIDE

AB ANNORA PHARMA 10MG A218018 001 Jul 01, 2024 Jun NEWA

INJECTABLE; INJECTION

BENTYL

+ @ ABBVIE 10MG/ML N008370 001 Oct 15, 1984 Apr DISC

	INJECTABLE; INJECTION						
>D>	BENTYL PRESERVATIVE FREE						
>D>	AP	+! ABBVIE	10MG/ML	N008370	002	Oct 15, 1984	Aug DISC
>A>		+ @	10MG/ML	N008370	002	Oct 15, 1984	Aug DISC
	DICYCLOMINE HYDROCHLORIDE						
	AP	! FOSUN PHARMA	10MG/ML	A210979	001	Jul 02, 2018	Apr CHRS
	DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE)						
>D>	AP	HIKMA	10MG/ML	A040465	001	Jun 30, 2003	Aug CHRS
>A>	AP	!	10MG/ML	A040465	001	Jun 30, 2003	Aug CHRS
	SYRUP; ORAL						
	DICYCLOMINE HYDROCHLORIDE						
AA	!	ENDO OPERATIONS	10MG/5ML	A040169	001	Mar 24, 2005	Apr CAHN
	TABLET; ORAL						
	DICYCLOMINE HYDROCHLORIDE						
AB		ANNORA PHARMA	20MG	A217566	001	May 07, 2024	Apr NEWA
	<u>DIFLORASONE DIACETATE</u>						
	OINTMENT; TOPICAL						
	DIFLORASONE DIACETATE						
>D>		@ SAPTALIS PHARMS	0.05%	A206572	001	Jul 24, 2015	Aug CAHN
		@	0.05%	A206572	001	Jul 24, 2015	Jun CAHN
>A>		@ SCIEGEN PHARMS INC	0.05%	A206572	001	Jul 24, 2015	Aug CAHN
	<u>DIFLUNISAL</u>						
	TABLET; ORAL						
	DIFLUNISAL						
>A>		HERITAGE PHARMA	250MG	A202845	002	Aug 16, 2024	Aug NEWA
>A>			375MG	A202845	003	Aug 16, 2024	Aug NFTG
	<u>DIFLUPREDNATE</u>						
	EMULSION; OPHTHALMIC						
	DIFLUPREDNATE						
AB		EPIC PHARMA LLC	0.05%	A207284	001	May 14, 2024	May NEWA
	<u>DIGOXIN</u>						
	ELIXIR; ORAL						
	DIGOXIN						
AA		VISTAPHARM LLC	0.05MG/ML	A213000	001	Oct 04, 2019	Feb CAHN
	INJECTABLE; INJECTION						
	DIGOXIN						
AP		HIKMA	0.25MG/ML	A083391	001		Jun CAHN
	<u>DIHYDROERGOTAMINE MESYLATE</u>						
	SPRAY, METERED; NASAL						
	DIHYDROERGOTAMINE MESYLATE						
		@ AMNEAL	0.5MG/SPRAY	A214105	001	Jan 04, 2022	Mar DISC
		TRUDHESA					
		+! IMPEL PHARMS	0.725MG/SPRAY	N213436	001	Sep 02, 2021	Jun CAHN
		+! JN BIDCO	0.725MG/SPRAY	N213436	001	Sep 02, 2021	Feb CAHN
	<u>DILTIAZEM HYDROCHLORIDE</u>						
	CAPSULE, EXTENDED RELEASE; ORAL						
	DILTIAZEM HYDROCHLORIDE						
AB3		ENDO OPERATIONS	120MG	A074984	001	Dec 20, 1999	Apr CAHN
AB3			180MG	A074984	002	Dec 20, 1999	Apr CAHN
AB3			240MG	A074984	003	Dec 20, 1999	Apr CAHN
AB3			300MG	A074984	004	Dec 20, 1999	Apr CAHN
		@	360MG	A209766	001	May 30, 2018	May CAHN
		@ SUN PHARM	360MG	A090492	005	Oct 28, 2011	Feb DISC
		TAZTIA XT					
		@ ACTAVIS LABS FL INC	120MG	A075401	001	Apr 10, 2003	Jul DISC
		@	180MG	A075401	002	Apr 10, 2003	Jul DISC
		@	240MG	A075401	003	Apr 10, 2003	Jul DISC
		@	300MG	A075401	004	Apr 10, 2003	Jul DISC
		@	360MG	A075401	005	Apr 10, 2003	Jul DISC
	INJECTABLE; INJECTION						
	DILTIAZEM HYDROCHLORIDE						
AP		HIKMA	5MG/ML	A078538	001	Dec 17, 2008	Mar CAHN
		@ HIKMA FARMACEUTICA	5MG/ML	A202651	001	Aug 09, 2012	Mar DISC

DIMETHYL FUMARATECAPSULE, DELAYED RELEASE;ORAL  
DIMETHYL FUMARATE

AB	MACLEODS PHARMS LTD	120MG	A210377	001	Jun 26, 2024	Jun	NEWA
AB		240MG	A210377	002	Jun 26, 2024	Jun	NEWA

DIPHENHYDRAMINE HYDROCHLORIDEINJECTABLE; INJECTION  
DIPHENHYDRAMINE HYDROCHLORIDE

AP	GLAND PHARMA LTD	50MG/ML	A218448	001	Mar 20, 2024	Mar	NEWA
	@ HIKMA	50MG/ML	A083183	001		Jun	CAHN
AP	! MYLAN INSTITUTIONAL	50MG/ML	A040498	001	Jul 12, 2005	May	CHRS

DIPYRIDAMOLE

TABLET; ORAL

DIPYRIDAMOLE

>A>	@ CHARTWELL RX	25MG	A040898	001	Apr 23, 2008	Aug	CAHN
>A>	@	50MG	A040898	002	Apr 23, 2008	Aug	CAHN
>A>	@	75MG	A040898	003	Apr 23, 2008	Aug	CAHN
>D>	@ GENUS	25MG	A040898	001	Apr 23, 2008	Aug	CAHN
	@	25MG	A040898	001	Apr 23, 2008	Jan	CAHN
>D>	@	50MG	A040898	002	Apr 23, 2008	Aug	CAHN
	@	50MG	A040898	002	Apr 23, 2008	Jan	CAHN
>D>	@	75MG	A040898	003	Apr 23, 2008	Aug	CAHN
	@	75MG	A040898	003	Apr 23, 2008	Jan	CAHN
AB	! IMPAX LABS	75MG	A040782	003	Jul 18, 2007	May	CHRS
	PERSANTINE						
	+ @ BOEHRINGER INGELHEIM	25MG	N012836	003	Dec 22, 1986	May	DISC
	+ @	50MG	N012836	004	Feb 06, 1987	May	DISC
	+ @	75MG	N012836	005	Feb 06, 1987	May	DISC

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE;ORAL

DIVALPROEX SODIUM

@ ENDO OPERATIONS	EQ 500MG VALPROIC ACID	A078411	001	Nov 03, 2008	May	CAHN
@ NORVIUM BIOSCIENCE	EQ 125MG VALPROIC ACID	A090062	001	Mar 17, 2009	Jun	CAHN
@	EQ 250MG VALPROIC ACID	A090062	002	Mar 17, 2009	Jun	CAHN
@	EQ 500MG VALPROIC ACID	A090062	003	Mar 17, 2009	Jun	CAHN

TABLET, EXTENDED RELEASE;ORAL

DIVALPROEX SODIUM

@ ENDO OPERATIONS	EQ 250MG VALPROIC ACID	A078445	001	Feb 26, 2009	May	CAHN
@	EQ 500MG VALPROIC ACID	A078445	002	Aug 04, 2009	May	CAHN

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

AP	ACIC PHARMS	80MG/4ML (20MG/ML)	A216677	002	Feb 28, 2024	Feb	NEWA
AP		20MG/ML (20MG/ML)	A216677	001	Feb 28, 2024	Feb	NEWA
	@ NORVIUM BIOSCIENCE	20MG/ML (20MG/ML)	A203892	001	May 11, 2023	Jun	CAHN
	@	80MG/4ML (20MG/ML)	A203892	002	May 11, 2023	Jun	CAHN

SOLUTION; INTRAVENOUS

DOCIVYX

+!	AVYXA HOLDINGS	20MG/2ML (10MG/ML)	N215813	001	Nov 22, 2022	Apr	CMFD
+ @		20MG/2ML (10MG/ML)	N215813	001	Nov 22, 2022	Apr	CTNA
+ @		20MG/2ML (10MG/ML)	N215813	001	Nov 22, 2022	Jan	CAHN
+!		80MG/8ML (10MG/ML)	N215813	002	Nov 22, 2022	Apr	CMFD
+ @		80MG/8ML (10MG/ML)	N215813	002	Nov 22, 2022	Apr	CTNA
+ @		80MG/8ML (10MG/ML)	N215813	002	Nov 22, 2022	Jan	CAHN
+!		160MG/16ML (10MG/ML)	N215813	003	Nov 22, 2022	Apr	CMFD
+ @		160MG/16ML (10MG/ML)	N215813	003	Nov 22, 2022	Apr	CTNA
+ @		160MG/16ML (10MG/ML)	N215813	003	Nov 22, 2022	Jan	CAHN

DOLASETRON MESYLATE

TABLET; ORAL

ANZEMET

+ @	VALIDUS PHARMS	50MG	N020623	001	Sep 11, 1997	Jun	DISC
-----	----------------	------	---------	-----	--------------	-----	------

DOLUTEGRAVIR SODIUMTABLET; ORAL  
TIVICAY

+ @	VIIV HLTHCARE	EQ 10MG BASE	N204790	002	Jun 09, 2016	Jan	DISC
+ @		EQ 25MG BASE	N204790	003	Jun 09, 2016	Jan	DISC

DONEPEZIL HYDROCHLORIDESYSTEM; TRANSDERMAL  
ADLARITY

+	CORIUM	5MG/DAY	N212304	001	Mar 11, 2022	Jun	CAHN
+	!	10MG/DAY	N212304	002	Mar 11, 2022	Jun	CAHN

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

@	ENDO OPERATIONS	23MG	A202542	001	Jul 24, 2013	May	CAHN
@	SUN PHARM INDS	5MG	A090493	001	May 31, 2011	May	DISC
@		10MG	A090493	002	May 31, 2011	May	DISC

TABLET, ORALLY DISINTEGRATING; ORAL

DONEPEZIL HYDROCHLORIDE

AB	!	MACLEODS PHARMS LTD	10MG	A201787	002	Dec 14, 2012	Mar	CHRS
	@	SANDOZ	5MG	A091198	001	May 10, 2011	Mar	DISC
	@		10MG	A091198	002	May 10, 2011	Mar	DISC

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

@	HIKMA	EQ 2% BASE	A077846	001	Oct 28, 2008	Mar	DISC
---	-------	------------	---------	-----	--------------	-----	------

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

@	HIKMA	EQ 2% BASE; EQ 0.5% BASE	A077847	001	Oct 28, 2008	Mar	DISC
---	-------	--------------------------	---------	-----	--------------	-----	------

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

AB		AUROBINDO PHARMA USA	EQ 1MG BASE	A075509	001	Oct 19, 2000	Mar	CMFD
AB			EQ 2MG BASE	A075509	002	Oct 19, 2000	Mar	CMFD
AB			EQ 4MG BASE	A075509	003	Oct 19, 2000	Mar	CMFD
AB			EQ 8MG BASE	A075509	004	Oct 19, 2000	Mar	CMFD

DOXEPIIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIIN HYDROCHLORIDE

>D>	AB		CHEMISTRY HLTH	EQ 10MG BASE	A211619	001	Mar 09, 2021	Aug	CAHN
>D>	AB			EQ 25MG BASE	A211619	002	Mar 09, 2021	Aug	CAHN
>D>	AB			EQ 50MG BASE	A211619	003	Mar 09, 2021	Aug	CAHN
>D>	AB			EQ 75MG BASE	A211619	004	Mar 09, 2021	Aug	CAHN
>D>	AB			EQ 100MG BASE	A211619	005	Mar 09, 2021	Aug	CAHN
		@	ENDO OPERATIONS	EQ 10MG BASE	A071422	002	Nov 09, 1987	Apr	CAHN
		@		EQ 25MG BASE	A071422	003	Nov 09, 1987	Apr	CAHN
		@		EQ 50MG BASE	A071422	004	Nov 09, 1987	Apr	CAHN
		@		EQ 75MG BASE	A071422	005	Nov 09, 1987	Apr	CAHN
		@		EQ 100MG BASE	A071422	001	Nov 09, 1987	Apr	CAHN
	AB	!		EQ 150MG BASE	A071422	006	Nov 09, 1987	Apr	CAHN
>A>	AB		LEADING	EQ 10MG BASE	A211619	001	Mar 09, 2021	Aug	CAHN
>A>	AB			EQ 25MG BASE	A211619	002	Mar 09, 2021	Aug	CAHN
>A>	AB			EQ 50MG BASE	A211619	003	Mar 09, 2021	Aug	CAHN
>A>	AB			EQ 75MG BASE	A211619	004	Mar 09, 2021	Aug	CAHN
>A>	AB			EQ 100MG BASE	A211619	005	Mar 09, 2021	Aug	CAHN
>D>	AB			EQ 150MG BASE	A211618	001	Mar 01, 2021	Aug	CAHN
>A>	AB		VELZEN PHARMA PVT	EQ 150MG BASE	A211618	001	Mar 01, 2021	Aug	CAHN

TABLET; ORAL

DOXEPIIN HYDROCHLORIDE

	AB		AJANTA PHARMA LTD	EQ 3MG BASE	A218564	001	Jul 01, 2024	Jun	NEWA
	AB			EQ 6MG BASE	A218564	002	Jul 01, 2024	Jun	NEWA
>D>	AB		AUROBINDO PHARMA LTD	EQ 3MG BASE	A216041	001	Jul 25, 2024	Aug	DISC
>A>		@		EQ 3MG BASE	A216041	001	Jul 25, 2024	Aug	DISC
	AB			EQ 3MG BASE	A216041	001	Jul 25, 2024	Jul	NEWA
>D>	AB			EQ 6MG BASE	A216041	002	Jul 25, 2024	Aug	DISC
>A>		@		EQ 6MG BASE	A216041	002	Jul 25, 2024	Aug	DISC
	AB			EQ 6MG BASE	A216041	002	Jul 25, 2024	Jul	NEWA

DOXERCALCIFEROLINJECTABLE; INJECTION  
DOXERCALCIFEROL

	@ AMNEAL	2MCG/ML (2MCG/ML)	A208974	001	May 24, 2017	Jan	DISC
	@	4MCG/2ML (2MCG/ML)	A208974	002	May 24, 2017	Jan	DISC
	@	4MCG/2ML (2MCG/ML)	A208975	001	May 24, 2017	Jul	DISC
AP		4MCG/2ML (2MCG/ML)	A208975	001	May 24, 2017	Jan	CMFD

DOXORUBICIN HYDROCHLORIDEINJECTABLE, LIPOSOMAL; INJECTION  
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

AB	FORDOZ	20MG/10ML (2MG/ML)	A215178	001	Jul 16, 2024	Jul	NEWA
AB		50MG/25ML (2MG/ML)	A215178	002	Jul 16, 2024	Jul	NEWA

DOXYCYCLINECAPSULE; ORAL  
DOXYCYCLINE

AB	ALEMBIC	40MG	A217674	001	Jun 27, 2024	Jun	NEWA
AB	APOTEX	40MG	A217170	001	Jul 11, 2024	Jul	NEWA
	@ COSETTE	EQ 50MG BASE	A204446	001	May 28, 2015	Apr	DISC
	@	EQ 75MG BASE	A204446	002	May 28, 2015	Apr	DISC
	@	EQ 100MG BASE	A204446	003	May 28, 2015	Apr	DISC
AB	DR REDDYS	40MG	A218034	001	Apr 08, 2024	Mar	NFTG
AB	LUPIN	40MG	A216631	001	Apr 08, 2024	Mar	NFTG
	ORACEA						
AB	+! GALDERMA LABS LP	40MG	N050805	001	May 26, 2006	Mar	CFTG
	FOR SUSPENSION; ORAL						
	DOXYCYCLINE						
AB	! LUPIN LTD	EQ 25MG BASE/5ML	A201678	001	Mar 18, 2013	Jun	CHRS
	VIBRAMYCIN						
	+ @ PFIZER	EQ 25MG BASE/5ML	N050006	001		Jun	DISC

DOXYCYCLINE HYCLATECAPSULE; ORAL  
ACTICLATE CAP

	+ @ CHARTWELL RX	EQ 75MG BASE	N208253	001	Apr 26, 2016	Jan	CAHN
	INJECTABLE; INJECTION						
	DOXYCYCLINE HYCLATE						
AP	ACIC PHARMS	EQ 100MG BASE/VIAL	A217854	001	Jul 23, 2024	Jul	NEWA
AP	LUPIN LTD	EQ 100MG BASE/VIAL	A217794	001	Mar 14, 2024	Mar	NEWA
	TABLET; ORAL						
	ACTICLATE						
AB	+ CHARTWELL RX	EQ 75MG BASE	N205931	001	Jul 25, 2014	Jan	CAHN
AB	+!	EQ 150MG BASE	N205931	002	Jul 25, 2014	Jan	CAHN
	DOXYCYCLINE HYCLATE						
	@ NOSTRUM LABS INC	EQ 100MG BASE	A209560	001	Apr 15, 2024	May	DISC
AB		EQ 100MG BASE	A209560	001	Apr 15, 2024	Apr	NEWA
>A>	@ ORYZA	EQ 100MG BASE	A213475	001	Mar 10, 2021	Aug	CAHN
>D>	@ PHARMOBEDIENT	EQ 100MG BASE	A213475	001	Mar 10, 2021	Aug	CAHN
	@ TORRENT	EQ 75MG BASE	A214356	001	Apr 15, 2024	Apr	DISC
AB		EQ 75MG BASE	A214356	001	Apr 15, 2024	Apr	NEWA
	@	EQ 150MG BASE	A214356	002	Apr 15, 2024	Apr	DISC
AB		EQ 150MG BASE	A214356	002	Apr 15, 2024	Apr	NEWA
	TABLET, DELAYED RELEASE; ORAL						
	DORYX						
	+ @ MAYNE PHARMA	EQ 75MG BASE	N050795	001	May 06, 2005	Feb	DISC
	+ @	EQ 150MG BASE	N050795	003	Jun 20, 2008	Feb	DISC

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDETABLET, DELAYED RELEASE; ORAL  
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE

AB	ENDO OPERATIONS	10MG; 10MG	A208518	001	Dec 06, 2017	Apr	CAHN
----	-----------------	------------	---------	-----	--------------	-----	------

DRONABINOLCAPSULE; ORAL  
DRONABINOL

	@ HIKMA	2.5MG	A079217	001	Jun 20, 2014	Mar	DISC
	@	5MG	A079217	002	Jun 20, 2014	Mar	DISC
	@	10MG	A079217	003	Jun 20, 2014	Mar	DISC
>D>	AB SVC PHARMA	2.5MG	A078292	001	Jun 27, 2008	Aug	DISC
>A>	@	2.5MG	A078292	001	Jun 27, 2008	Aug	DISC

CAPSULE;ORAL  
DRONABINOL

>D>	AB		5MG	A078292	002	Jun 27, 2008	Aug	DISC	
>A>		@	5MG	A078292	002	Jun 27, 2008	Aug	DISC	
>D>	AB		10MG	A078292	003	Jun 27, 2008	Aug	DISC	
>A>		@	10MG	A078292	003	Jun 27, 2008	Aug	DISC	
>D>									
>D>									
>D>		+!	BENUVIA OPERATIONS	5MG/ML	N205525	001	Mar 23, 2017	Aug	DISC
>A>		+ @		5MG/ML	N205525	001	Mar 23, 2017	Aug	DISC

DRONEDARONE HYDROCHLORIDE

## TABLET;ORAL

## DRONEDARONE HYDROCHLORIDE

AB			LUPIN	EQ 400MG BASE	A205904	001	Jan 31, 2024	Jan	NFTG
			MULTAQ						
AB		+!	SANOFI AVENTIS US	EQ 400MG BASE	N022425	001	Jul 01, 2009	Jan	CFTG

DROXIDOPA

## CAPSULE;ORAL

## DROXIDOPA

@ UPSHER SMITH LABS  
@  
@

100MG  
200MG  
300MG

A213661 001 Feb 18, 2021 Apr DISC  
A213661 002 Feb 18, 2021 Apr DISC  
A213661 003 Feb 18, 2021 Apr DISC

DULOXETINE HYDROCHLORIDE

## CAPSULE, DELAYED REL PELLETS;ORAL

## DRIZALMA SPRINKLE

+ SUN PHARM

EQ 20MG BASE  
EQ 30MG BASE  
EQ 40MG BASE  
EQ 60MG BASE

N212516 001 Jul 19, 2019 Apr CMFD  
N212516 002 Jul 19, 2019 Apr CMFD  
N212516 003 Jul 19, 2019 Apr CMFD  
N212516 004 Jul 19, 2019 Apr CMFD

## DULOXETINE HYDROCHLORIDE

@ ANCHEN PHARMS  
@  
@  
@ ENDO OPERATIONS  
@  
@

EQ 20MG BASE  
EQ 30MG BASE  
EQ 60MG BASE  
EQ 20MG BASE  
EQ 30MG BASE  
EQ 60MG BASE

A090780 001 Oct 28, 2015 Feb DISC  
A090780 002 Oct 28, 2015 Feb DISC  
A090780 003 Oct 28, 2015 Feb DISC  
A090780 001 Oct 28, 2015 May CAHN  
A090780 002 Oct 28, 2015 May CAHN  
A090780 003 Oct 28, 2015 May CAHN

DUTASTERIDE

## CAPSULE;ORAL

## AVODART

AB		+!	WAYLIS THERAP	0.5MG	N021319	001	Nov 20, 2001	Mar	CAHN
			DUTASTERIDE						
AB			CHARTWELL	0.5MG	A200899	001	Nov 20, 2015	Mar	CAHN
		@	NORVIUM BIOSCIENCE	0.5MG	A203241	001	Jun 14, 2016	Jun	CAHN
		@	VINTAGE	0.5MG	A202421	001	Nov 20, 2015	Feb	DISC

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

## CAPSULE;ORAL

## DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

AB			AUROBINDO PHARMA	0.5MG;0.4MG	A213300	001	Jul 18, 2024	Jul	NEWA
AB			ENDO OPERATIONS	0.5MG;0.4MG	A202509	001	Feb 26, 2014	Apr	CAHN
			JALYN						
AB		+!	WAYLIS THERAP	0.5MG;0.4MG	N022460	001	Jun 14, 2010	Apr	CAHN

DYPHYLLINE

## TABLET;ORAL

## LUFYLLIN

@ NORVIUM BIOSCIENCE  
@

200MG  
400MG

A084566 001 Jul CAHN  
A084566 002 Jul CAHN

EDARAVONE

## SOLUTION;INTRAVENOUS

## EDARAVONE

AP			DR REDDYS	60MG/100ML (0.6MG/ML)	A215917	001	May 06, 2024	Apr	NEWA
AP			GLAND PHARMA LTD	30MG/100ML (0.3MG/ML)	A216199	001	May 06, 2024	Apr	NFTG
AP				60MG/100ML (0.6MG/ML)	A216199	002	May 06, 2024	Apr	NFTG
AP			HIKMA	30MG/100ML (0.3MG/ML)	A215508	001	May 06, 2024	Apr	NFTG
AP			LONG GROVE PHARMS	30MG/100ML (0.3MG/ML)	A218354	001	May 06, 2024	Apr	NEWA

	SOLUTION;INTRAVENOUS								
	RADICAVA								
AP	+	! MITSUBISHI TANABE	30MG/100ML (0.3MG/ML)	N209176	001	May 05, 2017	Apr	CFTG	
AP	+	!	60MG/100ML (0.6MG/ML)	N209176	002	Nov 15, 2018	Apr	CFTG	
	<u>EDROPHONIUM CHLORIDE</u>								
	INJECTABLE;INJECTION								
	ENLON								
		@ NORVIUM BIOSCIENCE	10MG/ML	A088873	001	Aug 06, 1985	Jul	CAHN	
	<u>EFAVIRENZ</u>								
	TABLET;ORAL								
	EFAVIRENZ								
AB		MACLEODS PHARMS LTD	600MG	A091579	001	May 10, 2024	May	NEWA	
	<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE</u>								
	TABLET;ORAL								
	EFAVIRENZ; EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE								
		@ STRIDES PHARMA	600MG;200MG;300MG	A201802	001	Oct 03, 2023	Mar	DISC	
	EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE								
>A>	AB	MYLAN	600MG;200MG;300MG	A209061	001	Sep 05, 2024	Aug	NEWA	
	<u>EFINACONAZOLE</u>								
	SOLUTION;TOPICAL								
	EFINACONAZOLE								
>D>	AB	NIVAGEN PHARMS INC	10%	A211969	001	Jun 21, 2021	Aug	CAHN	
>A>	AB	UMEDICA	10%	A211969	001	Jun 21, 2021	Aug	CAHN	
		@ ZYDUS LIFESCIENCES	10%	A212178	001	Jul 15, 2022	May	CAHN	
	<u>ELAFIBRANOR</u>								
	TABLET;ORAL								
	IQIRVO								
	+	!	IPSEN	80MG	N218860	001	Jun 10, 2024	Jun	NEWA
	<u>ELIGLUSTAT TARTRATE</u>								
	CAPSULE;ORAL								
	ELIGLUSTAT TARTRATE								
AB		APOTEX	EQ 84MG BASE	A212425	001	Jul 10, 2024	Jun	NEWA	
	<u>ELTROMBOPAG OLAMINE</u>								
	FOR SUSPENSION;ORAL								
	ELTROMBOPAG OLAMINE								
AB		ANNORA PHARMA	EQ 12.5MG ACID/PACKET	A216620	001	Apr 18, 2024	Apr	NFTG	
AB			EQ 25MG ACID/PACKET	A216620	002	Apr 18, 2024	Apr	NFTG	
	PROMACTA KIT								
AB	+	NOVARTIS	EQ 12.5MG ACID/PACKET	N207027	002	Sep 27, 2018	Apr	CFTG	
AB	+	!	EQ 25MG ACID/PACKET	N207027	001	Aug 24, 2015	Apr	CFTG	
	<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE</u>								
	TABLET;ORAL								
	DESCOVY								
AB	+	GILEAD SCIENCES INC	120MG;EQ 15MG BASE	N208215	002	Jan 07, 2022	May	CFTG	
AB	+	!	200MG;EQ 25MG BASE	N208215	001	Apr 04, 2016	May	CFTG	
	EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE								
AB		APOTEX	120MG;EQ 15MG BASE	A214053	001	May 17, 2024	May	NFTG	
AB			200MG;EQ 25MG BASE	A214053	002	May 17, 2024	May	NFTG	
	<u>ENALAPRIL MALEATE</u>								
	FOR SOLUTION;ORAL								
	EPANED KIT								
	+	@ AZURITY	1MG/ML	N204308	001	Aug 13, 2013	Mar	CAHN	
	SOLUTION;ORAL								
	ENALAPRIL MALEATE								
AB		AMNEAL	1MG/ML	A212894	001	Jun 29, 2022	Mar	CMFD	
	<u>ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE</u>								
	TABLET;ORAL								
	ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE								
		@ COSETTE	5MG;12.5MG	A075727	001	Sep 18, 2001	Apr	DISC	
		@	10MG;25MG	A075727	002	Sep 18, 2001	Apr	DISC	

ENSIFENTRINESUSPENSION; INHALATION  
OHTUVAYRE

+! VERONA PHARMA 3MG/2.5ML N217389 001 Jun 26, 2024 Jun NEWA

ENTECAVIRTABLET; ORAL  
ENTECAVIR

	@ SWISS PHARM	0.5MG	A212106	001	Aug 10, 2020	Jul CAHN
	@	1MG	A212106	002	Aug 10, 2020	Jul CAHN
	@ VITRUVIAS	0.5MG	A212106	001	Aug 10, 2020	Jun DISC
	@	1MG	A212106	002	Aug 10, 2020	Jun DISC
AB	YUNG SHIN PHARM	0.5MG	A208195	001	Nov 10, 2021	Jun CMFD
AB		1MG	A208195	002	Nov 10, 2021	Jun CMFD

EPHEDRINE HYDROCHLORIDESOLUTION; INTRAVENOUS  
REZIPRES

+ @ DR REDDYS LABS SA 23.5MG/5ML (4.7MG/ML) N213536 001 Jun 14, 2021 May DISC

EPHEDRINE SULFATESOLUTION; INTRAVENOUS  
EPHEDRINE SULFATE

AP	CAPLIN	50MG/ML (50MG/ML)	A219050	001	Jul 18, 2024	Jul NEWA
	+! ENDO OPERATIONS	25MG/5ML (5MG/ML)	N213994	002	Apr 22, 2022	Apr CAHN
	+!	50MG/10ML (5MG/ML)	N213994	001	Oct 16, 2020	Apr CAHN

EPINEPHRINESOLUTION; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS  
EPINEPHRINE

>A>	AP	AM REGENT	EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	A217192	001	Sep 06, 2024	Aug NEWA
		+! BPI LABS	1MG/ML (1MG/ML)	N205029	005	Mar 04, 2024	Apr NEWA
		+!	30MG/30ML (1MG/ML)	N205029	004	Feb 14, 2024	Feb NEWA

SOLUTION; INTRAVENOUS  
EPINEPHRINE

		+ @ BPI LABS	1MG/ML (1MG/ML)	N205029	003	May 12, 2023	Jun DISC
>A>		SPRAY; NASAL					
>A>		NEFFY					
>A>		+! ARS PHARMS OPERATION	2MG/SPRAY	N214697	001	Aug 09, 2024	Aug NEWA

EPINEPHRINE; LIDOCAINE HYDROCHLORIDEINJECTABLE; INJECTION  
XYLOCAINE W/ EPINEPHRINE

+ @ FRESENIUS KABI USA 0.01MG/ML; 2% N006488 003 Feb CRLD

EPIRUBICIN HYDROCHLORIDEINJECTABLE; INJECTION  
EPIRUBICIN HYDROCHLORIDE

	@ NORVIUM BIOSCIENCE	50MG/25ML (2MG/ML)	A065371	001	Nov 28, 2007	Jul CAHN
	@	200MG/100ML (2MG/ML)	A065371	002	Nov 28, 2007	Jul CAHN

EPLERENONETABLET; ORAL  
EPLERENONE

	@ PRASCO	25MG	A203896	001	Feb 02, 2017	Mar DISC
	@	50MG	A203896	002	Feb 02, 2017	Mar DISC
AB	SLATE RUN PHARMA	25MG	A212765	001	Aug 10, 2020	Feb CAHN
AB		50MG	A212765	002	Aug 10, 2020	Feb CAHN

EPLONTERSEN SODIUMSOLUTION; SUBCUTANEOUS  
WAINUA (AUTOINJECTOR)

	+! ASTRAZENECA AB	EQ 45MG BASE/0.8ML (EQ 45MG BASE/0.8ML)	N217388	001	Dec 21, 2023	Feb CTNA
	+!	EQ 45MG BASE/0.8ML (EQ 45MG BASE/0.8ML)	N217388	001	Dec 21, 2023	Jan CAHN



EPOPROSTENOL SODIUMINJECTABLE; INJECTION  
EPOPROSTENOL SODIUM

AP1	MEITHEAL	EQ 0.5MG BASE/VIAL	A 078396	001	Apr 23, 2008	Jan	CAHN
AP1		EQ 1.5MG BASE/VIAL	A 078396	002	Apr 23, 2008	Jan	CAHN
AP2	MYLAN	EQ 0.5MG BASE/VIAL	A 213913	001	Jun 12, 2024	May	NEWA
AP2		EQ 1.5MG BASE/VIAL	A 213913	002	Jun 12, 2024	May	NEWA

EPTIFIBATIDEINJECTABLE; INJECTION  
EPTIFIBATIDE

	@ ACCORD HLTHCARE	2MG/ML	A 205557	001	Nov 06, 2017	May	DISC
	@	75MG/100ML	A 205557	002	Nov 06, 2017	May	DISC
AP	HONG KONG	2MG/ML	A 213599	001	May 09, 2024	May	NEWA
AP		75MG/100ML	A 213599	002	May 09, 2024	May	NEWA

ERGOLOID MESYLATESTABLET; ORAL  
ERGOLOID MESYLATES

	@ SUN PHARM INDUSTRIES	1MG	A 081113	001	Oct 31, 1991	Jul	DISC
--	------------------------	-----	----------	-----	--------------	-----	------

ERGOTAMINE TARTRATETABLET; SUBLINGUAL  
ERGOMAR

!	PANGEA	2MG	A 087693	001	Feb 24, 1983	Feb	CAHN
---	--------	-----	----------	-----	--------------	-----	------

ERIBULIN MESYLATESOLUTION; INTRAVENOUS  
ERIBULIN MESYLATE

AP	GLAND PHARMA LTD	1MG/2ML (0.5MG/ML)	A 218047	001	Apr 05, 2024	Mar	NFTG
AP	JIANGXI QINGFENG	1MG/2ML (0.5MG/ML)	A 218281	001	Jun 28, 2024	Jun	NEWA
AP	LONG GROVE PHARMS	1MG/2ML (0.5MG/ML)	A 214850	001	Jul 18, 2024	Jul	NEWA
	HALAVEN						
AP	+! EISAI INC	1MG/2ML (0.5MG/ML)	N 201532	001	Nov 15, 2010	Mar	CFTG

ERLOTINIB HYDROCHLORIDETABLET; ORAL  
ERLOTINIB HYDROCHLORIDE

AB	HETERO LABS LTD V	EQ 25MG BASE	A 209267	001	May 24, 2024	May	NEWA
AB		EQ 100MG BASE	A 209267	002	May 24, 2024	May	NEWA
AB		EQ 150MG BASE	A 209267	003	May 24, 2024	May	NEWA
	@ NATCO PHARMA LTD	EQ 25MG BASE	A 208488	001	Nov 05, 2019	Apr	DISC
>D>	AB	EQ 150MG BASE	A 208488	003	Nov 05, 2019	Aug	DISC
>A>	@	EQ 150MG BASE	A 208488	003	Nov 05, 2019	Aug	DISC

ERTAPENEM SODIUMINJECTABLE; INTRAMUSCULAR, INTRAVENOUS  
ERTAPENEM SODIUM

	@ SUN PHARM	EQ 1GM BASE/VIAL	A 209145	001	May 02, 2023	Jan	DISC
--	-------------	------------------	----------	-----	--------------	-----	------

ERYTHROMYCINCAPSULE, DELAYED REL PELLETS; ORAL  
ERYTHROMYCIN

AB	AZURITY	250MG	A 062746	001	Dec 22, 1986	Mar	CAHN
----	---------	-------	----------	-----	--------------	-----	------

OINTMENT; OPHTHALMIC  
ERYTHROMYCIN

AT	! BAUSCH AND LOMB	0.5%	A 064067	001	Jul 29, 1994	Mar	CHRS
	@ PADAGIS US	0.5%	A 062447	001	Sep 26, 1983	Mar	DISC

TABLET; ORAL  
ERYTHROMYCIN

AB	AZURITY	250MG	A 061621	001		Mar	CAHN
AB		500MG	A 061621	002		Mar	CAHN

TABLET, DELAYED RELEASE; ORAL  
ERY-TAB

AB	AZURITY	250MG	A 062298	001		Mar	CAHN
AB		333MG	A 062298	003	Mar 29, 1982	Mar	CAHN
AB	!	500MG	A 062298	002		Mar	CAHN

ERYTHROMYCIN

>A>	AB	TORRENT	333MG	A 211975	003	Aug 13, 2024	Aug	NEWA
-----	----	---------	-------	----------	-----	--------------	-----	------

ERYTHROMYCIN ETHYLSUCCINATE

		GRANULE; ORAL							
		ERYTHROMYCIN ETHYLSUCCINATE							
	@ ENDO OPERATIONS	EQ	200MG BASE/5ML	A211991	001	Oct 23, 2019	May	CAHN	
	@	EQ	400MG BASE/5ML	A211991	002	Oct 23, 2019	May	CAHN	
		TABLET; ORAL							
		E.E.S. 400							
	@ AZURITY	EQ	400MG BASE	A061905	001			Mar	CAHN
BX	!	EQ	400MG BASE	A061905	002	Aug 12, 1982	Mar	CAHN	
		ERYTHROMYCIN ETHYLSUCCINATE							
BX	!	AZURITY	EQ	400MG BASE	A061904	001		Mar	CAHN

ERYTHROMYCIN STEARATE

		TABLET; ORAL							
		ERYTHROCIN STEARATE							
	@ AZURITY	EQ	125MG BASE	A060359	002		Mar	CAHN	
	!	EQ	250MG BASE	A060359	001		Mar	CAHN	
	@	EQ	500MG BASE	A060359	003		Mar	CAHN	

ESCITALOPRAM OXALATE

		TABLET; ORAL							
		ESCITALOPRAM OXALATE							
	@ PHARM ASSOC	EQ	5MG BASE	A077512	001	Sep 12, 2012	Mar	DISC	
	@	EQ	10MG BASE	A077512	002	Sep 12, 2012	Mar	DISC	
	@	EQ	20MG BASE	A077512	003	Sep 12, 2012	Mar	DISC	

ESLICARBAZEPINE ACETATE

		TABLET; ORAL							
		ESLICARBAZEPINE ACETATE							
	@ APOTEX		200MG	A211236	001	Dec 07, 2023	Apr	DISC	
	@		400MG	A211236	002	Dec 07, 2023	Apr	DISC	
	@		600MG	A211236	003	Dec 07, 2023	Apr	DISC	
	@		800MG	A211236	004	Dec 07, 2023	Apr	DISC	
AB	LUPIN LTD		200MG	A211246	001	Mar 27, 2024	Mar	NEWA	
AB			400MG	A211246	002	Mar 27, 2024	Mar	NEWA	
AB			600MG	A211246	003	Mar 27, 2024	Mar	NEWA	
AB			800MG	A211246	004	Mar 27, 2024	Mar	NEWA	
	@ TORRENT		200MG	A211227	001	Feb 27, 2024	Mar	DISC	
AB			200MG	A211227	001	Feb 27, 2024	Feb	NEWA	
	@		400MG	A211227	002	Feb 27, 2024	Mar	DISC	
AB			400MG	A211227	002	Feb 27, 2024	Feb	NEWA	
	@		600MG	A211227	003	Feb 27, 2024	Mar	DISC	
AB			600MG	A211227	003	Feb 27, 2024	Feb	NEWA	
	@		800MG	A211227	004	Feb 27, 2024	Mar	DISC	
AB			800MG	A211227	004	Feb 27, 2024	Feb	NEWA	

ESOMEPRAZOLE SODIUM

		INJECTABLE; INTRAVENOUS							
		ESOMEPRAZOLE SODIUM							
	@ ACCORD HLTHCARE	EQ	40MG BASE/VIAL	A205379	001	Sep 25, 2015	May	DISC	
	! GLAND PHARMA LTD	EQ	20MG BASE/VIAL	A203349	001	Apr 01, 2020	May	CHRS	
>D> AP	HAINAN POLY	EQ	40MG BASE/VIAL	A215732	001	Feb 10, 2022	Aug	CHRS	
>A> AP	!	EQ	40MG BASE/VIAL	A215732	001	Feb 10, 2022	Aug	CHRS	
	@ SUN PHARM	EQ	40MG BASE/VIAL	A200882	002	Mar 18, 2013	May	DISC	
>D>	NEXIUM IV								
>D> AP	+! ASTRAZENECA	EQ	40MG BASE/VIAL	N021689	002	Mar 31, 2005	Aug	DISC	
>A>	+ @	EQ	40MG BASE/VIAL	N021689	002	Mar 31, 2005	Aug	DISC	

ESTRADIOL

		GEL; TRANSDERMAL							
		DIVIGEL							
AB	+! VERTICAL PHARMS	0.1%	(0.25GM/PACKET)	N022038	001	Jun 04, 2007	Jul	CPOT	
AB	+!	0.1%	(0.5GM/PACKET)	N022038	002	Jun 04, 2007	Jul	NEWA	
AB	+!	0.1%	(1GM/PACKET)	N022038	003	Jun 04, 2007	Jul	NEWA	
AB	+!	0.1%	(0.75GM/PACKET)	N022038	004	Aug 17, 2018	Jul	NEWA	
AB	+!	0.1%	(1.25GM/PACKET)	N022038	005	Dec 12, 2019	Jul	NEWA	
		ESTRADIOL							
AB	AMNEAL	0.1%	(0.25GM/PACKET)	A216055	001	Jul 12, 2024	Jul	NEWA	
AB		0.1%	(0.5GM/PACKET)	A216055	002	Jul 12, 2024	Jul	NEWA	
AB		0.1%	(0.75GM/PACKET)	A216055	003	Jul 12, 2024	Jul	NEWA	
AB		0.1%	(1GM/PACKET)	A216055	004	Jul 12, 2024	Jul	NEWA	

## GEL; TRANSDERMAL

## ESTRADIOL

AB		0.1% (1.25GM/PACKET)	A216055	005	Jul 12, 2024	Jul	NEWA
AB	CHEMO RESEARCH SL	0.1% (0.25GM/PACKET)	A211783	001	Aug 10, 2022	Jul	CPOT
AB		0.1% (0.5GM/PACKET)	A211783	002	Aug 10, 2022	Jul	NEWA
AB		0.1% (1GM/PACKET)	A211783	003	Aug 10, 2022	Jul	NEWA
AB	NOVITIUM PHARMA	0.1% (0.25GM/PACKET)	A217610	001	Aug 24, 2023	Jul	CPOT
AB		0.1% (0.5GM/PACKET)	A217610	002	Aug 24, 2023	Jul	NEWA
AB		0.1% (0.75GM/PACKET)	A217610	003	Aug 24, 2023	Jul	NEWA
AB		0.1% (1GM/PACKET)	A217610	004	Aug 24, 2023	Jul	NEWA
AB		0.1% (1.25GM/PACKET)	A217610	005	Aug 24, 2023	Jul	NEWA
AB	PADAGIS ISRAEL	0.1% (0.25GM/PACKET)	A216524	001	Nov 14, 2023	Jul	CPOT
AB		0.1% (0.5GM/PACKET)	A216524	002	Nov 14, 2023	Jul	NEWA
AB		0.1% (0.75GM/PACKET)	A216524	003	Nov 14, 2023	Jul	NEWA
AB		0.1% (1GM/PACKET)	A216524	004	Nov 14, 2023	Jul	NEWA
AB		0.1% (1.25GM/PACKET)	A216524	005	Nov 14, 2023	Jul	NEWA
AB	SOLARIS PHARMA CORP	0.1% (0.25GM/PACKET)	A217863	001	Jul 12, 2024	Jul	NEWA
AB		0.1% (0.5GM/PACKET)	A217863	002	Jul 12, 2024	Jul	NEWA
AB		0.1% (0.75GM/PACKET)	A217863	003	Jul 12, 2024	Jul	NEWA
AB		0.1% (1GM/PACKET)	A217863	004	Jul 12, 2024	Jul	NEWA
AB		0.1% (1.25GM/PACKET)	A217863	005	Jul 12, 2024	Jul	NEWA

## GEL, METERED; TRANSDERMAL

## ESTRADIOL

AB	SOLARIS PHARMA CORP	0.06% (1.25GM/ACTIVATION)	A216160	001	Apr 22, 2024	Apr	NFTG
AB	ESTROGEL						
AB	+! ASCEND THERAPS US	0.06% (1.25GM/ACTIVATION)	N021166	002	Feb 09, 2004	Apr	CFTG

## TABLET; VAGINAL

## ESTRADIOL

AB	AUROBINDO PHARMA	10MCG	A216550	001	Aug 02, 2024	Jul	NEWA
----	------------------	-------	---------	-----	--------------	-----	------

ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE

## INJECTABLE; INTRAMUSCULAR

## LUNELLE

	+ @ PHARMACIA AND UPJOHN	5MG/0.5ML; 25MG/0.5ML	N020874	001	Oct 05, 2000	Feb	CRLD
--	--------------------------	-----------------------	---------	-----	--------------	-----	------

ESTRADIOL VALERATE

## INJECTABLE; INJECTION

## DELESTROGEN

AO	+! ENDO OPERATIONS	10MG/ML	N009402	002		Apr	CAHN
AO	+!	20MG/ML	N009402	004		Apr	CAHN
AO	+!	40MG/ML	N009402	003		Apr	CAHN

ESTRADIOL; NORETHINDRONE ACETATE

## TABLET; ORAL

## ESTRADIOL AND NORETHINDRONE ACETATE

AB	NAARI PTE LTD	1MG; 0.5MG	A210233	001	Feb 28, 2018	Apr	CMFD
----	---------------	------------	---------	-----	--------------	-----	------

ESTRADIOL; NORGESTIMATE

## TABLET; ORAL

## ESTRADIOL AND NORGESTIMATE

>D>	! BARR	1MG, 1MG; N/A, 0.09MG	A076812	001	Apr 29, 2005	Aug	DISC
>A>	@	1MG, 1MG; N/A, 0.09MG	A076812	001	Apr 29, 2005	Aug	DISC

ESTRAMUSTINE PHOSPHATE SODIUM

## CAPSULE; ORAL

## EMCYT

	+ @ PHARMACIA AND UPJOHN	EQ 140MG PHOSPHATE	N018045	001		Jun	DISC
--	--------------------------	--------------------	---------	-----	--	-----	------

ESTROGENS, ESTERIFIED

## TABLET; ORAL

## MENEST

@ MONARCH PHARMS

0.3MG

A084951 001

Jul DISC

@ 0.625MG

A084948 001

Jul DISC

@ 1.25MG

A084950 001

Jul DISC

@ 2.5MG

A084949 001

Jul DISC

ESZOPICLONE

## TABLET; ORAL

## LUNESTA

AB	+ WAYLIS THERAP	1MG	N021476	001	Dec 15, 2004	Apr	CAHN
AB	+	2MG	N021476	002	Dec 15, 2004	Apr	CAHN
AB	+!	3MG	N021476	003	Dec 15, 2004	Apr	CAHN

ETHACRYNATE SODIUMINJECTABLE; INJECTION  
ETHACRYNATE SODIUM

AP	ENDO OPERATIONS	EQ 50MG BASE/VIAL	A205473	001	Jul 29, 2015	Apr	CAHN
AP	STERIMAX	EQ 50MG BASE/VIAL	A208663	001	Jun 09, 2020	Mar	CAHN

ETHACRYNIC ACIDTABLET; ORAL  
ETHACRYNIC ACID

@	ENDO OPERATIONS	25MG	A208501	001	Jul 21, 2017	May	CAHN
@	PAR PHARM INC	25MG	A208501	001	Jul 21, 2017	Apr	DISC

ETHAMBUTOL HYDROCHLORIDETABLET; ORAL  
MYAMBUTOL

>A>	AB	+	KANCHAN HLTHCARE	100MG	N016320	001	Aug	CAHN
>A>		@		200MG	N016320	002	Aug	CAHN
>A>	AB	+	!	400MG	N016320	003	Aug	CAHN
>A>		@		500MG	N016320	004	Aug	CAHN
>D>	AB	+	STI PHARMA LLC	100MG	N016320	001	Aug	CAHN
>D>		@		200MG	N016320	002	Aug	CAHN
>D>	AB	+	!	400MG	N016320	003	Aug	CAHN
>D>		@		500MG	N016320	004	Aug	CAHN

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB	XIROMED	0.03MG; 0.15MG	A200490	001	Apr 21, 2015	Apr	CAHN
AB3	LUPIN LTD	0.02MG; 0.1MG	A217087	001	Feb 15, 2024	Feb	NEWA

TABLET; ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

@	XIROMED	0.02MG; 0.1MG	A202247	001	Dec 08, 2014	Apr	CAHN
@		0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG	A202970	001	Mar 23, 2018	May	CAHN
AB	ENDO OPERATIONS	0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG	A077502	001	Nov 23, 2011	May	CAHN
	ORSYTHIA						
@	ENDO OPERATIONS	0.02MG; 0.1MG	A077099	001	May 11, 2011	May	CAHN

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

CYCLAFEM 0.5/35

@	ENDO OPERATIONS	0.035MG; 0.5MG	A203413	001	Dec 16, 2015	Apr	CAHN
@	ENDO OPERATIONS	0.035MG; 1MG	A076337	001	Nov 12, 2010	May	CAHN
@	ENDO OPERATIONS	0.035MG, 0.035MG, 0.035MG; 0.5MG, 0.75MG, 1MG	A076338	001	Nov 16, 2010	May	CAHN
AB	ENDO OPERATIONS	0.035MG; 0.4MG	A078376	001	Nov 06, 2012	May	CAHN
	NORETHINDRONE AND ETHINYL ESTRADIOL						
@	XIROMED	0.035MG; 0.4MG	A200897	001	May 11, 2015	Apr	CAHN
@		0.05MG; 1MG	A203006	001	Aug 05, 2013	Apr	CAHN

TABLET, CHEWABLE; ORAL

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	+	!	TEVA BRANDED PHARM	0.025MG; 0.8MG	N022573	001	Dec 22, 2010	Mar	CAHN
----	---	---	--------------------	----------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE; ORAL

MERZEE

AB	WILSHIRE PHARMS INC	0.02MG; 1MG	A212706	001	Dec 18, 2020	Jul	CAHN
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
@	AMNEAL PHARMS	0.02MG; 1MG	A214292	001	Jul 20, 2021	Feb	DISC

TABLET; ORAL

GILDESS 24 FE

AB	ENDO OPERATIONS	0.02MG; 1MG	A090293	001	Dec 01, 2014	May	CAHN
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL						
@	XIROMED	0.0025MG; 0.5MG	A207260	001	Feb 02, 2017	Apr	CAHN
@		0.005MG; 1MG	A207259	001	Dec 27, 2016	Apr	CAHN

<u>TABLET;ORAL</u>									
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE									
	@ XIROMED	0.01MG,0.01MG;1MG,N/A		A205049	001	May 31, 2016	May	CAHN	
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE									
	@ XIROMED	0.02MG;1MG		A206120	001	Sep 12, 2017	May	CAHN	
	OSHIH								
	@ AUROBINDO PHARMA	0.02MG;1MG		A216558	001	Dec 06, 2023	May	DISC	
<u>TABLET;ORAL-21</u>									
GILDESS 1.5/30									
	@ ENDO OPERATIONS	0.03MG;1.5MG		A077075	002	Jul 24, 2012	May	CAHN	
GILDESS 1/20									
	@ ENDO OPERATIONS	0.02MG;1MG		A077077	002	Jul 24, 2012	May	CAHN	
<u>TABLET;ORAL-28</u>									
GILDESS FE 1.5/30									
	@ ENDO OPERATIONS	0.03MG;1.5MG		A077075	001	Apr 28, 2005	May	CAHN	
GILDESS FE 1/20									
	@ ENDO OPERATIONS	0.02MG;1MG		A077077	001	May 20, 2005	May	CAHN	
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL									
AB	XIROMED	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG		A205069	001	Jun 22, 2018	Apr	CAHN	
<u>TABLET, ORALLY DISINTEGRATING;ORAL</u>									
FEMLYV									
+	MILLICENT PR	0.02MG;1MG		N218718	001	Jul 22, 2024	Jul	NEWA	
<u>ETHINYL ESTRADIOL; NORGESTIMATE</u>									
<u>TABLET;ORAL-28</u>									
NORGESTIMATE AND ETHINYL ESTRADIOL									
	@ XIROMED	0.025MG,0.025MG,0.025MG;0.18MG,0.2		A202132	001	Sep 09, 2015	May	CAHN	
		15MG,0.25MG							
	@	0.035MG,0.035MG,0.035MG;0.18MG,0.2		A201897	001	Jan 27, 2016	May	CAHN	
		15MG,0.25MG							
PREVIFEM									
AB	ENDO OPERATIONS	0.035MG;0.25MG		A076334	001	Jan 09, 2004	May	CAHN	
TRI-PREVIFEM									
	@ ENDO OPERATIONS	0.035MG,0.035MG,0.035MG;0.18MG,0.2		A076335	001	Mar 26, 2004	May	CAHN	
		15MG,0.25MG							
<u>ETHOSUXIMIDE</u>									
<u>CAPSULE;ORAL</u>									
ETHOSUXIMIDE									
AB	EPIC PHARMA LLC	250MG		A040686	001	May 28, 2008	Jan	CAHN	
<u>ETODOLAC</u>									
<u>CAPSULE;ORAL</u>									
ETODOLAC									
AB	IPCA LABS LTD	200MG		A205448	001	Aug 01, 2024	Jul	NEWA	
AB		300MG		A205448	002	Aug 01, 2024	Jul	NEWA	
<u>TABLET;ORAL</u>									
ETODOLAC									
AB	EDENBRIDGE PHARMS	400MG		A209888	001	Nov 30, 2018	Jul	CMFD	
AB		500MG		A209888	002	Nov 30, 2018	Jul	CMFD	
AB	IPCA LABS LTD	400MG		A204729	001	May 01, 2024	Apr	NEWA	
AB		500MG		A204729	002	May 01, 2024	Apr	NEWA	
AB	PANGEA	400MG		A074903	001	Apr 11, 1997	Jun	CAHN	
AB		500MG		A074903	002	Apr 19, 1999	Jun	CAHN	
<u>ETOMIDATE</u>									
<u>INJECTABLE;INJECTION</u>									
ETOMIDATE									
	@ ENDO OPERATIONS	2MG/ML		A091297	001	Jun 20, 2012	May	CAHN	
<u>EZETIMIBE</u>									
<u>TABLET;ORAL</u>									
EZETIMIBE									
AB	MACLEODS PHARMS LTD	10MG		A211159	001	Apr 29, 2024	Apr	NEWA	
<u>EZETIMIBE; SIMVASTATIN</u>									
<u>TABLET;ORAL</u>									
EZETIMIBE AND SIMVASTATIN									
AB	AUROBINDO PHARMA USA	10MG;10MG		A200082	001	Dec 17, 2020	Mar	CMFD	
AB		10MG;20MG		A200082	002	Dec 17, 2020	Mar	CMFD	
AB		10MG;40MG		A200082	003	Dec 17, 2020	Mar	CMFD	
AB		10MG;80MG		A200082	004	Dec 17, 2020	Mar	CMFD	

FAMOTIDINE

FOR SUSPENSION;ORAL

FAMOTIDINE

AB	CEROVENE INC	40MG/5ML	A217605	001	Jan 16, 2024	Jan	NEWA
----	--------------	----------	---------	-----	--------------	-----	------

TABLET;ORAL

FAMOTIDINE

>D>	AB	GRAVITI PHARMS	20MG	A218181	001	Dec 22, 2023	Aug	CAHN
>D>	AB		40MG	A218181	002	Dec 22, 2023	Aug	CAHN
	AB	MSN	20MG	A217400	001	Aug 06, 2024	Jul	NEWA
	AB		40MG	A217400	002	Aug 06, 2024	Jul	NEWA
>A>	AB	RISING	20MG	A218181	001	Dec 22, 2023	Aug	CAHN
>A>	AB		40MG	A218181	002	Dec 22, 2023	Aug	CAHN

FAMOTIDINE; IBUPROFEN

TABLET;ORAL

FAMOTIDINE AND IBUPROFEN

@ TORRENT

26.6MG;800MG

A215925 001 Mar 18, 2024 Mar NEWA

IBUPROFEN AND FAMOTIDINE

AB	!	ALKEM LABS LTD	26.6MG;800MG	A211890	001	Aug 03, 2021	Feb	CHRS
----	---	----------------	--------------	---------	-----	--------------	-----	------

FEBUXOSTAT

TABLET;ORAL

FEBUXOSTAT

@ LUPIN LTD

40MG

A205406 001 Jan 17, 2024 Apr DISC

AB			40MG	A205406	001	Jan 17, 2024	Jan	NEWA
----	--	--	------	---------	-----	--------------	-----	------

@

80MG

A205406 002 Jan 17, 2024 Apr DISC

AB			80MG	A205406	002	Jan 17, 2024	Jan	NEWA
----	--	--	------	---------	-----	--------------	-----	------

BX		MSN	40MG	A210461	001	Dec 30, 2019	Jun	CTEC
----	--	-----	------	---------	-----	--------------	-----	------

BX			80MG	A210461	002	Dec 30, 2019	Jun	CTEC
----	--	--	------	---------	-----	--------------	-----	------

FEDRATINIB HYDROCHLORIDE

CAPSULE;ORAL

INREBIC

+! BRISTOL-MYERS EQ 100MG BASE

N212327 001 Aug 16, 2019 Feb CAHN

FELODIPINE

TABLET, EXTENDED RELEASE;ORAL

FELODIPINE

AB		ENDO OPERATIONS	2.5MG	A200815	001	Oct 28, 2011	Apr	CAHN
----	--	-----------------	-------	---------	-----	--------------	-----	------

AB			5MG	A200815	002	Oct 28, 2011	Apr	CAHN
----	--	--	-----	---------	-----	--------------	-----	------

AB			10MG	A200815	003	Oct 28, 2011	Apr	CAHN
----	--	--	------	---------	-----	--------------	-----	------

FENOFIBRATE

CAPSULE;ORAL

FENOFIBRATE (MICRONIZED)

AB		CHARTWELL	67MG	A211407	001	Jan 31, 2024	Mar	CAHN
----	--	-----------	------	---------	-----	--------------	-----	------

AB			134MG	A211407	002	Jan 31, 2024	Mar	CAHN
----	--	--	-------	---------	-----	--------------	-----	------

AB			200MG	A211407	003	Jan 31, 2024	Mar	CAHN
----	--	--	-------	---------	-----	--------------	-----	------

@ INVAGEN PHARMS

67MG

A207378 001 Mar 28, 2017 Mar DISC

@

134MG

A207378 002 Mar 28, 2017 Mar DISC

@

200MG

A207378 003 Mar 28, 2017 Mar DISC

AB		YOUNGTECH PHARMS INC	67MG	A211407	001	Jan 31, 2024	Jan	NEWA
----	--	----------------------	------	---------	-----	--------------	-----	------

AB			134MG	A211407	002	Jan 31, 2024	Jan	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

AB			200MG	A211407	003	Jan 31, 2024	Jan	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

TABLET;ORAL

FENOFIBRATE

! AUROBINDO PHARMA 145MG

A205118 002 May 05, 2016 Mar CHRS

BX		CREEKWOOD PHARMS	40MG	A217732	001	Sep 07, 2023	Jun	CTEC
----	--	------------------	------	---------	-----	--------------	-----	------

BX			120MG	A217732	002	Sep 07, 2023	Jun	CTEC
----	--	--	-------	---------	-----	--------------	-----	------

>D>	AB	GRAVITI PHARMS	48MG	A211122	001	Mar 18, 2020	Aug	CAHN
-----	----	----------------	------	---------	-----	--------------	-----	------

>D>	AB		54MG	A210606	001	Aug 17, 2018	Aug	CAHN
-----	----	--	------	---------	-----	--------------	-----	------

>D>	AB		145MG	A211122	002	Mar 18, 2020	Aug	CAHN
-----	----	--	-------	---------	-----	--------------	-----	------

>D>	AB		160MG	A210606	002	Aug 17, 2018	Aug	CAHN
-----	----	--	-------	---------	-----	--------------	-----	------

! MYLAN PHARMS INC 120MG

A204475 002 Jun 23, 2016 May CHRS

>A>	AB	RISING	48MG	A211122	001	Mar 18, 2020	Aug	CAHN
-----	----	--------	------	---------	-----	--------------	-----	------

>A>	AB		54MG	A210606	001	Aug 17, 2018	Aug	CAHN
-----	----	--	------	---------	-----	--------------	-----	------

>A>	AB		145MG	A211122	002	Mar 18, 2020	Aug	CAHN
-----	----	--	-------	---------	-----	--------------	-----	------

>A>	AB		160MG	A210606	002	Aug 17, 2018	Aug	CAHN
-----	----	--	-------	---------	-----	--------------	-----	------

AB		YICHANG HUMANWELL	54MG	A218548	001	Apr 24, 2024	Apr	NEWA
----	--	-------------------	------	---------	-----	--------------	-----	------

AB			160MG	A218548	002	Apr 24, 2024	Apr	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

	TABLET;ORAL								
	FENOGLIDE								
	+ @	SALIX	40MG	N022118	001	Aug 10, 2007	May	DISC	
	+ @		120MG	N022118	002	Aug 10, 2007	May	DISC	
>D>		TRICOR							
>D>	AB	+ ABBVIE	48MG	N021656	001	Nov 05, 2004	Aug	DISC	
>A>		+ @	48MG	N021656	001	Nov 05, 2004	Aug	DISC	
		+ @	145MG	N021656	002	Nov 05, 2004	Mar	DISC	
	<u>FENOLDOPAM MESYLATE</u>								
	INJECTABLE;INJECTION								
	CORLOPAM								
	+ @	HOSPIRA	EQ 10MG BASE/ML	N019922	001	Sep 23, 1997	May	DISC	
		FENOLDOPAM MESYLATE							
	@	HIKMA	EQ 10MG BASE/ML	A076582	001	Oct 12, 2004	May	DISC	
	@	SANDOZ	EQ 10MG BASE/ML	A077155	001	Feb 15, 2005	May	DISC	
	<u>FENOPROFEN CALCIUM</u>								
	CAPSULE;ORAL								
	FENOPROFEN CALCIUM								
>D>		MISEMER	EQ 200MG BASE	A215548	001	May 16, 2023	Aug	DISC	
>A>		@	EQ 200MG BASE	A215548	001	May 16, 2023	Aug	DISC	
			EQ 200MG BASE	A215548	001	May 16, 2023	May	CTEC	
>D>			EQ 300MG BASE	A215548	002	May 16, 2023	Aug	DISC	
>A>		@	EQ 300MG BASE	A215548	002	May 16, 2023	Aug	DISC	
>D>	AB		EQ 400MG BASE	A215548	003	May 16, 2023	Aug	DISC	
>A>		@	EQ 400MG BASE	A215548	003	May 16, 2023	Aug	DISC	
>D>	AB	! RISING	EQ 400MG BASE	A214475	001	Jul 18, 2022	Aug	CTEC	
>A>		!	EQ 400MG BASE	A214475	001	Jul 18, 2022	Aug	CTEC	
	AB	!	EQ 400MG BASE	A214475	001	Jul 18, 2022	May	CHRS	
		NALFON							
	+ @	KEY THERAP	EQ 200MG BASE	N017604	003		May	DISC	
AB	+		EQ 200MG BASE	N017604	003		Apr	CAHN	
	+ @		EQ 400MG BASE	N017604	004	Jul 21, 2009	May	DISC	
AB	+!		EQ 400MG BASE	N017604	004	Jul 21, 2009	Apr	CAHN	
	TABLET;ORAL								
	FENOPROFEN CALCIUM								
	@	KEY THERAP	EQ 600MG BASE	A072267	001	Aug 17, 1988	May	DISC	
	!		EQ 600MG BASE	A072267	001	Aug 17, 1988	Apr	CAHN	
	<u>FESOTERODINE FUMARATE</u>								
	TABLET, EXTENDED RELEASE;ORAL								
	FESOTERODINE FUMARATE								
	@	ANI PHARMS	4MG	A204504	001	Jan 04, 2023	Apr	DISC	
	@		8MG	A204504	002	Jan 04, 2023	Apr	DISC	
	<u>FIDAXOMICIN</u>								
	TABLET;ORAL								
	DIFICID								
	+!	CUBIST PHARMS LLC	200MG	N201699	001	May 27, 2011	Jul	CTEC	
AB	+!		200MG	N201699	001	May 27, 2011	Jan	CFTG	
		FIDAXOMICIN							
	@	ACTAVIS LABS FL	200MG	A208443	001	Jan 16, 2024	Jul	DISC	
AB			200MG	A208443	001	Jan 16, 2024	Jan	NEWA	
	<u>FINASTERIDE</u>								
	TABLET;ORAL								
	FINASTERIDE								
	@	CIPLA	1MG	A077335	001	Nov 20, 2014	Mar	DISC	
	<u>FINASTERIDE; TADALAFIL</u>								
	CAPSULE;ORAL								
	ENTADFI								
AB	+!	BLUE WATER BIOTECH	5MG;5MG	N215423	001	Dec 09, 2021	Mar	CFTG	
		FINASTERIDE AND TADALAFIL							
AB		ZYDUS	5MG;5MG	A218232	001	Mar 15, 2024	Mar	NFTG	
AB		ZYDUS LIFESCIENCES	5MG;5MG	A218232	001	Mar 15, 2024	May	CAHN	

FINGOLIMOD HYDROCHLORIDE

CAPSULE;ORAL

FINGOLIMOD HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	EQ 0.5MG BASE	A207983	001	Feb 28, 2024	Feb	NEWA
AB	BIOCON LTD	EQ 0.5MG BASE	A207979	001	Dec 04, 2019	Feb	CMFD

FLORTAUCIPIR F-18

SOLUTION;INTRAVENOUS

TAUVID

+ @	AVID RADIOPHARMS INC	30ML (8.1-51mCi/ML)	N212123	001	May 28, 2020	Jun	DISC
+ @		50ML (8.1-51mCi/ML)	N212123	002	May 28, 2020	Jun	DISC

FLUCONAZOLE

INJECTABLE;INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

@ NORVIUM BIOSCIENCE 200MG/100ML (2MG/ML)

@ 400MG/200ML (2MG/ML)

A076888	001	Mar 25, 2005	Jul	CAHN
A076888	002	Mar 25, 2005	Jul	CAHN

FLUDARABINE PHOSPHATE

INJECTABLE;INJECTION

FLUDARABINE PHOSPHATE

@ EXTROVIS 50MG/2ML (25MG/ML)

@ RISING 50MG/VIAL

A200647	001	Dec 21, 2011	Jun	CAHN
A200648	001	Oct 16, 2012	Feb	CAHN

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP	! CARDINAL HEALTH 414	20-500mCi/ML	A203603	002	Sep 27, 2018	May	CHRS
	@ SOFIE	20-500mCi/ML	A203665	001	Feb 14, 2013	May	DISC

FLUOCINOLONE ACETONIDE

OIL;TOPICAL

FLUOCINOLONE ACETONIDE

AT	TARO	0.01%	A209336	001	May 19, 2016	Jan	CAHN
----	------	-------	---------	-----	--------------	-----	------

OIL/DROPS;OTIC

FLUOCINOLONE ACETONIDE

>D>	AT	TASMAN PHARMA	0.01%	A213264	001	Feb 05, 2021	Aug	CAHN
>A>	AT	TRUPHARMA	0.01%	A213264	001	Feb 05, 2021	Aug	CAHN

SHAMPOO;TOPICAL

CAPEX

+ @	GALDERMA LABS LP	0.01%	N020001	001	Aug 27, 1990	May	DISC
-----	------------------	-------	---------	-----	--------------	-----	------

FLUOCINONIDE

CREAM;TOPICAL

FLUOCINONIDE

@ AMNEAL 0.1%

@ PADAGIS ISRAEL 0.1%

>D>	+ @	TARO	0.05%	N019117	001	Jun 26, 1984	Aug	CAHN
-----	-----	------	-------	---------	-----	--------------	-----	------

>A>	+ @		0.05%	N019117	001	Jun 26, 1984	Aug	CAHN
-----	-----	--	-------	---------	-----	--------------	-----	------

GEL;TOPICAL

FLUOCINONIDE

+ @	ALVOGEN	0.05%	N017373	001			May	DISC
@	COSETTE	0.05%	A072537	001	Feb 07, 1989	Apr	DISC	
@	PADAGIS US	0.05%	A209030	001	Jun 19, 2018	Jan	CAHN	

SOLUTION;TOPICAL

FLUOCINONIDE

@	COSETTE	0.05%	A071535	001	Dec 02, 1988	Apr	DISC
---	---------	-------	---------	-----	--------------	-----	------

FLUOROURACIL

CREAM;TOPICAL

FLUOROURACIL

@ EXTROVIS 0.5%

INJECTABLE;INJECTION

FLUOROURACIL

AP	EUGIA PHARMA SPECLTS	500MG/10ML (50MG/ML)	A202668	001	Jul 17, 2012	Apr	CMFD
AP		1GM/20ML (50MG/ML)	A202668	002	Jul 17, 2012	Apr	CMFD
AP		2.5GM/50ML (50MG/ML)	A202669	001	Jul 17, 2012	Apr	CMFD
AP		5GM/100ML (50MG/ML)	A202669	002	Jul 17, 2012	Apr	CMFD



FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE HYDROCHLORIDE

@ SUN PHARM INDS LTD EQ 40MG BASE

A076990 001 Dec 13, 2004 Jan DISC

SOLUTION;ORAL

FLUOXETINE HYDROCHLORIDE

@ BAJAJ EQ 20MG BASE/5ML

A075920 001 Jan 29, 2002 Mar CAHN

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

AB ENDO OPERATIONS EQ 10MG BASE

A203836 001 Aug 19, 2016 Apr CAHN

AB EQ 20MG BASE

A203836 002 Aug 19, 2016 Apr CAHN

AB EQ 60MG BASE

A209419 001 Nov 16, 2017 Apr CAHN

AB STRIDES PHARMA EQ 10MG BASE

A212684 001 Apr 05, 2024 Mar NEWA

AB EQ 20MG BASE

A212684 002 Apr 05, 2024 Mar NEWA

@ TEVA EQ 10MG BASE

A075872 001 Jan 29, 2002 Jan DISC

@ EQ 20MG BASE

A075872 002 Jan 04, 2019 Jan DISC

@ TEVA PHARMS USA EQ 60MG BASE

A211051 001 Dec 03, 2018 Jan DISC

@ UPSHER SMITH LABS EQ 10MG BASE

A211696 001 Jan 30, 2019 Jun DISC

@ EQ 20MG BASE

A211696 002 Jan 30, 2019 Jun DISC

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE;ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

AB ENDO OPERATIONS EQ 25MG BASE;EQ 3MG BASE

A077742 001 Nov 02, 2012 Apr CAHN

AB EQ 25MG BASE;EQ 6MG BASE

A077742 002 Nov 02, 2012 Apr CAHN

AB EQ 25MG BASE;EQ 12MG BASE

A077742 003 Nov 02, 2012 Apr CAHN

AB EQ 50MG BASE;EQ 6MG BASE

A077742 004 Nov 02, 2012 Apr CAHN

AB EQ 50MG BASE;EQ 12MG BASE

A077742 005 Nov 02, 2012 Apr CAHN

FLUPHENAZINE DECANOATE

INJECTABLE;INJECTION

FLUPHENAZINE DECANOATE

AO ENDO OPERATIONS 25MG/ML

A203732 001 Jul 03, 2014 Apr CAHN

FLUPHENAZINE HYDROCHLORIDE

TABLET;ORAL

FLUPHENAZINE HYDROCHLORIDE

AB ALEMBIC 1MG

A218173 001 Jul 23, 2024 Jul NEWA

AB 2.5MG

A218173 002 Jul 23, 2024 Jul NEWA

AB 5MG

A218173 003 Jul 23, 2024 Jul NEWA

AB 10MG

A218173 004 Jul 23, 2024 Jul NEWA

AB RISING 1MG

A218283 001 Jun 07, 2024 May NEWA

AB 2.5MG

A218283 002 Jun 07, 2024 May NEWA

AB 5MG

A218283 003 Jun 07, 2024 May NEWA

AB 10MG

A218283 004 Jun 07, 2024 May NEWA

AB ZAMEER PHARMS 1MG

A215141 001 Oct 20, 2021 Feb CAHN

AB 2.5MG

A215141 002 Oct 20, 2021 Feb CAHN

AB 5MG

A215141 003 Oct 20, 2021 Feb CAHN

AB 10MG

A215141 004 Oct 20, 2021 Feb CAHN

FLURBIPROFEN

TABLET;ORAL

FLURBIPROFEN

&gt;D&gt; @ MYLAN 50MG

A074358 001 Jun 20, 1994 Aug CAHN

&gt;D&gt; @ 100MG

A074358 002 Jun 20, 1994 Aug CAHN

&gt;A&gt; @ NATCO PHARMA 50MG

A074358 001 Jun 20, 1994 Aug CAHN

&gt;A&gt; @ 100MG

A074358 002 Jun 20, 1994 Aug CAHN

FLUTICASONE PROPIONATE

POWDER;INHALATION

ARMONAIR DIGIHALER

+ @ TEVA PHARM 0.055MG/INH

N208798 004 Feb 20, 2020 Jun DISC

+ @ 0.113MG/INH

N208798 005 Feb 20, 2020 Jun DISC

+ @ 0.232MG/INH

N208798 006 Feb 20, 2020 Jun DISC

SPRAY, METERED;NASAL

FLUTICASONE PROPIONATE

@ HIKMA 0.05MG/SPRAY

A077570 001 Jan 16, 2008 Mar DISC

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

POWDER; INHALATION

AIRDUO DIGIHALER

+ @	TEVA PHARM	0.055MG/INH;EQ 0.014MG BASE/INH	N208799	004	Jul 12, 2019	Jun	DISC
+ @		0.113MG/INH;EQ 0.014MG BASE/INH	N208799	005	Jul 12, 2019	Jun	DISC
+ @		0.232MG/INH;EQ 0.014MG BASE/INH	N208799	006	Jul 12, 2019	Jun	DISC

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

FLUVOXAMINE MALEATE

AB	ENDO OPERATIONS	100MG	A091476	001	Mar 13, 2013	Apr	CAHN
AB		150MG	A091476	002	Mar 13, 2013	Apr	CAHN

TABLET; ORAL

FLUVOXAMINE MALEATE

AB	BIONPHARMA	25MG	A217917	001	Jan 22, 2024	Jan	NEWA
AB		50MG	A217917	002	Jan 22, 2024	Jan	NEWA
AB		100MG	A217917	003	Jan 22, 2024	Jan	NEWA

FOLIC ACID

TABLET; ORAL

FOLIC ACID

@	ENDO OPERATIONS	1MG	A040756	001	Jun 04, 2010	May	CAHN
---	-----------------	-----	---------	-----	--------------	-----	------

FONDAPARINUX SODIUM

INJECTABLE; SUBCUTANEOUS

FONDAPARINUX SODIUM

>A>	AP	HANGZHOU ZHONGMEI	2.5MG/0.5ML	A216493	001	Aug 19, 2024	Aug	NEWA
>A>	AP		5MG/0.4ML	A216493	002	Aug 19, 2024	Aug	NEWA
>A>	AP		7.5MG/0.6ML	A216493	003	Aug 19, 2024	Aug	NEWA
>A>	AP		10MG/0.8ML	A216493	004	Aug 19, 2024	Aug	NEWA

FORMOTEROL FUMARATE

SOLUTION; INHALATION

FORMOTEROL FUMARATE

AN	MICRO LABS	0.02MG/2ML	A218304	001	Jun 26, 2024	Jun	NEWA
AN	RITEDOSE CORP	0.02MG/2ML	A216486	001	Nov 25, 2022	May	CAHN
AN	WILSHIRE PHARMS INC	0.02MG/2ML	A215621	001	Dec 13, 2022	Jul	CAHN

FOSAMPRENAVIR CALCIUM

TABLET; ORAL

FOSAMPRENAVIR CALCIUM

AB	!	MYLAN	EQ 700MG BASE	A204060	001	Apr 15, 2016	Jan	CHRS
		LEXIVA						
	+ @	VIIIV HLTHCARE	EQ 700MG BASE	N021548	001	Oct 20, 2003	Jan	DISC

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS

FOSAPREPITANT DIMEGLUMINE

@	ACCORD HLTHCARE	EQ 150MG BASE/VIAL	A204025	001	Aug 26, 2020	May	DISC
@	GENEYORK PHARMS	EQ 150MG BASE/VIAL	A211624	001	Sep 05, 2019	Jul	CAHN

FOSCARNET SODIUM

INJECTABLE; INJECTION

FOSCARNET SODIUM

AP	AMNEAL	2.4GM/100ML	A216602	001	Mar 01, 2024	Feb	NEWA
----	--------	-------------	---------	-----	--------------	-----	------

FOSFOMYCIN TROMETHAMINE

FOR SOLUTION; ORAL

FOSFOMYCIN TROMETHAMINE

AA	AMNEAL	EQ 3GM BASE/PACKET	A216600	001	Mar 25, 2024	Mar	NEWA
----	--------	--------------------	---------	-----	--------------	-----	------

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

@	NORVIUM BIOSCIENCE	EQ 50MG PHENYTOIN NA/ML	A078736	001	Jun 08, 2010	Jul	CAHN
---	--------------------	-------------------------	---------	-----	--------------	-----	------

FROVATRIPTAN SUCCINATE

TABLET; ORAL  
FROVA

AB +! ENDO OPERATIONS EQ 2.5MG BASE N021006 001 Nov 08, 2001 Apr CAHN

FULVESTRANT

SOLUTION; INTRAMUSCULAR  
FULVESTRANT

>D> FRESENIUS KABI USA 250MG/5ML (50MG/ML) N210326 001 May 20, 2019 Aug CTEC  
>A> AO 250MG/5ML (50MG/ML) N210326 001 May 20, 2019 Aug CTEC  
>A> @ TEVA PHARMS USA INC 250MG/5ML (50MG/ML) N210063 001 Aug 19, 2019 Jun DISC

FUROSEMIDE

INJECTABLE; INJECTION  
FUROSEMIDE

>D> @ HIKMA 10MG/ML N018267 001 Aug CMFD  
>A> AP 10MG/ML N018267 001 Aug CMFD  
AP SABA ILAC SANAYIVE 10MG/ML A215856 001 Apr 02, 2024 Mar NEWA

GABAPENTIN

CAPSULE; ORAL  
GABAPENTIN

>D> AB GRAVITI PHARMS 100MG A207099 001 Mar 24, 2017 Aug CAHN  
>D> AB 300MG A207099 002 Mar 24, 2017 Aug CAHN  
>D> AB 400MG A207099 003 Mar 24, 2017 Aug CAHN  
>A> AB RISING 100MG A207099 001 Mar 24, 2017 Aug CAHN  
>A> AB 300MG A207099 002 Mar 24, 2017 Aug CAHN  
>A> AB 400MG A207099 003 Mar 24, 2017 Aug CAHN  
>A> @ SUN PHARM INDS LTD 100MG A077242 001 Aug 24, 2006 May DISC  
>A> @ 300MG A077242 002 Aug 24, 2006 May DISC  
>A> @ 400MG A077242 003 Aug 24, 2006 May DISC

SOLUTION; ORAL  
GABAPENTIN

AA ANNORA PHARMA 250MG/5ML A217682 001 Jan 17, 2024 Jan NEWA

TABLET; ORAL  
GABAPENTIN

AB1 ACI 600MG A203244 002 Jul 12, 2013 Jan CTEC  
AB1 800MG A203244 001 Jul 12, 2013 Jan CTEC  
AB1 ACTAVIS ELIZABETH 600MG A075694 001 Oct 21, 2004 Jan CTEC  
AB1 800MG A075694 002 Oct 21, 2004 Jan CTEC  
AB1 ALKEM LABS LTD 600MG A206402 001 Dec 23, 2015 Jan CTEC  
AB1 800MG A206402 002 Dec 23, 2015 Jan CTEC  
AB2 ANNORA PHARMA 300MG A218075 001 Feb 26, 2024 Feb NEWA  
AB2 600MG A218075 002 Feb 26, 2024 Feb NEWA  
AB1 APOTEX 100MG A077894 001 Oct 10, 2006 Jan CTEC  
AB1 300MG A077894 002 Oct 10, 2006 Jan CTEC  
AB1 400MG A077894 003 Oct 10, 2006 Jan CTEC  
AB1 ASCENT PHARMS INC 600MG A214957 001 Oct 01, 2021 Jan CTEC  
AB1 800MG A214957 002 Oct 01, 2021 Jan CTEC  
AB1 AUROBINDO PHARMA LTD 600MG A200651 001 Oct 06, 2011 Jan CTEC  
AB1 800MG A200651 002 Oct 06, 2011 Jan CTEC  
AB1 CSPC OUYI 600MG A207057 001 Oct 26, 2017 Jan CTEC  
AB1 800MG A207057 002 Oct 26, 2017 Jan CTEC  
AB1 GLENMARK PHARMS LTD 600MG A077662 001 Aug 18, 2006 Jan CTEC  
AB1 800MG A077662 002 Aug 18, 2006 Jan CTEC  
AB1 GRANULES 600MG A217116 001 Mar 28, 2023 Jan CTEC  
AB1 800MG A217116 002 Mar 28, 2023 Jan CTEC  
AB2 HUMANWELL 300MG A216252 001 Feb 26, 2024 Feb NEWA  
AB2 600MG A216252 002 Feb 26, 2024 Feb NEWA  
>A> AB2 INCEPTA PHARMS LTD 600MG A203643 001 Sep 09, 2024 Aug NEWA  
>A> @ INVAGEN PHARMS 600MG A202764 001 Oct 16, 2012 Mar DISC  
AB1 600MG A202764 001 Oct 16, 2012 Jan CTEC  
AB1 800MG A202764 002 Oct 16, 2012 Mar DISC  
AB1 800MG A202764 002 Oct 16, 2012 Jan CTEC  
AB1 IPCA LABS LTD 600MG A209855 001 May 29, 2024 May NEWA  
AB1 800MG A209855 002 May 29, 2024 May NEWA  
AB1 IVAX SUB TEVA PHARMS 100MG A076017 001 Apr 28, 2004 Jan CTEC  
AB1 300MG A076017 002 Apr 28, 2004 Jan CTEC  
AB1 400MG A076017 003 Apr 28, 2004 Jan CTEC  
AB1 LAURUS 600MG A217965 001 Apr 08, 2024 Mar NEWA  
AB1 800MG A217965 002 Apr 08, 2024 Mar NEWA  
AB1 RISING 600MG A217995 001 Jul 19, 2023 Jan CTEC

<u>TABLET;ORAL</u>							
<u>GABAPENTIN</u>							
AB1		800MG		A217995	002	Jul 19, 2023	Jan CTEC
AB1	RUBICON	600MG		A077661	004	Sep 13, 2006	Jan CTEC
AB1		800MG		A077661	005	Sep 13, 2006	Jan CTEC
AB1	SCIEGEN PHARMS INC	600MG		A205101	001	Feb 04, 2016	Jan CTEC
AB1		800MG		A205101	002	Feb 04, 2016	Jan CTEC
AB1	STRIDES PHARMA	600MG		A211313	001	Mar 04, 2024	Feb NEWA
AB1		800MG		A211313	002	Mar 04, 2024	Feb NEWA
AB1	SUN PHARM INDS LTD	600MG		A077525	001	Aug 24, 2006	Jan CTEC
AB1		800MG		A077525	002	Aug 24, 2006	Jan CTEC
AB2	ZYDUS PHARMS	300MG		A203934	001	Jan 24, 2024	Jan NEWA
AB2		600MG		A203934	002	Jan 24, 2024	Jan NEWA
AB1	ZYDUS PHARMS USA INC	600MG		A078926	001	Feb 11, 2011	Jan CTEC
AB1		800MG		A078926	002	Feb 11, 2011	Jan CTEC
<u>GRALISE</u>							
AB2	+! ALMATICA	300MG		N022544	001	Jan 28, 2011	Jan CTEC
AB2	+	600MG		N022544	002	Jan 28, 2011	Jan CTEC
EX	+	600MG		N022544	002	Jan 28, 2011	Jan CHRS
	+!	900MG		N022544	005	Apr 18, 2023	Jan CHRS
<u>NEURONTIN</u>							
AB1	+ VIATRIS	600MG		N020882	001	Oct 09, 1998	Jan CTEC
AB1	+!	800MG		N020882	002	Oct 09, 1998	Jan CTEC
<u>GADOBUTROL</u>							
<u>SOLUTION;INTRAVENOUS</u>							
<u>GADOBUTROL</u>							
AP	HENGRUI PHARMA	1.20944GM/2ML (604.72MG/ML)		A216081	003	Nov 17, 2022	Jul CMS1
AP		4.5354GM/7.5ML (604.72MG/ML)		A216081	004	Nov 17, 2022	Jul CMS1
AP		6.0472GM/10ML (604.72MG/ML)		A216081	005	Nov 17, 2022	Jul CMS1
AP		9.0708GM/15ML (604.72MG/ML)		A216081	006	Nov 17, 2022	Jul CMS1
<u>GADODIAMIDE</u>							
<u>INJECTABLE;INJECTION</u>							
<u>OMNISCAN</u>							
	+ @ GE HEALTHCARE	14.35GM/50ML (287MG/ML)		N022066	001	Sep 05, 2007	Mar CRLD
	+ @	28.7GM/100ML (287MG/ML)		N022066	002	Sep 05, 2007	Mar DISC
<u>GADOTERATE MEGLUMINE</u>							
<u>SOLUTION;INTRAVENOUS</u>							
<u>GADOTERATE MEGLUMINE</u>							
AP	HAINAN POLY	1.8845GM/5ML (376.9MG/ML)		A218073	001	Jun 17, 2024	Jun NEWA
AP		3.769GM/10ML (376.9MG/ML)		A218073	002	Jun 17, 2024	Jun NEWA
AP		5.6535GM/15ML (376.9MG/ML)		A218073	003	Jun 17, 2024	Jun NEWA
AP		7.538GM/20ML (376.9MG/ML)		A218073	004	Jun 17, 2024	Jun NEWA
AP		37.69GM/100ML (376.9MG/ML)		A218073	005	Jun 17, 2024	Jun NEWA
<u>GANCICLOVIR SODIUM</u>							
<u>INJECTABLE;INJECTION</u>							
<u>GANCICLOVIR SODIUM</u>							
AP	ENDO OPERATIONS	EQ 500MG BASE/VIAL		A204950	001	Dec 06, 2016	May CAHN
<u>GATIFLOXACIN</u>							
<u>SOLUTION/DROPS;OPHTHALMIC</u>							
<u>GATIFLOXACIN</u>							
	@ HIKMA	0.5%		A203189	001	Sep 03, 2014	Mar DISC
<u>GEMCITABINE HYDROCHLORIDE</u>							
<u>INJECTABLE;INJECTION</u>							
<u>GEMCITABINE HYDROCHLORIDE</u>							
	@ ACCORD HLTHCARE	EQ 200MG BASE/VIAL		A091594	001	Jul 25, 2011	Apr DISC
	@	EQ 1GM BASE/VIAL		A091594	002	Jul 25, 2011	Apr DISC
	@	EQ 2GM BASE/VIAL		A091594	003	Jul 25, 2011	Apr DISC
<u>GEPİRONE HYDROCHLORIDE</u>							
<u>TABLET, EXTENDED RELEASE;ORAL</u>							
<u>EXXUA</u>							
	+ @ FABRE KRAMER	EQ 18.2MG BASE		N021164	001	Sep 22, 2023	Jun DISC
	+ @	EQ 36.3MG BASE		N021164	002	Sep 22, 2023	Jun DISC
	+ @	EQ 54.5MG BASE		N021164	003	Sep 22, 2023	Jun DISC
	+ @	EQ 72.6MG BASE		N021164	004	Sep 22, 2023	Jun DISC

GIVINOSTAT HYDROCHLORIDESUSPENSION;ORAL  
DUVYZAT

+! ITALFARMACO SPA EQ 8.86MG BASE/ML N217865 001 Mar 21, 2024 Mar NEWA

GLIPIZIDETABLET;ORAL  
GLIPIZIDE

@	ACCORD HLTHCARE	5MG	A074550	001	Sep 11, 1997	May	DISC
@		10MG	A074550	002	Sep 11, 1997	May	DISC
@	SANDOZ	5MG	A074305	001	Apr 07, 1995	Jun	DISC
@		10MG	A074305	002	Apr 07, 1995	Jun	DISC

TABLET, EXTENDED RELEASE;ORAL

GLIPIZIDE

@	ENDO OPERATIONS	5MG	A076159	002	Sep 20, 2013	May	CAHN
@		10MG	A076159	001	Sep 20, 2013	May	CAHN

GLUCAGON HYDROCHLORIDEPOWDER;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS  
GLUCAGON

+! FRESENIUS KABI USA EQ 1MG BASE/VIAL N201849 002 Sep 19, 2019 Apr CMS1

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

AB	HERITAGE PHARMS	1.25MG;250MG	A079009	001	Jun 03, 2009	Feb	CMFD
AB		2.5MG;500MG	A079009	002	Jun 03, 2009	Feb	CMFD
AB		5MG;500MG	A079009	003	Jun 03, 2009	Feb	CMFD

GLYCEROL PHENYLBUTYRATE

LIQUID;ORAL

GLYCEROL PHENYLBUTYRATE

@ ENDO OPERATIONS 1.1GM/ML A205742 001 Dec 02, 2021 May CAHN

GLYCOPYRROLATE

INJECTABLE;INJECTION

GLYCOPYRROLATE

>D>	AP	NIVAGEN PHARMS INC	0.2MG/ML	A212591	001	Oct 13, 2021	Aug	CAHN
	AP		0.2MG/ML	A212591	001	Oct 13, 2021	Feb	CAHN
>A>	AP	UMEDICA	0.2MG/ML	A212591	001	Oct 13, 2021	Aug	CAHN

SOLUTION;ORAL

GLYCOPYRROLATE

>A>	AA	CHARTWELL RX	1MG/5ML	A216368	001	Aug 28, 2024	Aug	NEWA
>A>	AA	GRANULES	1MG/5ML	A214735	001	Aug 19, 2024	Aug	NEWA

TABLET;ORAL

GLYCOPYRROLATE

>A>	AA	ADAPTIS	1MG	A091182	001	Feb 03, 2014	Aug	CAHN
>A>	AA		2MG	A091182	002	Feb 03, 2014	Aug	CAHN
>D>	AA	INDOCO	1MG	A091182	001	Feb 03, 2014	Aug	CAHN
>D>	AA		2MG	A091182	002	Feb 03, 2014	Aug	CAHN
>D>	AA	LEADING	1MG	A090195	001	Sep 21, 2012	Aug	CAHN
>D>	AA		2MG	A090195	002	Sep 21, 2012	Aug	CAHN
	!	LGM PHARMA	1.5MG	A091522	001	Mar 12, 2012	Jul	CHRS
	AA	QUAGEN	1MG	A212696	001	Jul 10, 2024	Jun	NEWA
	AA		2MG	A212696	002	Jul 10, 2024	Jun	NEWA
>A>	AA	VELZEN PHARMA PVT	1MG	A090195	001	Sep 21, 2012	Aug	CAHN
>A>	AA		2MG	A090195	002	Sep 21, 2012	Aug	CAHN

GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

PREVDUO

+! AZURITY 0.6MG/3ML (0.2MG/ML);3MG/3ML (1MG/ML) N216903 001 Feb 23, 2023 Feb CAHN

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

AT	NORDIC PHARMA	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A065187	001	Oct 28, 2005	Jun	CAHN
----	---------------	---	---------	-----	--------------	-----	------

GRANISETRON

INJECTABLE;SUBCUTANEOUS  
SUSTOL

>A>	+	HERON THERAPS INC	10MG/0.4ML (10MG/0.4ML)	N022445	001	Aug 09, 2016	Aug CMS1
		INJECTION, EXTENDED RELEASE;SUBCUTANEOUS					
		SUSTOL					
>D>	+	HERON THERAPS INC	10MG/0.4ML (10MG/0.4ML)	N022445	001	Aug 09, 2016	Aug CMS1

GRISEOFULVIN, MICROSIZE

TABLET;ORAL  
FULVICIN-U/F

AB		CHARTWELL RX	250MG	A060569	002		Jan CTEC
			250MG	A060569	002		Jan CAIN
AB			500MG	A060569	001		Jan CTEC
			500MG	A060569	001		Jan CAIN
		GRISEOFULVIN					
AB		SANDOZ	250MG	A091592	001	Aug 07, 2013	Jan CTEC

GRISEOFULVIN, ULTRAMICROSIZE

TABLET;ORAL  
FULVICIN P/G

AB		CHARTWELL RX	125MG	A061996	001		Jan CTEC
			125MG	A061996	001		Jan CAIN
AB			250MG	A061996	002		Jan CTEC
			250MG	A061996	002		Jan CAIN
		FULVICIN P/G 165					
		CHARTWELL RX	165MG	A061996	003	Apr 06, 1982	Jan CAIN
		FULVICIN P/G 330					
		CHARTWELL RX	330MG	A061996	004	Apr 06, 1982	Jan CAIN

GUANFACINE HYDROCHLORIDE

TABLET;ORAL  
GUANFACINE HYDROCHLORIDE

AB		XIROMED	EQ 1MG BASE	A218326	001	Feb 23, 2024	Feb NEWA
AB			EQ 2MG BASE	A218326	002	Feb 23, 2024	Feb NEWA
		TABLET, EXTENDED RELEASE;ORAL					
		GUANFACINE HYDROCHLORIDE					
AB		WANBANG BIOPHARMS	EQ 1MG BASE	A217638	001	Jun 12, 2024	May NEWA
AB			EQ 2MG BASE	A217638	002	Jun 12, 2024	May NEWA
AB			EQ 3MG BASE	A217638	003	Jun 12, 2024	May NEWA
AB			EQ 4MG BASE	A217638	004	Jun 12, 2024	May NEWA

HALCINONIDE

OINTMENT;TOPICAL  
HALOG

	+	@ SUN PHARM INDS INC	0.1%	N017824	001		Jan DISC
--	---	----------------------	------	---------	-----	--	----------

SOLUTION;TOPICAL  
HALCINONIDE

		ENCUBE	0.1%	A217671	001	May 29, 2024	May NFTG
--	--	--------	------	---------	-----	--------------	----------

HALOG

	+	@ SUN PHARM INDS INC	0.1%	N017823	001		Jan DISC
--	---	----------------------	------	---------	-----	--	----------

HALOBETASOL PROPIONATE

LOTION;TOPICAL  
ULTRAVATE

	+	@ MICAL PHARMS	0.05%	N208183	001	Nov 06, 2015	May CAHN
--	---	----------------	-------	---------	-----	--------------	----------

	+	@ SUN PHARM INDUSTRIES	0.05%	N208183	001	Nov 06, 2015	May DISC
--	---	------------------------	-------	---------	-----	--------------	----------

HALOPERIDOL

TABLET;ORAL  
HALOPERIDOL

AB		AUROBINDO PHARMA LTD	0.5MG	A218789	001	Apr 19, 2024	Apr NEWA
AB			1MG	A218789	002	Apr 19, 2024	Apr NEWA
AB			2MG	A218789	003	Apr 19, 2024	Apr NEWA
AB			5MG	A218789	004	Apr 19, 2024	Apr NEWA
AB			10MG	A218789	005	Apr 19, 2024	Apr NEWA
AB			20MG	A218789	006	Apr 19, 2024	Apr NEWA
AB		CHARTWELL RX	0.5MG	A071209	002	Nov 17, 1986	Jan CAHN
AB			1MG	A071209	003	Nov 17, 1986	Jan CAHN
		@	2MG	A071209	004	Nov 17, 1986	Jan CAHN
AB			5MG	A071209	001	Nov 17, 1986	Jan CAHN

TABLET; ORAL  
HALOPERIDOL

AB		10MG	A071210	001	Mar 11, 1988	Jan	CAHN
AB		20MG	A071211	001	Mar 11, 1988	Jan	CAHN
AB	MANKIND PHARMA	0.5MG	A216918	001	Apr 11, 2024	Apr	NEWA
AB		1MG	A216918	002	Apr 11, 2024	Apr	NEWA
AB		2MG	A216918	003	Apr 11, 2024	Apr	NEWA
AB		5MG	A216918	004	Apr 11, 2024	Apr	NEWA
AB		10MG	A216918	005	Apr 11, 2024	Apr	NEWA
AB		20MG	A216918	006	Apr 11, 2024	Apr	NEWA
AB	SCIEGEN PHARMS INC	5MG	A071130	002	Feb 17, 1987	May	CMS1
AB		10MG	A071130	003	May 12, 1987	May	CMS1

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION  
HALOPERIDOL DECANOATE

@	TEVA PHARMS USA	EQ 50MG BASE/ML	A075393	001	May 11, 1999	Jan	DISC
@		EQ 100MG BASE/ML	A075393	002	May 11, 1999	Jan	DISC

HALOPERIDOL LACTATE

CONCENTRATE; ORAL  
HALOPERIDOL

AA	RUBICON	EQ 2MG BASE/ML	A218371	001	Jan 31, 2024	Jan	NEWA
----	---------	----------------	---------	-----	--------------	-----	------

HEPARIN SODIUM

INJECTABLE; INJECTION  
HEPARIN SODIUM

@	ASPEN GLOBAL INC	1,000 UNITS/ML	N000552	008		Jun	CAHN
@		5,000 UNITS/ML	N000552	009		Jun	CAHN
@		10,000 UNITS/ML	N000552	010		Jun	CAHN
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%							
+	FRESENIUS KABI USA	50 UNITS/ML	N017029	022	Aug 24, 2017	Mar	NEWA
+		100 UNITS/ML	N017029	023	Aug 24, 2017	Mar	NEWA
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45%							
+	FRESENIUS KABI USA	50 UNITS/ML	N017029	024	Aug 24, 2017	Mar	NEWA
+		100 UNITS/ML	N017029	025	Aug 24, 2017	Mar	NEWA
LIQUAEMIN LOCK FLUSH							
@	ASPEN GLOBAL INC	100 UNITS/ML	N000552	007		Jun	CAHN
LIQUAEMIN SODIUM							
@	ASPEN GLOBAL INC	1,000 UNITS/ML	N000552	004		Jun	CAHN
@		5,000 UNITS/ML	N000552	003		Jun	CAHN
@		10,000 UNITS/ML	N000552	005		Jun	CAHN
@		20,000 UNITS/ML	N000552	001		Jun	CAHN
@		40,000 UNITS/ML	N000552	002		Jun	CAHN
LIQUAEMIN SODIUM PRESERVATIVE FREE							
@	ASPEN GLOBAL INC	1,000 UNITS/ML	N000552	011	Apr 11, 1986	Jun	CAHN
@		5,000 UNITS/ML	N000552	012	Apr 11, 1986	Jun	CAHN
@		10,000 UNITS/ML	N000552	013	Apr 11, 1986	Jun	CAHN

HISTRELIN ACETATE

IMPLANT; SUBCUTANEOUS  
SUPPRELIN LA

+	ENDO OPERATIONS	50MG	N022058	001	May 03, 2007	Apr	CAHN
+	@ ENDO OPERATIONS	50MG	N021732	001	Oct 12, 2004	May	CAHN

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE								
AA	!	ABHAI LLC	1.5MG/5ML; 5MG/5ML	A207487	001	Feb 21, 2017	Mar	CHRS
		@ GENUS	1.5MG/5ML; 5MG/5ML	A040613	001	Feb 08, 2008	Apr	CAHN
		@ PAI HOLDINGS PHARM	1.5MG/5ML; 5MG/5ML	A040613	001	Feb 08, 2008	Mar	DISC

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION  
HYDRALAZINE HYDROCHLORIDE

AP		ADRASTEIA PHARMA	20MG/ML	A203110	001	Jun 29, 2015	Feb	CAHN
>D>	AP	FRESENIUS KABI USA	20MG/ML	A040388	001	Mar 13, 2001	Aug	CHRS
>A>	AP	!	20MG/ML	A040388	001	Mar 13, 2001	Aug	CHRS
		@ NORVIUM BIOSCIENCE	20MG/ML	A204680	001	Apr 28, 2016	Jun	CAHN
>D>	AP	!	RISING	A040730	001	Apr 21, 2009	Aug	CHRS
>A>	AP		20MG/ML	A040730	001	Apr 21, 2009	Aug	CHRS

## TABLET;ORAL

## HYDRALAZINE HYDROCHLORIDE

AA	GLENMARK PHARMS LTD	10MG	A 090527	001	May 29, 2009	Jul	CMS1
AA		25MG	A 090527	002	May 29, 2009	Jul	CMS1
AA		50MG	A 090527	003	May 29, 2009	Jul	CMS1
AA		100MG	A 090527	004	May 29, 2009	Jul	CMS1
	@ INVAGEN PHARMS	10MG	A 090255	001	Dec 15, 2008	Mar	DISC
	@	25MG	A 090255	002	Dec 15, 2008	Mar	DISC
	@	50MG	A 090255	003	Dec 15, 2008	Mar	DISC
	@	100MG	A 090255	004	Dec 15, 2008	Mar	DISC
>A> AA	MACLEODS PHARMS LTD	10MG	A 211010	001	Aug 21, 2024	Aug	NEWA
>A> AA		25MG	A 211010	002	Aug 21, 2024	Aug	NEWA
>A> AA		50MG	A 211010	003	Aug 21, 2024	Aug	NEWA
>A> AA		100MG	A 211010	004	Aug 21, 2024	Aug	NEWA
	@ NORVIUM BIOSCIENCE	10MG	A 090413	001	Dec 08, 2010	Jul	CAHN
	@	25MG	A 090413	002	Dec 08, 2010	Jul	CAHN
	@	50MG	A 090413	003	Dec 08, 2010	Jul	CAHN
	@	100MG	A 090413	004	Dec 08, 2010	Jul	CAHN

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

## TABLET;ORAL

## ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE

AB	I3 PHARMS	37.5MG;20MG	A 215988	001	Jan 17, 2024	Jan	NEWA
----	-----------	-------------	----------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE

## TABLET;ORAL

## HYDROCHLOROTHIAZIDE

>D> AB	PRINSTON INC	25MG	A 040412	001	Mar 29, 2002	Aug	DISC
>A>	@	25MG	A 040412	001	Mar 29, 2002	Aug	DISC
>D> AB		50MG	A 040412	002	Mar 29, 2002	Aug	DISC
>A>	@	50MG	A 040412	002	Mar 29, 2002	Aug	DISC

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

## TABLET;ORAL

## LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

	@ GRANULES	12.5MG;50MG	A 218015	001	Sep 29, 2023	Mar	DISC
	@	12.5MG;100MG	A 218015	002	Sep 29, 2023	Mar	DISC
	@	25MG;100MG	A 218015	003	Sep 29, 2023	Mar	DISC

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

## TABLET;ORAL

## METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

	@ SUN PHARM INDS	25MG;50MG	A 090654	001	Jan 19, 2012	May	DISC
	@	25MG;100MG	A 090654	002	Jan 19, 2012	May	DISC
	@	50MG;100MG	A 090654	003	Jan 19, 2012	May	DISC

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

## TABLET;ORAL

## HYDROCHLOROTHIAZIDE AND OLMESARTAN MEDOXOMIL

AB	ALKEM LABS LTD	12.5MG;20MG	A 207037	001	Jul 11, 2024	Jul	NEWA
AB		12.5MG;40MG	A 207037	002	Jul 11, 2024	Jul	NEWA
AB		25MG;40MG	A 207037	003	Jul 11, 2024	Jul	NEWA
	OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE						
	@ TEVA PHARMS USA	12.5MG;40MG	A 200532	002	Apr 24, 2017	May	DISC

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

## TABLET;ORAL

## QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

	@ INVAGEN PHARMS	12.5MG;EQ 10MG BASE	A 201356	001	Apr 20, 2011	Mar	DISC
	@	12.5MG;EQ 20MG BASE	A 201356	002	Apr 20, 2011	Mar	DISC
	@	25MG;EQ 20MG BASE	A 201356	003	Apr 20, 2011	Mar	DISC

HYDROCORTISONE BUTYRATE

## LOTION;TOPICAL

## HYDROCORTISONE BUTYRATE

>D> AB	LUPIN LTD	0.1%	A 210209	001	Aug 17, 2018	Aug	CHRS
>A> AB	!	0.1%	A 210209	001	Aug 17, 2018	Aug	CHRS
>D>	LOCOID						
>D> AB	+! BAUSCH	0.1%	N 022076	001	May 18, 2007	Aug	DISC
>A>	+ @	0.1%	N 022076	001	May 18, 2007	Aug	DISC



HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

>A>		HYDROCORTISONE SODIUM SUCCINATE						
>A>	AP	CIPLA	EQ 100MG BASE/VIAL	A214050	001	Sep 05, 2024	Aug	NFTG
		SOLU-CORTEF						
>D>	+	PHARMACIA AND UPJOHN	EQ 100MG BASE/VIAL	N009866	001		Aug	CFTG
>A>	AP	+	EQ 100MG BASE/VIAL	N009866	001		Aug	CFTG

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

DILAUDID

AP	+	FRESENIUS KABI USA	0.2MG/ML	N019034	006	Jan 16, 2020	Feb	CFTG
AP	+		0.5MG/0.5ML	N019034	007	Feb 10, 2017	Feb	CFTG
	+		0.5MG/0.5ML	N019034	007	Feb 10, 2017	Jan	NEWA
>D>	+	@	4MG/ML	N019034	005	Apr 30, 2009	Aug	CMFD
>A>	AP	+	4MG/ML	N019034	005	Apr 30, 2009	Aug	CMFD

HYDROMORPHONE HYDROCHLORIDE

AP		HIKMA	0.2MG/ML	A216899	001	Feb 09, 2024	Feb	NFTG
AP			0.5MG/0.5ML	A216899	002	Feb 09, 2024	Feb	NFTG
AP			1MG/ML	A216899	003	Feb 09, 2024	Feb	NEWA
AP			2MG/ML	A216899	004	Feb 09, 2024	Feb	NEWA
>D>		HOSPIRA INC	4MG/ML	N200403	003	Dec 01, 2011	Aug	CTEC
>A>	AP		4MG/ML	N200403	003	Dec 01, 2011	Aug	CTEC

SOLUTION; ORAL

HYDROMORPHONE HYDROCHLORIDE

@ GENUS 5MG/5ML

A207108 001 Apr 22, 2020 Jan CAHN

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

@ GENUS 2MG

A077471 002 Dec 09, 2009 Jan CAHN

@ 4MG

A077471 003 Dec 09, 2009 Jan CAHN

@ 8MG

A077471 001 Dec 09, 2009 Jan CAHN

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

AB		ALLIED	200MG	A040150	001	Jan 27, 1996	Jun	CAHN
AB	!	APPCO	100MG	A210441	002	Sep 19, 2022	Jun	CHRS
AB		CREEKWOOD PHARMS	200MG	A040150	001	Jan 27, 1996	Jul	CAHN
AB			200MG	A040150	001	Jan 27, 1996	Apr	CMFD
		@	200MG	A040150	001	Jan 27, 1996	Jan	CAHN
AB		SENORES PHARMS	200MG	A212902	001	May 14, 2020	Feb	CAHN
AB		TEVA PHARMS	200MG	A040081	001	Sep 30, 1994	Feb	CMFD

HYDROXYPROPYL CELLULOSE

INSERT; OPHTHALMIC

LACRISERT

+ @ BAUSCH AND LOMB INC 5MG N018771 001 Jul DISC

HYDROXYUREA

CAPSULE; ORAL

HYDROXYUREA

AB QILU 500MG A218021 001 Mar 06, 2024 Feb NEWA

SOLUTION; ORAL

XROMI

+! NOVA LABS LTD 100MG/ML N216593 001 Apr 04, 2024 Apr NEWA

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL

HYDROXYZINE HYDROCHLORIDE

AA APOZEAL PHARMS 10MG/5ML A210634 001 Feb 26, 2019 Jun CMFD

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

@ INVAGEN PHARMS 10MG

A040812 001 Mar 12, 2008 Mar DISC

@ 25MG

A040812 002 Mar 12, 2008 Mar DISC

@ 50MG

A040812 003 Mar 12, 2008 Mar DISC

HYDROXYZINE PAMOATE

		CAPSULE; ORAL		HYDROXYZINE PAMOATE					
AB	!	HERITAGE PHARMA	EQ 50MG HYDROCHLORIDE	A201507	002	Jun 03, 2013	Jul	CHRS	
AB		SANDOZ	EQ 50MG HYDROCHLORIDE	A086183	001		Jul	CHRS	
		VISTARIL							
	+	@ PFIZER	EQ 100MG HYDROCHLORIDE	N011459	006		Jul	CRLD	

IBANDRONATE SODIUM

		INJECTABLE; INTRAVENOUS		IBANDRONATE SODIUM					
		@ SUN PHARM		EQ 3MG BASE/3ML	A090853	001	Feb 14, 2014	May	DISC
		TABLET; ORAL		IBANDRONATE SODIUM					
		@ WATSON LABS TEVA		EQ 150MG BASE	A079003	001	Mar 20, 2012	May	DISC

IBRUTINIB

		TABLET; ORAL		IMBRUVICA					
	+	!	PHARMACYCLICS LLC	420MG	N210563	003	Feb 16, 2018	Jan	CHRS

IBUPROFEN

		TABLET; ORAL		IBUPROFEN					
		@ ENDO OPERATIONS		300MG	A071230	001	Oct 22, 1986	May	CAHN
		@		400MG	A071231	001	Oct 22, 1986	May	CAHN
		@		400MG	A071644	001	Feb 01, 1988	May	CAHN
		@		600MG	A071232	001	Oct 22, 1986	May	CAHN
		@		800MG	A072004	001	Nov 18, 1987	May	CAHN
		SHANDONG XINHUA		300MG	A202413	004	Jul 05, 2024	Jul	NEWA

IBUTILIDE FUMARATE

		INJECTABLE; INJECTION		IBUTILIDE FUMARATE					
AP		AVET LIFESCIENCES	0.1MG/ML	A204146	001	Apr 01, 2024	Mar	NEWA	

ICATIBANT ACETATE

		INJECTABLE; SUBCUTANEOUS		ICATIBANT ACETATE					
AP		ALEMVIC	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A213773	001	Jun 14, 2024	Jun	NEWA	
AP		WILSHIRE PHARMS INC	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A211501	001	Sep 01, 2020	Jul	CAHN	

ICOSAPENT ETHYL

		CAPSULE; ORAL		ICOSAPENT ETHYL					
AB		ASCENT PHARMS INC	1GM	A216811	002	Feb 16, 2024	Feb	NEWA	
AB		ZYDUS LIFESCIENCES	500MG	A217656	001	Apr 20, 2023	Apr	CAHN	
AB			1GM	A217656	002	Apr 20, 2023	Apr	CAHN	

IDARUBICIN HYDROCHLORIDE

		INJECTABLE; INJECTION		IDARUBICIN HYDROCHLORIDE					
		@ RISING		1MG/ML	A200144	001	Oct 11, 2012	Feb	CAHN

IFOSFAMIDE

		INJECTABLE; INJECTION		IFOSFAMIDE					
		@ EXTROVIS		1GM/20ML (50MG/ML)	A201689	001	Nov 26, 2012	Jun	CAHN
		@		3GM/60ML (50MG/ML)	A201689	002	Nov 26, 2012	Jun	CAHN

ILOPROST

		SOLUTION; INHALATION		VENTAVIS					
	+	@	ACTELION	10MCG/ML (10MCG/ML)	N021779	002	Dec 08, 2005	Mar	DISC
	+	@		20MCG/ML (20MCG/ML)	N021779	003	Aug 07, 2009	Mar	DISC
		SOLUTION; INTRAVENOUS		AURLUMYN					
	+	!	EICOS SCI	100MCG/ML (100MCG/ML)	N217933	001	Feb 13, 2024	Feb	NEWA

IMETELSTAT SODIUMPOWDER; INTRAVENOUS  
RYTELO

+!	GERON	EQ 47MG BASE/VIAL	N217779	001	Jun 06, 2024	Jun	NEWA
+!		EQ 188MG BASE/VIAL	N217779	002	Jun 06, 2024	Jun	NEWA

IMIPRAMINE HYDROCHLORIDETABLET; ORAL  
IMIPRAMINE HYDROCHLORIDE

AB	!	LEADING	50MG	A040903	003	Oct 24, 2012	Apr	CHRS
	+	@ SPECGX LLC	10MG	A087846	002	May 22, 1984	Apr	DISC
	+	@	25MG	A087846	003	May 22, 1984	Apr	DISC
		TOFRANIL						
	+	@ SPECGX LLC	50MG	A087846	001	May 22, 1984	Apr	DISC

INDIUM IN-111 PENTETREOTIDE KITINJECTABLE; INJECTION  
INDIUM IN-111 PENTETREOTIDE KIT

AP		SUN PHARM INDS INC	3mCi/ML	A212785	001	Jul 01, 2024	Jun	NFTG
		OCTREOSCAN						
AP	+	CURIUM	3mCi/ML	N020314	001	Jun 02, 1994	Jun	CFTG

INDOMETHACINCAPSULE, EXTENDED RELEASE; ORAL  
INDOMETHACIN

>A>	@	MYLAN	75MG	A202139	001	Mar 20, 2014	Aug	CAHN
>D>	@	RISING	75MG	A202139	001	Mar 20, 2014	Aug	CAHN

SUPPOSITORY; RECTAL  
INDOMETHACIN

AB		ZYDUS LIFESCIENCES	50MG	A216184	001	Aug 02, 2023	Apr	CAHN
----	--	--------------------	------	---------	-----	--------------	-----	------

SUSPENSION; ORAL  
INDOCIN

AB	+	ZYLA	25MG/5ML	N018332	001	Oct 10, 1985	Jan	CTEC
		INDOMETHACIN						
AB		NOVITIUM PHARMA	25MG/5ML	A217883	001	Jan 12, 2024	Jan	NEWA

IOBENGUANE I-131SOLUTION; INTRAVENOUS  
AZEDRA

+	@	PROGENICS PHARMS INC	15mCi/ML	N209607	001	Jul 30, 2018	Feb	DISC
---	---	----------------------	----------	---------	-----	--------------	-----	------

IOPAMIDOLINJECTABLE; INJECTION  
IOPAMIDOL

AP		HAINAN POLY	51%	A217134	002	Apr 09, 2024	Mar	NEWA
AP			61%	A217134	003	Apr 09, 2024	Mar	NEWA
AP			76%	A217134	004	Apr 09, 2024	Mar	NEWA
		ISOVUE-250						
AP	+	BRACCO	51%	N018735	007	Jul 06, 1992	Mar	CTEC
		ISOVUE-300						
AP	+	BRACCO	61%	N018735	002	Dec 31, 1985	Mar	CTEC
		ISOVUE-370						
AP	+	BRACCO	76%	N018735	003	Dec 31, 1985	Mar	CTEC

IPRATROPIUM BROMIDESOLUTION; INHALATION  
IPRATROPIUM BROMIDE

@	NORVIUM BIOSCIENCE	0.02%	A074755	001	Jan 10, 1997	Jul	CAHN
---	--------------------	-------	---------	-----	--------------	-----	------

IRBESARTANTABLET; ORAL  
AVAPRO

+	@	SANOFI AVENTIS US	75MG	N020757	001	Sep 30, 1997	Jul	DISC
		IRBESARTAN						
AB		IPCA LABS LTD	75MG	A211056	001	May 22, 2024	May	NEWA
AB			150MG	A211056	002	May 22, 2024	May	NEWA
AB			300MG	A211056	003	May 22, 2024	May	NEWA

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION  
 IRINOTECAN HYDROCHLORIDE  
 @ HISUN PHARM HANGZHOU 40MG/2ML (20MG/ML)  
 @ 100MG/5ML (20MG/ML)

A090016 001 Jan 28, 2009 Jul DISC  
 A090016 002 Jan 28, 2009 Jul DISC

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION  
 ISOPROTERENOL HYDROCHLORIDE  
 @ CIPLA 0.2MG/ML  
 @ EUGIA PHARMA 0.2MG/ML  
 AP SOMERSET THERAPS LLC 0.2MG/ML

A210322 001 Jun 12, 2018 Mar DISC  
 A211864 001 Feb 09, 2021 Jun DISC  
 A211590 001 Aug 06, 2024 Jul NEWA

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL  
 DILATRATE-SR  
 + @ ENDO OPERATIONS 40MG  
 TABLET; ORAL  
 ISOSORBIDE DINITRATE

N019790 001 Sep 02, 1988 May CAHN

AB ENDO OPERATIONS 40MG  
 >D> AB ZYDUS 5MG  
 >D> AB 10MG  
 >D> AB 20MG  
 >D> AB 30MG  
 >D> AB 40MG  
 >A> AB ZYDUS LIFESCIENCES 5MG  
 >A> AB 10MG  
 >A> AB 20MG  
 >A> AB 30MG  
 >A> AB 40MG

A211290 001 Nov 23, 2021 Apr CAHN  
 A213057 001 Nov 20, 2019 Aug CAHN  
 A213057 002 Nov 20, 2019 Aug CAHN  
 A213057 003 Nov 20, 2019 Aug CAHN  
 A213057 004 Nov 20, 2019 Aug CAHN  
 A213057 005 Nov 20, 2019 Aug CAHN  
 A213057 001 Nov 20, 2019 Aug CAHN  
 A213057 002 Nov 20, 2019 Aug CAHN  
 A213057 003 Nov 20, 2019 Aug CAHN  
 A213057 004 Nov 20, 2019 Aug CAHN  
 A213057 005 Nov 20, 2019 Aug CAHN

ISOSORBIDE MONONITRATE

TABLET; ORAL  
 MONOKET  
 AB + OMNIVIVUM PHARMS 10MG  
 AB +! 20MG  
 TABLET, EXTENDED RELEASE; ORAL  
 ISOSORBIDE MONONITRATE

N020215 002 Jun 30, 1993 Jan CAHN  
 N020215 001 Jun 30, 1993 Jan CAHN

AB CHARTWELL MOLECULAR 120MG  
 AB ! RICONPHARMA LLC 120MG  
 AB SHANDONG 30MG  
 AB 60MG  
 AB 120MG  
 >D> AB ZYDUS PHARMS 30MG  
 >A> @ 30MG  
 AB 30MG  
 >D> AB 60MG  
 >A> @ 60MG  
 AB 60MG  
 >D> AB 120MG  
 >A> @ 120MG  
 AB 120MG

A075155 003 Aug 04, 2000 Mar CHRS  
 A210918 003 Nov 05, 2018 Mar CHRS  
 A214115 002 Feb 08, 2024 Feb NEWA  
 A214115 003 Feb 08, 2024 Feb NEWA  
 A214115 001 Apr 29, 2022 Mar CMFD  
 A218255 001 Feb 15, 2024 Aug DISC  
 A218255 001 Feb 15, 2024 Aug DISC  
 A218255 001 Feb 15, 2024 Feb NEWA  
 A218255 002 Feb 15, 2024 Aug DISC  
 A218255 002 Feb 15, 2024 Aug DISC  
 A218255 002 Feb 15, 2024 Feb NEWA  
 A218255 003 Feb 15, 2024 Aug DISC  
 A218255 003 Feb 15, 2024 Aug DISC  
 A218255 003 Feb 15, 2024 Feb NEWA

ISOSULFAN BLUE

SOLUTION; SUBCUTANEOUS  
 ISOSULFAN BLUE  
 AP AM REGENT 1%  
 AP 50MG/5ML (10MG/ML)  
 @ BELOTECA 1%  
 @ 50MG/5ML (10MG/ML)  
 @ EUGIA PHARMA 1%  
 @ 50MG/5ML (10MG/ML)  
 @ FRESENIUS KABI USA 1%  
 @ 50MG/5ML (10MG/ML)  
 AP MEITHEAL 1%  
 AP 50MG/5ML (10MG/ML)  
 AP MSN 1%  
 AP 50MG/5ML (10MG/ML)  
 AP ! MYLAN INSTITUTIONAL 1%  
 AP ! 50MG/5ML (10MG/ML)  
 @ SOMERSET THERAPS LLC 1%  
 @ 50MG/5ML (10MG/ML)

A210294 001 May 17, 2023 May CDFR  
 A210294 001 May 17, 2023 May CPOT  
 A210714 001 Jan 16, 2019 May CDFR  
 A210714 001 Jan 16, 2019 May CPOT  
 A206831 001 Feb 02, 2016 May CDFR  
 A206831 001 Feb 02, 2016 May CPOT  
 A211869 001 Sep 08, 2022 May CDFR  
 A211869 001 Sep 08, 2022 May CPOT  
 A213130 001 Nov 03, 2021 May CDFR  
 A213130 001 Nov 03, 2021 May CPOT  
 A216090 001 Sep 16, 2022 May CDFR  
 A216090 001 Sep 16, 2022 May CPOT  
 A090874 001 Jul 20, 2010 May CDFR  
 A090874 001 Jul 20, 2010 May CPOT  
 A210558 001 Jul 12, 2019 May CDFR  
 A210558 001 Jul 12, 2019 May CPOT

SOLUTION;SUBCUTANEOUS  
LYMPHAZURIN

+ @ COVIDIEN	1%	N018310	001		May	CDFR
+ @	50MG/5ML (10MG/ML)	N018310	001		May	CPOI

ISOTRETINOIN

CAPSULE;ORAL  
ISOTRETINOIN

AB2	AUROBINDO PHARMA	10MG	A218194	001	Jan 29, 2024	Jan	NEWA
AB2		20MG	A218194	002	Jan 29, 2024	Jan	NEWA
AB2		25MG	A218194	003	Jan 29, 2024	Jan	NEWA
AB2		30MG	A218194	004	Jan 29, 2024	Jan	NEWA
AB2		35MG	A218194	005	Jan 29, 2024	Jan	NEWA
AB2		40MG	A218194	006	Jan 29, 2024	Jan	NEWA

ITRACONAZOLE

CAPSULE;ORAL  
ITRACONAZOLE

@ ACCORD HLTHCARE	100MG	A205991	001	May 26, 2016	May	DISC
@ RISING	100MG	A205724	001	Dec 13, 2016	Apr	CAHN

IVABRADINE HYDROCHLORIDE

TABLET;ORAL  
IVABRADINE HYDROCHLORIDE

>A>	AB	BIONPHARMA	EQ 5MG BASE	A213276	001	Sep 05, 2024	Aug	NEWA
>A>	AB		EQ 7.5MG BASE	A213276	002	Sep 05, 2024	Aug	NEWA
	AB	INGENUS PHARMS LLC	EQ 5MG BASE	A214051	001	Dec 30, 2021	May	CMFD
	AB		EQ 7.5MG BASE	A214051	002	Dec 30, 2021	May	CMFD

IVERMECTIN

CREAM;TOPICAL  
IVERMECTIN

AB	ZYDUS LIFESCIENCES	1%	A215210	001	Aug 02, 2022	Mar	CAHN
----	--------------------	----	---------	-----	--------------	-----	------

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION  
KETALAR

>D>	AP	+	ENDO OPERATIONS	EQ 50MG BASE/ML	N016812	002		Aug	CHRS
>A>	AP	+		EQ 50MG BASE/ML	N016812	002		Aug	CHRS
>D>	AP	+		EQ 100MG BASE/ML	N016812	003		Aug	CHRS
>A>	AP	+		EQ 100MG BASE/ML	N016812	003		Aug	CHRS
			KETAMINE HYDROCHLORIDE						
>D>	AP		HIKMA	EQ 50MG BASE/ML	A074524	001	Mar 22, 1996	Aug	CHRS
>A>	AP	!		EQ 50MG BASE/ML	A074524	001	Mar 22, 1996	Aug	CHRS
>D>	AP			EQ 100MG BASE/ML	A074524	002	Mar 22, 1996	Aug	CHRS
>A>	AP	!		EQ 100MG BASE/ML	A074524	002	Mar 22, 1996	Aug	CHRS

KETOCONAZOLE

AEROSOL, FOAM;TOPICAL  
KETOCONAZOLE

AB	!	XIROMED	2%	A213601	001	May 21, 2021	Feb	CHRS
----	---	---------	----	---------	-----	--------------	-----	------

CREAM;TOPICAL  
KETOCONAZOLE

>D>	AB	TASMAN PHARMA	2%	A215185	001	Nov 17, 2021	Aug	CAHN
>A>	AB	TRUPHARMA	2%	A215185	001	Nov 17, 2021	Aug	CAHN

SHAMPOO;TOPICAL  
KETOCONAZOLE

AB		COSETTE	2%	A076942	001	Apr 11, 2005	Jul	CAHN
----	--	---------	----	---------	-----	--------------	-----	------

TABLET;ORAL  
KETOCONAZOLE

AB		SENORES PHARMS	200MG	A075912	001	Jan 10, 2002	Feb	CAHN
----	--	----------------	-------	---------	-----	--------------	-----	------

KETOROLAC TROMETHAMINE

SOLUTION/DROPS;OPHTHALMIC  
KETOROLAC TROMETHAMINE

AT		CAPLIN	0.5%	A218204	001	Mar 26, 2024	Mar	NEWA
----	--	--------	------	---------	-----	--------------	-----	------

L-GLUTAMINE

FOR SOLUTION;ORAL  
ENDARI

AA	+	EMMAUS MEDCL	5GM/PACKET	N208587	001	Jul 07, 2017	Jun CFTG
AA		NOVITIUM PHARMA	5GM/PACKET	A215647	001	Jul 08, 2024	Jun NFTG

LABETALOL HYDROCHLORIDE

SOLUTION;INTRAVENOUS  
LABETALOL HYDROCHLORIDE

>A>	+	HIKMA	20MG/4ML (5MG/ML)	N213330	006	Aug 19, 2024	Aug NEWA
		TABLET;ORAL					
		LABETALOL HYDROCHLORIDE					
>A>	AB	ANDAS 5 HOLDING	100MG	A075215	001	Jul 29, 1999	Aug CAHN
>A>	AB		200MG	A075215	002	Jul 29, 1999	Aug CAHN
>A>	AB		300MG	A075215	003	Jul 29, 1999	Aug CAHN
	AB	ENDO OPERATIONS	100MG	A200908	001	Jul 10, 2012	Apr CAHN
	AB	!	200MG	A200908	002	Jul 10, 2012	Apr CAHN
	AB		300MG	A200908	003	Jul 10, 2012	Apr CAHN
>D>	AB	INNOGENIX	100MG	A075215	001	Jul 29, 1999	Aug CAHN
>D>	AB		200MG	A075215	002	Jul 29, 1999	Aug CAHN
>D>	AB		300MG	A075215	003	Jul 29, 1999	Aug CAHN

LACOSAMIDE

SOLUTION;INTRAVENOUS  
LACOSAMIDE

AP		DR REDDYS	200MG/20ML (10MG/ML)	A217718	001	Mar 25, 2024	Mar NEWA
AP		HAINAN POLY	200MG/20ML (10MG/ML)	A217311	001	Feb 13, 2024	Feb NEWA
AP		HIKMA	200MG/20ML (10MG/ML)	A216806	001	Apr 05, 2024	Mar NEWA

SOLUTION;ORAL  
LACOSAMIDE

		@ AMNEAL PHARMS	10MG/ML	A204839	001	Mar 27, 2024	Apr DISC
AA			10MG/ML	A204839	001	Mar 27, 2024	Mar NEWA
AA		AUROBINDO PHARMA LTD	10MG/ML	A209224	001	Jan 24, 2024	Jan NEWA
AA		CHARTWELL RX	10MG/ML	A215154	001	May 15, 2024	May NEWA

TABLET;ORAL

LACOSAMIDE

AB		MACLEODS PHARMS LTD	50MG	A208466	001	May 24, 2024	May NEWA
AB			100MG	A208466	002	May 24, 2024	May NEWA
AB			150MG	A208466	003	May 24, 2024	May NEWA
AB			200MG	A208466	004	May 24, 2024	May NEWA
AB		MEDLEY PHARMS	50MG	A218014	001	Apr 02, 2024	Mar NEWA
AB			100MG	A218014	002	Apr 02, 2024	Mar NEWA
AB			150MG	A218014	003	Apr 02, 2024	Mar NEWA
AB			200MG	A218014	004	Apr 02, 2024	Mar NEWA
>A>	AB	UNICHEM	50MG	A213109	001	Sep 04, 2024	Aug NEWA
>A>	AB		100MG	A213109	002	Sep 04, 2024	Aug NEWA
>A>	AB		150MG	A213109	003	Sep 04, 2024	Aug NEWA
>A>	AB		200MG	A213109	004	Sep 04, 2024	Aug NEWA
		@ ZYDUS PHARMS	50MG	A204947	001	Dec 15, 2023	May DISC
		@	100MG	A204947	002	Dec 15, 2023	May DISC
		@	150MG	A204947	003	Dec 15, 2023	May DISC
		@	200MG	A204947	004	Dec 15, 2023	May DISC

LACTULOSE

SOLUTION;ORAL  
LACTULOSE

AA		APOZEAL PHARMS	10GM/15ML	A207786	001	Jun 11, 2018	Jul CMFD
		@ HIKMA	10GM/15ML	A074076	001	Jul 03, 1995	Mar DISC
AA		! PHARM ASSOC	10GM/15ML	A074623	001	Jul 30, 1996	Mar CHRS

SOLUTION;ORAL, RECTAL  
GENERLAC

AA		CHARTWELL RX	10GM/15ML	A074603	001	Oct 31, 1996	Jun CAHN
		LACTULOSE					
AA		APOZEAL PHARMS	10GM/15ML	A203762	001	Mar 27, 2015	Jul CMFD
		@ PAI HOLDINGS PHARM	10GM/15ML	A074077	001	Jul 03, 1995	Feb DISC

LAMIVUDINE

	SOLUTION;ORAL								
	EPIVIR-HBV								
	+ @ GLAXOSMITHKLINE	5MG/ML		N021004	001	Dec 08, 1998	Apr	DISC	
	TABLET;ORAL								
	EPIVIR-HBV								
	+ @ GLAXOSMITHKLINE	100MG		N021003	001	Dec 08, 1998	Apr	DISC	
	LAMIVUDINE								
AB	! APOTEX	100MG		A202941	001	Jan 02, 2014	Apr	CHRS	
	@ MYLAN LABS LTD	150MG		A078545	001	Mar 05, 2019	Jan	DISC	
	@	300MG		A078545	002	Mar 05, 2019	Jan	DISC	
	@ NATCO	150MG		A204528	001	Mar 04, 2016	Jun	CAHN	
	@	300MG		A204528	002	Mar 04, 2016	Jun	CAHN	

LAMIVUDINE; ZIDOVUDINE

	TABLET;ORAL								
	COMBIVIR								
	+ @ VIIV HLTHCARE	150MG;300MG		N020857	001	Sep 26, 1997	Jan	DISC	
	LAMIVUDINE AND ZIDOVUDINE								
AB	! HETERO LABS LTD III	150MG;300MG		A079124	001	Sep 17, 2015	Jan	CHRS	
	@ NATCO	150MG;300MG		A204005	001	Aug 28, 2014	Jun	CAHN	
	@ NORVIUM BIOSCIENCE	150MG;300MG		A079079	001	Aug 12, 2019	Jul	CAHN	

LAMOTRIGINE

	TABLET;ORAL								
	LAMOTRIGINE								
AB	GLENMARK PHARMS LTD	25MG		A090169	001	May 04, 2012	Jul	CMS1	
AB		25MG		A090169	001	May 12, 2012	Mar	CAHN	
AB		100MG		A090169	002	May 04, 2012	Jul	CMS1	
AB		100MG		A090169	002	May 12, 2012	Mar	CAHN	
AB		150MG		A090169	003	May 04, 2012	Jul	CMS1	
AB		150MG		A090169	003	May 12, 2012	Mar	CAHN	
AB		200MG		A090169	004	May 04, 2012	Jul	CMS1	
AB		200MG		A090169	004	May 12, 2012	Mar	CAHN	
	@ NORVIUM BIOSCIENCE	25MG		A078443	001	Feb 11, 2009	Jul	CAHN	
	@	100MG		A078443	002	Feb 11, 2009	Jul	CAHN	
	@	150MG		A078443	003	Feb 11, 2009	Jul	CAHN	
	@	200MG		A078443	004	Feb 11, 2009	Jul	CAHN	
	TABLET, EXTENDED RELEASE;ORAL								
	LAMOTRIGINE								
	@ ANCHEN PHARMS	25MG		A201374	001	Dec 26, 2012	Feb	DISC	
	@	50MG		A201374	002	Dec 26, 2012	Feb	DISC	
	@	100MG		A201374	003	Dec 26, 2012	Feb	DISC	
	@	200MG		A201374	004	Dec 26, 2012	Feb	DISC	
	@	250MG		A201374	005	Dec 26, 2012	Feb	DISC	
	@	300MG		A201374	006	Dec 26, 2012	Feb	DISC	
	@ ENDO OPERATIONS	25MG		A201374	001	Dec 26, 2012	May	CAHN	
AB		25MG		A201791	001	Jan 18, 2013	Apr	CAHN	
	@	50MG		A201374	002	Dec 26, 2012	May	CAHN	
AB		50MG		A201791	002	Jan 18, 2013	Apr	CAHN	
	@	100MG		A201374	003	Dec 26, 2012	May	CAHN	
AB		100MG		A201791	003	Jan 18, 2013	Apr	CAHN	
	@	200MG		A201374	004	Dec 26, 2012	May	CAHN	
AB		200MG		A201791	004	Jan 18, 2013	Apr	CAHN	
	@	250MG		A201374	005	Dec 26, 2012	May	CAHN	
AB		250MG		A201791	005	Jan 18, 2013	Apr	CAHN	
	@	300MG		A201374	006	Dec 26, 2012	May	CAHN	
AB		300MG		A201791	006	Jan 18, 2013	Apr	CAHN	
	TABLET, ORALLY DISINTEGRATING;ORAL								
	LAMOTRIGINE								
AB	ENDO OPERATIONS	25MG		A204158	001	Oct 27, 2015	Apr	CAHN	
AB		50MG		A204158	002	Oct 27, 2015	Apr	CAHN	
AB		100MG		A204158	003	Oct 27, 2015	Apr	CAHN	
AB		200MG		A204158	004	Oct 27, 2015	Apr	CAHN	

LANREOTIDE ACETATE

	SOLUTION;SUBCUTANEOUS								
	LANREOTIDE ACETATE								
AB	INVAGEN PHARMS	EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML)		A217193	001	May 21, 2024	May	NFTG	
AB		EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)		A217193	002	May 21, 2024	May	NFTG	

## SOLUTION;SUBCUTANEOUS

		LANREOTIDE ACETATE							
AB			EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML)	A217193	003	May 21, 2024	May	NFTG	
		SOMATULINE DEPOT							
AB	+	IPSEN PHARMA	EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML)	N022074	001	Aug 30, 2007	May	CFTG	
AB	+		EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)	N022074	002	Aug 30, 2007	May	CFTG	
AB	+		EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML)	N022074	003	Aug 30, 2007	May	CFTG	

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

@ SUN PHARM

15MG

A202637

001

Sep 13, 2013

May DISC

@

30MG

A091509

001

Sep 13, 2013

May DISC

LAPATINIB DITOSYLATE

TABLET;ORAL

LAPATINIB DITOSYLATE

>A>	AB	TEVA PHARMS USA INC	EQ 250MG BASE	A217968	001	Aug 16, 2024	Aug	NEWA	
-----	----	---------------------	---------------	---------	-----	--------------	-----	------	--

LAZERTINIB MESYLATE

&gt;A&gt; TABLET;ORAL

&gt;A&gt; LAZCLUZE

>A>	+	JANSSEN BIOTECH	EQ 80MG BASE	N219008	001	Aug 19, 2024	Aug	NEWA	
-----	---	-----------------	--------------	---------	-----	--------------	-----	------	--

>A>	+		EQ 240MG BASE	N219008	002	Aug 19, 2024	Aug	NEWA	
-----	---	--	---------------	---------	-----	--------------	-----	------	--

LEFAMULIN ACETATE

SOLUTION;INTRAVENOUS

XENLETA

	+	NABRIVA	EQ 150MG BASE/15ML (EQ 10MG BASE/ML)	N211673	001	Aug 19, 2019	Apr	CMFD	
--	---	---------	--------------------------------------	---------	-----	--------------	-----	------	--

LENALIDOMIDE

CAPSULE;ORAL

LENALIDOMIDE

>A>	AB	NOVUGEN	2.5MG	A217281	001	Sep 11, 2024	Aug	NEWA	
>A>	AB		5MG	A217281	002	Sep 11, 2024	Aug	NEWA	
>A>	AB		10MG	A217281	003	Sep 11, 2024	Aug	NEWA	
>A>	AB		15MG	A217281	004	Sep 11, 2024	Aug	NEWA	
>A>	AB		20MG	A217281	005	Sep 11, 2024	Aug	NEWA	
>A>	AB		25MG	A217281	006	Sep 11, 2024	Aug	NEWA	
	AB	@ QILU	2.5MG	A217265	001	Feb 22, 2024	Jul	DISC	
	AB	@	2.5MG	A217265	001	Feb 22, 2024	Feb	NEWA	
	AB	@	5MG	A217265	002	Feb 22, 2024	Jul	DISC	
	AB	@	5MG	A217265	002	Feb 22, 2024	Feb	NEWA	
	AB	@	10MG	A217265	003	Feb 22, 2024	Jul	DISC	
	AB	@	10MG	A217265	003	Feb 22, 2024	Feb	NEWA	
	AB	@	15MG	A217265	004	Feb 22, 2024	Jul	DISC	
	AB	@	15MG	A217265	004	Feb 22, 2024	Feb	NEWA	
	AB	@	20MG	A217265	005	Feb 22, 2024	Jul	DISC	
	AB	@	20MG	A217265	005	Feb 22, 2024	Feb	NEWA	
	AB	@	25MG	A217265	006	Feb 22, 2024	Jul	DISC	
	AB	@	25MG	A217265	006	Feb 22, 2024	Feb	NEWA	

LETERMOVIR

&gt;A&gt; PELLETS;ORAL

&gt;A&gt; PREVYMIS

>A>	+	MSD	20MG/PACKET	N219104	001	Aug 30, 2024	Aug	NEWA	
-----	---	-----	-------------	---------	-----	--------------	-----	------	--

>A>	+		120MG/PACKET	N219104	002	Aug 30, 2024	Aug	NEWA	
-----	---	--	--------------	---------	-----	--------------	-----	------	--

LEUCOVORIN CALCIUM

INJECTABLE;INJECTION

LEUCOVORIN CALCIUM

AP		MEITHEAL	EQ 50MG BASE/VIAL	A216590	001	Jul 19, 2023	Jun	CAHN	
AP			EQ 100MG BASE/VIAL	A216590	002	Jul 19, 2023	Jun	CAHN	
AP			EQ 200MG BASE/VIAL	A216590	003	Jul 19, 2023	Jun	CAHN	
AP			EQ 350MG BASE/VIAL	A216590	004	Jul 19, 2023	Jun	CAHN	
AP			EQ 500MG BASE/VIAL	A216590	005	Jul 19, 2023	Jun	CAHN	



LEUPROLIDE ACETATE

SOLUTION; SUBCUTANEOUS

LEUPROLIDE ACETATE

AP	AMNEAL	1MG/0.2ML	A215336	001	Oct 28, 2022	Jul	CDFR
AP		14MG/2.8ML (1MG/0.2ML)	A215336	001	Oct 28, 2022	Jul	CPOT
AP	EUGIA PHARMA	1MG/0.2ML	A212963	001	Jun 06, 2022	Jul	CDFR
AP		14MG/2.8ML (1MG/0.2ML)	A212963	001	Jun 06, 2022	Jul	CPOT
	@ GENZYME	1MG/0.2ML	A075721	001	Nov 29, 2001	Jul	CDFR
	@	14MG/2.8ML (1MG/0.2ML)	A075721	001	Nov 29, 2001	Jul	CPOT
AP	MEITHEAL	1MG/0.2ML	A075471	001	Oct 25, 2000	Jul	CDFR
AP		14MG/2.8ML (1MG/0.2ML)	A075471	001	Oct 25, 2000	Jul	CPOT
AP	RK PHARMA	1MG/0.2ML	A213829	001	Aug 13, 2021	Jul	CDFR
AP		14MG/2.8ML (1MG/0.2ML)	A213829	001	Aug 13, 2021	Jul	CPOT
AP	! SANDOZ	1MG/0.2ML	A074728	001	Aug 04, 1998	Jul	CDFR
AP	!	14MG/2.8ML (1MG/0.2ML)	A074728	001	Aug 04, 1998	Jul	CPOT
AP	SUN PHARM	1MG/0.2ML	A078885	001	Mar 09, 2009	Jul	CDFR
AP		14MG/2.8ML (1MG/0.2ML)	A078885	001	Mar 09, 2009	Jul	CPOT
	LUPRON						
	+ @ ABBVIE ENDOCRINE INC	1MG/0.2ML	N019010	001	Apr 09, 1985	Jul	CDFR
	+ @	14MG/2.8ML (1MG/0.2ML)	N019010	001	Apr 09, 1985	Jul	CPOT

LEVABUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVABUTEROL HYDROCHLORIDE

AN	! MYLAN SPECIALITY LP	EQ 0.25% BASE	A078309	001	Mar 20, 2009	Apr	CHRS
	@ NORVIUM BIOSCIENCE	EQ 0.0103% BASE	A077800	001	Mar 15, 2013	Jul	CAHN
	@	EQ 0.021% BASE	A077800	002	Mar 15, 2013	Jul	CAHN
	@	EQ 0.042% BASE	A077800	003	Mar 15, 2013	Jul	CAHN
	@ SUN PHARM	EQ 0.0103% BASE	A207820	001	Nov 05, 2018	May	DISC
	@	EQ 0.021% BASE	A207820	002	Nov 05, 2018	May	DISC
	@	EQ 0.042% BASE	A207820	003	Nov 05, 2018	May	DISC
AN	! TEVA PHARMS USA	EQ 0.0103% BASE	A090297	001	Apr 26, 2013	Apr	CHRS
AN	!	EQ 0.021% BASE	A090297	002	Apr 26, 2013	Apr	CHRS
AN	!	EQ 0.042% BASE	A090297	003	Apr 26, 2013	Apr	CHRS
	XOPENEX						
	+ @ HIKMA	EQ 0.0103% BASE	N020837	003	Jan 30, 2002	Apr	DISC
	+ @	EQ 0.021% BASE	N020837	001	Mar 25, 1999	Apr	DISC
	+ @	EQ 0.042% BASE	N020837	002	Mar 25, 1999	Apr	DISC
	+ @	EQ 0.25% BASE	N020837	004	Jul 18, 2003	Apr	DISC

LEVAMLODIPINE MALEATE

TABLET; ORAL

CONJUPRI

	+ CSPEC OUYI	EQ 2.5MG BASE	N212895	002	Dec 19, 2019	Mar	CMFD
	+!	EQ 5MG BASE	N212895	003	Dec 19, 2019	Mar	CMFD

LEVETIRACETAM

INJECTABLE; INTRAVENOUS

LEVETIRACETAM

AP	ADRASTEIA PHARMA	500MG/5ML (100MG/ML)	A091485	001	Aug 05, 2011	Feb	CAHN
	@ SUN PHARM INDS LTD	500MG/5ML (100MG/ML)	A090754	001	Jun 16, 2010	May	DISC
AP	XGEN PHARMS	500MG/5ML (100MG/ML)	A091485	001	Aug 05, 2011	Jul	CAHN
	LEVETIRACETAM IN SODIUM CHLORIDE						
AP	B BRAUN MEDICAL INC	500MG/100ML (5MG/ML)	A209705	001	Feb 27, 2024	Feb	NEWA
AP		1GM/100ML (10MG/ML)	A209705	002	Feb 27, 2024	Feb	NEWA
AP		1.5GM/100ML (15MG/ML)	A209705	003	Feb 27, 2024	Feb	NEWA
AP	BAXTER HLTHCARE CORP	500MG/100ML (5MG/ML)	A217059	001	Oct 02, 2023	Feb	CTNA
AP		1GM/100ML (10MG/ML)	A217059	002	Oct 02, 2023	Feb	CTNA
AP		1.5GM/100ML (15MG/ML)	A217059	003	Oct 02, 2023	Feb	CTNA
	@ FRESENIUS KABI USA	500MG/100ML (5MG/ML)	A208619	001	Jan 31, 2023	Mar	DISC
	@	1GM/100ML (10MG/ML)	A208619	002	Jan 31, 2023	Mar	DISC
	@	1.5GM/100ML (15MG/ML)	A208619	003	Jan 31, 2023	Mar	DISC
AP	HIKMA	500MG/100ML (5MG/ML)	A211356	001	Feb 12, 2024	Feb	NEWA
AP		1GM/100ML (10MG/ML)	A211356	002	Feb 12, 2024	Feb	NEWA
AP		1.5GM/100ML (15MG/ML)	A211356	003	Feb 12, 2024	Feb	NEWA
	SOLUTION; ORAL						
	LEVETIRACETAM						
	@ HIKMA	100MG/ML	A090601	001	Feb 28, 2012	Mar	DISC
	@ STRIDES PHARMA	100MG/ML	A214673	001	Nov 20, 2023	May	DISC

## TABLET;ORAL

## LEVETIRACETAM

@	ACCORD HLTHCARE	250MG	A090843	001	Feb 14, 2011	May	DISC
@		500MG	A090843	002	Feb 14, 2011	May	DISC
@		750MG	A090843	003	Feb 14, 2011	May	DISC
@		1GM	A090843	004	Feb 14, 2011	May	DISC
@	GRANULES	250MG	A217878	001	Jun 13, 2023	Mar	DISC
@		500MG	A217878	002	Jun 13, 2023	Mar	DISC
@		750MG	A217878	003	Jun 13, 2023	Mar	DISC
@		1GM	A217878	004	Jun 13, 2023	Mar	DISC
@	INVAGEN PHARMS	250MG	A078234	001	Jan 15, 2009	Mar	DISC
@		500MG	A078234	002	Jan 15, 2009	Mar	DISC
@		750MG	A078234	003	Jan 15, 2009	Mar	DISC

## TABLET, EXTENDED RELEASE;ORAL

## LEVETIRACETAM

@	ANCHEN PHARMS	500MG	A091360	001	Oct 04, 2011	Feb	DISC
@		750MG	A091360	002	Oct 04, 2011	Feb	DISC
@	ENDO OPERATIONS	500MG	A091360	001	Oct 04, 2011	May	CAHN
@		750MG	A091360	002	Oct 04, 2011	May	CAHN
>D> AB	PRINSTON INC	500MG	A202533	001	Jul 20, 2012	Aug	DISC
>A>	@	500MG	A202533	001	Jul 20, 2012	Aug	DISC
>D> AB		750MG	A202533	002	Jul 20, 2012	Aug	DISC
>A>	@	750MG	A202533	002	Jul 20, 2012	Aug	DISC

LEVOBUNOLOL HYDROCHLORIDE

## SOLUTION/DROPS;OPHTHALMIC

## LEVOBUNOLOL HYDROCHLORIDE

@	CHARTWELL RX	0.5%	A074850	001	Oct 28, 1996	Jul	CAHN
---	--------------	------	---------	-----	--------------	-----	------

LEVOPUPIVACAINE HYDROCHLORIDE

## INJECTABLE;INJECTION

## CHIROCAINE

+	@	PURDUE PHARMA LP	EQ 2.5MG BASE/ML	N020997	001	Aug 05, 1999	Jun	CRLD
+	@		EQ 5MG BASE/ML	N020997	002	Aug 05, 1999	Jun	CRLD
+	@		EQ 7.5MG BASE/ML	N020997	003	Aug 05, 1999	Jun	CRLD

LEVOCARNITINE

## SOLUTION;ORAL

## LEVOCARNITINE

@	HIKMA	1GM/10ML	A077399	001	Oct 25, 2007	Mar	DISC
---	-------	----------	---------	-----	--------------	-----	------

LEVOCETIRIZINE DIHYDROCHLORIDE

## TABLET;ORAL

## LEVOCETIRIZINE DIHYDROCHLORIDE

AB		IPCA LABS LTD	5MG	A204626	001	May 06, 2024	Apr	NEWA
----	--	---------------	-----	---------	-----	--------------	-----	------

LEVODOPA

## POWDER;INHALATION

## INBRIJA

+	!	MERZ PHARMS GMBH	42MG	N209184	001	Dec 21, 2018	Jul	CAHN
---	---	------------------	------	---------	-----	--------------	-----	------

LEVOFLOXACIN

## INJECTABLE;INJECTION

## LEVOFLOXACIN

	@	NORVIUM BIOSCIENCE	EQ 500MG/20ML (EQ 25MG/ML)	A200560	001	Jun 20, 2011	Jun	CAHN
	@		EQ 750MG/30ML (EQ 25MG/ML)	A200560	002	Jun 20, 2011	Jun	CAHN
			LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER					
	@	KNACK	EQ 250MG/50ML (EQ 5MG/ML)	A216164	001	Jan 29, 2024	Jul	DISC
AP			EQ 250MG/50ML (EQ 5MG/ML)	A216164	001	Jan 29, 2024	Jan	NEWA
	@		EQ 500MG/100ML (EQ 5MG/ML)	A216164	002	Jan 29, 2024	Jul	DISC
AP			EQ 500MG/100ML (EQ 5MG/ML)	A216164	002	Jan 29, 2024	Jan	NEWA
	@		EQ 750MG/150ML (EQ 5MG/ML)	A216164	003	Jan 29, 2024	Jul	DISC
AP			EQ 750MG/150ML (EQ 5MG/ML)	A216164	003	Jan 29, 2024	Jan	NEWA

LEVOLEUCOVORIN CALCIUM

## POWDER;INTRAVENOUS

## FUSILEV

+	@	ACROTECH BIOPHARMA	EQ 50MG BASE/VIAL	N020140	001	Mar 07, 2008	May	DISC
+	!		EQ 50MG BASE/VIAL	N020140	001	Mar 07, 2008	Mar	CTEC
			LEVOLEUCOVORIN CALCIUM					
	@	MEITHEAL	EQ 50MG BASE/VIAL	A211003	001	Aug 22, 2019	Mar	DISC

SOLUTION; INTRAVENOUS  
LEVOLEUCOVORIN CALCIUM

@ NORVIUM BIOSCIENCE	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203576	001	Oct 20, 2015	Jun CAHN
@	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203576	002	Oct 20, 2015	Jun CAHN
@ PRAXGEN	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A213797	001	Nov 02, 2021	Jul CAHN

LEVONORGESTREL

SYSTEM; INTRAUTERINE  
KYLEENA

+! BAYER HLTHCARE	19.5MG	N208224	001	Sep 16, 2016	Jun CDFR
LILETTA					
+! MEDICINES360	52MG	N206229	001	Feb 26, 2015	Jun CDFR
MIRENA					
+! BAYER HLTHCARE	52MG	N021225	001	Dec 06, 2000	Jun CDFR
SKYLA					
+! BAYER HLTHCARE	13.5MG	N203159	001	Jan 09, 2013	Jun CDFR

TABLET; ORAL  
LEVONORGESTREL

@ XIROMED	0.75MG	A202740	001	Sep 02, 2016	May CAHN
-----------	--------	---------	-----	--------------	----------

LEVOTHYROXINE SODIUM

POWDER; INTRAVENOUS  
LEVOTHYROXINE SODIUM

@ ENDO OPERATIONS	200MCG/VIAL	A205366	001	Dec 07, 2015	May CAHN
-------------------	-------------	---------	-----	--------------	----------

LEVOTHYROXINE SODIUM \*\*

\*\*See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET; ORAL

LEVOTHYROXINE SODIUM

AB2	AUROBINDO PHARMA	0.137MG	A216414	001	Jul 16, 2024	Jul NEWA
AB2		0.15MG	A216414	002	Jul 16, 2024	Jul NEWA
AB2		0.175MG	A216414	003	Jul 16, 2024	Jul NEWA
AB2		0.2MG	A216414	004	Jul 16, 2024	Jul NEWA
AB2		0.3MG	A216414	005	Jul 16, 2024	Jul NEWA
AB1,	WATSON LABS TEVA	0.025MG	A207588	001	May 10, 2022	Feb CTEC
AB2,						
AB3,						
AB4						
AB1,		0.05MG	A207588	002	May 10, 2022	Feb CTEC
AB2,						
AB3,						
AB4						
AB1,		0.075MG	A207588	003	May 10, 2022	Feb CTEC
AB2,						
AB3,						
AB4						
AB1,		0.088MG	A207588	004	May 10, 2022	Feb CTEC
AB2,						
AB3,						
AB4						
AB1,		0.1MG	A207588	005	May 10, 2022	Feb CTEC
AB2,						
AB3,						
AB4						
AB1,		0.112MG	A207588	006	May 10, 2022	Feb CTEC
AB2,						
AB3,						
AB4						
AB1,		0.125MG	A207588	007	May 10, 2022	Feb CTEC
AB2,						
AB3,						
AB4						
AB1,		0.137MG	A207588	008	May 10, 2022	Feb CTEC
AB2,						
AB3,						
AB4						
AB1,		0.15MG	A207588	009	May 10, 2022	Feb CTEC
AB2,						
AB3,						
AB4						
AB1,		0.175MG	A207588	010	May 10, 2022	Feb CTEC
AB2,						
AB3,						
AB4						

TABLET;ORAL

LEVOTHYROXINE SODIUM

AB1, AB2, AB3, AB4	0.2MG	A207588	011	May 10, 2022	Feb	CTEC
AB1, AB2, AB3, AB4	0.3MG	A207588	012	May 10, 2022	Feb	CTEC

LIDOCAINE

OINTMENT;TOPICAL

LIDOCAINE

AT	AUROBINDO PHARMA LTD	5%	A217117	001	Jun 18, 2024	Jun	NEWA
	@ COSETTE	5%	A211019	001	Dec 12, 2018	Apr	DISC
	@ GENEYORK PHARMS	5%	A212486	001	Oct 17, 2019	Jul	CAHN

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE

AP	FRESENIUS KABI USA	1%	A088586	002		Apr	CMS1
AP		2%	A088586	003		Apr	CMS1
>D> AP	INTL MEDICATION	1%	A083173	001		Aug	CRLD
>A> AP	+	1%	A083173	001		Aug	CRLD
	LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE						
	@ EXTROVIS	2%	A090665	001	Sep 27, 2010	Jun	CAHN
AP	HIKMA	1%	A084625	001		Jun	CAHN
AP		2%	A084625	002		Jun	CAHN

SOLUTION;ORAL

LIDOCAINE HYDROCHLORIDE VISCOUS

AT	PAI HOLDINGS PHARM	2%	A218138	001	Feb 20, 2024	Feb	NEWA
----	--------------------	----	---------	-----	--------------	-----	------

SOLUTION;TOPICAL

LIDOCAINE HYDROCHLORIDE

AT	THE J MOLNER	4%	A218411	001	Apr 29, 2024	Apr	NEWA
----	--------------	----	---------	-----	--------------	-----	------

LIDOCAINE; PRILOCAINE

CREAM;TOPICAL

LIDOCAINE AND PRILOCAINE

	@ HIKMA	2.5%;2.5%	A076290	001	Sep 25, 2003	Mar	DISC
AB	PAI HOLDINGS PHARM	2.5%;2.5%	A205887	001	Jun 29, 2018	Jun	CMFD
AB	RHODES PHARMS	2.5%;2.5%	A213253	001	Sep 21, 2020	Jun	CMFD

LIDOCAINE; TETRACAINE

CREAM;TOPICAL

PLIAGLIS

+	@ CRESCITA THERAP	7%;7%	N021717	001	Jun 29, 2006	Jul	CAHN
---	-------------------	-------	---------	-----	--------------	-----	------

LIFITEGRAST

SOLUTION/DROPS;OPHTHALMIC

LIFITEGRAST

	@ EUGIA PHARMA	5%	A215063	001	Nov 07, 2023	May	DISC
	@ MICRO LABS	5%	A215081	001	Aug 04, 2023	May	DISC
	XIIDRA						
	+! BAUSCH AND LOMB INC	5%	N208073	001	Jul 11, 2016	May	CTEC
AB	+!	5%	N208073	001	Jul 11, 2016	Jan	CAHN

LINAGLIPTIN

TABLET;ORAL

LINAGLIPTIN

>A> AB	INVAGEN PHARMS	5MG	A208423	001	Sep 03, 2024	Aug	NEWA
--------	----------------	-----	---------	-----	--------------	-----	------

LINCOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION

LINCOMYCIN HYDROCHLORIDE

AP	ARTHUR GRP	EQ 300MG BASE/ML	A212770	001	Mar 12, 2021	Jul	CAHN
AP	GENEYORK PHARMS	EQ 300MG BASE/ML	A212770	001	Mar 12, 2021	May	CMFD

LIOETHYRONINE SODIUM

INJECTABLE; INJECTION  
TRIOSTAT

+ @ ENDO OPERATIONS EQ 0.01MG BASE/ML N020105 001 Dec 31, 1991 May CAHN  
TABLET; ORAL

LIOETHYRONINE SODIUM

AB	BIOCON PHARMA	EQ 0.005MG BASE	A218070	001	Feb 06, 2024	Mar	CAHN
AB		EQ 0.005MG BASE	A218070	001	Feb 06, 2024	Feb	CAHN
AB		EQ 0.025MG BASE	A218070	002	Feb 06, 2024	Mar	CAHN
AB		EQ 0.025MG BASE	A218070	002	Feb 06, 2024	Feb	CAHN
AB		EQ 0.05MG BASE	A218070	003	Feb 06, 2024	Mar	CAHN
AB		EQ 0.05MG BASE	A218070	003	Feb 06, 2024	Feb	CAHN
AB	CARNEGIE	EQ 0.005MG BASE	A218070	001	Feb 06, 2024	Jan	NEWA
AB		EQ 0.025MG BASE	A218070	002	Feb 06, 2024	Jan	NEWA
AB		EQ 0.05MG BASE	A218070	003	Feb 06, 2024	Jan	NEWA
	@ NORVIUM BIOSCIENCE	EQ 0.005MG BASE	A090326	001	Jul 14, 2009	Jul	CAHN
	@	EQ 0.025MG BASE	A090326	002	Jul 14, 2009	Jul	CAHN
	@	EQ 0.05MG BASE	A090326	003	Jul 14, 2009	Jul	CAHN
>D>	AB ZYDUS	EQ 0.005MG BASE	A214803	001	Jan 22, 2021	Aug	CAHN
>D>	AB	EQ 0.025MG BASE	A214803	002	Jan 22, 2021	Aug	CAHN
>D>	AB	EQ 0.05MG BASE	A214803	003	Jan 22, 2021	Aug	CAHN
>A>	AB ZYDUS LIFESCIENCES	EQ 0.005MG BASE	A214803	001	Jan 22, 2021	Aug	CAHN
>A>	AB	EQ 0.025MG BASE	A214803	002	Jan 22, 2021	Aug	CAHN
>A>	AB	EQ 0.05MG BASE	A214803	003	Jan 22, 2021	Aug	CAHN

LIRAGLUTIDE

SOLUTION; SUBCUTANEOUS  
SAXENDA

+! NOVO 18MG/3ML (6MG/ML) N206321 001 Dec 23, 2014 Mar CAIN  
VICTOZA  
+! NOVO NORDISK INC 18MG/3ML (6MG/ML) N022341 001 Jan 25, 2010 Mar CAIN

LISDEXAMFETAMINE DIMESYLATE

CAPSULE; ORAL

LISDEXAMFETAMINE DIMESYLATE

	@ ACTAVIS ELIZABETH	10MG	A202802	001	Aug 25, 2023	Feb	DISC
	@	20MG	A202802	002	Aug 25, 2023	Feb	DISC
	@	30MG	A202802	003	Aug 25, 2023	Feb	DISC
	@	40MG	A202802	004	Aug 25, 2023	Feb	DISC
	@	50MG	A202802	005	Aug 25, 2023	Feb	DISC
	@	60MG	A202802	006	Aug 25, 2023	Feb	DISC
	@	70MG	A202802	007	Aug 25, 2023	Feb	DISC
AB	HIKMA	10MG	A202827	007	Jan 17, 2024	Jan	NEWA
>D>	AB SANDOZ	20MG	A202836	001	Jul 26, 2024	Aug	DISC
>A>	@	20MG	A202836	001	Jul 26, 2024	Aug	DISC
AB		20MG	A202836	001	Jul 26, 2024	Jul	NEWA
>D>	AB	30MG	A202836	002	Jul 26, 2024	Aug	DISC
>A>	@	30MG	A202836	002	Jul 26, 2024	Aug	DISC
AB		30MG	A202836	002	Jul 26, 2024	Jul	NEWA
>D>	AB	40MG	A202836	003	Jul 26, 2024	Aug	DISC
>A>	@	40MG	A202836	003	Jul 26, 2024	Aug	DISC
AB		40MG	A202836	003	Jul 26, 2024	Jul	NEWA
>D>	AB	50MG	A202836	004	Jul 26, 2024	Aug	DISC
>A>	@	50MG	A202836	004	Jul 26, 2024	Aug	DISC
AB		50MG	A202836	004	Jul 26, 2024	Jul	NEWA
>D>	AB	60MG	A202836	005	Jul 26, 2024	Aug	DISC
>A>	@	60MG	A202836	005	Jul 26, 2024	Aug	DISC
AB		60MG	A202836	005	Jul 26, 2024	Jul	NEWA
>D>	AB	70MG	A202836	006	Jul 26, 2024	Aug	DISC
>A>	@	70MG	A202836	006	Jul 26, 2024	Aug	DISC
AB		70MG	A202836	006	Jul 26, 2024	Jul	NEWA

TABLET, CHEWABLE; ORAL

LISDEXAMFETAMINE DIMESYLATE

AB	MSN	10MG	A218306	001	Feb 02, 2024	Jan	NEWA
AB		20MG	A218306	002	Feb 02, 2024	Jan	NEWA
AB		30MG	A218306	003	Feb 02, 2024	Jan	NEWA
AB		40MG	A218306	004	Feb 02, 2024	Jan	NEWA
AB		50MG	A218306	005	Feb 02, 2024	Jan	NEWA
AB		60MG	A218306	006	Feb 02, 2024	Jan	NEWA
>D>	@ TEVA PHARMS	10MG	A215415	001	Aug 25, 2023	Aug	CMFD
>A>	AB	10MG	A215415	001	Aug 25, 2023	Aug	CMFD
	@	10MG	A215415	001	Aug 25, 2023	Feb	DISC

TABLET, CHEWABLE;ORALLISDEXAMFETAMINE DIMESYLATE

>D>	@	20MG	A215415	002	Aug 25, 2023	Aug	CMFD
>A>	AB	20MG	A215415	002	Aug 25, 2023	Aug	CMFD
	@	20MG	A215415	002	Aug 25, 2023	Feb	DISC
>D>	@	30MG	A215415	003	Aug 25, 2023	Aug	CMFD
>A>	AB	30MG	A215415	003	Aug 25, 2023	Aug	CMFD
	@	30MG	A215415	003	Aug 25, 2023	Feb	DISC
>D>	@	40MG	A215415	004	Aug 25, 2023	Aug	CMFD
>A>	AB	40MG	A215415	004	Aug 25, 2023	Aug	CMFD
	@	40MG	A215415	004	Aug 25, 2023	Feb	DISC
>D>	@	50MG	A215415	005	Aug 25, 2023	Aug	CMFD
>A>	AB	50MG	A215415	005	Aug 25, 2023	Aug	CMFD
	@	50MG	A215415	005	Aug 25, 2023	Feb	DISC
>D>	@	60MG	A215415	006	Aug 25, 2023	Aug	CMFD
>A>	AB	60MG	A215415	006	Aug 25, 2023	Aug	CMFD
	@	60MG	A215415	006	Aug 25, 2023	Feb	DISC

LISINAPRIL

## TABLET;ORAL

LISINAPRIL

@	ACCORD HLTHCARE	2.5MG	A202554	001	Jul 30, 2013	May	DISC
@		5MG	A202554	002	Jul 30, 2013	May	DISC
@		10MG	A202554	003	Jul 30, 2013	May	DISC
@		20MG	A202554	004	Jul 30, 2013	May	DISC
@		30MG	A202554	005	Jul 30, 2013	May	DISC
@		40MG	A202554	006	Jul 30, 2013	May	DISC

LITHIUM CITRATE

## SYRUP;ORAL

LITHIUM CITRATE

	@	PAI HOLDINGS PHARM	EQ 300MG CARBONATE/5ML	A070755	001	May 21, 1986	Feb	DISC
AA	!	RUBICON	EQ 300MG CARBONATE/5ML	A218036	001	Aug 14, 2023	Mar	NEWA
	!		EQ 300MG CARBONATE/5ML	A218036	001	Aug 14, 2023	Mar	CTEC
AA	!		EQ 300MG CARBONATE/5ML	A218036	001	Aug 14, 2023	Feb	CHRS

LOFEXIDINE HYDROCHLORIDE

## TABLET;ORAL

LOFEXIDINE HYDROCHLORIDE

>A>								
>A>	AB	INDOCO	EQ 0.18MG BASE	A218613	001	Aug 20, 2024	Aug	NFTG
		LUCEMYRA						
>D>	+	USWM	EQ 0.18MG BASE	N209229	001	May 16, 2018	Aug	CFTG
>A>	AB	+	EQ 0.18MG BASE	N209229	001	May 16, 2018	Aug	CFTG

LOMITAPIDE MESYLATE

## CAPSULE;ORAL

JUXTAPID

+	CHIESI	EQ 5MG BASE	N203858	001	Dec 21, 2012	Jan	CAHN
+		EQ 10MG BASE	N203858	002	Dec 21, 2012	Jan	CAHN
+		EQ 20MG BASE	N203858	003	Dec 21, 2012	Jan	CAHN
+		EQ 30MG BASE	N203858	004	Apr 23, 2015	Jan	CAHN
+	@	EQ 40MG BASE	N203858	005	Apr 23, 2015	Jan	CAHN
+	@	EQ 60MG BASE	N203858	006	Apr 23, 2015	Jan	CAHN

LOMUSTINE

## CAPSULE;ORAL

GLEOSTINE

+	@	LATINA PHARMA	5MG	N017588	004	Dec 19, 2014	Feb	CAHN
+			10MG	N017588	001		Feb	CAHN
+	!		40MG	N017588	002		May	CHRS
+			40MG	N017588	002		Feb	CAHN
+			100MG	N017588	003		May	CHRS
+	!		100MG	N017588	003		Feb	CAHN

LONAFARNIB

## CAPSULE;ORAL

ZOKINVY

+		SENTYNL THERAPS INC	50MG	N213969	001	Nov 20, 2020	May	CAHN
+	!		75MG	N213969	002	Nov 20, 2020	May	CAHN

LOPINAVIR; RITONAVIR

TABLET; ORAL

LOPINAVIR AND RITONAVIR

AB	MACLEODS PHARMS LTD	100MG;25MG	A204739	001	Jul 25, 2024	Jul	NEWA
AB		200MG;50MG	A204739	002	Jul 25, 2024	Jul	NEWA
AB	MYLAN LABS LTD	100MG;25MG	A079074	001	Feb 07, 2024	Jan	NEWA
AB		200MG;50MG	A079074	002	Feb 07, 2024	Jan	NEWA

LORAZEPAM

CONCENTRATE; ORAL

LORAZEPAM

@ HIKMA 2MG/ML

A200169 001 Jan 30, 2012 Mar DISC

INJECTABLE; INJECTION

LORAZEPAM

@ ENDO OPERATIONS 2MG/ML

A074793 001 Mar 16, 2000 Apr CAHN

@ 4MG/ML

A074793 002 Mar 16, 2000 Apr CAHN

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

@ AIPING PHARM INC 25MG

A090544 001 Oct 06, 2010 Feb CAHN

@ 50MG

A090544 002 Oct 06, 2010 Feb CAHN

@ 100MG

A090544 003 Oct 06, 2010 Feb CAHN

AB APOTEX 25MG

A218551 001 Jun 04, 2024 May NEWA

AB 50MG

A218551 002 Jun 04, 2024 May NEWA

AB 100MG

A218551 003 Jun 04, 2024 May NEWA

AB CHARTWELL RX 25MG

A077424 001 Oct 06, 2010 Jan CAHN

AB 50MG

A077424 002 Oct 06, 2010 Jan CAHN

AB 100MG

A077424 003 Oct 06, 2010 Jan CAHN

LOTEPREDNOL ETABONATE

GEL; OPHTHALMIC

LOTEPREDNOL ETABONATE

AB HIKMA 0.5%

A213956 001 Nov 29, 2023 Apr CAHN

SUSPENSION/DROPS; OPHTHALMIC

LOTEPREDNOL ETABONATE

AB LUPIN LTD 0.5%

A215719 001 Apr 24, 2024 Apr NEWA

AB PADAGIS US 0.2%

A215203 001 Jul 10, 2024 Jun NEWA

LUBIPROSTONE

CAPSULE; ORAL

LUBIPROSTONE

@ ENDO OPERATIONS 8MCG

A201442 001 Jun 27, 2022 Apr CAHN

@ 24MCG

A201442 002 Jun 27, 2022 Apr CAHN

LURASIDONE HYDROCHLORIDE

TABLET; ORAL

LURASIDONE HYDROCHLORIDE

>A> AB ANNORA PHARMA 20MG

A218174 001 Aug 21, 2024 Aug NEWA

>A> AB 40MG

A218174 002 Aug 21, 2024 Aug NEWA

>A> AB 60MG

A218174 003 Aug 21, 2024 Aug NEWA

>A> AB 80MG

A218174 004 Aug 21, 2024 Aug NEWA

>A> AB 120MG

A218174 005 Aug 21, 2024 Aug NEWA

AB SLATE RUN PHARMA 20MG

A212091 001 Dec 28, 2020 Feb CAHN

AB 40MG

A212091 002 Dec 28, 2020 Feb CAHN

AB 60MG

A212091 003 Dec 28, 2020 Feb CAHN

AB 80MG

A212091 004 Dec 28, 2020 Feb CAHN

AB 120MG

A212091 005 Dec 28, 2020 Feb CAHN

MACITENTAN

TABLET; ORAL

MACITENTAN

@ APOTEX 10MG

A211195 001 Jan 09, 2024 Apr DISC

>D> AB TORRENT 10MG

A211107 001 Aug 05, 2024 Aug DISC

>A> @ 10MG

A211107 001 Aug 05, 2024 Aug DISC

AB 10MG

A211107 001 Aug 05, 2024 Jul NFTG

@ ZYDUS LIFESCIENCES 10MG

A211224 001 Apr 06, 2021 May CAHN

OPSUMIT

>D> AB +! ACTELION 10MG

N204410 001 Oct 18, 2013 Aug CTEC

>A> +! 10MG

N204410 001 Oct 18, 2013 Aug CTEC

AB +! 10MG

N204410 001 Oct 18, 2013 Jul CFTG

	TABLET;ORAL								
	OPSUMIT								
	+!	10MG		N204410	001	Oct 18, 2013		Apr	CTEC
	<u>MACITENTAN; TADALAFIL</u>								
	TABLET;ORAL								
	OPSYNVI								
	+	ACTELION	10MG;20MG	N218490	001	Mar 22, 2024		Mar	NEWA
	+!		10MG;40MG	N218490	002	Mar 22, 2024		Mar	NEWA
	<u>MAFENIDE ACETATE</u>								
	FOR SOLUTION;TOPICAL								
	MAFENIDE ACETATE								
	@	ENDO OPERATIONS	5%	A201511	001	Feb 12, 2013		May	CAHN
	<u>MAGNESIUM SULFATE</u>								
	SOLUTION;INTRAMUSCULAR, INTRAVENOUS								
	MAGNESIUM SULFATE								
>D>	AP	EXELA PHARMA	5GM/10ML (500MG/ML)	A206039	001	Dec 18, 2014		Aug	DISC
>A>		@	5GM/10ML (500MG/ML)	A206039	001	Dec 18, 2014		Aug	DISC
	<u>MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE</u>								
	SOLUTION;ORAL								
	MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE								
AA		TARO	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A206431	001	Mar 19, 2024		Mar	NEWA
		SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE							
AA		BIONPHARMA	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A204135	001	Jun 24, 2024		Jun	NEWA
AA		LANNETT CO INC	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A209941	001	Jul 15, 2024		Jul	NEWA
AA		TARO	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A206431	001	Mar 19, 2024		Jun	CMS1
	<u>MANNITOL</u>								
	INJECTABLE;INJECTION								
	OSMITROL 20% IN WATER IN PLASTIC CONTAINER								
AP	+!	BAXTER HLTHCARE	20GM/100ML	N013684	007			Jul	CHRS
AP	+		20GM/100ML	N013684	007			Jul	CRLD
	POWDER;INHALATION								
	ARIDOL KIT								
	+!	PHARMAXIS EUROPE	N/A, 5MG, 10MG, 20MG, 40MG	N022368	001	Oct 05, 2010		May	CAHN
		BRONCHITOL							
>D>	+!	CHIESI	40MG	N202049	001	Oct 30, 2020		Aug	CAHN
>A>	+!	PHARMAXIS EUROPE	40MG	N202049	001	Oct 30, 2020		Aug	CAHN
	<u>MARALIXIBAT CHLORIDE</u>								
	SOLUTION;ORAL								
	LIVMARLI								
	+!	MIRUM	EQ 19MG BASE/ML	N214662	002	Jul 24, 2024		Jul	NEWA
	<u>MARAVIROC</u>								
	TABLET;ORAL								
	SELZENTRY								
	+ @	VIIV HLTHCARE	25MG	N022128	003	Nov 04, 2016		Jan	DISC
	+ @		75MG	N022128	004	Nov 04, 2016		Jan	DISC
	<u>MAVORIXAFOR</u>								
	CAPSULE;ORAL								
	XOLREMDI								
	+!	X4 PHARMS	100MG	N218709	001	Apr 26, 2024		Apr	NEWA
	<u>MECLIZINE HYDROCHLORIDE</u>								
	TABLET;ORAL								
	MECLIZINE HYDROCHLORIDE								
AA		AMNEAL PHARMS	50MG	A201451	003	Feb 23, 2011		Mar	CHRS
AA	!		50MG	A201451	003	Feb 23, 2011		Feb	CMFD
	@	INVAGEN PHARMS	12.5MG	A200432	001	Feb 17, 2022		Mar	DISC
	@		25MG	A200432	002	Feb 17, 2022		Mar	DISC
	@		50MG	A200432	003	Feb 17, 2022		Mar	DISC
	@	WILSHIRE PHARMS INC	12.5MG	A205136	001	Feb 22, 2019		Jul	DISC
	@		25MG	A205136	002	Feb 22, 2019		Jul	DISC
	@		50MG	A205136	003	Feb 22, 2019		Jul	DISC



TABLET, CHEWABLE;ORAL  
MECLIZINE HYDROCHLORIDE  
@ INVAGEN PHARMS 25MG

A200791 001 Feb 17, 2022 Mar DISC

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION  
MEDROXYPROGESTERONE ACETATE

AB HONG KONG 150MG/ML

A076553 001 Jul 28, 2004 Jan CAHN

MEGESTROL ACETATE

SUSPENSION;ORAL  
MEGACE ES

AB +! ENDO OPERATIONS 125MG/ML

N021778 001 Jul 05, 2005 May CAHN

MEGESTROL ACETATE

@ CHARTWELL 125MG/ML

A204688 001 Dec 01, 2017 Mar CAHN

@ HIKMA 40MG/ML

A203960 001 Jun 09, 2017 Mar DISC

AB NOVITIUM PHARMA 40MG/ML

A077404 001 Feb 16, 2006 May CMFD

MELOXICAM

TABLET;ORAL  
MELOXICAM

AB AIPING PHARM INC 7.5MG

A077920 001 Jul 19, 2006 Jun CAHN

AB 15MG

A077920 002 Jul 19, 2006 Jun CAHN

AB SCIEGEN PHARMS INC 7.5MG

A077920 001 Jul 19, 2006 Apr CMFD

AB 15MG

A077920 002 Jul 19, 2006 Apr CMFD

AB ! ZYDUS PHARMS USA 15MG

A077921 002 Jul 19, 2006 Jan CTEC

MOBIC

+ @ BOEHRINGER INGELHEIM 7.5MG

N020938 001 Apr 13, 2000 Jan DISC

+ @ 15MG

N020938 002 Aug 23, 2000 Jan DISC

MELPHALAN

TABLET;ORAL  
MELPHALAN

@ ALVOGEN 2MG

A207809 001 Mar 22, 2017 May DISC

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION  
MELPHALAN HYDROCHLORIDE

AP @ ENDO OPERATIONS EQ 50MG BASE/VIAL

A204773 001 Aug 22, 2016 May CAHN

HETERO LABS EQ 50MG BASE/VIAL

A215024 001 May 23, 2024 May NEWA

SOLUTION; INTRAVENOUS  
IVRA

+! APOTEX EQ 90MG BASE/ML (EQ 90MG BASE/ML)

N217110 001 Aug 18, 2023 Jul CTNA

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL  
MEMANTINE HYDROCHLORIDE

@ ENDO OPERATIONS 7MG

A205784 001 Jun 09, 2017 Apr CAHN

@ 14MG

A205784 002 Jun 09, 2017 Apr CAHN

@ 21MG

A205784 003 Jun 09, 2017 Apr CAHN

@ 28MG

A205784 004 Jun 09, 2017 Apr CAHN

AB XIAMEN LP PHARM CO 21MG

A213985 004 Feb 06, 2024 Jan NEWA

AB ! ZYDUS PHARMS 28MG

A203293 004 Aug 03, 2017 Jul CHRS

NAMENDA XR

+ @ ABBVIE 14MG

N022525 002 Jun 21, 2010 Jul DISC

+ @ 21MG

N022525 003 Jun 21, 2010 Jul DISC

+ @ 28MG

N022525 004 Jun 21, 2010 Jul DISC

TABLET;ORAL

MEMANTINE HYDROCHLORIDE

>A> AB ACME LABS 5MG

A209527 001 May 07, 2018 Aug CAHN

>A> AB 10MG

A209527 002 May 07, 2018 Aug CAHN

AB ALLIED 5MG

A090073 001 Sep 04, 2015 Jul CAHN

AB 10MG

A090073 002 Sep 04, 2015 Jul CAHN

>D> AB RENATA 5MG

A209527 001 May 07, 2018 Aug CAHN

AB 5MG

A209527 001 May 07, 2018 Jan CAHN

>D> AB 10MG

A209527 002 May 07, 2018 Aug CAHN

AB 10MG

A209527 002 May 07, 2018 Jan CAHN

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL

MEPERIDINE HYDROCHLORIDE

AA	!	EPIC PHARMA LLC	50MG	A 040331	001	May 28, 1999	Feb	CTEC
	!		50MG	A 040331	001	May 28, 1999	Feb	CHRS
AA		GENUS	50MG	A 040893	001	Jun 24, 2009	Feb	CMFD
	@		50MG	A 040893	001	Jun 24, 2009	Jan	CAHN
	@		75MG	A 040893	002	Jun 24, 2009	Jan	CAHN
	@		100MG	A 040893	003	Jun 24, 2009	Jan	CAHN
	@		150MG	A 040893	004	Jun 24, 2009	Jan	CAHN

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

AP		QILU	500MG/VIAL	A 216424	001	Jul 22, 2024	Jul	NEWA
AP			1GM/VIAL	A 216424	002	Jul 22, 2024	Jul	NEWA

MESALAMINE

CAPSULE, EXTENDED RELEASE; ORAL

MESALAMINE

>A>	AB	NOVAST LABS	375MG	A 218410	001	Aug 22, 2024	Aug	NEWA
	AB	ANNORA PHARMA	1.2GM	A 216334	001	Feb 05, 2024	Jan	NEWA
>A>	AB	TEVA PHARMS INC	800MG	A 213191	001	Aug 22, 2024	Aug	NEWA
>D>	!	ZYDUS PHARMS	800MG	A 203286	001	Jul 21, 2017	Aug	CTEC
>A>	AB	!	800MG	A 203286	001	Jul 21, 2017	Aug	CTEC

MESNA

INJECTABLE; INTRAVENOUS

MESNA

	@	RISING	100MG/ML	A 203364	001	Jul 18, 2014	Feb	CAHN
--	---	--------	----------	----------	-----	--------------	-----	------

METAPROTERENOL SULFATE

SYRUP; ORAL

METAPROTERENOL SULFATE

!		GENUS	10MG/5ML	A 073632	001	Jul 22, 1992	Jan	CAHN
---	--	-------	----------	----------	-----	--------------	-----	------

METARAMINOL BITARTRATE

INJECTABLE; INJECTION

METARAMINOL BITARTRATE

		AZURITY	EQ 10MG BASE/ML	A 211304	001	Aug 24, 2021	Jul	CAHN
--	--	---------	-----------------	----------	-----	--------------	-----	------

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

	@	AMNEAL PHARMS NY	500MG	A 077880	001	Jun 05, 2006	Jul	DISC
	@		850MG	A 077880	002	Jun 05, 2006	Jul	DISC
	@		1GM	A 077880	003	Jun 05, 2006	Jul	DISC
AB1		HARMAN FINOCHEM	500MG	A 218673	001	Jul 05, 2024	Jun	NEWA
AB			750MG	A 218673	002	Jul 05, 2024	Jun	NEWA
AB3		MACLEODS PHARMS LTD	1GM	A 211163	001	Mar 13, 2024	Mar	NEWA

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

	@	CHARTWELL RX	500MG;EQ 15MG BASE	A 091273	001	Apr 16, 2013	Jan	CAHN
	@		850MG;EQ 15MG BASE	A 091273	002	Apr 16, 2013	Jan	CAHN

METFORMIN HYDROCHLORIDE; SITAGLIPTIN

TABLET, EXTENDED RELEASE; ORAL

ZITUVIMET XR

>D>	+	ZYDUS	500MG;50MG	N 216778	001	Jul 18, 2024	Aug	CAHN
	+		500MG;50MG	N 216778	001	Jul 18, 2024	Jul	NEWA
>D>	+		1GM;50MG	N 216778	002	Jul 18, 2024	Aug	CAHN
	+		1GM;50MG	N 216778	002	Jul 18, 2024	Jul	NEWA
>D>	+	!	1GM;100MG	N 216778	003	Jul 18, 2024	Aug	CAHN
	+	!	1GM;100MG	N 216778	003	Jul 18, 2024	Jul	NEWA
>A>	+	ZYDUS LIFESCIENCES	500MG;50MG	N 216778	001	Jul 18, 2024	Aug	CAHN

	TABLET, EXTENDED RELEASE;ORAL						
	ZITUVIMET XR						
>A>	+	1GM;50MG	N216778	002	Jul 18, 2024	Aug CAHN	
>A>	+!	1GM;100MG	N216778	003	Jul 18, 2024	Aug CAHN	
	<u>METHADONE HYDROCHLORIDE</u>						
	CONCENTRATE;ORAL						
	METHADONE HYDROCHLORIDE						
AA	VISTAPHARM LLC	10MG/ML	A040088	001	Nov 30, 1994	Apr CAHN	
	SOLUTION;ORAL						
	METHADONE HYDROCHLORIDE						
	@ VISTAPHARM LLC	5MG/5ML	A090707	001	Jun 30, 2010	Jun DISC	
AA		5MG/5ML	A090707	001	Jun 30, 2010	Apr CAHN	
	@	10MG/5ML	A090707	002	Jun 30, 2010	Jun DISC	
AA		10MG/5ML	A090707	002	Jun 30, 2010	Apr CAHN	
	TABLET;ORAL						
	METHADONE HYDROCHLORIDE						
>D>	@ ELITE LABS INC	5MG	A210484	001	Aug 02, 2018	Aug CMFD	
>A>	AA	5MG	A210484	001	Aug 02, 2018	Aug CMFD	
	@	5MG	A210484	001	Aug 02, 2018	Jun CAHN	
>D>	@	10MG	A210484	002	Aug 02, 2018	Aug CMFD	
>A>	AA	10MG	A210484	002	Aug 02, 2018	Aug CMFD	
	@	10MG	A210484	002	Aug 02, 2018	Jun CAHN	
	@ VISTAPHARM LLC	5MG	A040241	001	May 29, 1998	Apr CAHN	
AA		10MG	A040241	002	May 29, 1998	Apr CAHN	
AA		10MG	A204166	001	Mar 16, 2020	Apr CAHN	
	<u>METHENAMINE HIPPURATE</u>						
	TABLET;ORAL						
	METHENAMINE HIPPURATE						
AB	JUBILANT CADISTA	1GM	A217675	001	Dec 01, 2023	Apr CAHN	
	<u>METHOCARBAMOL</u>						
	SOLUTION;IM-IV						
	METHOCARBAMOL						
	@ NORVIUM BIOSCIENCE	1GM/10ML (100MG/ML)	A204404	001	Dec 05, 2014	Jul CAHN	
	TABLET;ORAL						
	METHOCARBAMOL						
>A>	AA	ALLIED	500MG	A212623	001	Apr 30, 2021	Aug CAHN
>A>	AA		750MG	A212623	002	Apr 30, 2021	Aug CAHN
	AA	DBL PHARMS	500MG	A203550	001	Feb 08, 2017	Feb CAHN
	AA		750MG	A203550	002	Feb 08, 2017	Feb CAHN
	AA	HANGZHOU BINJIANG	500MG	A200958	001	Oct 21, 2011	Mar CAHN
	AA		750MG	A200958	002	Oct 21, 2011	Mar CAHN
	AB	!	1GM	A200958	003	Dec 06, 2021	Mar CAHN
>D>	AA	MLV	500MG	A212623	001	Apr 30, 2021	Aug CAHN
>D>	AA		750MG	A212623	002	Apr 30, 2021	Aug CAHN
	ROBAXIN						
	+ @ ENDO OPERATIONS	500MG	N011011	004		May CAHN	
	ROBAXIN-750						
	+ @ ENDO OPERATIONS	750MG	N011011	006		May CAHN	
	<u>METHOTREXATE SODIUM</u>						
	INJECTABLE;INJECTION						
	METHOTREXATE SODIUM PRESERVATIVE FREE						
	@ EXTROVIS	EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A201530	001	Mar 29, 2012	Jun CAHN	
	TABLET;ORAL						
	METHOTREXATE SODIUM						
AB	ALEMIC	EQ 2.5MG BASE	A217552	001	Jun 03, 2024	May NEWA	
AB	ELITE LABS INC	EQ 2.5MG BASE	A216453	001	May 16, 2024	May NEWA	
	@ LOTUS PHARM CO LTD	EQ 2.5MG BASE	A209787	001	Apr 23, 2021	Apr DISC	
	<u>METHSCOPOLAMINE BROMIDE</u>						
	TABLET;ORAL						
	METHSCOPOLAMINE BROMIDE						
AA	AACE PHARMS	2.5MG	A216786	001	Feb 01, 2024	Jan NEWA	
AA		5MG	A216786	002	Feb 01, 2024	Jan NEWA	
AA	NE RX PHARMA	2.5MG	A216786	001	Feb 01, 2024	May CAHN	
AA		5MG	A216786	002	Feb 01, 2024	May CAHN	

METHYLDOPATABLET; ORAL  
METHYLDOPA

@	CHARTWELL RX	250MG	N018934	001	Jun 29, 1984	Feb	DISC
		250MG	N018934	001	Jun 29, 1984	Jan	CMFD
@		500MG	N018934	002	Jun 29, 1984	Feb	DISC
!		500MG	N018934	002	Jun 29, 1984	Jan	CMFD

METHYLENE BLUESOLUTION; INTRAVENOUS  
METHYLENE BLUE

AP	ZYDUS LIFESCIENCES	10MG/2ML (5MG/ML)	A215636	001	Dec 05, 2023	Apr	CAHN
AP		50MG/10ML (5MG/ML)	A215636	002	Dec 05, 2023	Apr	CAHN

METHYLNALTREXONE BROMIDE

SOLUTION; SUBCUTANEOUS

METHYLNALTREXONE BROMIDE

>A>								
>A>	AP	ACTAVIS LLC	8MG/0.4ML (8MG/0.4ML)	A208112	001	Aug 26, 2024	Aug	NFTG
>A>	AP		12MG/0.6ML (12MG/0.6ML)	A208112	002	Aug 26, 2024	Aug	NFTG
		RELISTOR						
>D>	+	SALIX PHARMS	8MG/0.4ML (8MG/0.4ML)	N021964	002	Sep 27, 2010	Aug	CFTG
>A>	AP	+	8MG/0.4ML (8MG/0.4ML)	N021964	002	Sep 27, 2010	Aug	CFTG
>D>	+		12MG/0.6ML (12MG/0.6ML)	N021964	003	Sep 27, 2010	Aug	CFTG
>A>	AP	+	12MG/0.6ML (12MG/0.6ML)	N021964	003	Sep 27, 2010	Aug	CFTG

METHYLPHENIDATETABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE; ORAL  
COTEMPLA XR-ODT

>A>	+	NEOS THERAPS INC	34.6MG	N205489	004	Aug 19, 2024	Aug	NEWA
-----	---	------------------	--------	---------	-----	--------------	-----	------

METHYLPHENIDATE HYDROCHLORIDE

SOLUTION; ORAL

METHYLPHENIDATE HYDROCHLORIDE

@	BRECKENRIDGE	5MG/5ML	A201466	001	Nov 12, 2013	Mar	DISC
@		10MG/5ML	A201466	002	Nov 12, 2013	Mar	DISC

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	CEDIPROF INC	5MG	A208737	001	Feb 01, 2019	Mar	CMFD
AB		10MG	A208737	002	Feb 01, 2019	Mar	CMFD
AB		20MG	A208737	003	Feb 01, 2019	Mar	CMFD

METHYLPREDNISOLONE

TABLET; ORAL

METHYLPREDNISOLONE

AB	ENDO OPERATIONS	4MG	A040183	001	Dec 22, 1998	Apr	CAHN
	@ PRAXGEN	4MG	A212262	001	Jun 27, 2019	Feb	DISC

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE ACETATE

AB	ENDO OPERATIONS	40MG/ML	A214297	001	Jan 21, 2022	Apr	CAHN
AB		80MG/ML	A214297	002	Jan 21, 2022	Apr	CAHN
AB	HONG KONG	40MG/ML	A040557	001	Feb 23, 2005	Jan	CAHN
AB		80MG/ML	A040557	002	Feb 23, 2005	Jan	CAHN
	@ TEVA PHARMS USA	40MG/ML	A040620	001	Oct 27, 2006	Jan	DISC
	@	80MG/ML	A040620	002	Oct 27, 2006	Jan	DISC
AB	WILSHIRE PHARMS INC	40MG/ML	A214870	002	May 10, 2023	Jul	CAHN
AB		80MG/ML	A214870	001	Jan 03, 2023	Jul	CAHN

METOCLOPRAMIDE HYDROCHLORIDE

SOLUTION; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AA	!	GENUS	EQ 5MG BASE/5ML	A072744	001	May 28, 1991	Apr	CAHN
----	---	-------	-----------------	---------	-----	--------------	-----	------

METOLAZONE

TABLET; ORAL

METOLAZONE

AB	LEADING	2.5MG	A218606	001	Apr 17, 2024	Apr	NEWA
AB		5MG	A218606	002	Apr 17, 2024	Apr	NEWA
AB		10MG	A218606	003	Apr 17, 2024	Apr	NEWA

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL		METOPROLOL SUCCINATE					
	@ GRANULES	EQ 25MG TARTRATE	A216509	001	Aug 07, 2023	Mar	DISC
	@	EQ 50MG TARTRATE	A216509	002	Aug 07, 2023	Mar	DISC
	@	EQ 100MG TARTRATE	A216509	003	Aug 07, 2023	Mar	DISC
	@	EQ 200MG TARTRATE	A216509	004	Aug 07, 2023	Mar	DISC
AB	SUNSHINE	EQ 25MG TARTRATE	A214004	004	May 23, 2024	May	NEWA
AB	ZHEJIANG JUTAI PHARM	EQ 50MG TARTRATE	A214110	001	Jul 26, 2024	Jul	NEWA
AB		EQ 100MG TARTRATE	A214110	002	Jul 26, 2024	Jul	NEWA
AB		EQ 200MG TARTRATE	A214110	003	Jul 26, 2024	Jul	NEWA

METRONIDAZOLE

GEL;TOPICAL		METROGEL					
	+ @ GALDERMA LABS LP	0.75%	N019737	001	Nov 22, 1988	May	DISC
AB	! COSETTE	0.75%	A078178	001	Jan 19, 2011	May	CHRS
GEL;VAGINAL		METRONIDAZOLE					
AB	ENCUBE	1.3%	A216795	001	Mar 18, 2024	Mar	NFTG
AB	+! CHEMO RESEARCH SL	1.3%	N205223	001	Mar 24, 2014	Mar	CFTG
TABLET;ORAL		METRONIDAZOLE					
	@ FLAMINGO PHARMS	250MG	A207309	001	May 16, 2016	Mar	DISC
	@	500MG	A207309	002	May 16, 2016	Mar	DISC

MEXILETINE HYDROCHLORIDE

CAPSULE;ORAL		MEXILETINE HYDROCHLORIDE						
>D>	AB	CHEMISTRY HLTH	150MG	A215876	001	Feb 27, 2023	Aug	CAHN
>D>	AB		200MG	A215876	002	Feb 27, 2023	Aug	CAHN
>D>	AB		250MG	A215876	003	Feb 27, 2023	Aug	CAHN
>A>	AB	LEADING	150MG	A215876	001	Feb 27, 2023	Aug	CAHN
>A>	AB		200MG	A215876	002	Feb 27, 2023	Aug	CAHN
>A>	AB		250MG	A215876	003	Feb 27, 2023	Aug	CAHN

MICAFUNGIN SODIUM

INJECTABLE;INTRAVENOUS		MICAFUNGIN SODIUM					
	@ APOTEX	EQ 50MG BASE/VIAL	A208366	001	Nov 05, 2020	Jul	DISC
	@	EQ 100MG BASE/VIAL	A208366	002	Nov 05, 2020	Jul	DISC
AP	BIOCON PHARMA	EQ 50MG BASE/VIAL	A216438	001	May 29, 2024	May	NEWA
AP		EQ 100MG BASE/VIAL	A216438	002	May 29, 2024	May	NEWA

MIDAZOLAM

SOLUTION;INTRAVENOUS		MIDAZOLAM IN 0.8% SODIUM CHLORIDE						
	+ @ EXELA PHARMA	50MG/50ML (1MG/ML)	N215868	001	Jul 20, 2022	May	DISC	
		MIDAZOLAM IN 0.9% SODIUM CHLORIDE						
>A>	AP	GLAND PHARMA LTD	50MG/50ML (1MG/ML)	A218993	001	Aug 12, 2024	Aug	NEWA
>A>	AP		100MG/100ML (1MG/ML)	A218993	002	Aug 12, 2024	Aug	NEWA

MIDAZOLAM HYDROCHLORIDE

INJECTABLE;INJECTION		MIDAZOLAM HYDROCHLORIDE						
	@ FRESENIUS KABI USA	EQ 5MG BASE/ML	A208878	001	Mar 28, 2017	Jan	DISC	
		MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE						
>D>	AP	STERISCIENCE	EQ 1MG BASE/ML	A090315	001	Nov 29, 2010	Aug	CAHN
>D>	AP		EQ 5MG BASE/ML	A090315	002	Nov 29, 2010	Aug	CAHN
>A>	AP	STERISCIENCE SPECLTS	EQ 1MG BASE/ML	A090315	001	Nov 29, 2010	Aug	CAHN
>A>	AP		EQ 5MG BASE/ML	A090315	002	Nov 29, 2010	Aug	CAHN
		MIDAZOLAM HYDROCHLORIDE						
>D>	AP	STERISCIENCE	EQ 1MG BASE/ML	A090316	001	May 04, 2011	Aug	CAHN
>D>	AP		EQ 5MG BASE/ML	A090316	002	May 04, 2011	Aug	CAHN
>A>	AP	STERISCIENCE SPECLTS	EQ 1MG BASE/ML	A090316	001	May 04, 2011	Aug	CAHN
>A>	AP		EQ 5MG BASE/ML	A090316	002	May 04, 2011	Aug	CAHN

## SYRUP; ORAL

MIDAZOLAM HYDROCHLORIDE

@ PAI HOLDINGS

EQ 2MG BASE/ML

A075958 001 Sep 04, 2003 Jul CAHN

MIDODRINE HYDROCHLORIDE

## TABLET; ORAL

MIDODRINE HYDROCHLORIDE

AB	ENDO OPERATIONS	2.5MG	A207169	001	Oct 29, 2018	Apr	CAHN
AB		5MG	A207169	002	Oct 29, 2018	Apr	CAHN
AB		10MG	A207169	003	Oct 29, 2018	Apr	CAHN

MIDOSTAURIN

## CAPSULE; ORAL

MIDOSTAURIN

AB	DR REDDYS	25MG	A215921	001	Jun 28, 2024	Jun	NEWA
AB	LUPIN	25MG	A216015	001	May 10, 2024	May	NEWA
AB	TEVA PHARMS	25MG	A216076	001	Apr 29, 2024	Apr	NFTG
	RYDAPT						
AB	+! NOVARTIS	25MG	N207997	001	Apr 28, 2017	Apr	CFTG

MILRINONE LACTATE

## INJECTABLE; INJECTION

MILRINONE LACTATE IN DEXTROSE 5%

@ WOODWARD

EQ 40MG BASE/200ML (EQ 0.2MG  
BASE/ML)

A077151 002 Jul 20, 2005 Jun DISC

MINOCYCLINE HYDROCHLORIDE

## TABLET; ORAL

MINOCYCLINE HYDROCHLORIDE

@ SUN PHARM INDUSTRIES EQ 50MG BASE

A090217 001 Jan 29, 2016 Jul DISC

@ EQ 75MG BASE

A090217 002 Jan 29, 2016 Jul DISC

@ EQ 100MG BASE

A090217 003 Jan 29, 2016 Jul DISC

## TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

AB	!	ALKEM LABS LTD	EQ 115MG BASE	A204453	007	Mar 16, 2018	Jul	CHRS
AB	!		EQ 135MG BASE	A204453	005	Sep 28, 2016	Jul	CHRS
AB		SANDOZ	EQ 135MG BASE	A090422	003	Aug 13, 2009	Jul	CHRS
>D>	AB	SIDMAK LABS INDIA	EQ 45MG BASE	A204394	001	Dec 30, 2015	Aug	CAHN
>D>	AB		EQ 55MG BASE	A204394	002	Oct 07, 2022	Aug	CAHN
>D>	AB		EQ 65MG BASE	A204394	003	Oct 07, 2022	Aug	CAHN
>D>	AB		EQ 80MG BASE	A204394	004	Dec 30, 2015	Aug	CAHN
>D>	AB		EQ 105MG BASE	A204394	005	Dec 30, 2015	Aug	CAHN
>D>	AB		EQ 115MG BASE	A204394	006	Oct 07, 2022	Aug	CAHN
>D>	AB		EQ 135MG BASE	A204394	007	Dec 30, 2015	Aug	CAHN
>A>	AB	SUN PHARM	EQ 45MG BASE	A204394	001	Dec 30, 2015	Aug	CAHN
>A>	AB		EQ 55MG BASE	A204394	002	Oct 07, 2022	Aug	CAHN
>A>	AB		EQ 65MG BASE	A204394	003	Oct 07, 2022	Aug	CAHN
>A>	AB		EQ 80MG BASE	A204394	004	Dec 30, 2015	Aug	CAHN
>A>	AB		EQ 105MG BASE	A204394	005	Dec 30, 2015	Aug	CAHN
>A>	AB		EQ 115MG BASE	A204394	006	Oct 07, 2022	Aug	CAHN
>A>	AB		EQ 135MG BASE	A204394	007	Dec 30, 2015	Aug	CAHN
		@ SUN PHARM INDS LTD	EQ 45MG BASE	A091118	001	Sep 25, 2014	Jan	DISC
		@	EQ 65MG BASE	A091118	003	Dec 03, 2019	Jan	DISC
		@	EQ 80MG BASE	A091118	004	Sep 25, 2014	Jan	DISC
		@	EQ 90MG BASE	A091118	005	Sep 25, 2014	Jan	DISC
		@	EQ 105MG BASE	A091118	006	Sep 25, 2014	Jan	DISC
		@	EQ 115MG BASE	A091118	007	Dec 03, 2019	Jan	DISC
		@	EQ 135MG BASE	A091118	008	Sep 25, 2014	Jan	DISC
		@ ZYDUS PHARMS	EQ 45MG BASE	A203553	001	Nov 16, 2017	Jan	DISC
		@	EQ 55MG BASE	A203553	002	Jun 16, 2023	Jan	DISC
		@	EQ 65MG BASE	A203553	003	Jun 16, 2023	Jan	DISC
		@	EQ 80MG BASE	A203553	004	Nov 16, 2017	Jan	DISC
		@	EQ 90MG BASE	A203553	005	Nov 16, 2017	Jan	DISC
		@	EQ 105MG BASE	A203553	006	Nov 16, 2017	Jan	DISC
		@	EQ 115MG BASE	A203553	007	Jun 16, 2023	Jan	DISC
		@	EQ 135MG BASE	A203553	008	Nov 16, 2017	Jan	DISC
		MINOLIRA						
		@ EPI HLTH	EQ 105MG BASE	N209269	001	May 08, 2017	Jul	DISC
		@	EQ 135MG BASE	N209269	002	May 08, 2017	Jul	DISC
		SOLODYN						
		+ @ BAUSCH	EQ 55MG BASE	N050808	008	Aug 27, 2010	Jun	DISC
		+ @	EQ 65MG BASE	N050808	004	Jul 23, 2009	Jun	DISC
		+ @	EQ 80MG BASE	N050808	007	Aug 27, 2010	Jun	DISC

TABLET, EXTENDED RELEASE;ORAL  
SOLODYN

+ @	EQ 105MG BASE	N050808	006	Aug 27, 2010	Jun DISC
+ @	EQ 115MG BASE	N050808	005	Jul 23, 2009	Jun DISC

MINOXIDIL

TABLET;ORAL  
MINOXIDIL

AB	ENDO OPERATIONS	2.5MG	A071826	001	Nov 14, 1988	Apr CAHN
AB		10MG	A071839	001	Nov 14, 1988	Apr CAHN

MIRABEGRON

TABLET, EXTENDED RELEASE;ORAL  
MIRABEGRON

AB	ALKEM LABS LTD	25MG	A215948	001	Feb 12, 2024	Feb NEWA
AB		50MG	A215948	002	Feb 12, 2024	Feb NEWA
AB	ZYDUS PHARMS	25MG	A209488	001	Sep 29, 2022	Mar CMFD
AB		50MG	A209488	002	Sep 29, 2022	Mar CMFD

MIRTAZAPINE

TABLET;ORAL  
MIRTAZAPINE

AB	AIPING PHARM INC	15MG	A076219	001	Jun 19, 2003	Feb CAHN
AB		30MG	A076219	002	Jun 19, 2003	Feb CAHN
AB		45MG	A076219	003	Jun 19, 2003	Feb CAHN
AB	CHARTWELL RX	15MG	A076219	001	Jun 19, 2003	Jun CAHN
AB		30MG	A076219	002	Jun 19, 2003	Jun CAHN
AB		45MG	A076219	003	Jun 19, 2003	Jun CAHN

MITOMYCIN

INJECTABLE;INJECTION  
MITOMYCIN

AP	FRESENIUS KABI USA	5MG/VIAL	A211269	001	Apr 05, 2024	Mar NEWA
AP		20MG/VIAL	A211269	002	Apr 05, 2024	Mar NEWA
AP		40MG/VIAL	A211269	003	Apr 05, 2024	Mar NEWA

MITOXANTRONE HYDROCHLORIDE

INJECTABLE;INJECTION  
MITOXANTRONE HYDROCHLORIDE

@	RISING	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A201014	001	Dec 11, 2012	Mar CAHN
---	--------	------------------------------------	---------	-----	--------------	----------

MIVACURIUM CHLORIDE

SOLUTION;INTRAVENOUS  
MIVACURIUM CHLORIDE

@	WOODWARD	EQ 10MG BASE/5ML (EQ 2MG BASE/ML)	A209708	001	Oct 12, 2021	Jul DISC
@		EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A209708	002	Oct 12, 2021	Jul DISC

MOMETASONE FUROATE

LOTION;TOPICAL  
MOMETASONE FUROATE

@	COSETTE	0.1%	A077678	001	Nov 21, 2007	Apr DISC
---	---------	------	---------	-----	--------------	----------

SPRAY, METERED;NASAL  
MOMETASONE FUROATE

AB	AUROBINDO PHARMA	0.05MG/SPRAY	A215878	001	Mar 18, 2024	Mar NEWA
----	------------------	--------------	---------	-----	--------------	----------

MONTELUKAST SODIUM

GRANULE;ORAL  
MONTELUKAST SODIUM

@	TEVA PHARMS	EQ 4MG BASE/PACKET	A090955	001	Aug 03, 2012	Jan DISC
---	-------------	--------------------	---------	-----	--------------	----------

TABLET;ORAL  
MONTELUKAST SODIUM

>D>	AB	GRAVITI PHARMS	EQ 10MG BASE	A209012	001	Apr 24, 2017	Aug CAHN
>A>	AB	RISING	EQ 10MG BASE	A209012	001	Apr 24, 2017	Aug CAHN
	@	SANDOZ INC	EQ 10MG BASE	A200889	001	Aug 03, 2012	Jul DISC

MORPHINE SULFATE

SOLUTION;ORAL  
MORPHINE SULFATE

@	HIKMA	100MG/5ML	A208809	001	Jul 06, 2017	Mar DISC	
>D>	AA	PHARM ASSOC	10MG/5ML	A206573	002	Sep 12, 2023	Aug DISC
>A>	@		10MG/5ML	A206573	002	Sep 12, 2023	Aug DISC
>D>	AA		100MG/5ML	A206573	001	Nov 14, 2016	Aug DISC

## SOLUTION;ORAL

## MORPHINE SULFATE

>A>	@	100MG/5ML	A206573	001	Nov 14, 2016	Aug	DISC
AA	WINDER LABS LLC	10MG/5ML	A211454	001	Feb 12, 2021	Jan	CMFD
AA		20MG/5ML	A211454	002	Feb 12, 2021	Jan	CMFD
AA		100MG/5ML	A211454	003	Feb 12, 2021	Jan	CMFD

MOXIFLOXACIN HYDROCHLORIDE

## SOLUTION/DROPS;OPHTHALMIC

## MOXIFLOXACIN HYDROCHLORIDE

>A>	AT1	ADAPTIS	EQ 0.5% BASE	A202525	001	Mar 06, 2015	Aug	CAHN
>D>	AT1	INDOCO	EQ 0.5% BASE	A202525	001	Mar 06, 2015	Aug	CAHN
		VIGAMOX						
	AT1	+! HARROW EYE	EQ 0.5% BASE	N021598	001	Apr 15, 2003	Jan	CAHN

## TABLET;ORAL

## MOXIFLOXACIN HYDROCHLORIDE

## @ NATCO EQ 400MG BASE

A204635	001	Aug 31, 2015	Jun	CAHN
---------	-----	--------------	-----	------

MYCOPHENOLATE MOFETIL

## SUSPENSION;ORAL

## MYHIBBIN

## +! AZURITY 200MG/ML

N216482	001	May 01, 2024	May	NEWA
---------	-----	--------------	-----	------

## TABLET;ORAL

## MYCOPHENOLATE MOFETIL

## @ ANNEAL 500MG

A090606	001	Jul 16, 2010	Feb	DISC
---------	-----	--------------	-----	------

AB	AUROBINDO PHARMA	500MG	A217937	001	Feb 20, 2024	Feb	NEWA
----	------------------	-------	---------	-----	--------------	-----	------

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

## INJECTABLE;INJECTION

## MYCOPHENOLATE MOFETIL HYDROCHLORIDE

AP	ENDO OPERATIONS	500MG/VIAL	A203575	001	Oct 28, 2016	Apr	CAHN	
>D>	AP	STERISCIENCE	500MG/VIAL	A216390	001	Dec 23, 2022	Aug	CAHN
>A>	AP	STERISCIENCE SPECLTS	500MG/VIAL	A216390	001	Dec 23, 2022	Aug	CAHN

MYCOPHENOLIC SODIUM

## TABLET, DELAYED RELEASE;ORAL

## MYCOPHENOLIC SODIUM

AB	AUROBINDO PHARMA LTD	EQ 180MG BASE	A218603	001	Feb 27, 2024	Feb	NEWA
AB		EQ 360MG BASE	A218603	002	Feb 27, 2024	Feb	NEWA
AB	BIOCON PHARMA	EQ 180MG BASE	A217031	001	Nov 29, 2023	Jun	CAHN
AB		EQ 360MG BASE	A217031	002	Nov 29, 2023	Jun	CAHN
AB	NOVUGEN	EQ 180MG BASE	A216637	001	May 29, 2024	May	NEWA
AB		EQ 360MG BASE	A216637	002	May 29, 2024	May	NEWA
AB	SKG PHARMA	EQ 180MG BASE	A217031	001	Nov 29, 2023	Apr	CAHN
AB		EQ 360MG BASE	A217031	002	Nov 29, 2023	Apr	CAHN
AB	WANBANG BIOPHARMS	EQ 180MG BASE	A216637	001	May 29, 2024	Jun	CAHN
AB		EQ 360MG BASE	A216637	002	May 29, 2024	Jun	CAHN

>D> NABILONE

## &gt;D&gt; CAPSULE;ORAL

## &gt;D&gt; CESAMET

>D>	+! BAUSCH	1MG	N018677	001	Dec 26, 1985	Aug	DISC
>A>	+ @	1MG	N018677	001	Dec 26, 1985	Aug	DISC

NADOLOL

## TABLET;ORAL

## CORCARD

>D>	AB	+ USWM	20MG	N018063	005	Oct 28, 1986	Aug	DISC
>A>		+ @	20MG	N018063	005	Oct 28, 1986	Aug	DISC
>D>	AB	+	40MG	N018063	001		Aug	DISC
>A>		+ @	40MG	N018063	001		Aug	DISC
>D>	AB	+!	80MG	N018063	002		Aug	DISC
>A>		+ @	80MG	N018063	002		Aug	DISC

## NADOLOL

>D>	AB	INVAGEN PHARMS	80MG	A203455	003	Dec 18, 2015	Aug	CHRS
>A>	AB	!	80MG	A203455	003	Dec 18, 2015	Aug	CHRS



NALBUPHINE HYDROCHLORIDEINJECTABLE; INJECTION  
NUBAIN

+ @	ENDO OPERATIONS	10MG/ML	N018024	001			May	CAHN
+ @		20MG/ML	N018024	002	May 27, 1982		May	CAHN

NALMEFENE HYDROCHLORIDESOLUTION; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS  
NALMEFENE HYDROCHLORIDE

!	CHENGDU SHUODE	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A216007	001	Nov 15, 2023		Jun	CMFD
@		EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A216007	001	Nov 15, 2023		May	DISC
AP		EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	A216007	002	Nov 15, 2023		Jun	CMFD
	@	EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	A216007	002	Nov 15, 2023		May	DISC
AP	!	PURDUE PHARMA LP	EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	A212955	001	Feb 08, 2022	Jun	CTEC
	!		EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	A212955	001	Feb 08, 2022	May	CTEC
>A>		SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS						
>A>		ZURNAI (AUTOINJECTOR)						
>A>	+!	PURDUE PHARMA LP	EQ 1.5MG BASE/0.5ML (EQ 1.5MG BASE/0.5ML)	N218590	001	Aug 07, 2024	Aug	NEWA

NALOXONE HYDROCHLORIDEINJECTABLE; INJECTION  
NALOXONE HYDROCHLORIDE

@	EUGIA PHARMA	0.4MG/ML	A212455	001	Oct 15, 2019		Jun	DISC
AP	FRESENIUS KABI USA	0.4MG/ML	A213573	001	Apr 02, 2024		Mar	NEWA
AP		1MG/ML	A213573	002	Apr 02, 2024		Mar	NEWA
AP	HIKMA	0.4MG/ML	A212300	002	Mar 07, 2024		Mar	NEWA
AP	MANKIND PHARMA	0.4MG/ML	A218404	001	Feb 29, 2024		Feb	NEWA

SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS  
ZIMHI

+!	ZMI PHARMA	5MG/0.5ML (5MG/0.5ML)	N212854	001	Oct 15, 2021		May	CAHN
		SPRAY; NASAL						
		REZENOPY						
+!	SUMMIT BIOSCI	10MG/SPRAY	N215487	001	Apr 19, 2024		Apr	NEWA
		SPRAY, METERED; NASAL						
		REXTOVY						
+!	AMPHASTAR PHARMS INC	4MG/SPRAY	N208969	001	Mar 07, 2023		Apr	CMFD

NALTREXONEFOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR  
NALTREXONE

@	TEVA PHARMS USA INC	380MG/VIAL	A213195	001	Jul 06, 2023		Jan	DISC
		VIVITROL						
+!	ALKERMES	380MG/VIAL	N021897	001	Apr 13, 2006		Jan	CTEC

NAPROXENTABLET; ORAL  
NAPROXEN

@	INVAGEN PHARMS	250MG	A091305	001	Aug 24, 2011		Mar	DISC
@		375MG	A091305	002	Aug 24, 2011		Mar	DISC
@		500MG	A091305	003	Aug 24, 2011		Mar	DISC

TABLET, DELAYED RELEASE; ORAL  
NAPROXEN

AB	NOVITIUM PHARMA	375MG	A218497	001	Jun 12, 2024		May	NEWA
AB		500MG	A218497	002	Jun 12, 2024		May	NEWA

NARATRIPTAN HYDROCHLORIDETABLET; ORAL  
NARATRIPTAN

@	SUN PHARM INDS LTD	EQ 2.5MG BASE	A091552	001	Feb 14, 2011		May	DISC
---	--------------------	---------------	---------	-----	--------------	--	-----	------

NEBIVOLOL HYDROCHLORIDETABLET; ORAL  
NEBIVOLOL HYDROCHLORIDE

@	APOTEX	EQ 10MG BASE	A209741	001	Feb 27, 2024		May	DISC
AB		EQ 10MG BASE	A209741	001	Feb 27, 2024		Feb	NEWA
	@	EQ 20MG BASE	A209741	002	Feb 27, 2024		May	DISC
AB		EQ 20MG BASE	A209741	002	Feb 27, 2024		Feb	NEWA
AB	GLENMARK PHARMS LTD	EQ 2.5MG BASE	A203821	001	May 25, 2017		Jun	CMFD

## TABLET; ORAL

## NEBIVOLOL HYDROCHLORIDE

AB		EQ 5MG BASE	A203821	002	May 25, 2017	Jun	CMFD
AB		EQ 10MG BASE	A203821	003	May 25, 2017	Jun	CMFD
AB		EQ 20MG BASE	A203821	004	May 25, 2017	Jun	CMFD
>D>	@ UNICHEM	EQ 2.5MG BASE	A213830	001	Mar 15, 2022	Aug	CMFD
>A>	AB	EQ 2.5MG BASE	A213830	001	Mar 15, 2022	Aug	CMFD
>D>	@	EQ 5MG BASE	A213830	002	Mar 15, 2022	Aug	CMFD
>A>	AB	EQ 5MG BASE	A213830	002	Mar 15, 2022	Aug	CMFD
>D>	@	EQ 10MG BASE	A213830	003	Mar 15, 2022	Aug	CMFD
>A>	AB	EQ 10MG BASE	A213830	003	Mar 15, 2022	Aug	CMFD
>D>	@	EQ 20MG BASE	A213830	004	Mar 15, 2022	Aug	CMFD
>A>	AB	EQ 20MG BASE	A213830	004	Mar 15, 2022	Aug	CMFD

NEFAZODONE HYDROCHLORIDE

## TABLET; ORAL

## NEFAZODONE HYDROCHLORIDE

@ CHARTWELL RX

50MG

A076302 001 Sep 16, 2003 Jun CAHN

@

100MG

A076302 002 Sep 16, 2003 Jun CAHN

@

150MG

A076302 003 Sep 16, 2003 Jun CAHN

@

200MG

A076302 004 Sep 16, 2003 Jun CAHN

@

250MG

A076302 005 Sep 16, 2003 Jun CAHN

NELARABINE

## INJECTABLE; INTRAVENOUS

## NELARABINE

AP	ALEMBIC	250MG/50ML (5MG/ML)	A218554	001	Aug 01, 2024	Jul	NEWA
AP	MEITHEAL	250MG/50ML (5MG/ML)	A216038	001	Jan 10, 2023	Jun	CAHN
>A>	AP	XGEN PHARMS	A216510	001	Sep 05, 2024	Aug	NEWA

NEOSTIGMINE METHYLSULFATE

## SOLUTION; INTRAVENOUS

## BLOXIVERZ

+ @ EXELA PHARMA

5MG/5ML (1MG/ML)

N204078 003 Oct 27, 2023 May DISC

## NEOSTIGMINE METHYLSULFATE

>A>	AP	ADAPTIS	5MG/10ML (0.5MG/ML)	A210652	001	Oct 01, 2021	Aug	CAHN
>A>	AP		10MG/10ML (1MG/ML)	A210652	002	Oct 01, 2021	Aug	CAHN
	AP	ENDO OPERATIONS	5MG/10ML (0.5MG/ML)	A208405	001	Apr 26, 2017	Apr	CAHN
	AP		10MG/10ML (1MG/ML)	A208405	002	Apr 26, 2017	Apr	CAHN
		@ EUGIA PHARMA	5MG/10ML (0.5MG/ML)	A213244	001	Nov 02, 2023	May	DISC
		@	10MG/10ML (1MG/ML)	A213244	002	Nov 02, 2023	May	DISC
>D>	AP	INDOCO	5MG/10ML (0.5MG/ML)	A210652	001	Oct 01, 2021	Aug	CAHN
>D>	AP		10MG/10ML (1MG/ML)	A210652	002	Oct 01, 2021	Aug	CAHN
>D>	AP	NIVAGEN PHARMS INC	5MG/10ML (0.5MG/ML)	A212627	001	Nov 03, 2022	Aug	CAHN
	AP		5MG/10ML (0.5MG/ML)	A212627	001	Nov 03, 2022	Jan	CAHN
>D>	AP		10MG/10ML (1MG/ML)	A212627	002	Nov 03, 2022	Aug	CAHN
	AP		10MG/10ML (1MG/ML)	A212627	002	Nov 03, 2022	Jan	CAHN
>A>	AP	UMEDICA	5MG/10ML (0.5MG/ML)	A212627	001	Nov 03, 2022	Aug	CAHN
>A>	AP		10MG/10ML (1MG/ML)	A212627	002	Nov 03, 2022	Aug	CAHN

NESIRITIDE

## FOR SOLUTION; INTRAVENOUS

## NATRECOR

+ @ SCIOS LLC

1.5MG/VIAL

N020920 001 Aug 10, 2001 Mar CAIN

NEVIRAPINE

## SUSPENSION; ORAL

## NEVIRAPINE

AA	!	AUROBINDO	50MG/5ML	A077702	001	May 22, 2012	Jun	CHRS
		VIRAMUNE						
		+ @ BOEHRINGER INGELHEIM	50MG/5ML	N020933	001	Sep 11, 1998	Jun	DISC
		TABLET; ORAL						
		NEVIRAPINE						
		@ NORVIUM BIOSCIENCE	200MG	A078864	001	May 22, 2012	Jul	CAHN
		TABLET, EXTENDED RELEASE; ORAL						
		NEVIRAPINE						
AB	!	MACLEODS PHARMS LTD	400MG	A206879	001	Oct 06, 2017	Jun	CHRS
		VIRAMUNE XR						
		+ @ BOEHRINGER INGELHEIM	100MG	N201152	002	Nov 08, 2012	Jun	DISC
		+ @	400MG	N201152	001	Mar 25, 2011	Jun	DISC

NIACIN

TABLET, EXTENDED RELEASE;ORAL  
NIACIN

AB	HIBROW HLTHCARE	500MG	A213090	001	Aug 25, 2023	Jul	CAHN
AB		750MG	A213090	002	Aug 25, 2023	Jul	CAHN
AB		1GM	A213090	003	Aug 25, 2023	Jul	CAHN

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL  
NICARDIPINE HYDROCHLORIDE

AB	SKG PHARMA	20MG	A218202	001	Apr 10, 2024	Mar	NEWA
AB		30MG	A218202	002	Apr 10, 2024	Mar	NEWA

INJECTABLE;INJECTION

NICARDIPINE HYDROCHLORIDE

>A>	AP	CHENGDU SHUODE	25MG/10ML (2.5MG/ML)	A217548	001	Sep 06, 2024	Aug	NEWA
	AP	RK PHARMA	25MG/10ML (2.5MG/ML)	A090664	001	Nov 17, 2009	Feb	CMFD
>D>		@ WOCKHARDT	25MG/10ML (2.5MG/ML)	A090671	001	Nov 17, 2009	Aug	CMFD
>A>	AP		25MG/10ML (2.5MG/ML)	A090671	001	Nov 17, 2009	Aug	CMFD

INJECTABLE;INTRAVENOUS

CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER

AP	+!	CHIESI	40MG/200ML (0.2MG/ML)	N019734	004	Nov 07, 2008	Apr	CFTG
			CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER					
AP	+!	CHIESI	20MG/200ML (0.1MG/ML)	N019734	003	Jul 31, 2008	Apr	CFTG
			NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE					
AP		INFORLIFE	40MG/200ML (0.2MG/ML)	A203978	002	Apr 17, 2024	Apr	NFTG
			NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE					
AP		INFORLIFE	20MG/200ML (0.1MG/ML)	A203978	001	Apr 17, 2024	Apr	NFTG

NIFEDIPINE

CAPSULE;ORAL

NIFEDIPINE

>D>	AB	ACTAVIS ELIZABETH	20MG	A072556	001	Sep 20, 1990	Aug	DISC
>A>		@	20MG	A072556	001	Sep 20, 1990	Aug	DISC
>D>	AB	LEADING	10MG	A073250	001	Oct 08, 1991	Aug	CAHN
>D>	AB		20MG	A074045	001	Apr 30, 1992	Aug	CAHN
>A>	AB	VELZEN PHARMA PVT	10MG	A073250	001	Oct 08, 1991	Aug	CAHN
>A>	AB		20MG	A074045	001	Apr 30, 1992	Aug	CAHN

TABLET, EXTENDED RELEASE;ORAL

NIFEDIPINE

@ ENDO OPERATIONS

@

@

@ SWISS PHARM

@

		30MG	A077899	001	Dec 13, 2006	May	CAHN
		60MG	A077899	002	Dec 13, 2006	May	CAHN
		90MG	A077899	003	May 25, 2012	May	CAHN
		30MG	A216019	001	Nov 18, 2022	Jul	CAHN
		60MG	A216019	002	Nov 18, 2022	Jul	CAHN

NILOTINIB HYDROCHLORIDE

CAPSULE;ORAL

NILOTINIB HYDROCHLORIDE

@ APOTEX

@

@

TASIGNA

+ NOVARTIS

+

+!

		EQ 50MG BASE	A203640	001	Jan 05, 2024	Apr	DISC
		EQ 150MG BASE	A203640	002	Jan 05, 2024	Apr	DISC
		EQ 200MG BASE	A203640	003	Jan 05, 2024	Apr	DISC
		EQ 50MG BASE	N022068	003	Mar 22, 2018	Apr	CTEC
		EQ 150MG BASE	N022068	002	Jun 17, 2010	Apr	CTEC
		EQ 200MG BASE	N022068	001	Oct 29, 2007	Apr	CTEC

NIMODIPINE

SOLUTION;ORAL

NIMODIPINE

ANNORA PHARMA

		3MG/ML	A216937	001	Jul 09, 2024	Jun	NFTG
--	--	--------	---------	-----	--------------	-----	------

NIRAPARIB TOSYLATE

CAPSULE;ORAL

ZEJULA

+ @ GLAXOSMITHKLINE

		EQ 100MG BASE	N208447	001	Mar 27, 2017	Feb	DISC
--	--	---------------	---------	-----	--------------	-----	------

NIRMATRELVIR; RITONAVIR

TABLET; ORAL

PAXLOVID (COPACKAGED)

+! PFIZER 150MG;100MG N217188 001 May 25, 2023 Jul CHRS

NIROGACESTAT HYDROBROMIDE

TABLET; ORAL

OGSIVEO

+ SPRINGWORKS EQ 50MG BASE N217677 001 Nov 27, 2023 Apr CHRS

+ EQ 100MG BASE N217677 002 Apr 04, 2024 Apr NEWA

+! EQ 150MG BASE N217677 003 Apr 04, 2024 Apr NEWA

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

NISOLDIPINE

AB AMTA 8.5MG A216606 001 Apr 10, 2023 Jun CMFD

NITRIC OXIDE

GAS; INHALATION

INOMAX

+! MALLINCKRODT HOSP 4880PPM N020845 004 Jan 17, 2023 May NEWA

NOXIVENT

! LINDE GAS EQUIP 100PPM A207141 001 Oct 02, 2018 May CHRS

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN

@ ACTAVIS LABS FL INC 25MG A091095 001 Jun 18, 2015 Feb DISC

@ 50MG A091095 002 Jun 18, 2015 Feb DISC

@ 100MG A091095 003 Jun 18, 2015 Feb DISC

NITROGLYCERIN

OINTMENT; INTRA-ANAL

NITROGLYCERIN

AB COSETTE 0.4% A216103 001 Feb 16, 2024 Feb NFTG

RECTIV

AB +! ABBVIE 0.4% N021359 001 Jun 21, 2011 Feb CFTG

NIZATIDINE

CAPSULE; ORAL

NIZATIDINE

>D> @ MYLAN PHARMS INC 150MG A075806 001 Jul 05, 2002 Aug CAHN

>D> @ 300MG A075806 002 Jul 05, 2002 Aug CAHN

>A> @ NORVIUM BIOSCIENCE 150MG A075806 001 Jul 05, 2002 Aug CAHN

>A> @ 300MG A075806 002 Jul 05, 2002 Aug CAHN

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

NOREPINEPHRINE BITARTRATE

AP DDREG PHARMA EQ 1MG BASE/ML A218758 001 May 13, 2024 May NEWA

AP RISING EQ 1MG BASE/ML A218758 001 May 13, 2024 May CAHN

SOLUTION; INTRAVENOUS

NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

+! LONG GROVE PHARMS EQ 4MG BASE/250 ML (EQ 16MCG BASE/ML) N214628 001 Oct 06, 2022 Jan CMFD

+! EQ 8MG BASE/250ML (EQ 32MCG BASE/ML) N214628 002 Oct 06, 2022 Jan CMFD

+! EQ 16MG BASE/250ML (EQ 64MCG BASE/ML) N214628 003 Oct 06, 2022 Jan CMFD

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

NORTRIPTYLINE HYDROCHLORIDE

@ RISING EQ 10MG BASE A074234 001 Jul 26, 1993 Feb CAHN

@ EQ 25MG BASE A074234 002 Jul 26, 1993 Feb CAHN

@ EQ 50MG BASE A074234 003 Jul 26, 1993 Feb CAHN

@ EQ 75MG BASE A074234 004 Jul 26, 1993 Feb CAHN

NYSTATIN

		POWDER; TOPICAL							
		NYSTATIN							
AT		ADRASTEIA PHARMA	100,000 UNITS/GM	A065175	001	Dec 17, 2004	Mar	CAHN	
		SUSPENSION; ORAL							
		NYSTATIN							
AA	!	LEADING	100,000 UNITS/ML	A214346	001	Mar 10, 2022	Jul	CHRS	
	@	PAI HOLDINGS	100,000 UNITS/ML	A064042	001	Feb 28, 1994	Jul	CAHN	
AA		WOCKHARDT BIO AG	100,000 UNITS/ML	A062512	001	Oct 29, 1984	Jul	CHRS	
		TABLET; ORAL							
		NYSTATIN							
>D>	AA	SUN PHARM INDUSTRIES	500,000 UNITS	A062838	001	Dec 22, 1988	Aug	DISC	
>A>	@		500,000 UNITS	A062838	001	Dec 22, 1988	Aug	DISC	

NYSTATIN; TRIAMCINOLONE ACETONIDE

		CREAM; TOPICAL							
		MYKACET							
	@	COSETTE	100,000 UNITS/GM; 0.1%	A062367	001	May 28, 1985	Apr	DISC	
		OINTMENT; TOPICAL							
		MYKACET							
	@	COSETTE	100,000 UNITS/GM; 0.1%	A062733	001	Mar 06, 1987	Apr	DISC	

OCTREOTIDE ACETATE

		INJECTABLE; INJECTION							
		OCTREOTIDE ACETATE							
AP		SHUANGCHENG	EQ 0.1MG BASE/ML	A217860	001	May 02, 2024	Apr	NEWA	
AB		TEVA PHARMS USA INC	EQ 10MG BASE/VIAL	A210317	001	Dec 05, 2023	Jan	CTEC	
AB			EQ 20MG BASE/VIAL	A210317	002	Dec 05, 2023	Jan	CTEC	
AB			EQ 30MG BASE/VIAL	A210317	003	Dec 05, 2023	Jan	CTEC	
		SANDOSTATIN LAR							
AB	+	NOVARTIS	EQ 10MG BASE/VIAL	N021008	001	Nov 25, 1998	Jan	CTEC	
AB	+		EQ 20MG BASE/VIAL	N021008	002	Nov 25, 1998	Jan	CTEC	
AB	+	!	EQ 30MG BASE/VIAL	N021008	003	Nov 25, 1998	Jan	CTEC	

ODEVIXIBAT

		CAPSULE; ORAL							
		BYLVAY							
	+	IPSEN	0.4MG	N215498	002	Jul 20, 2021	Jan	CAHN	
	+	!	1.2MG	N215498	004	Jul 20, 2021	Jan	CAHN	
		CAPSULE, PELLETS; ORAL							
		BYLVAY							
	+	IPSEN	0.2MG	N215498	001	Jul 20, 2021	Jan	CAHN	
	+	!	0.6MG	N215498	003	Jul 20, 2021	Jan	CAHN	

OFLOXACIN

		SOLUTION/DROPS; OPHTHALMIC							
		OFLOXACIN							
AT		AMNEAL	0.3%	A211524	001	Mar 01, 2024	Feb	NEWA	
AT		CAPLIN	0.3%	A217904	001	Apr 12, 2024	Apr	NEWA	
AT		SOMERSET	0.3%	A213597	001	Aug 01, 2024	Jul	NEWA	
		SOLUTION/DROPS; OTIC							
		OFLOXACIN							
	@	HIKMA	0.3%	A076616	001	Mar 17, 2008	Mar	DISC	

OLANZAPINE

		TABLET; ORAL							
		OLANZAPINE							
	@	INDOCO	2.5MG	A206155	001	Jul 31, 2020	Mar	DISC	
	@		5MG	A206155	002	Jul 31, 2020	Mar	DISC	
	@		7.5MG	A206155	003	Jul 31, 2020	Mar	DISC	
	@		10MG	A206155	004	Jul 31, 2020	Mar	DISC	
	@		15MG	A206155	005	Jul 31, 2020	Mar	DISC	
	@		20MG	A206155	006	Jul 31, 2020	Mar	DISC	
>D>	@	MYLAN	2.5MG	A076866	001	Apr 23, 2012	Aug	CAHN	
>D>	@		5MG	A076866	002	Apr 23, 2012	Aug	CAHN	
>D>	@		7.5MG	A076866	003	Apr 23, 2012	Aug	CAHN	
>D>	@		10MG	A076866	004	Apr 23, 2012	Aug	CAHN	
>D>	@		15MG	A076866	005	Apr 23, 2012	Aug	CAHN	
>D>	@		20MG	A076866	006	Apr 23, 2012	Aug	CAHN	
>A>	@	NATCO PHARMA	2.5MG	A076866	001	Apr 23, 2012	Aug	CAHN	
>A>	@		5MG	A076866	002	Apr 23, 2012	Aug	CAHN	

## TABLET;ORAL

## OLANZAPINE

>A>	@	7.5MG	A076866	003	Apr 23, 2012	Aug CAHN
>A>	@	10MG	A076866	004	Apr 23, 2012	Aug CAHN
>A>	@	15MG	A076866	005	Apr 23, 2012	Aug CAHN
>A>	@	20MG	A076866	006	Apr 23, 2012	Aug CAHN
	@ SUN PHARM INDS	2.5MG	A091038	001	Apr 23, 2012	May DISC
	@	5MG	A091038	002	Apr 23, 2012	May DISC
	@	7.5MG	A091038	003	Apr 23, 2012	May DISC
	@	10MG	A091038	004	Apr 23, 2012	May DISC
	@	15MG	A091038	005	Apr 23, 2012	May DISC
	@	20MG	A091038	006	Apr 23, 2012	May DISC

## TABLET, ORALLY DISINTEGRATING;ORAL

## OLANZAPINE

	@ SUN PHARM INDS	5MG	A090881	001	Feb 28, 2012	May DISC
	@	10MG	A090881	002	Feb 28, 2012	May DISC
	@	15MG	A090881	003	Feb 28, 2012	May DISC
	@	20MG	A090881	004	Feb 28, 2012	May DISC

OLMESARTAN MEDOXOMIL

## TABLET;ORAL

## OLMESARTAN MEDOXOMIL

AB	BRECKENRIDGE	5MG	A206227	001	Jan 25, 2024	Jan NEWA
AB		20MG	A206227	002	Jan 25, 2024	Jan NEWA
AB		40MG	A206227	003	Jan 25, 2024	Jan NEWA
AB	CHARTWELL RX	5MG	A206227	001	Jan 25, 2024	Mar CAHN
AB		20MG	A206227	002	Jan 25, 2024	Mar CAHN
AB		40MG	A206227	003	Jan 25, 2024	Mar CAHN
AB	INVENTIA	5MG	A208659	001	May 18, 2020	May CMFD
AB		20MG	A208659	002	May 18, 2020	May CMFD
AB		40MG	A208659	003	May 18, 2020	May CMFD

OLOPATADINE HYDROCHLORIDE

## SPRAY, METERED;NASAL

## OLOPATADINE HYDROCHLORIDE

	@ HIKMA	0.665MG/SPRAY	A213757	001	Aug 19, 2020	Mar DISC
--	---------	---------------	---------	-----	--------------	----------

OMACETAXINE MEPESUCCINATE

## POWDER;SUBCUTANEOUS

## SYNRIBO

	+ @ TEVA PHARMS INTL	3.5MG/VIAL	N203585	001	Oct 26, 2012	Jun DISC
--	----------------------	------------	---------	-----	--------------	----------

OMEGA-3-ACID ETHYL ESTERS

## CAPSULE;ORAL

## OMEGA-3-ACID ETHYL ESTERS

AB	CHARTWELL	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A206455	001	Aug 07, 2019	Mar CAHN
AB	WILSHIRE PHARMS INC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A211345	001	Dec 07, 2023	Jul CAHN

OMEPRAZOLE; SODIUM BICARBONATE

## CAPSULE;ORAL

## OMEPRAZOLE AND SODIUM BICARBONATE

AB	! AJANTA PHARMA LTD	40MG;1.1GM	A204228	002	Jul 15, 2016	Mar CHRS
	ZEGERID					
	+ @ SALIX	20MG;1.1GM	N021849	001	Feb 27, 2006	Mar DISC
	+ @	40MG;1.1GM	N021849	002	Feb 27, 2006	Mar DISC
	FOR SUSPENSION;ORAL					
	OMEPRAZOLE AND SODIUM BICARBONATE					
AB	! AJANTA PHARMA LTD	40MG/PACKET;1.68GM/PACKET	A205545	002	Jul 27, 2016	Mar CHRS
	ZEGERID					
	+ @ SALIX	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Mar DISC
	+ @	40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Mar DISC

ONDANSETRON

## TABLET, ORALLY DISINTEGRATING;ORAL

## ONDANSETRON

	@ MYLAN	4MG	A078139	001	Jun 25, 2007	Jun DISC
	@	8MG	A078139	002	Jun 25, 2007	Jun DISC
	@ SUN PHARM INDS LTD	4MG	A078602	001	Feb 24, 2011	Jan DISC
	@	8MG	A078602	002	Feb 24, 2011	Jan DISC

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

@ ACCORD HLTHCARE EQ 2MG BASE/ML A206845 001 Mar 10, 2016 May DISC

SOLUTION; ORAL

ONDANSETRON HYDROCHLORIDE

@ PHARM ASSOC EQ 4MG BASE/5ML A078127 001 Jun 25, 2007 Feb DISC

@ TARO EQ 4MG BASE/5ML A077009 001 Nov 30, 2007 May DISC

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

@ CHARTWELL RX EQ 4MG BASE A077517 001 Jun 25, 2007 Jun CAHN

@ EQ 8MG BASE A077517 002 Jun 25, 2007 Jun CAHN

@ EQ 24MG BASE A077517 003 Jun 25, 2007 Jun CAHN

OPICAPONE

CAPSULE; ORAL

ONGENTYS

+ AMNEAL 25MG N212489 001 Apr 24, 2020 Apr CAHN

+! 50MG N212489 002 Apr 24, 2020 Apr CAHN

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL

ORPHENADRINE CITRATE

@ STEVENS J 100MG A040368 001 Jun 23, 2000 Jun CAHN

OSELTAMIVIR PHOSPHATE

CAPSULE; ORAL

OSELTAMIVIR PHOSPHATE

AB LAURUS EQ 30MG BASE A218565 001 May 01, 2024 Apr NEWA

AB EQ 45MG BASE A218565 002 May 01, 2024 Apr NEWA

AB EQ 75MG BASE A218565 003 May 01, 2024 Apr NEWA

FOR SUSPENSION; ORAL

OSELTAMIVIR PHOSPHATE

AB AUROBINDO PHARMA LTD EQ 6MG BASE/ML A218131 001 May 10, 2024 May NEWA

>D> @ CHEMISTRY HLTH EQ 6MG BASE/ML A214949 001 Feb 28, 2022 Aug CAHN

>A> @ LEADING EQ 6MG BASE/ML A214949 001 Feb 28, 2022 Aug CAHN

AB ORYZA EQ 6MG BASE/ML A217303 001 Jul 02, 2024 Jun NEWA

OSPEMIFENE

TABLET; ORAL

OSPEMIFENE

AB HETERO LABS LTD V 60MG A215574 001 Feb 13, 2024 Feb NFTG

AB +! DUCHESNAY 60MG N203505 001 Feb 26, 2013 Feb CFTG

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

>D> @ STERISCIENCE EQ 1GM BASE/VIAL A091486 001 Aug 25, 2014 Aug CAHN

>D> AP EQ 2GM BASE/VIAL A091486 002 Aug 25, 2014 Aug CAHN

>A> @ STERISCIENCE SPECLTS EQ 1GM BASE/VIAL A091486 001 Aug 25, 2014 Aug CAHN

>A> AP EQ 2GM BASE/VIAL A091486 002 Aug 25, 2014 Aug CAHN

OXALIPLATIN

INJECTABLE; INTRAVENOUS

ELOXATIN

+ @ SANOFI AVENTIS US 50MG/10ML (5MG/ML) N021759 001 Jan 31, 2005 Jun DISC

+ @ 100MG/20ML (5MG/ML) N021759 002 Jan 31, 2005 Jun DISC

OXALIPLATIN

AP ! GLAND 50MG/10ML (5MG/ML) A207325 001 Feb 10, 2017 Jun CHRS

AP ! 100MG/20ML (5MG/ML) A207325 002 Feb 10, 2017 Jun CHRS

AP KINDOS 50MG/10ML (5MG/ML) A217348 001 Jan 11, 2024 Jan NEWA

AP 100MG/20ML (5MG/ML) A217348 002 Jan 11, 2024 Jan NEWA

AP MEITHEAL 50MG/10ML (5MG/ML) A217348 001 Jan 11, 2024 Jun CAHN

AP 100MG/20ML (5MG/ML) A217348 002 Jan 11, 2024 Jun CAHN

@ NORVIUM BIOSCIENCE 50MG/VIAL A200979 001 Aug 08, 2012 Jul CAHN

@ 100MG/VIAL A200979 002 Aug 08, 2012 Jul CAHN

OXAPROZIN

TABLET; ORAL  
OXAPROZIN

AB	PANGEA	600MG	A075845	001	Jan 31, 2001	Jun CAHN
	@ TEVA	600MG	A075849	001	Jul 03, 2002	Jan DISC

OXCARBAZEPINE

SUSPENSION; ORAL  
OXCARBAZEPINE

AB	ALKEM LABS LTD	300MG/5ML	A213183	001	Mar 18, 2023	Mar NEWA
AB	BIOCON PHARMA	300MG/5ML	A218278	001	Mar 01, 2024	Apr CAHN
AB	CARNEGIE	300MG/5ML	A218278	001	Mar 01, 2024	Feb NEWA
AB	MEDLEY PHARMS	300MG/5ML	A217782	001	Feb 14, 2024	Feb NEWA
AB	RISING	300MG/5ML	A218278	001	Mar 01, 2024	Mar CAHN

TABLET; ORAL  
OXCARBAZEPINE

AB	ANI PHARMS	150MG	A078005	001	Dec 11, 2007	Jul CMFD
AB		300MG	A078005	002	Dec 11, 2007	Jul CMFD
AB		600MG	A078005	003	Dec 11, 2007	Jul CMFD
AB	RUBICON	150MG	A207717	001	Mar 05, 2024	Feb NEWA
AB		300MG	A207717	002	Mar 05, 2024	Feb NEWA
AB		600MG	A207717	003	Mar 05, 2024	Feb NEWA
	@ ZYDUS	150MG	A211747	001	Jul 03, 2023	Jan DISC
	@	300MG	A211747	002	Jul 03, 2023	Jan DISC
	@	600MG	A211747	003	Jul 03, 2023	Jan DISC

TABLET, EXTENDED RELEASE; ORAL  
OXCARBAZEPINE

>D>	AB	AJANTA PHARMA LTD	150MG	A217659	001	Feb 22, 2024	Aug DISC
>A>		@	150MG	A217659	001	Feb 22, 2024	Aug DISC
	AB		150MG	A217659	001	Feb 22, 2024	Feb NEWA
>D>	AB		300MG	A217659	002	Feb 22, 2024	Aug DISC
>A>		@	300MG	A217659	002	Feb 22, 2024	Aug DISC
	AB		300MG	A217659	002	Feb 22, 2024	Feb NEWA
>D>	AB		600MG	A217659	003	Feb 22, 2024	Aug DISC
>A>		@	600MG	A217659	003	Feb 22, 2024	Aug DISC
	AB		600MG	A217659	003	Feb 22, 2024	Feb NEWA
>D>		@ APOTEX	150MG	A213369	001	Jul 13, 2023	Aug CMFD
>A>	AB		150MG	A213369	001	Jul 13, 2023	Aug CMFD
>D>		@	300MG	A213369	002	Jul 13, 2023	Aug CMFD
>A>	AB		300MG	A213369	002	Jul 13, 2023	Aug CMFD
>D>		@	600MG	A213369	003	Jul 13, 2023	Aug CMFD
>A>	AB		600MG	A213369	003	Jul 13, 2023	Aug CMFD
		OXTELLAR XR					
AB	+	SUPERNUS PHARMS	150MG	N202810	001	Oct 19, 2012	Feb CTEC
AB	+		300MG	N202810	002	Oct 19, 2012	Feb CTEC
AB	+		600MG	N202810	003	Oct 19, 2012	Feb CTEC

OXYBUTYNIN CHLORIDE

SYRUP; ORAL  
OXYBUTYNIN CHLORIDE

	@ PHARM ASSOC	5MG/5ML	A075137	001	Dec 18, 1998	Feb DISC
--	---------------	---------	---------	-----	--------------	----------

TABLET; ORAL  
OXYBUTYNIN CHLORIDE

	@ EYWA	5MG	A211062	001	Feb 06, 2019	Mar DISC
	@ HIBROW HLTHCARE	5MG	A211062	001	Feb 06, 2019	Jul CAHN

OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL  
OXYCODONE HYDROCHLORIDE

	@ HIKMA	5MG/5ML	A208817	001	Aug 10, 2017	Mar DISC
	@	100MG/5ML	A208795	001	Aug 07, 2017	Mar DISC
+	@ VISTAPHARM LLC	5MG/5ML	N201194	001	Jan 12, 2012	Apr CAHN
	@ XTTRIUM LABS INC	5MG/5ML	A206456	001	Jun 16, 2015	Mar CAHN

TABLET; ORAL  
OXYCODONE HYDROCHLORIDE

>D>		@ STRIDES PHARMA	5MG	A077712	003	Mar 02, 2009	Aug CMFD
>A>	AB		5MG	A077712	003	Mar 02, 2009	Aug CMFD
>D>		@	10MG	A077712	004	Apr 13, 2015	Aug CMFD
>A>	AB		10MG	A077712	004	Apr 13, 2015	Aug CMFD
>D>		@	15MG	A077712	001	Jan 31, 2007	Aug CMFD
>A>	AB		15MG	A077712	001	Jan 31, 2007	Aug CMFD



## TABLET;ORAL

## OXYCODONE HYDROCHLORIDE

>D>	@	20MG	A077712	005	Apr 13, 2015	Aug	CMFD	
>A>	AB	20MG	A077712	005	Apr 13, 2015	Aug	CMFD	
>D>	@	30MG	A077712	002	Jan 31, 2007	Aug	CMFD	
>A>	AB	30MG	A077712	002	Jan 31, 2007	Aug	CMFD	
	@	SUN PHARM INDS INC	5MG	A090659	001	Apr 10, 2009	Jun	DISC
	@		10MG	A090659	005	Nov 06, 2012	Jun	DISC
	@		15MG	A090659	002	Apr 10, 2009	Jun	DISC
	@		20MG	A090659	004	Nov 06, 2012	Jun	DISC
	@		30MG	A090659	003	Apr 10, 2009	Jun	DISC

OXYMETHOLONE

## TABLET;ORAL

## ANADROL-50

+	@	NORVIUM BIOSCIENCE	50MG	N016848	001		Jun	CAHN
---	---	--------------------	------	---------	-----	--	-----	------

OXYMORPHONE HYDROCHLORIDE

## TABLET, EXTENDED RELEASE;ORAL

## OPANA ER

+	@	ENDO OPERATIONS	5MG	N021610	001	Jun 22, 2006	May	CAHN
+	@		7.5MG	N021610	005	Feb 29, 2008	May	CAHN
+	@		10MG	N021610	002	Jun 22, 2006	May	CAHN
+	@		15MG	N021610	006	Feb 29, 2008	May	CAHN
+	@		20MG	N021610	003	Jun 22, 2006	May	CAHN
+	@		30MG	N021610	007	Feb 29, 2008	May	CAHN
+	@		40MG	N021610	004	Jun 22, 2006	May	CAHN

OZANIMOD HYDROCHLORIDE

## CAPSULE;ORAL

## ZEPOSIA

+		BRISTOL	EQ 0.23MG BASE	N209899	001	Mar 25, 2020	Jan	CAHN
+			EQ 0.46MG BASE	N209899	002	Mar 25, 2020	Jan	CAHN
+	!		EQ 0.92MG BASE	N209899	003	Mar 25, 2020	Jan	CAHN

PACLITAXEL

## POWDER; INTRAVENOUS

## ABRAXANE

AB	+	!	BRISTOL-MYERS	100MG/VIAL	N021660	001	Jan 07, 2005	Jan	CTEC
			PACLITAXEL						
AB	+	!	AM REGENT	100MG/VIAL	N211875	001	Jul 27, 2022	Apr	CTEC
AB	+	!	TEVA PHARMS INC	100MG/VIAL	N216338	001	May 11, 2023	Jan	CMFD

PALBOCICLIB

## TABLET;ORAL

## IBRANCE

AB	+		PFIZER	75MG	N212436	001	Nov 01, 2019	May	CFTG
				75MG	N212436	001	Nov 01, 2019	Jan	CTEC
AB	+			100MG	N212436	002	Nov 01, 2019	May	CFTG
				100MG	N212436	002	Nov 01, 2019	Jan	CTEC
AB	+	!		125MG	N212436	003	Nov 01, 2019	May	CFTG
				125MG	N212436	003	Nov 01, 2019	Jan	CTEC

## PALBOCICLIB

AB			SYNTHON PHARMS INC	75MG	A215570	001	Jun 05, 2024	May	NFTG
AB				100MG	A215570	002	Jun 05, 2024	May	NFTG
AB				125MG	A215570	003	Jun 05, 2024	May	NFTG

PALIPERIDONE

## TABLET, EXTENDED RELEASE;ORAL

## PALIPERIDONE

	@	ACTAVIS LABS FL INC	1.5MG	A202645	001	Aug 03, 2015	Jul	DISC
	@		3MG	A202645	002	Aug 03, 2015	Jul	DISC
	@		6MG	A202645	003	Aug 03, 2015	Jul	DISC
	@		9MG	A202645	004	Aug 03, 2015	Jul	DISC
AB		AJANTA PHARMA LTD	1.5MG	A218514	001	Jun 26, 2024	Jun	NEWA
AB			3MG	A218514	002	Jun 26, 2024	Jun	NEWA
AB			6MG	A218514	003	Jun 26, 2024	Jun	NEWA
AB			9MG	A218514	004	Jun 26, 2024	Jun	NEWA
BX		LUPIN LTD	1.5MG	A208643	001	Jun 29, 2022	Jun	CTEC
BX			3MG	A208643	002	Jun 29, 2022	Jun	CTEC
BX			6MG	A208643	003	Jun 29, 2022	Jun	CTEC
BX			9MG	A208643	004	Jun 29, 2022	Jun	CTEC

PALIPERIDONE PALMITATESUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR  
ERZOFRI

>D>	+	LUYE INNOMIND PHARMA	39MG/0.25ML (39MG/0.25ML)	N216352	001	Jul 26, 2024	Aug	CHRS
>A>	+		39MG/0.25ML (39MG/0.25ML)	N216352	001	Jul 26, 2024	Aug	CHRS
	+		39MG/0.25ML (39MG/0.25ML)	N216352	001	Jul 26, 2024	Jul	NEWA
>D>	+		78MG/0.5ML (78MG/0.5ML)	N216352	002	Jul 26, 2024	Aug	CHRS
>A>	+		78MG/0.5ML (78MG/0.5ML)	N216352	002	Jul 26, 2024	Aug	CHRS
	+		78MG/0.5ML (78MG/0.5ML)	N216352	002	Jul 26, 2024	Jul	NEWA
>D>	+		117MG/0.75ML (117MG/0.75ML)	N216352	003	Jul 26, 2024	Aug	CHRS
>A>	+		117MG/0.75ML (117MG/0.75ML)	N216352	003	Jul 26, 2024	Aug	CHRS
	+		117MG/0.75ML (117MG/0.75ML)	N216352	003	Jul 26, 2024	Jul	NEWA
>D>	+		156MG/ML (156MG/ML)	N216352	004	Jul 26, 2024	Aug	CHRS
>A>	+		156MG/ML (156MG/ML)	N216352	004	Jul 26, 2024	Aug	CHRS
	+		156MG/ML (156MG/ML)	N216352	004	Jul 26, 2024	Jul	NEWA
>D>	+		234MG/1.5ML (156MG/ML)	N216352	005	Jul 26, 2024	Aug	CHRS
>A>	+		234MG/1.5ML (156MG/ML)	N216352	005	Jul 26, 2024	Aug	CHRS
	+		234MG/1.5ML (156MG/ML)	N216352	005	Jul 26, 2024	Jul	NEWA
	+		351MG/2.25ML (156MG/ML)	N216352	006	Jul 26, 2024	Jul	NEWA

INVEGA SUSTENNA

AB	+	JANSSEN PHARMS	39MG/0.25ML (39MG/0.25ML)	N022264	001	Jul 31, 2009	May	CTEC
AB	+		78MG/0.5ML (78MG/0.5ML)	N022264	002	Jul 31, 2009	May	CTEC
AB	+		117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	May	CTEC
AB	+		156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009	May	CTEC
AB	+		234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009	May	CTEC

INVEGA TRINZA

>D>	+	JANSSEN PHARMS	273MG/0.875ML (273MG/0.875ML)	N207946	001	May 18, 2015	Aug	CHRS
>A>	+		273MG/0.875ML (273MG/0.875ML)	N207946	001	May 18, 2015	Aug	CHRS
>D>	+		410MG/1.315ML (311.79MG/ML)	N207946	002	May 18, 2015	Aug	CHRS
>A>	+		410MG/1.315ML (311.79MG/ML)	N207946	002	May 18, 2015	Aug	CHRS
>D>	+		546MG/1.75ML (312MG/ML)	N207946	003	May 18, 2015	Aug	CHRS
>A>	+		546MG/1.75ML (312MG/ML)	N207946	003	May 18, 2015	Aug	CHRS

PALIPERIDONE PALMITATE

AB		TEVA PHARMS USA	39MG/0.25ML (39MG/0.25ML)	A211149	001	Jul 06, 2021	May	CMFD
AB			78MG/0.5ML (78MG/0.5ML)	A211149	002	Jul 06, 2021	May	CMFD
AB			117MG/0.75ML (117MG/0.75ML)	A211149	003	Jul 06, 2021	May	CMFD
AB			156MG/ML (156MG/ML)	A211149	004	Jul 06, 2021	May	CMFD
AB			234MG/1.5ML (156MG/ML)	A211149	005	Jul 06, 2021	May	CMFD

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

AP		MEITHEAL	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A215861	001	Aug 14, 2023	Jun	CAHN
----	--	----------	--	---------	-----	--------------	-----	------

SOLUTION; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

>D>		AVYXA HOLDINGS	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N203050	001	Mar 01, 2016	Aug	CRLD
>A>	+	@	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N203050	001	Mar 01, 2016	Aug	CRLD
		@	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N203050	001	Mar 01, 2016	Apr	CAHN
>D>		@	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N203050	002	Mar 01, 2016	Aug	CMFD
>A>	+	!	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N203050	002	Mar 01, 2016	Aug	CMFD
		@	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N203050	002	Mar 01, 2016	Apr	CAHN
>A>		POSFREA						
>A>	+	@ AVYXA HOLDINGS	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N203050	001	Mar 01, 2016	Aug	CTNA
>A>	+	!	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N203050	002	Mar 01, 2016	Aug	CTNA

PALOPEGTERIPARATIDE

SOLUTION; SUBCUTANEOUS

YORVIPATH

>A>	+	ASCENDIS PHARMA BONE	EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML)	N216490	001	Aug 09, 2024	Aug	NEWA
>A>	+		EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML)	N216490	002	Aug 09, 2024	Aug	NEWA
>A>	+		EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML)	N216490	003	Aug 09, 2024	Aug	NEWA

PANCURONIUM BROMIDEINJECTABLE; INJECTION  
PANCURONIUM BROMIDE

!	DR REDDYS	1MG/ML	A072759	001	Jul 31, 1990	May	CTEC
@	HOSPIRA	1MG/ML	A072320	001	Jan 19, 1989	May	DISC

PANTOPRAZOLE SODIUMINJECTABLE; INTRAVENOUS  
PANTOPRAZOLE SODIUM

AP	HANGZHOU ZHONGMEI	EQ 40MG BASE/VIAL	A209524	001	Aug 30, 2021	Mar	CAHN
	@ SUN PHARM	EQ 40MG BASE/VIAL	A077674	001	Aug 19, 2019	Feb	DISC

POWDER; INTRAVENOUS  
PANTOPRAZOLE SODIUM

AP	FRESENIUS KABI USA	EQ 40MG BASE/VIAL	A216021	001	Aug 01, 2024	Jul	NEWA
AP	+! HIKMA	EQ 40MG BASE/VIAL	N209463	001	Jun 30, 2017	Jul	CFTG

SOLUTION; INTRAVENOUS

PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE

+!	BAXTER HLTHCARE CORP	EQ 40MG BASE/100ML (EQ 0.4MG BASE/ML)	N217512	001	Feb 14, 2024	Feb	NEWA
+!		EQ 40MG BASE/50ML (EQ 0.8MG BASE/ML)	N217512	002	Feb 14, 2024	Feb	NEWA
+!		EQ 80MG BASE/100ML (EQ 0.8MG BASE/ML)	N217512	003	Feb 14, 2024	Feb	NEWA

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

AB	MANKIND PHARMA	EQ 20MG BASE	A215880	002	Apr 25, 2024	Apr	NEWA
----	----------------	--------------	---------	-----	--------------	-----	------

PARICALCITOL

SOLUTION; INTRAVENOUS

PARICALCITOL

@	HOSPIRA	0.002MG/ML (0.002MG/ML)	N201657	001	Oct 21, 2014	May	DISC
@		0.005MG/ML (0.005MG/ML)	N201657	002	Oct 21, 2014	May	DISC
@		0.01MG/2ML (0.005MG/ML)	N201657	003	Oct 21, 2014	May	DISC

PATIROMER SORBITE X CALCIUM

POWDER; ORAL

VELTASSA

>D>	+ @ VIFOR PHARMA	EQ 1GM BASE/PACKET	N205739	004	Oct 02, 2023	Aug	CMFD
>A>	+	EQ 1GM BASE/PACKET	N205739	004	Oct 02, 2023	Aug	CMFD
	+ @	EQ 1GM BASE/PACKET	N205739	004	Oct 02, 2023	Feb	DISC
	+!	EQ 16.8GM BASE/PACKET	N205739	002	Oct 21, 2015	Jul	CHRS
	+ @	EQ 25.2GM BASE/PACKET	N205739	003	Oct 21, 2015	Jul	DISC

PAZOPANIB HYDROCHLORIDE

TABLET; ORAL

PAZOPANIB HYDROCHLORIDE

AB	NOVUGEN	EQ 200MG BASE	A218231	001	Apr 23, 2024	Apr	NEWA
----	---------	---------------	---------	-----	--------------	-----	------

PEGULICIANINE ACETATE

POWDER; INTRAVENOUS

LUMISIGHT

+!	LUMICELL	EQ 40MG BASE/VIAL	N214511	001	Apr 17, 2024	Apr	NEWA
----	----------	-------------------	---------	-----	--------------	-----	------

PEMETREXED DIPOTASSIUM

POWDER; INTRAVENOUS

PEMETREXED

+!	AVYXA HOLDINGS	EQ 100MG BASE/VIAL	N210661	001	Jun 28, 2024	Jun	NEWA
+!		EQ 500MG BASE/VIAL	N210661	002	Jun 28, 2024	Jun	NEWA

PEMETREXED DISODIUM

POWDER; INTRAVENOUS

PEMETREXED DISODIUM

AP	HETERO LABS LTD VI	EQ 100MG BASE/VIAL	A215460	001	Jun 14, 2024	Jun	NEWA
AP		EQ 500MG BASE/VIAL	A215460	002	Jun 14, 2024	Jun	NEWA
AP	RELIANCE LIFE	EQ 100MG BASE/VIAL	A211899	001	May 25, 2022	Jun	CAHN
AP		EQ 500MG BASE/VIAL	A211899	002	May 25, 2022	Jun	CAHN

PENBUTOLOL SULFATE

TABLET; ORAL

LEVATOL

+ @ ENDO OPERATIONS	10MG	N018976	001	Dec 30, 1987	May	CAHN
+ @	20MG	N018976	004	Jan 05, 1989	May	CAHN

PENICILLAMINE

CAPSULE; ORAL

LUXZYLA

>A>	@ ANI PHARMS	250MG	A209921	001	May 07, 2019	Aug	CTNA
>A>	AB	250MG	A209921	001	May 07, 2019	Aug	CTNA

>D>	PENICILLAMINE							
>D>	AB	ANI PHARMS	250MG	A209921	001	May 07, 2019	Aug	CTNA
	AB	ENDO OPERATIONS	250MG	A211231	001	Dec 23, 2019	Apr	CAHN

TABLET; ORAL

PENICILLAMINE

AB	ENDO OPERATIONS	250MG	A211196	001	Dec 23, 2019	Apr	CAHN
----	-----------------	-------	---------	-----	--------------	-----	------

PENICILLIN V POTASSIUM

TABLET; ORAL

PENICILLIN V POTASSIUM

AB	!	AUROBINDO PHARMA	EQ 500MG BASE	A065435	002	Apr 29, 2008	Jan	CHRS
		@ SANDOZ	EQ 250MG BASE	A064071	001	Nov 30, 1995	Jan	DISC
		@	EQ 500MG BASE	A064071	002	Nov 30, 1995	Jan	DISC

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINE

AB	ANI PHARMS	400MG	A074878	001	Jul 09, 1997	Jan	CMFD
AB	RISING	400MG	A074425	001	Jul 08, 1997	Jun	CMFD

PERMETHRIN

CREAM; TOPICAL

PERMETHRIN

@ DR REDDYS LABS EU	5%	A209732	001	Aug 01, 2023	Jan	DISC
---------------------	----	---------	-----	--------------	-----	------

PERPHENAZINE

TABLET; ORAL

PERPHENAZINE

AB	ENDO OPERATIONS	2MG	A040226	001	Dec 31, 1998	Apr	CAHN
AB		4MG	A040226	002	Dec 31, 1998	Apr	CAHN
AB		8MG	A040226	003	Dec 31, 1998	Apr	CAHN
AB		16MG	A040226	004	Dec 31, 1998	Apr	CAHN
AB	MACLEODS PHARMS LTD	2MG	A212545	001	May 06, 2024	Apr	NEWA
AB		4MG	A212545	002	May 06, 2024	Apr	NEWA
AB		8MG	A212545	003	May 06, 2024	Apr	NEWA
AB		16MG	A212545	004	May 06, 2024	Apr	NEWA

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENOXYBENZAMINE HYDROCHLORIDE

AB	!	ENDO OPERATIONS	10MG	A204522	001	Jan 24, 2017	May	CAHN
----	---	-----------------	------	---------	-----	--------------	-----	------

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

ADIPEX-P

+ @ TEVA	37.5MG	A088023	001	Aug 02, 1983	Feb	DISC
----------	--------	---------	-----	--------------	-----	------

PHENTERMINE HYDROCHLORIDE

@ INVAGEN PHARMS	15MG	A202858	001	Feb 14, 2014	Mar	DISC		
@	30MG	A202858	002	Feb 14, 2014	Mar	DISC		
@	30MG	A204414	001	May 05, 2014	Mar	DISC		
@	37.5MG	A202846	001	Feb 05, 2014	Mar	DISC		
AA	!	NUVO PHARM	37.5MG	A205017	001	Sep 25, 2014	Feb	CHRS

TABLET; ORAL

PHENTERMINE HYDROCHLORIDE

@ INVAGEN PHARMS	37.5MG	A202942	001	Feb 05, 2014	Mar	DISC
------------------	--------	---------	-----	--------------	-----	------

PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

CAPSULE, EXTENDED RELEASE;ORAL

PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE

AB		ACTAVIS LABS FL INC	EQ 3.75MG BASE;23MG	A204982	001	Jun 25, 2024	Jun NFTG
AB			EQ 7.5MG BASE;46MG	A204982	002	Jun 25, 2024	Jun NFTG
AB			EQ 11.25MG BASE;69MG	A204982	003	Jun 25, 2024	Jun NFTG
AB			EQ 15MG BASE;92MG	A204982	004	Jun 25, 2024	Jun NFTG
		QSYMIA					
AB	+	VIVUS LLC	EQ 3.75MG BASE;23MG	N022580	001	Jul 17, 2012	Jun CFTG
	+		EQ 3.75MG BASE;23MG	N022580	001	Jul 17, 2012	May CAHN
AB	+		EQ 7.5MG BASE;46MG	N022580	002	Jul 17, 2012	Jun CFTG
	+		EQ 7.5MG BASE;46MG	N022580	002	Jul 17, 2012	May CAHN
AB	+		EQ 11.25MG BASE;69MG	N022580	003	Jul 17, 2012	Jun CFTG
	+		EQ 11.25MG BASE;69MG	N022580	003	Jul 17, 2012	May CAHN
AB	+		EQ 15MG BASE;92MG	N022580	004	Jul 17, 2012	Jun CFTG
	+		EQ 15MG BASE;92MG	N022580	004	Jul 17, 2012	May CAHN

PHENTOLAMINE MESYLATE

SOLUTION;OPHTHALMIC

RYZUMVI

	+	FAMYGEN LIFE SCI	EQ 0.75% BASE	N217064	001	Sep 25, 2023	Jan CAHN
--	---	------------------	---------------	---------	-----	--------------	----------

PHENYLBUTAZONE

CAPSULE;ORAL

PHENYLBUTAZONE

>A>	@	CHARTWELL RX	100MG	A087774	001	Jun 16, 1982	Aug CAHN
>D>	@	FOSUN PHARMA	100MG	A087774	001	Jun 16, 1982	Aug CAHN

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

PHENYLEPHRINE HYDROCHLORIDE

	@	ACCORD HLTHCARE	10MG/ML (10MG/ML)	A213237	001	Jul 01, 2020	May DISC
	@		50MG/5ML (10MG/ML)	A213237	002	Jul 01, 2020	May DISC
	@		100MG/10ML (10MG/ML)	A213237	003	Jul 01, 2020	May DISC
AP1		ASPIRO	10MG/ML (10MG/ML)	A218110	001	May 10, 2024	May NEWA
AP1			50MG/5ML (10MG/ML)	A218110	002	May 10, 2024	May NEWA
AP1			100MG/10ML (10MG/ML)	A218110	003	May 10, 2024	May NEWA
	@	ENDO OPERATIONS	10MG/ML (10MG/ML)	A210025	001	Dec 21, 2018	Apr CAHN
AP1			50MG/5ML (10MG/ML)	A210025	002	Dec 21, 2018	Apr CAHN
AP1			100MG/10ML (10MG/ML)	A210025	003	Dec 21, 2018	Apr CAHN

SOLUTION/DROPS;OPHTHALMIC

PHENYLEPHRINE HYDROCHLORIDE

AT		CAPLIN	2.5%	A215183	001	May 23, 2024	May NEWA
AT			10%	A215183	002	May 23, 2024	May NEWA

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE

AA	!	GENUS	5MG/5ML; 6.25MG/5ML	A040654	001	Dec 07, 2006	Apr CAHN
	@	HIKMA	5MG/5ML; 6.25MG/5ML	A040675	001	Dec 23, 2014	Mar DISC

PHENYTOIN

SUSPENSION;ORAL

PHENYTOIN

	@	PAI HOLDINGS PHARM	125MG/5ML	A040420	001	Apr 19, 2002	Feb DISC
	@	VISTAPHARM	125MG/5ML	A040342	001	Jan 31, 2001	Apr DISC
	@		125MG/5ML	A040342	002	Aug 18, 2005	Apr DISC

TABLET, CHEWABLE;ORAL

PHENYTOIN

AB		TARO	50MG	A200565	001	Apr 17, 2014	Apr CAHN
----	--	------	------	---------	-----	--------------	----------

PHENYTOIN SODIUM

INJECTABLE;INJECTION

PHENYTOIN SODIUM

AP	+	HIKMA	50MG/ML	A084307	001		Jun CAHN
----	---	-------	---------	---------	-----	--	----------

PHYTONADIONE

TABLET; ORAL

PHYTONADIONE

AB	!	ZYDUS LIFESCIENCES	5MG		A210189	001	Feb 20, 2019	Jul	CAHN
----	---	--------------------	-----	--	---------	-----	--------------	-----	------

PIMAVANSERIN TARTRATE

CAPSULE; ORAL

NUPLAZID

	+	ACADIA PHARMS INC	EQ 34MG BASE		N210793	001	Jun 28, 2018	Jul	CTEC
AB	+		EQ 34MG BASE		N210793	001	Jun 28, 2018	Jan	CFTG

PIMAVANSERIN

	@	MSN	EQ 34MG BASE		A214925	001	Jan 16, 2024	Feb	DISC
AB			EQ 34MG BASE		A214925	001	Jan 16, 2024	Jan	NEWA
	@	ZYDUS	EQ 34MG BASE		A214493	001	Jan 16, 2024	Jul	DISC
AB			EQ 34MG BASE		A214493	001	Jan 16, 2024	Jan	CAHN
AB		ZYDUS PHARMS	EQ 34MG BASE		A214493	001	Jan 16, 2024	Jan	NEWA

TABLET; ORAL

NUPLAZID

	+	ACADIA PHARMS INC	EQ 10MG BASE		N207318	002	Jun 28, 2018	Jul	CTEC
AB	+		EQ 10MG BASE		N207318	002	Jun 28, 2018	Jan	CFTG

PIMAVANSERIN

	@	ZYDUS	EQ 10MG BASE		A214502	001	Jan 16, 2024	Jul	DISC
AB			EQ 10MG BASE		A214502	001	Jan 16, 2024	Jan	CAHN
AB		ZYDUS PHARMS	EQ 10MG BASE		A214502	001	Jan 16, 2024	Jan	NEWA

PIMOZIDE

TABLET; ORAL

PIMOZIDE

ENDO OPERATIONS

			1MG		A204521	001	Sep 28, 2015	Apr	CAHN
	!		2MG		A204521	002	Sep 28, 2015	Apr	CAHN

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE

AB		COREPHARMA	EQ 15MG BASE		A210165	001	Jan 22, 2021	Jul	CAHN
AB			EQ 30MG BASE		A210165	002	Jan 22, 2021	Jul	CAHN
AB			EQ 45MG BASE		A210165	003	Jan 22, 2021	Jul	CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

@ EUGIA PHARMA

			EQ 12GM BASE/VIAL;EQ 1.5GM		A217409	002	Oct 12, 2023	Apr	DISC
--	--	--	----------------------------	--	---------	-----	--------------	-----	------

@

			EQ 36GM BASE/VIAL;EQ 4.5GM		A217409	001	Oct 12, 2023	Apr	DISC
--	--	--	----------------------------	--	---------	-----	--------------	-----	------

@ FRESENIUS KABI USA

			EQ 12GM BASE/VIAL;EQ 1.5GM		A206204	001	May 11, 2018	Feb	DISC
--	--	--	----------------------------	--	---------	-----	--------------	-----	------

STERISCIENCE

>D>	AP		EQ 2GM BASE/VIAL;EQ 250MG		A065458	001	Aug 15, 2014	Aug	CAHN
-----	----	--	---------------------------	--	---------	-----	--------------	-----	------

STERISCIENCE

>D>	AP		EQ 3GM BASE/VIAL;EQ 375MG		A065458	002	Aug 15, 2014	Aug	CAHN
-----	----	--	---------------------------	--	---------	-----	--------------	-----	------

STERISCIENCE

>D>	AP		EQ 4GM BASE/VIAL;EQ 500MG		A065458	003	Aug 15, 2014	Aug	CAHN
-----	----	--	---------------------------	--	---------	-----	--------------	-----	------

STERISCIENCE

>A>	AP	SPECCLTS	EQ 2GM BASE/VIAL;EQ 250MG		A065458	001	Aug 15, 2014	Aug	CAHN
-----	----	----------	---------------------------	--	---------	-----	--------------	-----	------

STERISCIENCE

>A>	AP		EQ 3GM BASE/VIAL;EQ 375MG		A065458	002	Aug 15, 2014	Aug	CAHN
-----	----	--	---------------------------	--	---------	-----	--------------	-----	------

STERISCIENCE

>A>	AP		EQ 4GM BASE/VIAL;EQ 500MG		A065458	003	Aug 15, 2014	Aug	CAHN
-----	----	--	---------------------------	--	---------	-----	--------------	-----	------

PIROXICAM

CAPSULE; ORAL

PIROXICAM

@ FLAMINGO PHARMS

			10MG		A207938	001	Sep 09, 2016	Mar	DISC
--	--	--	------	--	---------	-----	--------------	-----	------

@

			20MG		A207938	002	Sep 09, 2016	Mar	DISC
--	--	--	------	--	---------	-----	--------------	-----	------

PITAVASTATIN CALCIUM

TABLET; ORAL

PITAVASTATIN CALCIUM

>A>	AB	AMNEAL PHARMS NY	EQ 1MG BASE		A205961	001	Aug 20, 2024	Aug	NEWA
>A>	AB		EQ 2MG BASE		A205961	002	Aug 20, 2024	Aug	NEWA
>A>	AB		EQ 4MG BASE		A205961	003	Aug 20, 2024	Aug	NEWA
	AB	HETERO LABS LTD V	EQ 1MG BASE		A205977	001	Apr 30, 2024	Apr	NEWA

## TABLET;ORAL

## PITAVASTATIN CALCIUM

AB		EQ 2MG BASE	A205977	002	Apr 30, 2024	Apr	NEWA
AB		EQ 4MG BASE	A205977	003	Apr 30, 2024	Apr	NEWA

>D> PIVMECILLINAM HYDROCHLORIDE

&gt;D&gt; TABLET;ORAL

&gt;D&gt; PIVYA

>D>	+	UTILITY THERAP	EQ 185MG BASE	N216483	001	Apr 24, 2024	Aug	DISC
>A>	+	@	EQ 185MG BASE	N216483	001	Apr 24, 2024	Aug	DISC
	+	!	EQ 185MG BASE	N216483	001	Apr 24, 2024	Apr	NEWA

PLERIXAFOR

SOLUTION;SUBCUTANEOUS

## PLERIXAFOR

AP		GLAND PHARMA LTD	24MG/1.2ML (20MG/ML)	A206644	001	May 03, 2024	Apr	NEWA
AP		MEITHEAL	24MG/1.2ML (20MG/ML)	A215698	001	Jul 24, 2023	Jun	CAHN
	@	ZYDUS PHARMS	24MG/1.2ML (20MG/ML)	A208980	001	Jul 26, 2023	May	DISC

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION;ORAL

PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

	@	EXTROVIS	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT	A090409	001	Apr 02, 2010	Jun	CAHN
AA		NOVEL LABS INC	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT	A090019	001	May 27, 2009	Jun	CMFD

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL

## COLYTE

	@	NORVIUM BIOSCIENCE	120GM/PACKET;1.49GM/PACKET;3.36GM/PACKET;2.92GM/PACKET;11.36GM/PACKET	N018983	005	Oct 26, 1984	Jul	CAHN
	@		227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N018983	004	Oct 26, 1984	Jul	CAHN
	@		227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989	Jul	CAHN
	@		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	007	Jun 12, 1987	Jul	CAHN
	@		360GM/PACKET;4.47GM/PACKET;10.08GM/PACKET;8.76GM/PACKET;34.08GM/PACKET	N018983	006	Oct 26, 1984	Jul	CAHN
	@	MYLAN SPECIALITY LP	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Apr	DISC
	@	NORVIUM BIOSCIENCE	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Jul	CAHN
	@	NORVIUM BIOSCIENCE	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	008	Nov 14, 1991	Jul	CAHN
	@		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	009	Nov 14, 1991	Jul	CAHN
	@	EXTROVIS	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A090928	001	Jan 28, 2010	Jun	CAHN
		NOVEL LABS INC	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	A090186	001	Jun 01, 2009	Apr	CTEC

POLYMYXIN B SULFATE

INJECTABLE;INJECTION

## POLYMYXIN B SULFATE

AP		ADRASTEIA PHARMA	EQ 500,000 UNITS BASE/VIAL	A063000	001	Sep 30, 1994	Feb	CAHN
----	--	------------------	----------------------------	---------	-----	--------------	-----	------

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS;OPHTHALMIC

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT		SOMERSET THERAPS LLC	10,000 UNITS/ML;EQ 1MG BASE/ML	A211572	001	Aug 05, 2024	Jul	NEWA
----	--	----------------------	--------------------------------	---------	-----	--------------	-----	------

POMALIDOMIDE

CAPSULE;ORAL		POMALIDOMIDE							
AB	APOTEX	1MG		A210164	001	Jun 11, 2024	May	NEWA	
AB		2MG		A210164	002	Jun 11, 2024	May	NEWA	
AB		3MG		A210164	003	Jun 11, 2024	May	NEWA	
AB		4MG		A210164	004	Jun 11, 2024	May	NEWA	
POMALYST									
AB	+ BRISTOL	1MG		N204026	001	Feb 08, 2013	May	CTEC	
AB	+	2MG		N204026	002	Feb 08, 2013	May	CTEC	
AB	+	3MG		N204026	003	Feb 08, 2013	May	CTEC	
AB	+	4MG		N204026	004	Feb 08, 2013	May	CTEC	

PONESIMOD

TABLET;ORAL		PONVORY							
	+! VANDA PHARMS INC	2MG		N213498	001	Mar 18, 2021	May	CAHN	
	+	3MG		N213498	002	Mar 18, 2021	May	CAHN	
	+	4MG		N213498	003	Mar 18, 2021	May	CAHN	
	+	5MG		N213498	004	Mar 18, 2021	May	CAHN	
	+	6MG		N213498	005	Mar 18, 2021	May	CAHN	
	+	7MG		N213498	006	Mar 18, 2021	May	CAHN	
	+	8MG		N213498	007	Mar 18, 2021	May	CAHN	
	+	9MG		N213498	008	Mar 18, 2021	May	CAHN	
	+	10MG		N213498	009	Mar 18, 2021	May	CAHN	
	+	20MG		N213498	010	Mar 18, 2021	May	CAHN	

POSACONAZOLE

TABLET, DELAYED RELEASE;ORAL									
>D>	NOXAFIL								
>D>	AB +! MERCK SHARP DOHME	100MG		N205053	001	Nov 25, 2013	Aug	DISC	
>A>	+ @	100MG		N205053	001	Nov 25, 2013	Aug	DISC	
POSACONAZOLE									
>D>	AB AET PHARMA	100MG		A213454	001	Feb 01, 2021	Aug	CHRS	
>A>	AB !	100MG		A213454	001	Feb 01, 2021	Aug	CHRS	
	AB AUROBINDO PHARMA	100MG		A217119	001	Jul 18, 2024	Jul	NEWA	

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL		POTASSIUM CHLORIDE							
	@ ANCHEN PHARMS	8MEQ		A202886	001	Dec 26, 2013	Feb	DISC	
	@	10MEQ		A202886	002	Dec 26, 2013	Feb	DISC	
	@ ENDO OPERATIONS	8MEQ		A202886	001	Dec 26, 2013	May	CAHN	
	@	10MEQ		A202886	002	Dec 26, 2013	May	CAHN	
FOR SOLUTION;ORAL		POKONZA							
	+ GENUS	10MEQ		N208019	002	Aug 25, 2023	Jun	CAHN	
POTASSIUM CHLORIDE									
AA	+ GENUS	20MEQ		N208019	001	Aug 19, 2015	Jun	CAHN	
	+!	40MEQ		N208019	003	Aug 25, 2023	Jun	CAHN	
SOLUTION;ORAL		POTASSIUM CHLORIDE							
AA	STRIDES PHARMA	20MEQ/15ML		A211665	002	Jan 16, 2024	Jan	NEWA	
TABLET, EXTENDED RELEASE;ORAL		POTASSIUM CHLORIDE							
	@ CHARTWELL RX	10MEQ		A206630	001	Mar 29, 2019	May	CAHN	
	@	15MEQ		A206630	002	Mar 29, 2019	May	CAHN	
	@	20MEQ		A206630	003	Mar 29, 2019	May	CAHN	
>A>	AB2 MACLEODS PHARMS LTD	8MEQ		A212987	001	Sep 06, 2024	Aug	NEWA	
>A>	AB2	10MEQ		A212987	002	Sep 06, 2024	Aug	NEWA	
	AB1	10MEQ		A216269	001	May 09, 2024	May	NEWA	
	AB1	15MEQ		A216269	002	May 09, 2024	May	NEWA	
	AB1	20MEQ		A216269	003	May 09, 2024	May	NEWA	
>A>	! RUBICON	15MEQ		A215725	003	Aug 22, 2024	Aug	NEWA	

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE;ORAL		POTASSIUM CITRATE							
AB	HIBROW HLTHCARE	5MEQ		A214426	001	Feb 19, 2021	Jul	CAHN	
AB		10MEQ		A214426	002	Feb 19, 2021	Jul	CAHN	
AB		15MEQ		A214426	003	Feb 19, 2021	Jul	CAHN	



## TABLET, EXTENDED RELEASE;ORAL

## POTASSIUM CITRATE

	@ TORRENT	5MEQ	A213986	001	Feb 06, 2024	Feb	DISC
AB		5MEQ	A213986	001	Feb 06, 2024	Jan	NEWA
	@	10MEQ	A213986	002	Feb 06, 2024	Feb	DISC
AB		10MEQ	A213986	002	Feb 06, 2024	Jan	NEWA
	@	15MEQ	A213986	003	Feb 06, 2024	Feb	DISC
AB		15MEQ	A213986	003	Feb 06, 2024	Jan	NEWA

POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC

## SOLUTION;INTRAVENOUS

## POTASSIUM PHOSPHATES

AP	SOMERSET THERAPS LLC	1.18GM/5ML (236MG/ML);1.12GM/5ML (224MG/ML)	A217726	001	Jul 11, 2024	Jun	NEWA
AP		3.54GM/15ML (236MG/ML);3.36GM/15ML (224MG/ML)	A217726	002	Jul 11, 2024	Jun	NEWA
	POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE						
+!	AMNEAL	1.18GM/250ML (4.72MG/ML);1.12GM/250ML	N218343	001	Jul 26, 2024	Jul	NEWA

PRALSETINIB

## CAPSULE;ORAL

## GAVRETO

+!	BLUEPRINT MEDICINES	100MG	N213721	001	Sep 04, 2020	Feb	CAHN
+!	RIGEL PHARMS	100MG	N213721	001	Sep 04, 2020	Jun	CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

## TABLET;ORAL

## PRAMIPEXOLE DIHYDROCHLORIDE

AB	GLENMARK PHARMS LTD	0.125MG	A090781	001	Oct 08, 2010	Mar	CAHN
AB	!	0.25MG	A090781	002	Oct 08, 2010	Mar	CAHN
AB		0.5MG	A090781	003	Oct 08, 2010	Mar	CAHN
AB		0.75MG	A090781	006	Sep 11, 2015	Mar	CAHN
AB		1MG	A090781	004	Oct 08, 2010	Mar	CAHN
AB		1.5MG	A090781	005	Oct 08, 2010	Mar	CAHN
>D>	@ MYLAN	0.125MG	A077854	001	Oct 08, 2010	Aug	CAHN
>D>	@	0.25MG	A077854	002	Oct 08, 2010	Aug	CAHN
>D>	@	0.5MG	A077854	003	Oct 08, 2010	Aug	CAHN
>D>	@	1MG	A077854	004	Oct 08, 2010	Aug	CAHN
>D>	@	1.5MG	A077854	005	Oct 08, 2010	Aug	CAHN
>A>	@ NATCO	0.125MG	A077854	001	Oct 08, 2010	Aug	CAHN
>A>	@	0.25MG	A077854	002	Oct 08, 2010	Aug	CAHN
>A>	@	0.5MG	A077854	003	Oct 08, 2010	Aug	CAHN
>A>	@	1MG	A077854	004	Oct 08, 2010	Aug	CAHN
>A>	@	1.5MG	A077854	005	Oct 08, 2010	Aug	CAHN

## TABLET, EXTENDED RELEASE;ORAL

## MIRAPEX ER

>D>	AB	+!	BOEHRINGER INGELHEIM	0.375MG	N022421	001	Feb 19, 2010	Aug	DISC
>A>		+	@	0.375MG	N022421	001	Feb 19, 2010	Aug	DISC
>D>	AB	+		0.75MG	N022421	002	Feb 19, 2010	Aug	DISC
>A>		+	@	0.75MG	N022421	002	Feb 19, 2010	Aug	DISC
>D>	AB	+		1.5MG	N022421	003	Feb 19, 2010	Aug	DISC
>A>		+	@	1.5MG	N022421	003	Feb 19, 2010	Aug	DISC
>D>	AB	+		2.25MG	N022421	006	Jun 17, 2011	Aug	DISC
>A>		+	@	2.25MG	N022421	006	Jun 17, 2011	Aug	DISC
>D>	AB	+		3MG	N022421	004	Feb 19, 2010	Aug	DISC
>A>		+	@	3MG	N022421	004	Feb 19, 2010	Aug	DISC
>D>	AB	+		3.75MG	N022421	007	Jun 17, 2011	Aug	DISC
>A>		+	@	3.75MG	N022421	007	Jun 17, 2011	Aug	DISC
>D>	AB	+		4.5MG	N022421	005	Feb 19, 2010	Aug	DISC
>A>		+	@	4.5MG	N022421	005	Feb 19, 2010	Aug	DISC

## PRAMIPEXOLE DIHYDROCHLORIDE

>D>	AB		DR REDDYS	0.375MG	A203354	001	Aug 07, 2015	Aug	CHRS
>A>	AB	!		0.375MG	A203354	001	Aug 07, 2015	Aug	CHRS
		@	ENDO OPERATIONS	0.375MG	A202206	001	Feb 06, 2014	May	CAHN
		@		0.75MG	A202206	002	Feb 06, 2014	May	CAHN
		@		1.5MG	A202206	003	Feb 06, 2014	May	CAHN
		@		2.25MG	A202206	004	Feb 06, 2014	May	CAHN
		@		3MG	A202206	005	Feb 06, 2014	May	CAHN
		@		3.75MG	A202206	006	Feb 06, 2014	May	CAHN
		@		4.5MG	A202206	007	Feb 06, 2014	May	CAHN

PRAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

PRAZOSIN HYDROCHLORIDE

@	LANNETT CO INC	EQ 1MG BASE	A214083	001	Jan 03, 2024	Jul	DISC
@		EQ 2MG BASE	A214083	002	Jan 03, 2024	Jul	DISC
@		EQ 5MG BASE	A214083	003	Jan 03, 2024	Jul	DISC

PREDNISOLONE

SYRUP;ORAL

PREDNISOLONE

@	HIKMA	15MG/5ML	A040401	001	Feb 27, 2003	Mar	DISC
@	PHARM ASSOC	15MG/5ML	A040399	001	Mar 05, 2003	Feb	DISC

TABLET;ORAL

PREDNISOLONE

AB	ZHEJIANG XIANJU	5MG	A218083	001	May 02, 2024	Apr	NEWA
----	-----------------	-----	---------	-----	--------------	-----	------

PREDNISOLONE ACETATE

SUSPENSION;ORAL

FLO-PRED

>D>	@	TARO	EQ 5MG BASE/5ML	N022067	001	Jan 17, 2008	Aug	CAHN
>A>	@		EQ 5MG BASE/5ML	N022067	001	Jan 17, 2008	Aug	CAHN
>D>	@		EQ 15MG BASE/5ML	N022067	002	Jan 17, 2008	Aug	CAHN
>A>	@		EQ 15MG BASE/5ML	N022067	002	Jan 17, 2008	Aug	CAHN

SUSPENSION/DROPS;OPHTHALMIC

PREDNISOLONE ACETATE

AB	LUPIN LTD	1%	A216935	001	Aug 02, 2024	Jul	NFTG
----	-----------	----	---------	-----	--------------	-----	------

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL

PREDNISOLONE SODIUM PHOSPHATE

@	ENDO OPERATIONS	EQ 15MG BASE/5ML	A079010	001	May 26, 2009	May	CAHN
@	HIKMA	EQ 5MG BASE/5ML	A075183	001	Mar 26, 2003	Mar	DISC
@	PHARM ASSOC	EQ 30MG BASE/5ML	A204962	001	Mar 11, 2020	Mar	DISC

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

>A>	@	GENUS	EQ 0.23% PHOSPHATE;10%	A073630	001	May 27, 1993	Aug	CAHN
>D>	@	SANDOZ	EQ 0.23% PHOSPHATE;10%	A073630	001	May 27, 1993	Aug	CAHN

PREDNISONONE

SOLUTION;ORAL

PREDNISONONE INTENSOL

+! HIKMA 5MG/ML

A088810 001 Feb 20, 1985 Jan CRLD

TABLET;ORAL

PREDNISONONE

>A>	@	ALLIED	5MG	A212629	001	Dec 05, 2023	Aug	CAHN
>A>	@		10MG	A212629	002	Dec 05, 2023	Aug	CAHN
>A>	@		20MG	A212629	003	Dec 05, 2023	Aug	CAHN
BX		CHARTWELL MOLECULAR	20MG	A084275	001		Jul	CMFD
AB		ENDO OPERATIONS	1MG	A040584	001	Dec 21, 2004	Apr	CAHN
AB			2.5MG	A040581	001	Dec 21, 2004	Apr	CAHN
AB			5MG	A040256	001	Jul 12, 2002	Apr	CAHN
AB			10MG	A040256	002	Jul 12, 2002	Apr	CAHN
AB			20MG	A040392	001	Feb 12, 2003	Apr	CAHN
	@	GENEYORK PHARMS	1MG	A211496	001	Dec 28, 2018	Feb	DISC
	@		2.5MG	A210525	004	Dec 07, 2018	Feb	DISC
	@		5MG	A210525	005	Dec 07, 2018	Feb	DISC
	@		10MG	A210525	001	Dec 04, 2018	Feb	DISC
	@		20MG	A210525	002	Dec 04, 2018	Feb	DISC
	@		50MG	A210525	003	Dec 04, 2018	Feb	DISC
>D>	@	GRANULATION TECH	5MG	A212629	001	Dec 05, 2023	Aug	CAHN
	@		5MG	A212629	001	Dec 05, 2023	Jul	DISC
>D>	@		10MG	A212629	002	Dec 05, 2023	Aug	CAHN
	@		10MG	A212629	002	Dec 05, 2023	Jul	DISC
>D>	@		20MG	A212629	003	Dec 05, 2023	Aug	CAHN
	@		20MG	A212629	003	Dec 05, 2023	Jul	DISC
AB		STRIDES PHARMA	2.5MG	A208412	004	Nov 20, 2020	Jun	CMS1
AB			5MG	A208412	005	Nov 20, 2020	Jun	CMS1

PREGABALIN

CAPSULE; ORAL  
PREGABALIN

AB	ACI	25MG	A215755	001	Apr 26, 2023	Feb	CMFD
AB		50MG	A215755	002	Apr 26, 2023	Feb	CMFD
AB		75MG	A215755	003	Apr 26, 2023	Feb	CMFD
AB		100MG	A215755	004	Apr 26, 2023	Feb	CMFD
AB		150MG	A215755	005	Apr 26, 2023	Feb	CMFD
AB		200MG	A215755	006	Apr 26, 2023	Feb	CMFD
AB		225MG	A215755	007	Apr 26, 2023	Feb	CMFD
AB		300MG	A215755	008	Apr 26, 2023	Feb	CMFD
>A>	ACME LABS	50MG	A210585	001	Dec 26, 2019	Aug	CAHN
>A>		75MG	A210585	002	Dec 26, 2019	Aug	CAHN
>A>		100MG	A210585	003	Dec 26, 2019	Aug	CAHN
>A>		150MG	A210585	004	Dec 26, 2019	Aug	CAHN
>A>		200MG	A210585	005	Dec 26, 2019	Aug	CAHN
>A>		300MG	A210585	006	Dec 26, 2019	Aug	CAHN
>A>	ADAPTIS	25MG	A208113	001	May 17, 2024	Aug	CAHN
>A>		50MG	A208113	002	May 17, 2024	Aug	CAHN
>A>		75MG	A208113	004	May 17, 2024	Aug	CAHN
>A>		100MG	A208113	005	May 17, 2024	Aug	CAHN
>A>		150MG	A208113	003	May 17, 2024	Aug	CAHN
>A>		200MG	A208113	006	May 17, 2024	Aug	CAHN
>A>		225MG	A208113	007	May 17, 2024	Aug	CAHN
>A>		300MG	A208113	008	May 17, 2024	Aug	CAHN
@	CADILA PHARMS LTD	25MG	A206452	001	Jul 12, 2023	Jan	DISC
@		50MG	A206452	002	Jul 12, 2023	Jan	DISC
@		75MG	A206452	003	Jul 12, 2023	Jan	DISC
@		100MG	A206452	004	Jul 12, 2023	Jan	DISC
@		150MG	A206452	005	Jul 12, 2023	Jan	DISC
@		200MG	A206452	006	Jul 12, 2023	Jan	DISC
@		225MG	A206452	007	Jul 12, 2023	Jan	DISC
@		300MG	A206452	008	Jul 12, 2023	Jan	DISC
@	CIPLA	25MG	A212280	001	Jan 10, 2020	May	DISC
@		50MG	A212280	002	Jan 10, 2020	May	DISC
@		75MG	A212280	003	Jan 10, 2020	May	DISC
@		100MG	A212280	004	Jan 10, 2020	May	DISC
@		150MG	A212280	005	Jan 10, 2020	May	DISC
@		200MG	A212280	006	Jan 10, 2020	May	DISC
@		225MG	A212280	007	Jan 10, 2020	May	DISC
@		300MG	A212280	008	Jan 10, 2020	May	DISC
>D>	ESKAYEF	25MG	A212988	001	Mar 08, 2022	Aug	CAHN
>D>		50MG	A212988	002	Mar 08, 2022	Aug	CAHN
>D>		75MG	A212988	003	Mar 08, 2022	Aug	CAHN
>D>		100MG	A212988	004	Mar 08, 2022	Aug	CAHN
>D>		150MG	A212988	005	Mar 08, 2022	Aug	CAHN
>D>		200MG	A212988	006	Mar 08, 2022	Aug	CAHN
>D>		225MG	A212988	007	Mar 08, 2022	Aug	CAHN
>D>		300MG	A212988	008	Mar 08, 2022	Aug	CAHN
>D>	INDOCO	25MG	A208113	001	May 17, 2024	Aug	CAHN
		25MG	A208113	001	May 17, 2024	May	NEWA
>D>		50MG	A208113	002	May 17, 2024	Aug	CAHN
		50MG	A208113	002	May 17, 2024	May	NEWA
>D>		75MG	A208113	004	May 17, 2024	Aug	CAHN
		75MG	A208113	004	May 17, 2024	May	NEWA
>D>		100MG	A208113	005	May 17, 2024	Aug	CAHN
		100MG	A208113	005	May 17, 2024	May	NEWA
>D>		150MG	A208113	003	May 17, 2024	Aug	CAHN
		150MG	A208113	003	May 17, 2024	May	NEWA
>D>		200MG	A208113	006	May 17, 2024	Aug	CAHN
		200MG	A208113	006	May 17, 2024	May	NEWA
>D>		225MG	A208113	007	May 17, 2024	Aug	CAHN
		225MG	A208113	007	May 17, 2024	May	NEWA
>D>		300MG	A208113	008	May 17, 2024	Aug	CAHN
		300MG	A208113	008	May 17, 2024	May	NEWA
>D>	RENATA	50MG	A210585	001	Dec 26, 2019	Aug	CAHN
>D>		75MG	A210585	002	Dec 26, 2019	Aug	CAHN
>D>		100MG	A210585	003	Dec 26, 2019	Aug	CAHN
>D>		150MG	A210585	004	Dec 26, 2019	Aug	CAHN
>D>		200MG	A210585	005	Dec 26, 2019	Aug	CAHN
>D>		300MG	A210585	006	Dec 26, 2019	Aug	CAHN
>A>	RK PHARMA	25MG	A212988	001	Mar 08, 2022	Aug	CAHN
>A>		50MG	A212988	002	Mar 08, 2022	Aug	CAHN

CAPSULE;ORAL  
PREGABALIN

>A>	AB		75MG	A212988	003	Mar 08, 2022	Aug	CAHN
>A>	AB		100MG	A212988	004	Mar 08, 2022	Aug	CAHN
>A>	AB		150MG	A212988	005	Mar 08, 2022	Aug	CAHN
>A>	AB		200MG	A212988	006	Mar 08, 2022	Aug	CAHN
>A>	AB		225MG	A212988	007	Mar 08, 2022	Aug	CAHN
>A>	AB		300MG	A212988	008	Mar 08, 2022	Aug	CAHN
	AB	@ STRIDES PHARMA	25MG	A209883	001	Jan 24, 2024	Jul	DISC
			25MG	A209883	001	Jan 24, 2024	Jan	NEWA
	AB	@	50MG	A209883	002	Jan 24, 2024	Jul	DISC
	AB		50MG	A209883	002	Jan 24, 2024	Jan	NEWA
		@	75MG	A209883	003	Jan 24, 2024	Jul	DISC
	AB		75MG	A209883	003	Jan 24, 2024	Jan	NEWA
		@	100MG	A209883	004	Jan 24, 2024	Jul	DISC
	AB		100MG	A209883	004	Jan 24, 2024	Jan	NEWA
		@	150MG	A209883	005	Jan 24, 2024	Jul	DISC
	AB		150MG	A209883	005	Jan 24, 2024	Jan	NEWA
		@	200MG	A209883	006	Jan 24, 2024	Jul	DISC
	AB		200MG	A209883	006	Jan 24, 2024	Jan	NEWA
		@	225MG	A209883	007	Jan 24, 2024	Jul	DISC
	AB		225MG	A209883	007	Jan 24, 2024	Jan	NEWA
		@	300MG	A209883	008	Jan 24, 2024	Jul	DISC
	AB		300MG	A209883	008	Jan 24, 2024	Jan	NEWA
		@ SUN PHARM	25MG	A091157	001	Nov 29, 2019	Jan	DISC
		@	50MG	A091157	002	Nov 29, 2019	Jan	DISC
		@	75MG	A091157	003	Nov 29, 2019	Jan	DISC
		@	100MG	A091157	004	Nov 29, 2019	Jan	DISC
		@	150MG	A091157	005	Nov 29, 2019	Jan	DISC
		@	200MG	A091157	006	Nov 29, 2019	Jan	DISC
		@	225MG	A091157	007	Nov 29, 2019	Jan	DISC
		@	300MG	A091157	008	Nov 29, 2019	Jan	DISC
>D>	AB	TEVA PHARMS	25MG	A091219	001	Jul 19, 2019	Aug	DISC
>A>		@	25MG	A091219	001	Jul 19, 2019	Aug	DISC
>D>	AB		50MG	A091219	002	Jul 19, 2019	Aug	DISC
>A>		@	50MG	A091219	002	Jul 19, 2019	Aug	DISC
>D>	AB		75MG	A091224	001	Jul 19, 2019	Aug	DISC
>A>		@	75MG	A091224	001	Jul 19, 2019	Aug	DISC
>D>	AB		100MG	A091224	002	Jul 19, 2019	Aug	DISC
>A>		@	100MG	A091224	002	Jul 19, 2019	Aug	DISC
>D>	AB		150MG	A091224	003	Jul 19, 2019	Aug	DISC
>A>		@	150MG	A091224	003	Jul 19, 2019	Aug	DISC
>D>	AB		200MG	A091224	004	Jul 19, 2019	Aug	DISC
>A>		@	200MG	A091224	004	Jul 19, 2019	Aug	DISC
>D>	AB		225MG	A091224	005	Jul 19, 2019	Aug	DISC
>A>		@	225MG	A091224	005	Jul 19, 2019	Aug	DISC
>D>	AB		300MG	A091224	006	Jul 19, 2019	Aug	DISC
>A>		@	300MG	A091224	006	Jul 19, 2019	Aug	DISC

TABLET, EXTENDED RELEASE;ORAL  
PREGABALIN

		@ NORVIUM BIOSCIENCE	330MG	A211431	001	Jul 02, 2021	Jun	CAHN
--	--	----------------------	-------	---------	-----	--------------	-----	------

PRIMIDONE

SUSPENSION;ORAL  
MYSOLINE

		+ @ FHFA	250MG/5ML	N010401	001		Jan	CAHN
--	--	----------	-----------	---------	-----	--	-----	------

TABLET;ORAL  
PRIMIDONE

AB		CARNEGIE	50MG	A218366	001	Jan 23, 2024	Jan	NEWA
AB			250MG	A218366	002	Jan 23, 2024	Jan	NEWA

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION  
PROCAINAMIDE HYDROCHLORIDE

AP		GLAND PHARMA LTD	100MG/ML	A218135	001	Jul 22, 2024	Jul	NEWA
AP			500MG/ML	A218135	002	Jul 22, 2024	Jul	NEWA
		@ HIKMA	100MG/ML	A089029	001	Apr 17, 1986	Jun	CAHN

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION  
 PROCHLORPERAZINE EDISYLATE  
 @ HIKMA

EQ 5MG BASE/ML

A213630 001 Nov 22, 2022 Jul DISC

PROCHLORPERAZINE MALEATE

TABLET; ORAL  
 PROCHLORPERAZINE MALEATE

AB AJANTA PHARMA LTD EQ 5MG BASE  
 AB EQ 10MG BASE

A218515 001 May 09, 2024 Apr NEWA  
 A218515 002 May 09, 2024 Apr NEWA

PROGESTERONE

INJECTABLE; INJECTION  
 PROGESTERONE  
 @ ACCORD HLTHCARE

50MG/ML

A217707 001 Nov 21, 2023 Jul DISC

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION  
 PROMETHAZINE HYDROCHLORIDE

AP +! HIKMA 25MG/ML  
 AP +! 50MG/ML

A083312 001 Jun CAHN  
 A083312 002 Jun CAHN

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL  
 PROPAFENONE HYDROCHLORIDE

AB SINOTHERAPEUTICS INC 225MG  
 AB 325MG  
 AB 425MG  
 >D> AB TWI PHARMS 225MG  
 >A> @ 225MG  
 AB 225MG  
 >D> AB 325MG  
 >A> @ 325MG  
 AB 325MG  
 >D> AB 425MG  
 >A> @ 425MG  
 AB 425MG

A210339 001 Jan 04, 2019 May CTEC  
 A210339 002 Jan 04, 2019 May CTEC  
 A210339 003 Jan 04, 2019 May CTEC  
 A212928 001 Jun 18, 2020 Aug DISC  
 A212928 001 Jun 18, 2020 Aug DISC  
 A212928 001 Jun 18, 2020 Mar CAHN  
 A212928 002 Jun 18, 2020 Aug DISC  
 A212928 002 Jun 18, 2020 Aug DISC  
 A212928 002 Jun 18, 2020 Mar CAHN  
 A212928 002 Jun 18, 2020 Mar CAHN  
 A212928 003 Jun 18, 2020 Aug DISC  
 A212928 003 Jun 18, 2020 Aug DISC  
 A212928 003 Jun 18, 2020 Mar CAHN

TABLET; ORAL

PROPAFENONE HYDROCHLORIDE

@ SUN PHARM INDUSTRIES 150MG  
 @ 225MG  
 @ 300MG

A075998 001 Nov 29, 2001 Jul DISC  
 A075998 002 Nov 29, 2001 Jul DISC  
 A075998 003 Nov 29, 2001 Jul DISC

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC  
 PROPARACAINE HYDROCHLORIDE

&gt;A&gt; AT SOMERSET THERAPS LLC 0.5%

A215816 001 Aug 09, 2024 Aug NEWA

PROPOFOL

INJECTABLE; INJECTION  
 PROPOFOL

>A> AB AMNEAL 10MG/ML  
 AB ASPIRO 10MG/ML

A217525 001 Aug 15, 2024 Aug NEWA  
 A217013 001 Jun 20, 2024 Jun NEWA

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL  
 PROPRANOLOL HYDROCHLORIDE

@ EXTROVIS 60MG  
 @ 80MG  
 @ 120MG  
 @ 160MG  
 @ LUPIN LTD 60MG  
 AB 60MG  
 @ 80MG  
 AB 80MG  
 @ 120MG  
 AB 120MG  
 @ 160MG  
 AB 160MG

A078022 001 Feb 15, 2007 Jul CAHN  
 A078022 002 Feb 15, 2007 Jul CAHN  
 A078022 003 Feb 15, 2007 Jul CAHN  
 A078022 004 Feb 15, 2007 Jul CAHN  
 A204349 001 Jan 12, 2024 Apr DISC  
 A204349 001 Jan 12, 2024 Jan NEWA  
 A204349 002 Jan 12, 2024 Apr DISC  
 A204349 002 Jan 12, 2024 Jan NEWA  
 A204349 003 Jan 12, 2024 Apr DISC  
 A204349 003 Jan 12, 2024 Jan NEWA  
 A204349 004 Jan 12, 2024 Apr DISC  
 A204349 004 Jan 12, 2024 Jan NEWA

## SOLUTION;ORAL

## HEMANGEOL

+!	PIERRE FABRE	4.28MG/ML	N205410	001	Mar 14, 2014	May	CAHN
----	--------------	-----------	---------	-----	--------------	-----	------

## TABLET;ORAL

## PROPRANOLOL HYDROCHLORIDE

	@ AIPING PHARM INC	90MG	A071288	001	Oct 22, 1986	Jul	CAHN
AB	ENDO OPERATIONS	10MG	A070221	002	Aug 01, 1986	Apr	CAHN
AB		20MG	A070221	003	Aug 01, 1986	Apr	CAHN
AB		40MG	A070221	004	Aug 01, 1986	Apr	CAHN
AB		60MG	A070221	005	Sep 24, 1986	Apr	CAHN
AB		80MG	A070221	001	Apr 14, 1986	Apr	CAHN

PROPYLTHIOURACIL

## TABLET;ORAL

## PROPYLTHIOURACIL

AB	+! ENDO OPERATIONS	50MG	N006188	001		Apr	CAHN
----	--------------------	------	---------	-----	--	-----	------

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

## TABLET;ORAL

## CORPHED

>A>	@ CHARTWELL RX	60MG;2.5MG	A088602	001	Apr 11, 1985	Aug	CAHN
>D>	@ FOSUN PHARMA	60MG;2.5MG	A088602	001	Apr 11, 1985	Aug	CAHN

PYRIDOSTIGMINE BROMIDE

## TABLET;ORAL

## PYRIDOSTIGMINE BROMIDE

AB	ANI PHARMS	60MG	A040512	001	Oct 08, 2003	Jan	CMFD
AB	MLV	30MG	A211181	002	May 14, 2019	Mar	CAHN
AB		60MG	A211181	001	Jul 20, 2018	Mar	CAHN

QUETIAPINE FUMARATE

## TABLET;ORAL

## QUETIAPINE FUMARATE

AB	IPCA LABS LTD	EQ 25MG BASE	A205983	001	May 20, 2024	May	NEWA
AB		EQ 50MG BASE	A205983	002	May 20, 2024	May	NEWA
AB		EQ 100MG BASE	A205983	003	May 20, 2024	May	NEWA
AB		EQ 200MG BASE	A205983	004	May 20, 2024	May	NEWA
AB		EQ 300MG BASE	A205983	005	May 20, 2024	May	NEWA
AB		EQ 400MG BASE	A205983	006	May 20, 2024	May	NEWA

## TABLET, EXTENDED RELEASE;ORAL

## QUETIAPINE FUMARATE

	@ ENDO OPERATIONS	EQ 50MG BASE	A090482	001	May 09, 2017	May	CAHN
	@	EQ 150MG BASE	A090482	002	May 09, 2017	May	CAHN
	@	EQ 150MG BASE	A090757	001	Dec 01, 2017	May	CAHN
	@	EQ 200MG BASE	A090482	003	May 09, 2017	May	CAHN
	@	EQ 200MG BASE	A090757	002	Dec 01, 2017	May	CAHN
	@	EQ 300MG BASE	A090482	004	May 09, 2017	May	CAHN
	@	EQ 300MG BASE	A090757	003	Dec 01, 2017	May	CAHN
	@	EQ 400MG BASE	A090482	005	May 09, 2017	May	CAHN
	@	EQ 400MG BASE	A090757	004	Dec 01, 2017	May	CAHN
	@ PAR PHARM	EQ 50MG BASE	A090482	001	May 09, 2017	Feb	DISC
	@	EQ 150MG BASE	A090482	002	May 09, 2017	Feb	DISC
	@	EQ 200MG BASE	A090482	003	May 09, 2017	Feb	DISC
	@	EQ 300MG BASE	A090482	004	May 09, 2017	Feb	DISC
	@	EQ 400MG BASE	A090482	005	May 09, 2017	Feb	DISC
AB	PRINSTON INC	EQ 400MG BASE	A208781	005	Mar 11, 2024	Mar	NEWA

QUINAPRIL HYDROCHLORIDE

## TABLET;ORAL

## QUINAPRIL HYDROCHLORIDE

AB	CHARTWELL RX	EQ 5MG BASE	A076803	001	Mar 02, 2005	Jul	CMFD
AB		EQ 10MG BASE	A076803	002	Mar 02, 2005	Jul	CMFD
AB		EQ 20MG BASE	A076803	003	Mar 02, 2005	Jul	CMFD
AB		EQ 40MG BASE	A076803	004	Mar 02, 2005	Jul	CMFD
	@ INVAGEN PHARMS	EQ 5MG BASE	A078457	001	Aug 24, 2007	Mar	DISC
	@	EQ 10MG BASE	A078457	002	Aug 24, 2007	Mar	DISC
	@	EQ 20MG BASE	A078457	003	Aug 24, 2007	Mar	DISC
	@	EQ 40MG BASE	A078457	004	Aug 24, 2007	Mar	DISC

QUINIDINE SULFATE

TABLET;ORAL

QUINIDINE SULFATE

@ CHARTWELL RX	300MG	A089839	001	Sep 29, 1988	Jul	CAHN
----------------	-------	---------	-----	--------------	-----	------

QUININE SULFATE

CAPSULE;ORAL

QUALAQUIN

>D>						
>D>	AB	+!	SUN PHARM INDUSTRIES	324MG	N021799	001 Aug 12, 2005 Aug DISC
>A>		+	@	324MG	N021799	001 Aug 12, 2005 Aug DISC

QUININE SULFATE

>D>	AB		NOVAST LABS	324MG	A204372	001 Jul 22, 2015 Aug CHRS
>A>	AB	!		324MG	A204372	001 Jul 22, 2015 Aug CHRS

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL

ACIPHEX

		+	@ WAYLIS THERAP	10MG	N020973	001 May 29, 2002 Apr CAHN
AB		+	!	20MG	N020973	002 Aug 19, 1999 Apr CAHN

RAMELTEON

TABLET;ORAL

RAMELTEON

>A>	AB		ANDAS 5 HOLDING	8MG	A215435	001 Aug 24, 2022 Aug CAHN
>D>	AB		INNOGENIX	8MG	A215435	001 Aug 24, 2022 Aug CAHN

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

@	ACCORD HLTHCARE	1.25MG	A202392	001	Apr 15, 2014	May DISC
@		2.5MG	A202392	002	Apr 15, 2014	May DISC
@		5MG	A202392	003	Apr 15, 2014	May DISC
@		10MG	A202392	004	Apr 15, 2014	May DISC

RANITIDINE HYDROCHLORIDE

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

@	LANNETT CO INC	EQ 15MG BASE/ML	A091288	001	Dec 09, 2010	Mar DISC
@	PHARM ASSOC	EQ 15MG BASE/ML	A077405	001	Sep 21, 2007	Mar DISC

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

@	ENDO OPERATIONS	EQ 150MG BASE	A075180	001	Jan 28, 1999	May CAHN
@		EQ 300MG BASE	A075180	002	Jan 28, 1999	May CAHN
@	PAR PHARM	EQ 150MG BASE	A075180	001	Jan 28, 1999	Feb DISC
@		EQ 300MG BASE	A075180	002	Jan 28, 1999	Feb DISC

RANOLAZINE

GRANULES, EXTENDED RELEASE;ORAL

ASPRUZYO SPRINKLE

>D>						
>D>		+	SPIL	500MG	N216018	001 Feb 28, 2022 Aug DISC
>A>		+	@	500MG	N216018	001 Feb 28, 2022 Aug DISC
>D>		+	!	1GM	N216018	002 Feb 28, 2022 Aug DISC
>A>		+	@	1GM	N216018	002 Feb 28, 2022 Aug DISC

TABLET, EXTENDED RELEASE;ORAL

RANOLAZINE

@	PIRAMAL HLTHCARE UK	500MG	A213085	001	Jul 25, 2023	Jan DISC
@		1GM	A213085	002	Jul 25, 2023	Jan DISC

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

AB			MACLEODS PHARMS LTD	EQ 0.5MG BASE	A208866	001 Jun 28, 2024 Jun NEWA
AB				EQ 1MG BASE	A208866	002 Jun 28, 2024 Jun NEWA
AB			SKG PHARMA	EQ 0.5MG BASE	A218163	001 Apr 09, 2024 Mar NEWA
AB				EQ 1MG BASE	A218163	002 Apr 09, 2024 Mar NEWA

REGADENOSONSOLUTION; INTRAVENOUS  
REGADENOSON

AP	GE HEALTHCARE	0.4MG/5ML (0.08MG/ML)	A215955	001	Aug 05, 2024	Jul	NEWA
>A>	INDIES PHARMA	0.4MG/5ML (0.08MG/ML)	A218054	001	Aug 22, 2024	Aug	NEWA

REMIFENTANIL HYDROCHLORIDEINJECTABLE; INJECTION  
REMIFENTANIL HYDROCHLORIDE

AP	NIVAGEN PHARMS INC	EQ 1MG BASE/VIAL	A215635	001	Jun 28, 2024	Jun	NEWA
AP		EQ 2MG BASE/VIAL	A215635	002	Jun 28, 2024	Jun	NEWA
AP		EQ 5MG BASE/VIAL	A215635	003	Jun 28, 2024	Jun	NEWA

REPOTRECTINIBCAPSULE; ORAL  
AUGTYRO

+	BRISTOL	160MG	N218213	002	Jun 11, 2024	Jul	NEWA
---	---------	-------	---------	-----	--------------	-----	------

RESMETIROMTABLET; ORAL  
REZDIFFRA

+	MADRIGAL	60MG	N217785	001	Mar 14, 2024	Mar	NEWA
+		80MG	N217785	002	Mar 14, 2024	Mar	NEWA
+	!	100MG	N217785	003	Mar 14, 2024	Mar	NEWA

RETAPAMULINOINTMENT; TOPICAL  
ALTABAX

+	@ ALMIRALL	1%	N022055	001	Apr 12, 2007	May	DISC
---	------------	----	---------	-----	--------------	-----	------

REZAFUNGIN ACETATEPOWDER; INTRAVENOUS  
REZZAYO

+	!	MUNDIPHARMA	EQ 200MG BASE/VIAL	N217417	001	Mar 22, 2023	Jun	CAHN
---	---	-------------	--------------------	---------	-----	--------------	-----	------

RIFAMPINCAPSULE; ORAL  
RIFAMPIN

@	HIKMA	150MG	A065028	001	Mar 14, 2001	Mar	DISC
@		300MG	A065028	002	Mar 14, 2001	Mar	DISC

RILPIVIRINE HYDROCHLORIDE>D> TABLET, FOR SUSPENSION; ORAL  
>D> EDURANT PED

>D>	+	JANSSEN PRODS	EQ 2.5MG BASE	N219016	001	Mar 15, 2024	Aug	DISC
>A>	+	@	EQ 2.5MG BASE	N219016	001	Mar 15, 2024	Aug	DISC
	+	!	EQ 2.5MG BASE	N219016	001	Mar 15, 2024	Mar	NEWA

RILUZOLESUSPENSION; ORAL  
RILUZOLE

>A>	AB	ALKEM LABS LTD	50MG/10ML	A216035	001	Aug 22, 2024	Aug	NFTG
		TIGLUTIK KIT						
>D>	+	ITALFARMACO SA	50MG/10ML	N209080	001	Sep 05, 2018	Aug	CFTG
>A>	AB	+	50MG/10ML	N209080	001	Sep 05, 2018	Aug	CFTG
		TABLET; ORAL						
		RILUTEK						
	+	@ COVIS	50MG	N020599	001	Dec 12, 1995	May	DISC
		RILUZOLE						
AB	!	ALKEM LABS LTD	50MG	A204048	001	Mar 30, 2016	May	CHRS

RISEDRONATE SODIUMTABLET; ORAL  
RISEDRONATE SODIUM

BX	AUROBINDO PHARMA	150MG	A206768	001	Oct 21, 2016	Jun	CTEC
----	------------------	-------	---------	-----	--------------	-----	------



RISPERIDONE

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

RISVAN

	+	LABS FARMS ROVI SA	75MG	N214835	001	Mar 29, 2024	Mar NEWA
	+	!	100MG	N214835	002	Mar 29, 2024	Mar NEWA

INJECTABLE;INTRAMUSCULAR

RISPERDAL CONSTA

AB	+	JANSSEN PHARMS	12.5MG/VIAL	N021346	004	Apr 12, 2007	Jan CMS1
AB	+	!	25MG/VIAL	N021346	001	Oct 29, 2003	Jan CMS1
AB	+		37.5MG/VIAL	N021346	002	Oct 29, 2003	Jan CMS1
AB	+		50MG/VIAL	N021346	003	Oct 29, 2003	Jan CMS1

RISPERIDONE

AB		TEVA PHARMS USA INC	12.5MG/VIAL	A214068	001	Dec 05, 2023	Jan CMS1
AB			25MG/VIAL	A214068	002	Dec 05, 2023	Jan CMS1
AB			37.5MG/VIAL	A214068	003	Dec 05, 2023	Jan CMS1
AB			50MG/VIAL	A214068	004	Dec 05, 2023	Jan CMS1

SOLUTION;ORAL

RISPERIDONE

	@	HIKMA	1MG/ML	A076904	001	Jul 29, 2009	Mar DISC
	@	PHARM ASSOC	1MG/ML	A077719	001	Jul 29, 2009	Feb DISC

TABLET;ORAL

RISPERIDONE

>D>	AB	ALLIED	0.25MG	A078871	001	Oct 09, 2008	Aug CAHN
	AB		0.25MG	A078871	001	Oct 09, 2008	Jul CAHN
>D>	AB		0.5MG	A078871	002	Oct 09, 2008	Aug CAHN
	AB		0.5MG	A078871	002	Oct 09, 2008	Jul CAHN
>D>	AB		1MG	A078871	003	Oct 09, 2008	Aug CAHN
	AB		1MG	A078871	003	Oct 09, 2008	Jul CAHN
>D>	AB		2MG	A078871	004	Oct 09, 2008	Aug CAHN
	AB		2MG	A078871	004	Oct 09, 2008	Jul CAHN
>D>	AB		3MG	A078871	005	Oct 09, 2008	Aug CAHN
	AB		3MG	A078871	005	Oct 09, 2008	Jul CAHN
>D>	AB		4MG	A078871	006	Oct 09, 2008	Aug CAHN
	AB		4MG	A078871	006	Oct 09, 2008	Jul CAHN
	AB	IPCA LABS LTD	0.25MG	A205104	001	Jun 26, 2024	Jun NEWA
	AB		0.5MG	A205104	002	Jun 26, 2024	Jun NEWA
	AB		1MG	A205104	003	Jun 26, 2024	Jun NEWA
	AB		2MG	A205104	004	Jun 26, 2024	Jun NEWA
	AB		3MG	A205104	005	Jun 26, 2024	Jun NEWA
	AB		4MG	A205104	006	Jun 26, 2024	Jun NEWA
>A>	AB	NOVITIUM PHARMA	0.25MG	A078871	001	Oct 09, 2008	Aug CAHN
>A>	AB		0.5MG	A078871	002	Oct 09, 2008	Aug CAHN
>A>	AB		1MG	A078871	003	Oct 09, 2008	Aug CAHN
>A>	AB		2MG	A078871	004	Oct 09, 2008	Aug CAHN
>A>	AB		3MG	A078871	005	Oct 09, 2008	Aug CAHN
>A>	AB		4MG	A078871	006	Oct 09, 2008	Aug CAHN
	AB	RENATA	0.25MG	A078707	001	Dec 29, 2008	Feb CAHN
	AB		0.5MG	A078707	002	Dec 29, 2008	Feb CAHN
	AB		1MG	A078707	003	Dec 29, 2008	Feb CAHN
	AB		2MG	A078707	004	Dec 29, 2008	Feb CAHN
	AB		3MG	A078707	005	Dec 29, 2008	Feb CAHN
	AB		4MG	A078707	006	Dec 29, 2008	Feb CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

RISPERIDONE

		ENDO OPERATIONS	0.25MG	A077494	001	Apr 30, 2009	Apr CAHN
AB			0.5MG	A077494	002	Apr 30, 2009	Apr CAHN
AB			1MG	A077494	003	Oct 26, 2009	Apr CAHN
AB			2MG	A077494	004	Apr 30, 2009	Apr CAHN
AB			3MG	A077494	005	Apr 30, 2009	Apr CAHN
AB			4MG	A077494	006	Apr 30, 2009	Apr CAHN

RIVASTIGMINE TARTRATE

SOLUTION;ORAL

EXELON

	+	@ NOVARTIS	EQ 2MG BASE/ML	N021025	001	Apr 21, 2000	Apr CRLD
--	---	------------	----------------	---------	-----	--------------	----------

RIZATRIPTAN BENZOATE

FILM;ORAL

RIZAFILM

+ @ GENSCO EQ 10MG BASE N205394 001 Apr 14, 2023 Jun DISC

TABLET;ORAL

RIZATRIPTAN BENZOATE

&gt;D&gt; AB GLENMARK PHARMS LTD EQ 5MG BASE A201967 001 Dec 31, 2012 Aug DISC

&gt;A&gt; @ EQ 5MG BASE A201967 001 Dec 31, 2012 Aug DISC

&gt;D&gt; AB EQ 10MG BASE A201967 002 Dec 31, 2012 Aug DISC

&gt;A&gt; @ EQ 10MG BASE A201967 002 Dec 31, 2012 Aug DISC

@ INVAGEN PHARMS EQ 5MG BASE A204339 001 Jul 01, 2013 Apr DISC

@ EQ 10MG BASE A204339 002 Jul 01, 2013 Apr DISC

&gt;D&gt; AB NATCO PHARMA LTD EQ 5MG BASE A200482 001 Dec 31, 2012 Aug DISC

&gt;A&gt; @ EQ 5MG BASE A200482 001 Dec 31, 2012 Aug DISC

&gt;D&gt; AB EQ 10MG BASE A200482 002 Dec 31, 2012 Aug DISC

&gt;A&gt; @ EQ 10MG BASE A200482 002 Dec 31, 2012 Aug DISC

TABLET, ORALLY DISINTEGRATING;ORAL

RIZATRIPTAN BENZOATE

&gt;D&gt; AB GLENMARK PHARMS LTD EQ 5MG BASE A201914 001 Jul 01, 2013 Aug DISC

&gt;A&gt; @ EQ 5MG BASE A201914 001 Jul 01, 2013 Aug DISC

&gt;D&gt; AB EQ 10MG BASE A201914 002 Jul 01, 2013 Aug DISC

&gt;A&gt; @ EQ 10MG BASE A201914 002 Jul 01, 2013 Aug DISC

ROCURONIUM BROMIDE

INJECTABLE;INJECTION

ROCURONIUM BROMIDE

@ HIKMA 50MG/5ML (10MG/ML) A217034 001 May 24, 2023 Jul DISC

AP SHANDONG 50MG/5ML (10MG/ML) A215684 001 Jul 12, 2024 Jul NEWA

AP 100MG/10ML (10MG/ML) A215684 002 Jul 12, 2024 Jul NEWA

AP STERISCIENCE 50MG/5ML (10MG/ML) A217092 001 Jul 22, 2024 Jul NEWA

ROFLUMILAST

CREAM;TOPICAL

ZORYVE

+! ARCUTIS 0.15% N215985 002 Jul 09, 2024 Jul NEWA

TABLET;ORAL

ROFLUMILAST

@ BRECKENRIDGE 250MCG A208236 002 Oct 19, 2023 Jul DISC

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION

ROPIVACAINE HYDROCHLORIDE

AP CAPLIN 200MG/100ML (2MG/ML) A212808 005 May 23, 2024 May NEWA

AP 400MG/200ML (2MG/ML) A212808 006 May 23, 2024 May NEWA

&gt;A&gt; AP HIKMA 200MG/100ML (2MG/ML) A211907 001 Aug 15, 2024 Aug NEWA

&gt;A&gt; AP 400MG/200ML (2MG/ML) A211907 002 Aug 15, 2024 Aug NEWA

&gt;A&gt; AP 500MG/100ML (5MG/ML) A211907 003 Aug 15, 2024 Aug NEWA

@ HOSPIRA 20MG/10ML (2MG/ML) A090194 001 Sep 23, 2014 May DISC

@ 40MG/20ML (2MG/ML) A090194 005 Sep 23, 2014 May DISC

@ 100MG/10ML (10MG/ML) A090194 004 Sep 23, 2014 May DISC

@ 150MG/30ML (5MG/ML) A090194 002 Sep 23, 2014 May DISC

@ 150MG/20ML (7.5MG/ML) A090194 003 Sep 23, 2014 May DISC

@ 200MG/20ML (10MG/ML) A090194 006 Sep 23, 2014 May DISC

AP KINDOS 20MG/10ML (2MG/ML) A218713 001 Jul 30, 2024 Jul NEWA

AP 40MG/20ML (2MG/ML) A218713 002 Jul 30, 2024 Jul NEWA

AP 100MG/20ML (5MG/ML) A218713 003 Jul 30, 2024 Jul NEWA

AP 100MG/10ML (10MG/ML) A218713 004 Jul 30, 2024 Jul NEWA

AP 150MG/30ML (5MG/ML) A218713 005 Jul 30, 2024 Jul NEWA

AP 150MG/20ML (7.5MG/ML) A218713 006 Jul 30, 2024 Jul NEWA

AP 200MG/20ML (10MG/ML) A218713 007 Jul 30, 2024 Jul NEWA

ROSUVASTATIN CALCIUM

TABLET;ORAL

ROSUVASTATIN CALCIUM

@ SANDOZ EQ 5MG BASE A079171 001 Jul 19, 2016 Jan DISC

@ EQ 10MG BASE A079171 002 Jul 19, 2016 Jan DISC

@ EQ 20MG BASE A079171 003 Jul 19, 2016 Jan DISC

@ EQ 40MG BASE A079171 004 Jul 19, 2016 Jan DISC

RUCAPARIB CAMSYLATE

TABLET; ORAL

RUBRACA

	+	PHARMAAND	EQ 200MG BASE	N209115	001	Dec 19, 2016	Jul	CAHN
	+		EQ 250MG BASE	N209115	003	May 01, 2017	Jul	CAHN
	+	!	EQ 300MG BASE	N209115	002	Dec 19, 2016	Jul	CAHN

SACUBITRIL; VALSARTAN

CAPSULE, PELLETS; ORAL

ENTRESTO SPRINKLE

	+	NOVARTIS	6MG; 6MG	N218591	001	Apr 12, 2024	Apr	NEWA
	+	!	15MG; 16MG	N218591	002	Apr 12, 2024	Apr	NEWA

TABLET; ORAL

ENTRESTO

AB	+	NOVARTIS PHARMS CORP	24MG; 26MG	N207620	001	Jul 07, 2015	May	CFTG
AB	+		49MG; 51MG	N207620	002	Jul 07, 2015	May	CFTG
AB	+	!	97MG; 103MG	N207620	003	Jul 07, 2015	May	CFTG

SACUBITRIL AND VALSARTAN

AB		ALEMBIC	24MG; 26MG	A213682	001	May 28, 2024	May	NFTG
AB			49MG; 51MG	A213682	002	May 28, 2024	May	NFTG
AB			97MG; 103MG	A213682	003	May 28, 2024	May	NFTG
>A>	AB	BIOCON PHARMA	24MG; 26MG	A213680	001	Aug 30, 2024	Aug	NEWA
>A>	AB		49MG; 51MG	A213680	002	Aug 30, 2024	Aug	NEWA
>A>	AB		97MG; 103MG	A213680	003	Aug 30, 2024	Aug	NEWA
AB		CRYSTAL	24MG; 26MG	A213605	001	May 28, 2024	May	NFTG
AB			49MG; 51MG	A213605	002	May 28, 2024	May	NFTG
AB			97MG; 103MG	A213605	003	May 28, 2024	May	NFTG
AB		LAURUS	24MG; 26MG	A213676	001	May 28, 2024	May	NFTG
AB			49MG; 51MG	A213676	002	May 28, 2024	May	NFTG
AB			97MG; 103MG	A213676	003	May 28, 2024	May	NFTG
AB		MSN	24MG; 26MG	A213748	001	Jul 24, 2024	Jul	NEWA
AB			49MG; 51MG	A213748	002	Jul 24, 2024	Jul	NEWA
AB			97MG; 103MG	A213748	003	Jul 24, 2024	Jul	NEWA
>A>	AB	TORRENT	24MG; 26MG	A213604	001	Aug 22, 2024	Aug	NEWA
>A>	AB		49MG; 51MG	A213604	002	Aug 22, 2024	Aug	NEWA
>A>	AB		97MG; 103MG	A213604	003	Aug 22, 2024	Aug	NEWA
AB		ZYDUS PHARMS	24MG; 26MG	A213719	001	Jul 09, 2024	Jun	NEWA
AB			49MG; 51MG	A213719	002	Jul 09, 2024	Jun	NEWA
AB			97MG; 103MG	A213719	003	Jul 09, 2024	Jun	NEWA

SAFINAMIDE MESYLATE

TABLET; ORAL

SAFINAMIDE MESYLATE

AB		PRINSTON INC	EQ 50MG BASE	A215739	001	Apr 25, 2024	Apr	NEWA
AB			EQ 100MG BASE	A215739	002	Apr 25, 2024	Apr	NEWA
		XADAGO						
AB	+	MDD US	EQ 50MG BASE	N207145	001	Mar 21, 2017	Apr	CTEC
AB	+	!	EQ 100MG BASE	N207145	002	Mar 21, 2017	Apr	CTEC

SAXAGLIPTIN HYDROCHLORIDE

TABLET; ORAL

SAXAGLIPTIN

@ AMNEAL

@

EQ 2.5MG BASE	A205941	001	Jul 31, 2023	Feb	DISC
EQ 5MG BASE	A205941	002	Jul 31, 2023	Feb	DISC

SCOPOLAMINE

SYSTEM; TRANSDERMAL

SCOPOLAMINE

AB		RHODES PHARMS	1MG/72HR	A215329	001	May 06, 2024	Apr	NEWA
>A>	AB	ZYDUS PHARMS	1MG/72HR	A217893	001	Aug 29, 2024	Aug	NEWA

>A> SELADELPAR LYSINE

>A> CAPSULE; ORAL

>A> LIVDELZI

>A>	+	!	CYMABAY	EQ 10MG BASE	N217899	001	Aug 14, 2024	Aug	NEWA
-----	---	---	---------	--------------	---------	-----	--------------	-----	------

SELEGILINE HYDROCHLORIDE

CAPSULE;ORAL

ELDEPRYL

>A>	+ @ NORVIUM BIOSCIENCE	5MG	N020647	001	May 15, 1996	Aug	CAHN
>D>	+ @ SOMERSET	5MG	N020647	001	May 15, 1996	Aug	CAHN

TABLET;ORAL

SELEGILINE HYDROCHLORIDE

>A>	@ KENTON	5MG	A074912	001	Apr 30, 1998	May	CAHN
>A>	+ @ NORVIUM BIOSCIENCE	5MG	N019334	001	Jun 05, 1989	Aug	CAHN
>D>	+ @ SOMERSET	5MG	N019334	001	Jun 05, 1989	Aug	CAHN

SELEXIPAG

TABLET;ORAL

SELEXIPAG

@ ZYDUS LIFESCIENCES

@

@

@

@

@

@

@

@

A214302	001	Dec 21, 2022	May	CAHN
A214302	002	Dec 21, 2022	May	CAHN
A214302	003	Dec 21, 2022	May	CAHN
A214302	004	Dec 21, 2022	May	CAHN
A214302	005	Dec 21, 2022	May	CAHN
A214302	006	Dec 21, 2022	May	CAHN
A214302	007	Dec 21, 2022	May	CAHN
A214302	008	Dec 21, 2022	May	CAHN

SELPERCATINIB

TABLET;ORAL

RETEVMO

+ LOXO ONCOL ELI LILLY

+

+

+!

40MG
80MG
120MG
160MG

N218160	001	Apr 10, 2024	Apr	NEWA
N218160	002	Apr 10, 2024	Apr	NEWA
N218160	003	Apr 10, 2024	Apr	NEWA
N218160	004	Apr 10, 2024	Apr	NEWA

SERTRALINE HYDROCHLORIDE

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

@ APSCO

@

@

EQ 25MG BASE
EQ 50MG BASE
EQ 100MG BASE

A077713	001	Feb 06, 2007	May	CAHN
A077713	002	Feb 06, 2007	May	CAHN
A077713	003	Feb 06, 2007	May	CAHN

SEVELAMER CARBONATE

FOR SUSPENSION;ORAL

SEVELAMER CARBONATE

AB INVAGEN PHARMS

AB

AB MACLEODS PHARMS LTD

AB

800MG/PACKET
2.4GM/PACKET
800MG/PACKET
2.4GM/PACKET

A206234	001	Jul 12, 2024	Jul	NEWA
A206234	002	Jul 12, 2024	Jul	NEWA
A207291	001	Apr 25, 2024	Apr	NEWA
A207291	002	Apr 25, 2024	Apr	NEWA

TABLET;ORAL

SEVELAMER CARBONATE

>D>	@ ANXIN	800MG	A212970	001	Apr 09, 2020	Aug	CAHN
	@	800MG	A212970	001	Apr 09, 2020	Apr	DISC
>A>	@ SINOTHERAPEUTICS INC	800MG	A212970	001	Apr 09, 2020	Aug	CAHN
AB	STRIDES PHARMA	800MG	A211915	001	May 09, 2024	May	NEWA

SILDENAFIL CITRATE

SUSPENSION;ORAL

LIQREV

+ @ CMP DEV LLC

EQ 10MG BASE/ML

N214952	001	Apr 28, 2023	Jul	DISC
---------	-----	--------------	-----	------

TABLET;ORAL

SILDENAFIL CITRATE

BX @ MYLAN PHARMS INC

BX UMEDICA

BX

BX

EQ 20MG BASE
EQ 25MG BASE
EQ 50MG BASE
EQ 100MG BASE

A201150	001	Nov 09, 2012	Apr	DISC
A209302	003	Jun 15, 2021	Jun	CTEC
A209302	001	Aug 25, 2020	Jun	CTEC
A209302	002	Aug 25, 2020	Jun	CTEC

SILODOSIN

CAPSULE;ORAL

SILODOSIN

AB CHARTWELL RX

AB

4MG
8MG

A204726	001	Mar 31, 2017	Mar	CAHN
A204726	002	Mar 31, 2017	Mar	CAHN

SILVER SULFADIAZINECREAM; TOPICAL  
SSD

AB	+	DR REDDYS LA	1%	N018578	001	Feb 25, 1982	Jan	CRLD
AB	!		1%	N018578	001	Feb 25, 1982	Jan	CHRS

SIMVASTATINSUSPENSION; ORAL  
FLOLIPID

+	SALERNO PHARMS	20MG/5ML	N206679	001	Apr 21, 2016	Apr	CAHN
+	!	40MG/5ML	N206679	002	Apr 21, 2016	Apr	CAHN

SINCALIDEINJECTABLE; INJECTION  
KINEVAC

AP	+	BRACCO	0.005MG/VIAL	N017697	001		May	CTEC
----	---	--------	--------------	---------	-----	--	-----	------

POWDER; INTRAVENOUS  
KINEVAC

AP	+	BRACCO	0.005MG/VIAL	N017697	001		May	CDFR
----	---	--------	--------------	---------	-----	--	-----	------

SINCALIDE

AP	+	MAIA PHARMS INC	0.005MG/VIAL	N210850	001	Nov 22, 2022	May	CTEC
----	---	-----------------	--------------	---------	-----	--------------	-----	------

SODIUM ACETATEINJECTABLE; INJECTION  
SODIUM ACETATE

AP		FRESENIUS KABI USA	400MEQ/100ML (4MEQ/ML)	A206687	001	Oct 30, 2017	Apr	CPOT
AP		MILLA PHARMS	400MEQ/100ML (4MEQ/ML)	A214805	002	Aug 25, 2023	Apr	CPOT

SOLUTION; INTRAVENOUS  
SODIUM ACETATE

AP	!	FRESENIUS KABI USA	400MEQ/100ML (4MEQ/ML)	A206687	001	Oct 30, 2017	Apr	CDFR
AP		HIKMA	40MEQ/20ML (2MEQ/ML)	A216920	001	Mar 15, 2024	Mar	NEWA
AP			100MEQ/50ML (2MEQ/ML)	A216920	002	Mar 15, 2024	Mar	NEWA
AP			200MEQ/100ML (2MEQ/ML)	A216920	003	Mar 15, 2024	Mar	NEWA
AP	+	HOSPIRA	2MEQ/ML	N018893	001	May 04, 1983	Mar	CDFR
AP	+		40MEQ/20ML (2MEQ/ML)	N018893	001	May 04, 1983	Mar	CPOT
AP	+		100MEQ/50ML (2MEQ/ML)	N018893	002	Sep 02, 2014	Mar	CMS1
AP	+		200MEQ/100ML (2MEQ/ML)	N018893	003	Sep 02, 2014	Mar	CMS1
AP		MILLA PHARMS	2MEQ/ML	A214805	001	May 04, 2021	Mar	CDFR
AP			40MEQ/20ML (2MEQ/ML)	A214805	004	Jan 22, 2024	Mar	CMS1
AP			100MEQ/50ML (2MEQ/ML)	A214805	001	May 04, 2021	Mar	CPOT
AP			200MEQ/100ML (2MEQ/ML)	A214805	003	May 04, 2021	Mar	CMS1
AP			400MEQ/100ML (4MEQ/ML)	A214805	002	Aug 25, 2023	Apr	CDFR

SODIUM BENZOATE; SODIUM PHENYLACETATESOLUTION; INTRAVENOUS  
AMMONUL

+	@	BAUSCH	10%;10% (5GM/50ML;5GM/50ML)	N020645	001	Feb 17, 2005	Jul	DISC
---	---	--------	-----------------------------	---------	-----	--------------	-----	------

SODIUM PHENYLACETATE AND SODIUM BENZOATE

AP	!	AILEX PHARMS LLC	10%;10% (5GM/50ML;5GM/50ML)	A207096	001	Feb 24, 2016	Jul	CHRS
----	---	------------------	-----------------------------	---------	-----	--------------	-----	------

SODIUM BICARBONATEINJECTABLE; INJECTION  
SODIUM BICARBONATE

AP		LONG GROVE PHARMS	1MEQ/ML	A216042	001	Feb 27, 2024	Jun	CAHN
AP		NIVAGEN PHARMS INC	1MEQ/ML	A216042	001	Feb 27, 2024	Feb	NEWA
AP		STERISCIENCE	1MEQ/ML	A217594	001	Jun 28, 2023	Apr	CMFD
AP	@		1MEQ/ML	A217594	001	Jun 28, 2023	Jan	DISC

SODIUM CHLORIDESOLUTION; INJECTION  
SODIUM CHLORIDE 0.9%

@	HIKMA	90MG/10ML (9MG/ML)	A201850	001	Jan 20, 2012	Mar	DISC
---	-------	--------------------	---------	-----	--------------	-----	------

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AT		FRESENIUS KABI USA	900MG/100ML	A213688	001	Jun 24, 2024	Jun	NEWA
----	--	--------------------	-------------	---------	-----	--------------	-----	------

SODIUM FLUORIDE F-18INJECTABLE;INTRAVENOUS  
SODIUM FLUORIDE F-18

AP ! PETNET 10-200mCi/ML A203890 001 Sep 28, 2015 Jan CHRS

SODIUM PHENYL BUTYRATEPOWDER;ORAL  
SODIUM PHENYL BUTYRATE

AB ENDO OPERATIONS 3GM/TEASPOONFUL A203918 001 Jun 15, 2016 Apr CAHN

TABLET;ORAL  
SODIUM PHENYL BUTYRATE

AB ENDO OPERATIONS 500MG A204395 001 Apr 15, 2016 Apr CAHN

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUSINJECTABLE;INJECTION  
SODIUM PHOSPHATES

AP AM REGENT 142MG/ML;276MG/ML A218314 001 Jun 21, 2024 Jun NEWA

SOFPIRONIUM BROMIDEGEL, METERED;TOPICAL  
SOFDRA+! BOTANIX SB EQ 12.45% BASE (EQ 72MG  
BASE/ACTUATION) N217347 001 Jun 18, 2024 Jun NEWASOLIFENACIN SUCCINATETABLET;ORAL  
SOLIFENACIN SUCCINATE

AB MACLEODS PHARMS LTD 5MG A204374 001 Feb 20, 2024 Feb NEWA

AB 10MG A204374 002 Feb 20, 2024 Feb NEWA

SOTALOL HYDROCHLORIDETABLET;ORAL  
SOTALOL HYDROCHLORIDE@ RISING 80MG A075725 001 Dec 19, 2000 Feb CAHN  
@ 120MG A075725 002 Dec 19, 2000 Feb CAHN  
@ 160MG A075725 003 Dec 19, 2000 Feb CAHN  
@ 240MG A075725 004 Dec 19, 2000 Feb CAHNSOTORASIBTABLET;ORAL  
LUMAKRAS

+ AMGEN INC 240MG N214665 003 Jun 26, 2024 Jul NEWA

SOYBEAN OILINJECTABLE;INJECTION  
NUTRILIPID 10%

+ @ B BRAUN 10% N019531 001 May 28, 1993 Jul DISC

SPINOSADSUSPENSION;TOPICAL  
NATROBA

&gt;A&gt; +! CIPHER 0.9% N022408 001 Jan 18, 2011 Aug CAHN

&gt;D&gt; +! PARAPRO LLC 0.9% N022408 001 Jan 18, 2011 Aug CAHN

STERILE WATER FOR INJECTIONLIQUID;N/A  
STERILE WATER FOR INJECTION

AP AM REGENT 100% (5ML) A217341 003 Feb 09, 2024 Feb NEWA

STERILE WATER FOR IRRIGATIONLIQUID;IRRIGATION  
STERILE WATER FOR IRRIGATION

&gt;A&gt; AT FRESENIUS KABI USA 100% A216123 001 Aug 12, 2024 Aug NFTG

SUCCINYLCHOLINE CHLORIDEINJECTABLE;INJECTION  
SUCCINYLCHOLINE CHLORIDE

&gt;A&gt; AP @ ACCORD HLTHCARE 20MG/ML A213705 001 May 20, 2020 May DISC

ADAPTIS 20MG/ML A214308 001 May 22, 2020 Aug CAHN

@ EUGIA PHARMA 20MG/ML A217808 001 Oct 16, 2023 Apr DISC

&gt;D&gt; AP INDOCO 20MG/ML A214308 001 May 22, 2020 Aug CAHN

INJECTABLE; INJECTION

SUCCINYLMCHOLINE CHLORIDE

>D>	AP	NIVAGEN PHARMS INC	20MG/ML	A211625	001	May 19, 2020	Aug CAHN
	AP		20MG/ML	A211625	001	May 19, 2020	Jan CAHN
>A>	AP	UMEDICA	20MG/ML	A211625	001	May 19, 2020	Aug CAHN

SOLUTION; INTRAMUSCULAR, INTRAVENOUS  
SUCCINYLMCHOLINE CHLORIDE

	AP	DR REDDYS	100MG/5ML (20MG/ML)	A218467	001	Jan 17, 2024	Jan NEWA
	AP	+! HIKMA	100MG/5ML (20MG/ML)	N215143	001	Aug 20, 2021	Jan CFTG
	AP	STERISCIENCE	100MG/5ML (20MG/ML)	A217873	001	Jul 09, 2024	Jun NEWA

SUCRALFATE

SUSPENSION; ORAL  
SUCRALFATE

	AB	ABON PHARMS LLC	1GM/10ML	A216726	001	Mar 21, 2024	Mar NEWA
	AB	HIKMA	1GM/10ML	A212769	001	Jul 23, 2024	Jul NEWA
	AB	PD PARTNERS	1GM/10ML	A213549	001	Jan 17, 2024	Jan NEWA
	AB	STRIDES PHARMA	1GM/10ML	A216474	001	May 21, 2024	May NEWA
	AB	VISTAPHARM LLC	1GM/10ML	A211884	001	Mar 15, 2022	Apr CAHN

SUGAMMADEX SODIUM

SOLUTION; INTRAVENOUS  
SUGAMMADEX SODIUM

	@	ZYDUS PHARMS	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214290	001	Oct 04, 2023	Mar DISC
	@		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A214290	002	Oct 04, 2023	Mar DISC

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC  
SULFACETAMIDE SODIUM

>D>	@	AKORN	10%	A040215	001	May 25, 1999	Aug CAHN
>A>	@	SAPTALIS PHARMS	10%	A040215	001	May 25, 1999	Aug CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL  
SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB	!	AUROBINDO PHARMA	200MG/5ML; 40MG/5ML	A091348	001	Jun 08, 2010	Mar CHRS
	@	HIKMA	200MG/5ML; 40MG/5ML	A074650	001	Dec 29, 1997	Mar DISC

SULFANILAMIDE

CREAM; VAGINAL  
AVC  
+ @ NORVIUM BIOSCIENCE 15%  
SUPPOSITORY; VAGINAL  
AVC  
@ NORVIUM BIOSCIENCE 1.05GM

	N006530	003	Jan 27, 1987	Jun CAHN
	N006530	004	Jan 27, 1987	Jun CAHN

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS  
SUMATRIPTAN SUCCINATE

AP		CAPLIN	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A213998	001	Jul 13, 2021	Jun CAHN
	@	ENDO OPERATIONS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077332	001	Oct 09, 2009	May CAHN
	@		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077871	001	Jul 09, 2009	May CAHN
AP	!	EUGIA PHARMA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A202758	001	Apr 23, 2013	Jan CHRS
	@	PAR PHARM	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077332	001	Oct 09, 2009	Feb DISC
	+ @	ENDO OPERATIONS	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N022239	002	Nov 26, 2013	May CAHN
	+ @		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022239	001	Jul 15, 2009	May CAHN

SUNITINIB MALATE

CAPSULE; ORAL  
SUNITINIB MALATE

AB		EUGIA PHARMA	EQ 12.5MG BASE	A218615	001	Mar 14, 2024	Mar NEWA
AB			EQ 25MG BASE	A218615	002	Mar 14, 2024	Mar NEWA
AB			EQ 37.5MG BASE	A218615	003	Mar 14, 2024	Mar NEWA
AB			EQ 50MG BASE	A218615	004	Mar 14, 2024	Mar NEWA
>D>	AB	NOVUGEN	EQ 12.5MG BASE	A218012	001	Aug 21, 2023	Aug CAHN

CAPSULE;ORAL

## SUNITINIB MALATE

AB		EQ 12.5MG BASE	A218012	001	Aug 21, 2023	May	CMFD
	@	EQ 12.5MG BASE	A218012	001	Aug 21, 2023	Feb	DISC
>D>	AB	EQ 25MG BASE	A218012	002	Aug 21, 2023	Aug	CAHN
	AB	EQ 25MG BASE	A218012	002	Aug 21, 2023	May	CMFD
	@	EQ 25MG BASE	A218012	002	Aug 21, 2023	Feb	DISC
>D>	AB	EQ 37.5MG BASE	A218012	003	Aug 21, 2023	Aug	CAHN
	AB	EQ 37.5MG BASE	A218012	003	Aug 21, 2023	May	CMFD
	@	EQ 37.5MG BASE	A218012	003	Aug 21, 2023	Feb	DISC
>D>	AB	EQ 50MG BASE	A218012	004	Aug 21, 2023	Aug	CAHN
	AB	EQ 50MG BASE	A218012	004	Aug 21, 2023	May	CMFD
	@	EQ 50MG BASE	A218012	004	Aug 21, 2023	Feb	DISC
>A>	AB	EQ 12.5MG BASE	A218012	001	Aug 21, 2023	Aug	CAHN
>A>	AB	EQ 25MG BASE	A218012	002	Aug 21, 2023	Aug	CAHN
>A>	AB	EQ 37.5MG BASE	A218012	003	Aug 21, 2023	Aug	CAHN
>A>	AB	EQ 50MG BASE	A218012	004	Aug 21, 2023	Aug	CAHN

TACROLIMUS

## CAPSULE, EXTENDED RELEASE;ORAL

## ASTAGRAF XL

AB	+	ASTELLAS	EQ 0.5MG BASE	N204096	001	Jul 19, 2013	Jan	CFTG
AB	+		EQ 1MG BASE	N204096	002	Jul 19, 2013	Jan	CFTG
AB	+	!	EQ 5MG BASE	N204096	003	Jul 19, 2013	Jan	CFTG
		TACROLIMUS						
AB		CHENGDU	EQ 0.5MG BASE	A215012	001	Jan 25, 2024	Jan	NFTG
AB			EQ 1MG BASE	A215012	002	Jan 25, 2024	Jan	NFTG
AB			EQ 5MG BASE	A215012	003	Jan 25, 2024	Jan	NFTG

TADALAFIL

## TABLET;ORAL

## TADALAFIL

>A>	AB1	FOURRTS LABS	2.5MG	A217606	001	Aug 13, 2024	Aug	NEWA
>A>	AB1		5MG	A217606	002	Aug 13, 2024	Aug	NEWA
>A>	AB1		10MG	A217606	003	Aug 13, 2024	Aug	NEWA
>A>	AB1		20MG	A217606	004	Aug 13, 2024	Aug	NEWA
	AB1	HANGZHOU BINJIANG	2.5MG	A208824	001	Oct 27, 2020	Mar	CAHN
	AB1		5MG	A208824	002	Oct 27, 2020	Mar	CAHN
	AB1		10MG	A208824	003	Oct 27, 2020	Mar	CAHN
	AB1		20MG	A208824	004	Oct 27, 2020	Mar	CAHN
	AB1	SHANDONG	20MG	A216279	001	Mar 04, 2024	Feb	NEWA
	BX	UMEDICA	2.5MG	A211298	001	Oct 23, 2020	Jun	CTEC
	BX		5MG	A211298	002	Oct 23, 2020	Jun	CTEC
	BX		10MG	A211298	003	Oct 23, 2020	Jun	CTEC
	BX		20MG	A211298	004	Oct 23, 2020	Jun	CTEC
>D>		TABLET, CHEWABLE;ORAL						
>D>		CHEWTADZY						
>D>	+	B BETTER	5MG	N218527	001	Jun 28, 2024	Aug	DISC
>A>	+	@	5MG	N218527	001	Jun 28, 2024	Aug	DISC
	+		5MG	N218527	001	Jun 28, 2024	Jun	NEWA
>D>	+		10MG	N218527	002	Jun 28, 2024	Aug	DISC
>A>	+	@	10MG	N218527	002	Jun 28, 2024	Aug	DISC
	+		10MG	N218527	002	Jun 28, 2024	Jun	NEWA
>D>	+	!	20MG	N218527	003	Jun 28, 2024	Aug	DISC
>A>	+	@	20MG	N218527	003	Jun 28, 2024	Aug	DISC
	+	!	20MG	N218527	003	Jun 28, 2024	Jun	NEWA

TAFLUPROST

## SOLUTION/DROPS;OPHTHALMIC

## TAFLUPROST

	@	INGENUS PHARMS LLC	0.0015%	A218002	001	Apr 05, 2024	May	DISC
AT			0.0015%	A218002	001	Apr 05, 2024	Mar	NEWA

TALAZOPARIB TOSYLATE

## CAPSULE;ORAL

## TALZENNA

+	PFIZER	EQ 0.1MG BASE	N217439	001	Mar 07, 2024	Mar	NEWA
+		EQ 0.25MG BASE	N217439	002	Mar 07, 2024	Mar	NEWA
+		EQ 0.35MG BASE	N217439	003	Mar 07, 2024	Mar	NEWA
+		EQ 0.5MG BASE	N217439	004	Mar 07, 2024	Mar	NEWA
+		EQ 0.75MG BASE	N217439	005	Mar 07, 2024	Mar	NEWA
+	!	EQ 1MG BASE	N217439	006	Mar 07, 2024	Mar	NEWA



TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

TAMSULOSIN HYDROCHLORIDE

@ ENDO OPERATIONS	0.4MG	A202010	001	Jan 04, 2013	May	CAHN
@ NORVIUM BIOSCIENCE	0.4MG	A090408	001	Apr 27, 2010	Jul	CAHN

TAVABOROLE

SOLUTION;TOPICAL

KERYDIN

+ @ ANACOR PHARMS INC	5%	N204427	001	Jul 07, 2014	Mar	DISC
-----------------------	----	---------	-----	--------------	-----	------

TAVABOROLE

AB ! ENCUBE	5%	A211297	001	Oct 13, 2020	Mar	CHRS
-------------	----	---------	-----	--------------	-----	------

TAZAROTENE

CREAM;TOPICAL

TAZAROTENE

AB PADAGIS ISRAEL	0.05%	A217075	001	Jul 15, 2024	Jul	NFTG
-------------------	-------	---------	-----	--------------	-----	------

TAZORAC

AB +! ALLERGAN	0.05%	N021184	001	Sep 29, 2000	Jul	CFTG
----------------	-------	---------	-----	--------------	-----	------

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE;INJECTION

MYOVIEW

+! MEDI-PHYSICS	N/A	N020372	001	Feb 09, 1996	Jun	CAHN
-----------------	-----	---------	-----	--------------	-----	------

MYOVIEW 30ML

+! MEDI-PHYSICS	N/A	N020372	002	Jul 07, 2005	Jun	CAHN
-----------------	-----	---------	-----	--------------	-----	------

TEDUGLUTIDE

POWDER;SUBCUTANEOUS

GATTEX KIT

+! TAKEDA PHARMS USA	5MG/VIAL	N203441	001	Dec 21, 2012	Mar	CAIN
----------------------	----------	---------	-----	--------------	-----	------

TEMAZEPAM

CAPSULE;ORAL

TEMAZEPAM

AB CHARTWELL RX	15MG	A071427	001	Jan 12, 1988	Jan	CAHN
-----------------	------	---------	-----	--------------	-----	------

AB	30MG	A071428	001	Jan 12, 1988	Jan	CAHN
----	------	---------	-----	--------------	-----	------

TEMOZOLOMIDE

CAPSULE;ORAL

TEMOZOLOMIDE

@ EXTROVIS	5MG	A205227	001	Jun 29, 2016	Jun	CAHN
------------	-----	---------	-----	--------------	-----	------

@	20MG	A205227	002	Jun 29, 2016	Jun	CAHN
---	------	---------	-----	--------------	-----	------

@	100MG	A205227	003	Jun 29, 2016	Jun	CAHN
---	-------	---------	-----	--------------	-----	------

@	140MG	A205227	004	Jun 29, 2016	Jun	CAHN
---	-------	---------	-----	--------------	-----	------

@	180MG	A205227	005	Jun 29, 2016	Jun	CAHN
---	-------	---------	-----	--------------	-----	------

@	250MG	A205227	006	Jun 29, 2016	Jun	CAHN
---	-------	---------	-----	--------------	-----	------

>A> AB HETERO LABS LTD V	5MG	A210030	001	Aug 23, 2024	Aug	NEWA
--------------------------	-----	---------	-----	--------------	-----	------

>A> AB	20MG	A210030	002	Aug 23, 2024	Aug	NEWA
--------	------	---------	-----	--------------	-----	------

>A> AB	100MG	A210030	003	Aug 23, 2024	Aug	NEWA
--------	-------	---------	-----	--------------	-----	------

>A> AB	140MG	A210030	004	Aug 23, 2024	Aug	NEWA
--------	-------	---------	-----	--------------	-----	------

>A> AB	180MG	A210030	005	Aug 23, 2024	Aug	NEWA
--------	-------	---------	-----	--------------	-----	------

>A> AB	250MG	A210030	006	Aug 23, 2024	Aug	NEWA
--------	-------	---------	-----	--------------	-----	------

TENAPANOR HYDROCHLORIDE

TABLET;ORAL

XPHOZAH

+ @ ARDELYX INC	EQ 10MG BASE	N213931	001	Oct 17, 2023	Apr	DISC
-----------------	--------------	---------	-----	--------------	-----	------

TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

TENOFOVIR ALAFENAMIDE FUMARATE

@ APOTEX	EQ 25MG BASE	A213867	001	Mar 21, 2024	May	DISC
----------	--------------	---------	-----	--------------	-----	------

AB	EQ 25MG BASE	A213867	001	Mar 21, 2024	Mar	NEWA
----	--------------	---------	-----	--------------	-----	------

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

TERAZOSIN HYDROCHLORIDE

AB	BIONPHARMA	EQ 1MG BASE	A 075667	001	Jul 28, 2000	Jan	CMFD
AB		EQ 2MG BASE	A 075667	002	Jul 28, 2000	Jan	CMFD
AB		EQ 5MG BASE	A 075667	003	Jul 28, 2000	Jan	CMFD
AB		EQ 10MG BASE	A 075667	004	Jul 28, 2000	Jan	CMFD

&gt;D&gt; SOLUTION;ORAL

&gt;D&gt; TEZRULY

&gt;D&gt; +! NOVITIUM PHARMA EQ 1MG BASE/ML N218139 001 Jul 29, 2024 Aug DISC

&gt;A&gt; + @ EQ 1MG BASE/ML N218139 001 Jul 29, 2024 Aug DISC

+! EQ 1MG BASE/ML N218139 001 Jul 29, 2024 Jul NEWA

TERBINAFINE

GEL;TOPICAL

LAMISIL

@ KARO HLTHCARE

1%

N 020846 001 Apr 29, 1998 Feb CAHN

TERBINAFINE HYDROCHLORIDE

SOLUTION;TOPICAL

LAMISIL

@ KARO HLTHCARE

1%

N 020749 001 Oct 17, 1997 Feb CAHN

TABLET;ORAL

TERBINAFINE HYDROCHLORIDE

@ CIPLA

EQ 250MG BASE

A 077137 001 Jul 02, 2007 Mar DISC

TERBUTALINE SULFATE

INJECTABLE;INJECTION

TERBUTALINE SULFATE

AP AREVA PHARMS

1MG/ML

A 200122 001 Nov 08, 2013 Apr CAHN

TERIFLUNOMIDE

TABLET;ORAL

TERIFLUNOMIDE

@ AMNEAL PHARMS CO

7MG

A 209613 001 Sep 28, 2018 May DISC

@

14MG

A 209613 002 Sep 28, 2018 May DISC

AB TORRENT

7MG

A 209697 001 Apr 04, 2024 Mar NEWA

AB

14MG

A 209697 002 Apr 04, 2024 Mar NEWA

TERIPARATIDE

SOLUTION;SUBCUTANEOUS

TERIPARATIDE

+! ALMAJECT 0.6MG/2.4ML (0.25MG/ML)

N 218771 001 Jun 04, 2024 Jun NEWA

TESTOSTERONE

GEL;TRANSDERMAL

TESTIM

AB2 +! ENDO OPERATIONS 50MG/5GM PACKET

N 021454 001 Oct 31, 2002 Apr CAHN

GEL, METERED;TRANSDERMAL

FORTESTA

+ @ ENDO OPERATIONS 10MG/0.5GM ACTUATION

N 021463 001 Dec 29, 2010 Apr CAHN

+ @ ENDO PHARMS 10MG/0.5GM ACTUATION

N 021463 001 Dec 29, 2010 Jan DISC

TESTOSTERONE

! ACTAVIS LABS UT INC 10MG/0.5GM ACTUATION

A 204571 001 Aug 05, 2015 Jan CTEC

AB ! 10MG/0.5GM ACTUATION

A 204571 001 Aug 05, 2015 Jan CHRS

AB1 ! 12.5MG/1.25GM ACTUATION

A 076737 003 Mar 09, 2015 Apr CTEC

AB1 ENCUBE 12.5MG/1.25GM ACTUATION

A 212984 002 Feb 09, 2024 Apr NEWA

PELLET;IMPLANTATION

TESTOPEL

! ENDO OPERATIONS 75MG

A 080911 001 Apr CAHN

SOLUTION, METERED;TRANSDERMAL

TESTOSTERONE

AT ENCUBE 30MG/1.5ML ACTUATION

A 212301 001 Jan 11, 2021 Apr CAHN

AT FEMPHARM 30MG/1.5ML ACTUATION

A 212301 001 Jan 11, 2021 Mar CAHN

TESTOSTERONE CYPIONATE

SOLUTION; INTRAMUSCULAR  
 TESTOSTERONE CYPIONATE  
 + @ AZURITY

200MG/ML (200MG/ML)

N216318 001 Jun 02, 2022 Jul CAHN

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION  
 TESTOSTERONE ENANTHATE

AO EUGIA PHARMA  
 AO

200MG/ML  
 200MG/ML

A212659 001 Feb 28, 2024 Feb NEWA  
 A212659 001 Feb 28, 2024 Feb NEWA

TESTOSTERONE UNDECANOATE

CAPSULE; ORAL  
 TLANDO  
 +! VERITY  
 INJECTABLE; INTRAMUSCULAR  
 AVEED  
 +! ENDO OPERATIONS

112.5MG  
 750MG/3ML (250MG/ML)

N208088 001 Mar 28, 2022 Jan CAHN  
 N022219 001 Mar 05, 2014 Apr CAHN

TETRABENAZINE

TABLET; ORAL  
 TETRABENAZINE

AB SLATE RUN PHARMA  
 AB

12.5MG  
 25MG

A213316 001 Jan 22, 2020 Feb CAHN  
 A213316 002 Jan 22, 2020 Feb CAHN

TETRACYCLINE HYDROCHLORIDE

SUSPENSION; ORAL  
 SUMYCIN  
 @ ENDO OPERATIONS  
 TABLET; ORAL  
 SUMYCIN  
 STRIDES PHARMA  
 !

125MG/5ML  
 250MG  
 500MG

A060400 001 May CAHN  
 A061147 001 Jan CMFD  
 A061147 004 Jan CMFD

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL  
 THEO-24  
 ENDO OPERATIONS  
 +  
 !  
 TABLET, EXTENDED RELEASE; ORAL  
 THEOPHYLLINE

100MG  
 200MG  
 300MG  
 400MG

A087943 002 Aug 22, 1983 Apr CAHN  
 A087943 001 Aug 22, 1983 Apr CAHN  
 A087943 003 Aug 22, 1983 Apr CAHN  
 A087943 004 Feb 28, 1992 Apr CAHN

>D> AB  
 >D> AB  
 >A> AB  
 >A> AB  
 >A> AB  
 >A> AB  
 AB  
 AB  
 AB  
 AB

LEADING  
 @ RHODES PHARMS  
 STRIDES PHARMA  
 VELZEN PHARMA PVT  
 ZYDUS LIFESCIENCES  
 ZYDUS PHARMS

300MG  
 450MG  
 600MG  
 300MG  
 450MG  
 300MG  
 450MG  
 300MG  
 450MG

A214950 001 Jan 30, 2023 Aug CAHN  
 A214950 002 Jan 30, 2023 Aug CAHN  
 A040086 001 Apr 15, 1996 Jul DISC  
 A215312 001 Sep 05, 2024 Aug NEWA  
 A215312 002 Sep 05, 2024 Aug NEWA  
 A214950 001 Jan 30, 2023 Aug CAHN  
 A214950 002 Jan 30, 2023 Aug CAHN  
 A218063 001 May 21, 2024 May CAHN  
 A218063 002 May 21, 2024 May CAHN  
 A218063 001 May 21, 2024 May NEWA  
 A218063 002 May 21, 2024 May NEWA

THIOTEPA

POWDER; INTRACAVITARY, INTRAVENOUS, INTRAVESICAL  
 THIOTEPA  
 BELOTECA  
 MEITHEAL

>A> AP  
 AP  
 AP

15MG/VIAL  
 15MG/VIAL  
 100MG/VIAL

A217559 001 Aug 20, 2024 Aug NEWA  
 A216037 001 Dec 26, 2023 Jun CAHN  
 A216037 002 Dec 26, 2023 Jun CAHN

SOLUTION; INTRAVENOUS  
 TEPYLUTE  
 +! SHORLA

15MG/1.5ML (10MG/ML)

N216984 001 Jun 25, 2024 Jun NEWA

TICAGRELORTABLET; ORAL  
TICAGRELOR

>A>	AB	PRINSTON INC	90MG	A208599	001	Aug 16, 2024	Aug NEWA
-----	----	--------------	------	---------	-----	--------------	----------

TIGECYCLINEPOWDER; INTRAVENOUS  
TIGECYCLINE

		@ ACCORD HLTHCARE INC	50MG/VIAL	N208744	001	Jan 18, 2018	May DISC
--	--	-----------------------	-----------	---------	-----	--------------	----------

TIMOLOL MALEATESOLUTION, GEL FORMING/DROPS; OPHTHALMIC  
TIMOLOL MALEATE

		@ AMNEAL	EQ 0.25% BASE	A216343	001	May 23, 2024	Jun DISC
AB			EQ 0.25% BASE	A216343	001	May 23, 2024	May NEWA
		@	EQ 0.5% BASE	A216343	002	May 23, 2024	Jun DISC
AB			EQ 0.5% BASE	A216343	002	May 23, 2024	May NEWA

SOLUTION/DROPS; OPHTHALMIC  
TIMOLOL MALEATE

AT1		CAPLIN	EQ 0.5% BASE	A218460	001	Aug 07, 2024	Jul NEWA
AT1		SOMERSET	EQ 0.25% BASE	A217764	002	Jul 03, 2024	Jun NEWA
AT1			EQ 0.5% BASE	A217764	001	Jul 03, 2024	Jun NEWA
AT2		SOMERSET THERAPS LLC	EQ 0.5% BASE	A216653	001	Jul 03, 2024	Jun NEWA

TIOPRONINTABLET, DELAYED RELEASE; ORAL  
THIOLA EC

AB	+	MISSION PHARMACAL	100MG	N211843	001	Jun 28, 2019	Jan CFTG
AB		ENDO OPERATIONS	100MG	A217219	001	Feb 24, 2023	Jun CMFD
AB			300MG	A217219	002	Feb 24, 2023	Jun CMFD
AB		TEVA PHARMS INC	100MG	A216456	001	Jul 22, 2024	Jul NEWA
AB			300MG	A216456	002	Jul 22, 2024	Jul NEWA
AB		TORRENT	100MG	A216990	001	Jan 30, 2024	Jan NFTG
AB			300MG	A216990	002	Jan 30, 2024	Jan NEWA

TIRZEPATIDESOLUTION; SUBCUTANEOUS  
MOUNJARO

+	!	ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)	N215866	007	Jul 28, 2023	Jan NEWA
+	!		5MG/0.5ML (5MG/0.5ML)	N215866	008	Jul 28, 2023	Jan NEWA
+	!		7.5MG/0.5ML (7.5MG/0.5ML)	N215866	009	Jul 28, 2023	Jan NEWA
+	!		10MG/0.5ML (10MG/0.5ML)	N215866	010	Jul 28, 2023	Jan NEWA
+	!		12.5MG/0.5ML (12.5MG/0.5ML)	N215866	011	Jul 28, 2023	Jan NEWA
+	!		15MG/0.5ML (15MG/0.5ML)	N215866	012	Jul 28, 2023	Jan NEWA

MOUNJARO (AUTOINJECTOR)

+	!	ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)	N215866	001	May 13, 2022	Jan CTNA
+	!		5MG/0.5ML (5MG/0.5ML)	N215866	002	May 13, 2022	Jan CTNA
+	!		7.5MG/0.5ML (7.5MG/0.5ML)	N215866	003	May 13, 2022	Jan CTNA
+	!		10MG/0.5ML (10MG/0.5ML)	N215866	004	May 13, 2022	Jan CTNA
+	!		12.5MG/0.5ML (12.5MG/0.5ML)	N215866	005	May 13, 2022	Jan CTNA
+	!		15MG/0.5ML (15MG/0.5ML)	N215866	006	May 13, 2022	Jan CTNA

ZEPBOUND

+	!	ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)	N217806	007	Mar 28, 2024	Mar NEWA
+	!		5MG/0.5ML (5MG/0.5ML)	N217806	008	Mar 28, 2024	Mar NEWA
+	!		7.5MG/0.5ML (7.5MG/0.5ML)	N217806	009	Mar 28, 2024	Mar NEWA
+	!		10MG/0.5ML (10MG/0.5ML)	N217806	010	Mar 28, 2024	Mar NEWA
+	!		12.5MG/0.5ML (12.5MG/0.5ML)	N217806	011	Mar 28, 2024	Mar NEWA
+	!		15MG/0.5ML (15MG/0.5ML)	N217806	012	Mar 28, 2024	Mar NEWA

ZEPBOUND (AUTOINJECTOR)

+	!	ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)	N217806	001	Nov 08, 2023	Mar CTNA
+	!		5MG/0.5ML (5MG/0.5ML)	N217806	002	Nov 08, 2023	Mar CTNA
+	!		7.5MG/0.5ML (7.5MG/0.5ML)	N217806	003	Nov 08, 2023	Mar CTNA
+	!		10MG/0.5ML (10MG/0.5ML)	N217806	004	Nov 08, 2023	Mar CTNA
+	!		12.5MG/0.5ML (12.5MG/0.5ML)	N217806	005	Nov 08, 2023	Mar CTNA
+	!		15MG/0.5ML (15MG/0.5ML)	N217806	006	Nov 08, 2023	Mar CTNA

TIZANIDINE HYDROCHLORIDE

## CAPSULE;ORAL

## TIZANIDINE HYDROCHLORIDE

AB	APPCO	EQ 4MG BASE	A213365	001	May 13, 2024	May	NEWA
AB		EQ 6MG BASE	A213365	002	May 13, 2024	May	NEWA
	@ ENDO OPERATIONS	EQ 2MG BASE	A207199	001	Mar 14, 2017	May	CAHN
	@	EQ 4MG BASE	A207199	002	Mar 14, 2017	May	CAHN
	@	EQ 6MG BASE	A207199	003	Mar 14, 2017	May	CAHN

## TABLET;ORAL

## TIZANIDINE HYDROCHLORIDE

	@ ENDO OPERATIONS	EQ 2MG BASE	A207170	001	Jan 26, 2017	May	CAHN
	@	EQ 4MG BASE	A207170	002	Jan 26, 2017	May	CAHN
AB	GRAVITI PHARMS	EQ 4MG BASE	A218920	002	Aug 07, 2024	Jul	NEWA
AB		EQ 2MG BASE	A218920	001	Aug 07, 2024	Jul	NEWA

TOBRAMYCIN

## SOLUTION/DROPS;OPHTHALMIC

## TOBRAMYCIN

AT	! SOMERSET THERAPS LLC	0.3%	A207444	001	Jun 28, 2017	Apr	CHRS
	TOBREX						
	+ @ NOVARTIS	0.3%	N050541	001		Apr	DISC

TOFACITINIB CITRATE

## SOLUTION;ORAL

## TOFACITINIB CITRATE

AA	HIKMA	EQ 1MG BASE/ML	A216878	001	Sep 25, 2023	Apr	CAHN
----	-------	----------------	---------	-----	--------------	-----	------

## TABLET, EXTENDED RELEASE;ORAL

## TOFACITINIB

	@ AUROBINDO PHARMA LTD	EQ 11MG BASE	A218462	001	Jun 03, 2024	Jun	DISC
AB		EQ 11MG BASE	A218462	001	Jun 03, 2024	May	NEWA
	XELJANZ XR						
	+ PFIZER	EQ 11MG BASE	N208246	001	Feb 23, 2016	Jun	CTEC
AB	+	EQ 11MG BASE	N208246	001	Feb 23, 2016	May	CTEC

TOLAZAMIDE

## TABLET;ORAL

## TOLAZAMIDE

>D>	@ MYLAN PHARMS INC	250MG	A070259	001	Jan 02, 1986	Aug	CAHN
>D>	@	500MG	A070259	003	Mar 17, 1986	Aug	CAHN
>A>	@ NATCO	250MG	A070259	001	Jan 02, 1986	Aug	CAHN
>A>	@	500MG	A070259	003	Mar 17, 1986	Aug	CAHN

TOLCAPONE

## TABLET;ORAL

## TOLCAPONE

	@ ENDO OPERATIONS	100MG	A204584	001	Mar 26, 2015	May	CAHN
	@ PAR PHARM INC	100MG	A204584	001	Mar 26, 2015	Mar	DISC

TOLMETIN SODIUM

## CAPSULE;ORAL

## TOLMETIN SODIUM

>A>	@ CHARTWELL RX	EQ 400MG BASE	A073462	001	Apr 30, 1992	Aug	CAHN
>D>	@ FOSUN PHARMA	EQ 400MG BASE	A073462	001	Apr 30, 1992	Aug	CAHN

## TABLET;ORAL

## TOLMETIN SODIUM

>A>	@ CHARTWELL RX	EQ 200MG BASE	A073588	001	Jul 31, 1992	Aug	CAHN
>A>	@	EQ 600MG BASE	A074002	001	Sep 27, 1993	Aug	CAHN
>D>	@ FOSUN PHARMA	EQ 200MG BASE	A073588	001	Jul 31, 1992	Aug	CAHN
>D>	@	EQ 600MG BASE	A074002	001	Sep 27, 1993	Aug	CAHN

TOLTERODINE TARTRATE

## CAPSULE, EXTENDED RELEASE;ORAL

## TOLTERODINE TARTRATE

>A>	AB UNICHEM	2MG	A216917	001	Aug 27, 2024	Aug	NEWA
>A>	AB	4MG	A216917	002	Aug 27, 2024	Aug	NEWA

TOPIRAMATE

## CAPSULE;ORAL

## TOPIRAMATE

AB	ALKEM LABS LTD	15MG	A218482	001	Jun 13, 2024	Jun	NEWA
AB		25MG	A218482	002	Jun 13, 2024	Jun	NEWA
>A>	@ CHARTWELL RX	15MG	A079206	001	Oct 14, 2009	Aug	CAHN
>A>	@	25MG	A079206	002	Oct 14, 2009	Aug	CAHN
>D>	@ FOSUN PHARMA	15MG	A079206	001	Oct 14, 2009	Aug	CAHN
>D>	@	25MG	A079206	002	Oct 14, 2009	Aug	CAHN
AB	GLENMARK PHARMS LTD	15MG	A217869	001	Jul 16, 2024	Jul	NEWA
AB		25MG	A217869	002	Jul 16, 2024	Jul	NEWA
AB	STRIDES PHARMA	15MG	A078418	001	Oct 14, 2009	Apr	CMFD
AB		25MG	A078418	002	Oct 14, 2009	Apr	CMFD

## CAPSULE, EXTENDED RELEASE;ORAL

## TOPIRAMATE

	@ AJANTA PHARMA LTD	25MG	A215663	001	Aug 15, 2023	Feb	DISC
	@	50MG	A215663	002	Aug 15, 2023	Feb	DISC
	@	100MG	A215663	003	Aug 15, 2023	Feb	DISC
	@	200MG	A215663	004	Aug 15, 2023	Feb	DISC
AB1	LUPIN LTD	25MG	A215561	001	Jul 11, 2024	Jul	NEWA
AB1		50MG	A215561	002	Jul 11, 2024	Jul	NEWA
AB1		100MG	A215561	003	Jul 11, 2024	Jul	NEWA
AB1		200MG	A215561	004	Jul 11, 2024	Jul	NEWA

## TABLET;ORAL

## TOPIRAMATE

	@ AIPING PHARM INC	25MG	A078499	001	Jan 07, 2010	Feb	CAHN
	@	50MG	A078499	002	Jan 07, 2010	Feb	CAHN
	@	100MG	A078499	003	Jan 07, 2010	Feb	CAHN
	@	200MG	A078499	004	Jan 07, 2010	Feb	CAHN
	@ SUN PHARM INDS LTD	25MG	A076327	001	Mar 27, 2009	Jan	DISC
	@	100MG	A076327	002	Mar 27, 2009	Jan	DISC
	@	200MG	A076327	003	Mar 27, 2009	Jan	DISC

TOPOTECAN HYDROCHLORIDE

## INJECTABLE;INJECTION

## TOPOTECAN HYDROCHLORIDE

	@ RISING	EQ 4MG BASE/VIAL	A091542	001	Aug 28, 2012	Mar	CAHN
--	----------	------------------	---------	-----	--------------	-----	------

TOREMIFENE CITRATE

## TABLET;ORAL

## FARESTON

>D>	AB	+! KYOWA KIRIN	EQ 60MG BASE	N020497	001	May 29, 1997	Aug	DISC
>A>		+ @	EQ 60MG BASE	N020497	001	May 29, 1997	Aug	DISC
		TOREMIFENE CITRATE						
>D>	AB	RISING	EQ 60MG BASE	A208813	001	Dec 04, 2018	Aug	CHRS
>A>	AB	!	EQ 60MG BASE	A208813	001	Dec 04, 2018	Aug	CHRS

TORSEMIDE

## SOLUTION;INTRAVENOUS

## DEMADEX

	+ @ ROCHE	50MG/5ML (10MG/ML)	N020137	002	Aug 23, 1993	Mar	CDFR
	+ @	20MG/2ML (10MG/ML)	N020137	001	Aug 23, 1993	Mar	CDFR
	TOREMIFENE						
	@ AM REGENT	20MG/2ML (10MG/ML)	A090656	001	Apr 21, 2010	Mar	CDFR
	@	50MG/5ML (10MG/ML)	A090656	002	Apr 21, 2010	Mar	CDFR
	@ WEST-WARD PHARMS INT	20MG/2ML (10MG/ML)	A078007	001	Jun 11, 2008	Mar	CDFR
	@	50MG/5ML (10MG/ML)	A078007	002	Jun 11, 2008	Mar	CDFR

## TABLET;ORAL

## DEMADEX

	+ @ NORVIUM BIOSCIENCE	5MG	N020136	001	Aug 23, 1993	Jul	CAHN
	+ @	10MG	N020136	002	Aug 23, 1993	Jul	CAHN
	+ @	20MG	N020136	003	Aug 23, 1993	Jul	CAHN
	+ @	100MG	N020136	004	Aug 23, 1993	Jul	CAHN

TOVORAFENIB

## FOR SUSPENSION;ORAL

## OJEMDA

	+! DAY ONE BIOPHARMS	25MG/ML	N218033	001	Apr 23, 2024	Apr	NEWA
--	----------------------	---------	---------	-----	--------------	-----	------

## TABLET;ORAL

## OJEMDA

	+! DAY ONE BIOPHARMS	100MG	N217700	001	Apr 23, 2024	Apr	NEWA
--	----------------------	-------	---------	-----	--------------	-----	------

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

AB	GRAVITI PHARMS	100MG	A 075968	002	Aug 02, 2024	Jul	NEWA
	RUBICON	75MG	A 208708	004	Apr 04, 2024	Mar	NFTG
AB		100MG	A 208708	002	Jun 28, 2019	Jul	CTEC

TABLET, EXTENDED RELEASE; ORAL

TRAMADOL HYDROCHLORIDE

@	ENDO OPERATIONS	100MG
@		200MG
@		300MG
@	SUN PHARM	100MG
@		300MG

A 200491	001	Jun 27, 2012	Apr	CAHN
A 200491	002	Jun 27, 2012	Apr	CAHN
A 200491	003	Jun 27, 2012	Apr	CAHN
A 091607	001	Dec 30, 2011	May	DISC
A 091607	003	Dec 30, 2011	May	DISC

TRAMETINIB DIMETHYL SULFOXIDE

TABLET; ORAL

MEKINIST

>D>	AB	+	NOVARTIS	EQ 0.5MG	N 204114	001	May 29, 2013	Aug	CTEC
>A>		+		EQ 0.5MG	N 204114	001	May 29, 2013	Aug	CTEC
	AB	+		EQ 0.5MG	N 204114	001	May 29, 2013	Jul	CFTG
>D>	AB	+	!	EQ 2MG	N 204114	003	May 29, 2013	Aug	CTEC
>A>		+	!	EQ 2MG	N 204114	003	May 29, 2013	Aug	CTEC
	AB	+	!	EQ 2MG	N 204114	003	May 29, 2013	Jul	CFTG

TRAMETINIB DIMETHYL SULFOXIDE

>D>	AB		NOVUGEN	EQ 0.5MG	A 219002	001	Aug 06, 2024	Aug	DISC
>A>		@		EQ 0.5MG	A 219002	001	Aug 06, 2024	Aug	DISC
	AB			EQ 0.5MG	A 219002	001	Aug 06, 2024	Jul	NFTG
>D>	AB			EQ 2MG	A 219002	002	Aug 06, 2024	Aug	DISC
>A>		@		EQ 2MG	A 219002	002	Aug 06, 2024	Aug	DISC
	AB			EQ 2MG	A 219002	002	Aug 06, 2024	Jul	NFTG

TRANEXAMIC ACID

SOLUTION; INTRAVENOUS

TRANEXAMIC ACID

>A>	AP		FRESENIUS KABI USA	1GM/100ML (10MG/ML)	A 218242	001	Aug 15, 2024	Aug	NEWA
	AP		GLAND PHARMA LTD	1GM/100ML (10MG/ML)	A 218599	001	Apr 16, 2024	Apr	NEWA
	AP		NEXUS	1GM/100ML (10MG/ML)	A 216877	001	Apr 16, 2024	Apr	NEWA

TABLET; ORAL

TRANEXAMIC ACID

AB	RUBICON	650MG	A 218320	001	Jun 11, 2024	May	NEWA
----	---------	-------	----------	-----	--------------	-----	------

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC

TRAVOPROST

AT	GLAND PHARMA LTD	0.004%	A 218159	001	Jul 12, 2024	Jul	NEWA
AT	LUPIN LTD	0.004%	A 207040	001	May 03, 2024	Apr	NEWA

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

AB	CROSSMEDIKA SA	50MG	A 211116	001	May 20, 2024	May	NEWA	
AB		100MG	A 211116	002	May 20, 2024	May	NEWA	
AB		150MG	A 211116	003	May 20, 2024	May	NEWA	
AB		300MG	A 211116	004	May 20, 2024	May	NEWA	
>A>	AB	GRANULES	50MG	A 218988	001	Aug 08, 2024	Aug	NEWA
>A>	AB		100MG	A 218988	002	Aug 08, 2024	Aug	NEWA
>A>	AB		150MG	A 218988	003	Aug 08, 2024	Aug	NEWA
>A>	AB		300MG	A 218988	004	Aug 08, 2024	Aug	NEWA
>A>	AB	GRAVITI PHARMS	50MG	A 217740	001	Aug 27, 2024	Aug	NEWA
>A>	AB		100MG	A 217740	002	Aug 27, 2024	Aug	NEWA
>A>	AB		150MG	A 217740	003	Aug 27, 2024	Aug	NEWA
>A>	AB		300MG	A 217740	004	Aug 27, 2024	Aug	NEWA

TRETINOIN

CAPSULE; ORAL

TRETINOIN

AB	ENDO OPERATIONS	10MG	A 201687	001	Oct 24, 2012	Apr	CAHN
----	-----------------	------	----------	-----	--------------	-----	------

CREAM; TOPICAL

TRETINOIN

AB	ALEMBIC	0.1%	A 217804	001	Apr 29, 2024	Apr	NEWA
AB	ZYDUS LIFESCIENCES	0.1%	A 218561	001	Apr 25, 2024	Apr	NEWA

	GEL; TOPICAL								
	TRETINOIN								
>D>	@ MYLAN	0.1%	A202026	001	Jul 17, 2013	Aug	CAHN		
>A>	@ NORVIUM BIOSCIENCE	0.1%	A202026	001	Jul 17, 2013	Aug	CAHN		
	<u>TRIAMCINOLONE ACETONIDE</u>								
	OINTMENT; TOPICAL								
	TRIAMCINOLONE ACETONIDE								
	@ AUROBINDO PHARMA LTD	0.1%	A211315	001	Mar 18, 2020	Jan	CAHN		
	@	0.5%	A211315	002	Mar 18, 2020	Jan	CAHN		
	@ COSETTE	0.5%	A208925	001	Oct 06, 2017	Apr	DISC		
	+ @ EXTROVIS	0.025%	N011600	003		Jun	CAHN		
	+ @	0.1%	N011600	001		Jun	CAHN		
	PASTE; DENTAL								
	TRIAMCINOLONE ACETONIDE								
>D>	AT	SAPTALIS PHARMS	0.1%	A206312	001	Aug 11, 2016	Aug	DISC	
>A>		@	0.1%	A206312	001	Aug 11, 2016	Aug	DISC	
	AT		0.1%	A206312	001	Aug 11, 2016	Jun	CAHN	
	<u>TRIAZOLAM</u>								
	TABLET; ORAL								
	TRIAZOLAM								
	@ HIKMA	0.125MG	A074224	001	Jun 01, 1994	Feb	DISC		
	@	0.25MG	A074224	002	Jun 01, 1994	Feb	DISC		
	<u>TRIENTINE HYDROCHLORIDE</u>								
	CAPSULE; ORAL								
	TRIENTINE HYDROCHLORIDE								
AB	ENDO OPERATIONS	250MG	A210096	001	Sep 25, 2019	Apr	CAHN		
	<u>TRIFLUOPERAZINE HYDROCHLORIDE</u>								
	CONCENTRATE; ORAL								
	TRIFLUOPERAZINE HYDROCHLORIDE								
>A>	@ CHARTWELL RX	EQ 10MG BASE/ML	A085787	001	Apr 15, 1982	Aug	CAHN		
>D>	@ FOSUN PHARMA	EQ 10MG BASE/ML	A085787	001	Apr 15, 1982	Aug	CAHN		
	<u>TRIMETHOBENZAMIDE HYDROCHLORIDE</u>								
	CAPSULE; ORAL								
	TRIMETHOBENZAMIDE HYDROCHLORIDE								
>D>	AB	AVET LIFESCIENCES	300MG	A205950	001	Nov 21, 2023	Aug	CHRS	
>A>	AB	!	300MG	A205950	001	Nov 21, 2023	Aug	CHRS	
>D>	AB	!	SUN PHARM INDUSTRIES	300MG	A076570	001	Aug 28, 2003	Aug	DISC
>A>		@	300MG	A076570	001	Aug 28, 2003	Aug	DISC	
	INJECTABLE; INJECTION								
	TIGAN								
	+!	ENDO OPERATIONS	100MG/ML	N017530	001		Apr	CAHN	
	<u>TRIMIPRAMINE MALEATE</u>								
	CAPSULE; ORAL								
	TRIMIPRAMINE MALEATE								
AB	BRECKENRIDGE	EQ 25MG BASE	A208127	001	Apr 15, 2016	Mar	CAHN		
AB	!	EQ 50MG BASE	A208127	002	Apr 15, 2016	Mar	CAHN		
AB		EQ 100MG BASE	A208127	003	Apr 15, 2016	Mar	CAHN		
	<u>TROSPIUM CHLORIDE</u>								
	TABLET; ORAL								
	TROSPIUM CHLORIDE								
AB	MACLEODS PHARMS LTD	20MG	A206472	001	Jun 18, 2024	Jun	NEWA		
AB	ZAMEER PHARMS	20MG	A215781	001	Feb 16, 2022	Feb	CAHN		
	<u>UMECLIDINIUM BROMIDE</u>								
	POWDER; INHALATION								
	INCRUSE ELLIPTA								
	+!	GLAXO GRP ENGLAND	EQ 0.0625MG BASE/INH	N205382	001	Apr 30, 2014	Jan	CPOT	
	<u>UPADACITINIB</u>								
	SOLUTION; ORAL								
	RINVOQ LQ								
	+!	ABBVIE	1MG/ML	N218347	001	Apr 26, 2024	Apr	NEWA	



URSODIOL

CAPSULE;ORAL

URSODIOL

AB	HIBROW HLTHCARE	300MG	A212452	001	Oct 30, 2019	Jul	CAHN
>D>	LGM PHARMA	200MG	A205789	001	May 08, 2020	Aug	CHRS
>A>	!	200MG	A205789	001	May 08, 2020	Aug	CHRS

TABLET;ORAL

URSODIOL

AB	ENDO OPERATIONS	250MG	A202540	001	Feb 14, 2013	Apr	CAHN
AB		500MG	A202540	002	Feb 14, 2013	Apr	CAHN
>A>	EPIC PHARMA LLC	250MG	A214717	001	Aug 14, 2024	Aug	NEWA
>A>	AB	500MG	A214717	002	Aug 14, 2024	Aug	NEWA

VADADUSTAT

TABLET;ORAL

VAFSEO

+	AKEBIA	150MG	N215192	001	Mar 27, 2024	Mar	NEWA
+		300MG	N215192	002	Mar 27, 2024	Mar	NEWA
+	!	450MG	N215192	003	Mar 27, 2024	Mar	NEWA

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

	@ CIPLA	EQ 500MG BASE	A077135	001	May 24, 2010	Apr	DISC
	@	EQ 1GM BASE	A077135	002	May 24, 2010	Apr	DISC
AB	GRAVITI PHARMS	EQ 500MG BASE	A079012	001	May 24, 2010	Jun	CAHN
AB		EQ 1GM BASE	A079012	002	May 24, 2010	Jun	CAHN

VALBENAZINE TOSYLATE

CAPSULE;ORAL

INGREZZA

AB	+ NEUROCRINE	EQ 40MG BASE	N209241	001	Apr 11, 2017	Mar	CFTG
AB	+	EQ 60MG BASE	N209241	003	Apr 23, 2021	Jul	CFTG
AB	+	EQ 80MG BASE	N209241	002	Oct 04, 2017	Mar	CFTG
	INGREZZA SPRINKLE						
+	NEUROCRINE	EQ 40MG BASE	N218390	001	Apr 30, 2024	Apr	NEWA
+		EQ 60MG BASE	N218390	002	Apr 30, 2024	Apr	NEWA
+	!	EQ 80MG BASE	N218390	003	Apr 30, 2024	Apr	NEWA

VALBENAZINE TOSYLATE

AB	LUPIN LTD	EQ 40MG BASE	A216064	001	Apr 05, 2024	Mar	NFTG
AB		EQ 80MG BASE	A216064	002	Apr 05, 2024	Mar	NFTG
AB	ZYDUS	EQ 40MG BASE	A216137	001	Aug 07, 2024	Jul	NEWA
AB		EQ 60MG BASE	A216137	002	Aug 07, 2024	Jul	NFTG
AB		EQ 80MG BASE	A216137	003	Aug 07, 2024	Jul	NEWA

VALGANCICLOVIR HYDROCHLORIDE

TABLET;ORAL

VALGANCICLOVIR HYDROCHLORIDE

AB	GPP	EQ 450MG BASE	A212876	001	Jun 11, 2024	May	NEWA
----	-----	---------------	---------	-----	--------------	-----	------

VALPROIC ACID

CAPSULE;ORAL

VALPROIC ACID

@ EYWA 250MG

A207611 001 Aug 05, 2019 Mar DISC

@ HIBROW HLTHCARE 250MG

A207611 001 Aug 05, 2019 Jul CAHN

@ SUN PHARM INDS LTD 250MG

A091037 001 Feb 22, 2013 May DISC

SYRUP;ORAL

VALPROIC ACID

@ HIKMA 250MG/5ML

A074060 001 Jan 13, 1995 Mar DISC

AA QUAGEN 250MG/5ML

A090517 001 May 28, 2010 Jan CAHN

VALRUBICIN

SOLUTION;INTRAVESICAL

VALSTAR PRESERVATIVE FREE

AO	+	ENDO OPERATIONS	40MG/ML	N020892	001	Sep 25, 1998	Apr	CAHN
----	---	-----------------	---------	---------	-----	--------------	-----	------

VALSARTAN

## TABLET; ORAL

## VALSARTAN

AB	ZENARA	40MG	A218169	001	Aug 05, 2024	Jul	NEWA
AB		80MG	A218169	002	Aug 05, 2024	Jul	NEWA
AB		160MG	A218169	003	Aug 05, 2024	Jul	NEWA
AB		320MG	A218169	004	Aug 05, 2024	Jul	NEWA
AB	ZYDUS LIFESCIENCES	40MG	A218991	001	Jul 22, 2024	Jul	NEWA
AB		80MG	A218991	002	Jul 22, 2024	Jul	NEWA
AB		160MG	A218991	003	Jul 22, 2024	Jul	NEWA
AB		320MG	A218991	004	Jul 22, 2024	Jul	NEWA

VANCOMYCIN HYDROCHLORIDE

## CAPSULE; ORAL

## VANCOMYCIN HYDROCHLORIDE

@ PAI HOLDINGS PHARM

EQ 125MG BASE

A065478 001 Apr 09, 2012 Feb DISC

@

EQ 250MG BASE

A065478 002 Apr 09, 2012 Feb DISC

## INJECTABLE; INJECTION

## VANCOMYCIN HYDROCHLORIDE

&gt;A&gt; @ MEDIMETRIKS PHARMS

EQ 500MG BASE/VIAL

A065401 001 Jun 30, 2008 Aug CAHN

&gt;A&gt;

@

EQ 1GM BASE/VIAL

A065401 002 Jun 30, 2008 Aug CAHN

&gt;D&gt;

@ PHARM ASSOC

EQ 500MG BASE/VIAL

A065401 001 Jun 30, 2008 Aug CAHN

@

EQ 500MG BASE/VIAL

A065401 001 Jun 30, 2008 Feb DISC

&gt;D&gt;

@

EQ 1GM BASE/VIAL

A065401 002 Jun 30, 2008 Aug CAHN

@

EQ 1GM BASE/VIAL

A065401 002 Jun 30, 2008 Feb DISC

@ SANDOZ INC

EQ 5GM BASE/VIAL

A201048 001 Aug 10, 2012 Apr DISC

@

EQ 10GM BASE/VIAL

A201048 002 Aug 10, 2012 Apr DISC

## VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER

+! BAXTER HLTHCARE

EQ 500MG BASE/100ML

N050671 001 Apr 29, 1993 Feb CTNA

+!

EQ 750MG BASE/150ML

N050671 002 Dec 20, 2010 Feb CTNA

+!

EQ 1GM BASE/200ML

N050671 003 Mar 01, 1999 Feb CTNA

## POWDER; INTRAVENOUS

## VANCOMYCIN HYDROCHLORIDE

+! MYLAN LABS LTD

EQ 1.75GM BASE/VIAL

N209481 005 Jun 26, 2024 Jul NEWA

+!

EQ 2GM BASE/VIAL

N209481 006 Jun 26, 2024 Jul NEWA

## SOLUTION; INTRAVENOUS

## VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER

+! BAXTER HLTHCARE

EQ 500MG BASE/100ML (EQ 5MG  
BASE/ML)

N050671 001 Apr 29, 1993 Feb CPOT

+!

EQ 500MG BASE/100ML

N050671 001 Apr 29, 1993 Feb CDFR

+!

EQ 750MG BASE/150ML (EQ 5MG  
BASE/ML)

N050671 002 Dec 20, 2010 Feb CPOT

+!

EQ 750MG BASE/150ML

N050671 002 Dec 20, 2010 Feb CDFR

+!

EQ 1GM BASE/200ML (EQ 5MG BASE/ML)

N050671 003 Mar 01, 1999 Feb CPOT

+!

EQ 1GM BASE/200ML

N050671 003 Mar 01, 1999 Feb CDFR

+!

EQ 1.25GM BASE/250ML (EQ 5MG  
BASE/ML)

N050671 004 Jan 25, 2024 Feb NEWA

+!

EQ 1.5GM BASE/300ML (EQ 5MG  
BASE/ML)

N050671 005 Jan 25, 2024 Feb NEWA

VARENICLINE TARTRATE

## TABLET; ORAL

## VARENICLINE TARTRATE

AB	AJANTA PHARMA LTD	EQ 0.5MG BASE	A213019	001	Mar 19, 2024	Mar	NEWA
AB		EQ 1MG BASE	A213019	002	Mar 19, 2024	Mar	NEWA
AB	AVALANCHE PHARM	EQ 0.5MG BASE	A217283	001	Mar 06, 2024	Feb	NEWA
AB		EQ 1MG BASE	A217283	002	Mar 06, 2024	Feb	NEWA
AB	MYLAN	EQ 0.5MG BASE	A202019	001	Feb 28, 2024	Feb	NEWA
AB		EQ 1MG BASE	A202019	002	Feb 28, 2024	Feb	NEWA
AB	SLATE RUN PHARMA	EQ 0.5MG BASE	A217115	001	Jul 23, 2024	Jul	NEWA
AB		EQ 1MG BASE	A217115	002	Jul 23, 2024	Jul	NEWA

VASOPRESSIN

## SOLUTION; INTRAVENOUS

## VASOPRESSIN

AP	DR REDDYS	20UNITS/ML (20UNITS/ML)	A213988	001	May 08, 2024	Apr	NEWA
AP	GLAND PHARMA LTD	20UNITS/ML (20UNITS/ML)	A216963	001	Feb 09, 2024	Feb	NEWA
		VASOPRESSIN IN SODIUM CHLORIDE 0.9%					
+!	LONG GROVE PHARMS	20UNITS/100ML (0.2UNITS/ML)	N217766	001	Jul 11, 2024	Jul	NEWA
+!		40UNITS/100ML (0.4UNITS/ML)	N217766	002	Jul 11, 2024	Jul	NEWA
+!		50UNITS/50ML (1UNIT/ML)	N217766	003	Jul 11, 2024	Jul	NEWA

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL  
VENLAFAXINE HYDROCHLORIDE

AB	ALEMBIC	EQ 37.5MG BASE	A217767	001	Jun 06, 2024	May	NEWA
AB		EQ 75MG BASE	A217767	002	Jun 06, 2024	May	NEWA
AB		EQ 150MG BASE	A217767	003	Jun 06, 2024	May	NEWA
	@ ANCHEN PHARMS	EQ 37.5MG BASE	A078087	001	Mar 16, 2012	May	CAHN
	@	EQ 75MG BASE	A078087	002	Mar 16, 2012	May	CAHN
	@	EQ 150MG BASE	A078087	003	Mar 16, 2012	May	CAHN
	@ NOSTRUM PHARMS LLC	EQ 37.5MG BASE	A200430	001	Apr 04, 2023	May	DISC
	@	EQ 75MG BASE	A200430	002	Apr 04, 2023	May	DISC
	@	EQ 150MG BASE	A200430	003	Apr 04, 2023	May	DISC

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

	@ AMNEAL PHARMS	EQ 25MG BASE	A079098	001	May 11, 2010	Jun	DISC
	@	EQ 37.5MG BASE	A079098	002	May 11, 2010	Jun	DISC
	@	EQ 50MG BASE	A079098	003	May 11, 2010	Jun	DISC
	@	EQ 75MG BASE	A079098	004	May 11, 2010	Jun	DISC
	@	EQ 100MG BASE	A079098	005	May 11, 2010	Jun	DISC

TABLET, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

>D>	@ SUNNY	EQ 75MG BASE	A214423	001	Jan 04, 2022	Aug	CAHN
>D>	@	EQ 150MG BASE	A214423	002	Jan 04, 2022	Aug	CAHN
>A>	@ SWISS PHARM	EQ 75MG BASE	A214423	001	Jan 04, 2022	Aug	CAHN
>A>	@	EQ 150MG BASE	A214423	002	Jan 04, 2022	Aug	CAHN

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL  
VERELAN

>A>	AB	+ AZURITY	120MG	N019614	001	May 29, 1990	Aug	CAHN
>A>	AB	+	180MG	N019614	003	Jan 09, 1992	Aug	CAHN
>A>	AB	+	240MG	N019614	002	May 29, 1990	Aug	CAHN
>A>		+!	360MG	N019614	004	May 10, 1996	Aug	CAHN
>D>	AB	+ SOCIETAL CDMO	120MG	N019614	001	May 29, 1990	Aug	CAHN
>D>	AB	+	180MG	N019614	003	Jan 09, 1992	Aug	CAHN
>D>	AB	+	240MG	N019614	002	May 29, 1990	Aug	CAHN
>D>		+!	360MG	N019614	004	May 10, 1996	Aug	CAHN

VERELAN PM

>A>		+ AZURITY	100MG	N020943	001	Nov 25, 1998	Aug	CAHN
>A>		+	200MG	N020943	002	Nov 25, 1998	Aug	CAHN
>A>		+!	300MG	N020943	003	Nov 25, 1998	Aug	CAHN
>D>		+ SOCIETAL CDMO	100MG	N020943	001	Nov 25, 1998	Aug	CAHN
>D>		+	200MG	N020943	002	Nov 25, 1998	Aug	CAHN
>D>		+!	300MG	N020943	003	Nov 25, 1998	Aug	CAHN

INJECTABLE;INJECTION

VERAPAMIL HYDROCHLORIDE

	@ FRESENIUS KABI USA	2.5MG/ML	A216471	001	Apr 23, 2024	May	DISC
AP		2.5MG/ML	A216471	001	Apr 23, 2024	Apr	NEWA

SOLUTION;INTRAVENOUS

VERAPAMIL HYDROCHLORIDE

AP	NEPHRON	5MG/2ML (2.5MG/ML)	A213352	002	Sep 16, 2020	Apr	CAHN
AP		10MG/4ML (2.5MG/ML)	A213352	001	Mar 17, 2020	Apr	CAHN

VERTEPORFIN

INJECTABLE;INJECTION

VISUDYNE

	+!	BAUSCH LOMB IRELAND	15MG/VIAL	N021119	001	Apr 12, 2000	Jul	CAHN
--	----	---------------------	-----------	---------	-----	--------------	-----	------

VIGABATRIN

SOLUTION;ORAL

VIGAFYDE

	+!	PYROS PHARMS	100MG/ML	N217684	001	Jun 17, 2024	Jun	NEWA
--	----	--------------	----------	---------	-----	--------------	-----	------

VINORELBINE TARTRATE

INJECTABLE;INJECTION

VINORELBINE TARTRATE

	@ RISING	EQ 10MG BASE/ML	A200148	001	Aug 31, 2012	Mar	CAHN
--	----------	-----------------	---------	-----	--------------	-----	------

VORAPAXAR SULFATE

TABLET; ORAL  
ZONTIVITY

+ @ KEY THERAP	EQ 2.08MG BASE	N204886	001	May 08, 2014	May	DISC
+!	EQ 2.08MG BASE	N204886	001	May 08, 2014	Apr	CAHN

>A> VORASIDENIB

TABLET; ORAL  
VORANIGO

>A> + SERVIER	10MG	N218784	001	Aug 06, 2024	Aug	NEWA
>A> +!	40MG	N218784	002	Aug 06, 2024	Aug	NEWA

VORICONAZOLE

INJECTABLE; INTRAVENOUS  
VORICONAZOLE

AP ASPIRO	200MG/VIAL	A218533	001	Apr 03, 2024	Mar	NEWA
@ NORVIUM BIOSCIENCE	200MG/VIAL	A210849	001	Oct 11, 2022	Jul	CAHN

WARFARIN SODIUM

TABLET; ORAL  
WARFARIN SODIUM

@ BARR	1MG	A040145	001	Mar 26, 1997	Jun	DISC
@	2MG	A040145	002	Mar 26, 1997	Jun	DISC
@	2.5MG	A040145	003	Mar 26, 1997	Jun	DISC
@	3MG	A040145	008	Nov 05, 1998	Jun	DISC
@	4MG	A040145	004	Mar 26, 1997	Jun	DISC
@	5MG	A040145	005	Mar 26, 1997	Jun	DISC
@	6MG	A040145	009	Nov 05, 1998	Jun	DISC
@	7.5MG	A040145	006	Mar 26, 1997	Jun	DISC
@	10MG	A040145	007	Mar 26, 1997	Jun	DISC

ZINC SULFATE

SOLUTION; INTRAVENOUS  
ZINC SULFATE

AP APOTEX	EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A218059	001	Jun 10, 2024	May	NEWA
AP NIVAGEN PHARMS INC	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	A214597	001	Jul 05, 2024	Jun	NEWA
AP	EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A214597	002	Jul 05, 2024	Jun	NEWA
AP	EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	A214597	003	Jul 05, 2024	Jun	NEWA
AP SOMERSET THERAPS LLC	EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A216135	001	Jul 17, 2024	Jul	NEWA
AP	EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	A216135	002	Jul 17, 2024	Jul	NEWA

ZOLEDRONIC ACID

INJECTABLE; INTRAVENOUS  
ZOLEDRONIC ACID

@ HOSPIRA	EQ 4MG BASE/5ML	A090621	001	Mar 19, 2015	May	DISC
-----------	-----------------	---------	-----	--------------	-----	------

ZOLMITRIPTAN

SPRAY; NASAL  
ZOLMITRIPTAN

AB ! PADAGIS ISRAEL	5MG/SPRAY	A212469	002	Sep 30, 2021	Feb	CHRS
---------------------	-----------	---------	-----	--------------	-----	------

TABLET; ORAL  
ZOLMITRIPTAN

@ INVAGEN PHARMS	2.5MG	A204284	001	Apr 09, 2014	Mar	DISC
@	5MG	A204284	002	Apr 09, 2014	Mar	DISC

ZOLPIDEM TARTRATE

TABLET; ORAL  
ZOLPIDEM TARTRATE

@ INVAGEN PHARMS	5MG	A078184	001	Sep 07, 2007	Mar	DISC
@	10MG	A078184	002	Sep 07, 2007	Mar	DISC

TABLET; SUBLINGUAL  
ZOLPIDEM TARTRATE

AB ENDO OPERATIONS	1.75MG	A204229	001	Sep 11, 2017	Apr	CAHN
AB	3.5MG	A204229	002	Sep 11, 2017	Apr	CAHN
AB	5MG	A201509	001	Aug 01, 2016	May	CAHN
AB	10MG	A201509	002	Aug 01, 2016	May	CAHN

TABLET, EXTENDED RELEASE; ORAL  
ZOLPIDEM TARTRATE

@ ENDO OPERATIONS	6.25MG	A078148	002	Apr 14, 2011	May	CAHN
@	12.5MG	A078148	001	Dec 03, 2010	May	CAHN

ACETAMINOPHEN

SUPPOSITORY;RECTAL

ACEPHEN

@ COSETTE	120MG	N018060	001		Mar	DISC
@	325MG	A072344	001	Mar 27, 1992	Mar	DISC
@	650MG	A072237	001	Mar 27, 1992	Mar	DISC

ACETAMINOPHEN; IBUPROFEN

TABLET;ORAL

ACETAMINOPHEN AND IBUPROFEN

	AUROBINDO PHARMA LTD	250MG;125MG	A218359	001	Mar 26, 2024	Apr	CTNA
		250MG;125MG	A218359	001	Mar 26, 2024	Mar	NEWA
>A>	DR REDDYS	250MG;125MG	A218247	001	Aug 23, 2024	Aug	NEWA
	GLENMARK PHARMS LTD	250MG;125MG	A218311	001	Apr 26, 2024	Apr	NEWA

ALCAFTADINE

SOLUTION/DROPS;OPHTHALMIC

ALCAFTADINE

	GLAND PHARMA LTD	0.25%	A209706	001	Mar 01, 2024	Feb	NEWA
--	------------------	-------	---------	-----	--------------	-----	------

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE

	AMNEAL	0.2055MG/SPRAY	A216576	001	Jun 05, 2024	May	NEWA
@	PADAGIS ISRAEL	0.2055MG/SPRAY	A216801	001	May 08, 2024	May	DISC
		0.2055MG/SPRAY	A216801	001	May 08, 2024	Apr	NEWA

AZELASTINE HYDROCHLORIDE ALLERGY

	APOTEX	0.2055MG/SPRAY	A216421	001	May 29, 2024	May	NEWA
	AZELASTINE HYDROCHLORIDE CHILDREN'S ALLERGY						
	APOTEX	0.2055MG/SPRAY	A216421	002	May 29, 2024	May	NEWA

BRIMONIDINE TARTRATE

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE

	DR REDDYS LABS SA	0.025%	A216361	001	Feb 16, 2024	Feb	NFTG
--	-------------------	--------	---------	-----	--------------	-----	------

LUMIFY PRESERVATIVE FREE

+!	BAUSCH AND LOMB INC	0.025%	N218424	001	Apr 19, 2024	Apr	NEWA
----	---------------------	--------	---------	-----	--------------	-----	------

CETIRIZINE HYDROCHLORIDE

SOLUTION;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

	AMNEAL PHARMS	5MG/5ML	A090765	002	Oct 07, 2009	Feb	CDFR
@	APOZEAL PHARMS	5MG/5ML	A090474	002	Mar 30, 2009	Feb	CDFR
	AUROBINDO PHARMA	5MG/5ML	A090750	002	Feb 02, 2010	Feb	CDFR
	BAJAJ	5MG/5ML	A091327	001	Oct 17, 2011	Feb	CDFR
	CHARTWELL MOLECULAR	5MG/5ML	A091130	001	Apr 22, 2011	Feb	CDFR
@	CHARTWELL RX	5MG/5ML	A090378	002	May 09, 2008	Feb	CDFR
@	CYPRESS PHARM	5MG/5ML	A090300	001	Oct 10, 2008	Feb	CDFR
	HETERO LABS LTD III	5MG/5ML	A210622	001	Mar 13, 2019	Feb	CDFR
	PERRIGO R AND D	5MG/5ML	A204226	001	Sep 09, 2013	Feb	CDFR
		5MG/5ML	A090254	002	Apr 09, 2008	Feb	CDFR
@	PHARM ASSOC	5MG/5ML	A090188	002	Apr 22, 2008	Feb	CDFR
	QUAGEN	5MG/5ML	A212266	001	May 16, 2019	Feb	CDFR
@	RANBAXY LABS LTD	5MG/5ML	A090183	002	Apr 24, 2008	Feb	CDFR
	TARO	5MG/5ML	A090182	002	Apr 22, 2008	Feb	CDFR
		5MG/5ML	A201546	001	May 20, 2011	Feb	CDFR
@	TRIS PHARMA INC	5MG/5ML	A090572	001	Nov 16, 2012	Feb	CDFR

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

	AMNEAL PHARMS	5MG/5ML	A090765	001	Oct 07, 2009	Feb	CDFR
@	APOZEAL PHARMS	5MG/5ML	A090474	001	Mar 30, 2009	Feb	CDFR
	AUROBINDO PHARMA	5MG/5ML	A090750	001	Feb 02, 2010	Feb	CDFR
	BAJAJ	5MG/5ML	A091327	002	Oct 17, 2011	Feb	CDFR
	CHARTWELL MOLECULAR	5MG/5ML	A091130	002	Apr 22, 2011	Feb	CDFR
@	CHARTWELL RX	5MG/5ML	A090378	001	May 09, 2008	Feb	CDFR
@	CYPRESS PHARM	5MG/5ML	A090300	002	Oct 10, 2008	Feb	CDFR
	PERRIGO R AND D	5MG/5ML	A090254	001	Apr 09, 2008	Feb	CDFR
@	PHARM ASSOC	5MG/5ML	A090188	001	Apr 22, 2008	Feb	CDFR
@	RANBAXY LABS LTD	5MG/5ML	A090183	001	Apr 24, 2008	Feb	CDFR

SOLUTION;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF						
TARO	5MG/5ML	A090182	001	Apr 22, 2008	Feb	CDFR
	5MG/5ML	A201546	002	May 20, 2011	Feb	CDFR
@ TRIS PHARMA INC	5MG/5ML	A090572	002	Nov 16, 2012	Feb	CDFR
CHILDREN'S ZYRTEC ALLERGY						
+! J AND J CONSUMER INC	5MG/5ML	N022155	002	Nov 16, 2007	Feb	CDFR
CHILDREN'S ZYRTEC HIVES RELIEF						
+! J AND J CONSUMER INC	5MG/5ML	N022155	001	Nov 16, 2007	Feb	CDFR
TABLET, CHEWABLE;ORAL						
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY						
@ SUN PHARM	5MG	A090142	001	Aug 30, 2011	Mar	DISC
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF						
@ SUN PHARM	5MG	A090142	003	Aug 30, 2011	Mar	DISC

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL						
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE						
PPI-DAC	5MG;120MG	A210719	001	Nov 16, 2018	Jun	CAHN
>A> UNICHEM	5MG;120MG	A210507	001	Sep 10, 2024	Aug	NEWA

CLOTTRIMAZOLE

CREAM;VAGINAL						
TRIVAGIZOLE 3						
TARO	2%	N021143	001	Apr 12, 2000	Mar	CAHN

DICLOFENAC SODIUM

GEL;TOPICAL						
DICLOFENAC SODIUM						
CIPLA	1%	A209903	001	Aug 03, 2018	Jul	CMKT
@ HIKMA	1%	A209484	001	Nov 21, 2018	Mar	DISC

DIPHENHYDRAMINE CITRATE; IBUPROFEN

TABLET;ORAL						
IBUPROFEN AND DIPHENHYDRAMINE CITRATE						
PLD ACQUISITIONS LLC	38MG;200MG	A211404	001	Apr 11, 2024	Apr	NEWA

DOCOSANOL

CREAM;TOPICAL						
DOCOSANOL						
AUROBINDO PHARMA LTD	10%	A217090	001	Mar 01, 2024	Feb	NEWA
P AND L DEVELOPMENT	10%	A212385	001	Oct 07, 2022	Mar	CAHN

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL						
ESOMEPRAZOLE MAGNESIUM						
DR REDDYS	EQ 20MG BASE	A207198	001	Apr 30, 2024	Apr	NEWA
GLENMARK SPECLT	EQ 20MG BASE	A218092	001	Jun 11, 2024	May	NEWA
GUARDIAN DRUG	EQ 20MG BASE	A216149	001	Mar 15, 2023	Feb	CAHN
TABLET, DELAYED RELEASE;ORAL						
ESOMEPRAZOLE MAGNESIUM						
AUROBINDO PHARMA LTD	EQ 20MG BASE	A214473	001	Jul 12, 2023	Apr	CMFD
@	EQ 20MG BASE	A214473	001	Jul 12, 2023	Jan	DISC

FAMOTIDINE

TABLET;ORAL						
FAMOTIDINE						
CONTRACT PHARMACAL	10MG	A218003	001	May 28, 2024	May	NEWA
	20MG	A218003	002	May 28, 2024	May	NEWA
GRAVITI PHARMS	10MG	A218461	001	Mar 14, 2024	Mar	NEWA
	20MG	A218461	002	Mar 14, 2024	Mar	NEWA
@ SUN PHARM INDS LTD	10MG	A090283	001	Nov 17, 2009	Apr	DISC
@	20MG	A090283	002	Nov 17, 2009	Apr	DISC

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL						
FLUTICASONE PROPIONATE						
AUROBINDO PHARMA LTD	0.05MG/SPRAY	A217088	001	May 10, 2024	May	NEWA
@ HIKMA	0.05MG/SPRAY	A208024	001	Apr 17, 2019	Mar	DISC

IBUPROFEN

CAPSULE;ORAL

IBUPROFEN

@ AUROBINDO PHARMA LTD	EQ 200MG FREE ACID AND POTASSIUM SALT	A215777	001	Sep 14, 2023	Mar	DISC
PATHEON SOFTGELS	EQ 200MG FREE ACID AND POTASSIUM SALT	A217236	001	Feb 13, 2024	Mar	CAHN
	EQ 200MG FREE ACID AND POTASSIUM SALT	A217236	001	Feb 13, 2024	Feb	NEWA

SUSPENSION/DROPS;ORAL

IBUPROFEN

AUROBINDO PHARMA LTD	40MG/ML	A213506	001	Apr 08, 2024	Mar	NEWA
----------------------	---------	---------	-----	--------------	-----	------

TABLET;ORAL

IBUPROFEN

ENDO OPERATIONS	200MG	A071229	001	Apr 01, 1987	May	CAHN
@	200MG	A071639	001	Feb 02, 1988	May	CAHN
@	200MG	A072249	001	Jan 10, 1989	May	CAHN

LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL

NAARI PTE LTD	1.5MG	A207660	001	May 02, 2019	Apr	CMFD
@ XIROMED	0.75MG	A202740	001	Sep 02, 2016	May	CAHN
	1.5MG	A202739	001	Oct 31, 2014	May	CAHN

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

@ SUN PHARM INDS LTD	2MG;125MG	A077500	001	Sep 06, 2006	May	DISC
----------------------	-----------	---------	-----	--------------	-----	------

LORATADINE

SUSPENSION;ORAL

LORATADINE

>D>	+! TARO	1MG/ML	N021734	001	Oct 04, 2005	Aug	CAHN
>A>	+!	1MG/ML	N021734	001	Oct 04, 2005	Aug	CAHN

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

LORATADINE AND PSEUDOEPHEDRINE SULFATE

BIONPHARMA	10MG;240MG	A218017	001	May 14, 2024	May	NEWA
------------	------------	---------	-----	--------------	-----	------

MICONAZOLE NITRATE

CREAM;VAGINAL

MICONAZOLE NITRATE

@ COSETTE	2%	A074366	001	Feb 22, 1996	Apr	DISC
-----------	----	---------	-----	--------------	-----	------

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

M-ZOLE 3 COMBINATION PACK

COSETTE	2%,200MG	A074926	001	Apr 16, 1999	Jun	CAHN
---------	----------	---------	-----	--------------	-----	------

SUPPOSITORY;VAGINAL

MICONAZOLE NITRATE

COSETTE	100MG	A073507	001	Nov 19, 1993	Jun	CAHN
@	100MG	A074414	001	Apr 30, 1997	Apr	DISC

MINOXIDIL

AEROSOL, FOAM;TOPICAL

MINOXIDIL (FOR MEN)

AUROBINDO PHARMA	5%	A218616	001	Apr 22, 2024	Apr	NEWA
------------------	----	---------	-----	--------------	-----	------

MINOXIDIL (FOR WOMEN)

AUROBINDO PHARMA	5%	A218616	002	Apr 22, 2024	Apr	NEWA
------------------	----	---------	-----	--------------	-----	------

MOMETASONE FUROATE

SPRAY, METERED;NASAL

MOMETASONE FUROATE

APOTEX	0.05MG/SPRAY	A217438	001	Apr 23, 2024	Apr	NEWA
--------	--------------	---------	-----	--------------	-----	------

NALOXONE HYDROCHLORIDE

SPRAY, METERED;NASAL

NALOXONE HYDROCHLORIDE

AMNEAL	4MG/SPRAY	A217992	001	Apr 23, 2024	Apr	NEWA
TEVA PHARMS USA	4MG/SPRAY	A209522	001	Apr 19, 2019	Jun	CMKT

NAPROXEN SODIUM

TABLET;ORAL  
 NAPROXEN SODIUM  
 @ SUN PHARM INDS LTD 220MG A091183 001 May 20, 2011 Jan DISC

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL  
 NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE  
 AUROBINDO PHARMA 220MG;120MG A211360 001 Jun 01, 2022 Jul CMFD

NICOTINE POLACRILEX

TROCHE/LOZENGE;ORAL  
 NICORETTE  
 + HALEON US HOLDINGS EQ 2MG BASE N022360 001 May 18, 2009 Jan CAHN  
 +! EQ 4MG BASE N022360 002 May 18, 2009 Jan CAHN  
 NICOTINE POLACRILEX  
 PPI-DAC EQ 2MG BASE A090711 001 Jul 10, 2009 Jun CAHN  
 EQ 2MG BASE A203690 001 Oct 09, 2012 Jun CAHN  
 EQ 4MG BASE A090711 002 Jul 10, 2009 Jun CAHN  
 EQ 4MG BASE A203690 002 Oct 09, 2012 Jun CAHN

NORGESTREL

TABLET;ORAL  
 OPILL  
 +! LABORATOIRE HRA 0.075MG N017031 001 Feb CMFD

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC  
 OLOPATADINE HYDROCHLORIDE  
 >D> @ AKORN EQ 0.1% BASE A204532 001 Jan 10, 2017 Aug CAHN  
 >D> @ GLENMARK PHARMS INC EQ 0.1% BASE A200810 001 Jun 28, 2017 Aug CMFD  
 >A> EQ 0.1% BASE A200810 001 Jun 28, 2017 Aug CMFD  
 >A> @ SAPTALIS PHARMS EQ 0.1% BASE A204532 001 Jan 10, 2017 Aug CAHN  
 SOMERSET THERAPS LLC EQ 0.1% BASE A206306 001 Dec 07, 2015 Apr CMKT

OMEPRAZOLE; SODIUM BICARBONATE

FOR SUSPENSION;ORAL  
 OMEPRAZOLE AND SODIUM BICARBONATE  
 DR REDDYS 20MG/PACKET;1.68GM/PACKET A217784 001 May 09, 2024 May NFTG

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL  
 POLYETHYLENE GLYCOL 3350  
 PPI-DAC 17GM/PACKET A090685 001 Oct 06, 2009 Jun CAHN  
 17GM/SCOOPFUL A090685 002 Oct 06, 2009 Jun CAHN

POVIDONE-IODINE

SPONGE;TOPICAL  
 E-Z SCRUB 201  
 + @ BECTON DICKINSON 20% N019240 001 Nov 29, 1985 Feb DISC  
 E-Z SCRUB 241  
 + @ BECTON DICKINSON 10% N019476 001 Jan 07, 1987 Feb DISC

TERBINAFINE

GEL;TOPICAL  
 LAMISIL AT  
 +! KARO HLTHCARE 1% N021958 001 Jul 24, 2006 Feb CAHN

TERBINAFINE HYDROCHLORIDE

CREAM;TOPICAL  
 LAMISIL  
 +! KARO HLTHCARE 1% N020980 001 Mar 09, 1999 Feb CAHN  
 SOLUTION;TOPICAL  
 LAMISIL AT  
 +! KARO HLTHCARE 1% N021124 001 Mar 17, 2000 Feb CAHN  
 SPRAY;TOPICAL  
 LAMISIL AT  
 +! KARO HLTHCARE 1% N021124 002 Mar 17, 2000 Feb CAHN



**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND  
RESEARCH LIST**

**CUMULATIVE SUPPLEMENT NUMBER 8 AUGUST 2024**

NO AUGUST 2024 APPROVALS

## ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY  
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO AUGUST 2024 APPROVALS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABALOPARATIDE - TYMLOS</u>						
N 208743 001	11977067	Apr 30, 2038	DP			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 001	>A> 7855211	Sep 28, 2031	DS DP U-2135			
	>A> 7855211	Sep 28, 2031	DS DP U-3242			
	>A> 7855211	Sep 28, 2031	DS DP U-3265			
	>A> 7855211	Sep 28, 2031	DS DP U-3546			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 002	>A> 7855211	Sep 28, 2031	DS DP U-2135			
	>A> 7855211	Sep 28, 2031	DS DP U-3242			
	>A> 7855211	Sep 28, 2031	DS DP U-3265			
	>A> 7855211	Sep 28, 2031	DS DP U-3546			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 003	>A> 7855211	Sep 28, 2031	DS DP U-2135			
	>A> 7855211	Sep 28, 2031	DS DP U-3242			
	>A> 7855211	Sep 28, 2031	DS DP U-3265			
	>A> 7855211	Sep 28, 2031	DS DP U-3546			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 004	>A> 7855211	Sep 28, 2031	DS DP U-1981			
	>A> 7855211	Sep 28, 2031	DS DP U-2135			
	>A> 7855211	Sep 28, 2031	DS DP U-3242			
	>A> 7855211	Sep 28, 2031	DS DP U-3265			
	>A> 7855211	Sep 28, 2031	DS DP U-3546			
<u>ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA</u>						
N 216793 001	11986468	Jul 28, 2037	U-2830			
	11986469	Jul 28, 2037	U-2830			
	11992486	Jul 28, 2037	U-2830			
<u>ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA</u>						
N 216793 002	11986468	Jul 28, 2037	U-2830			
	11986469	Jul 28, 2037	U-2830			
	11992486	Jul 28, 2037	U-2830			
<u>ACETAMINOPHEN; IBUPROFEN - ACETAMINOPHEN AND IBUPROFEN</u>						
A 218311 001					PC	Nov 03, 2024
<u>ACETAMINOPHEN; IBUPROFEN - ADVIL DUAL ACTION WITH ACETAMINOPHEN</u>						
N 211733 001	11918693	Jul 09, 2041	DP			
<u>ACETAMINOPHEN; IBUPROFEN SODIUM - COMBOGESIC IV</u>						
N 215320 001	11896567	Oct 26, 2031	U-3744			
	11896567	Oct 26, 2031	U-3745			
<u>ACETYLCYSTEINE LYSINE - LEGUBETI</u>						
N 215040 001					NP	Feb 13, 2027
<u>ACETYLCYSTEINE LYSINE - LEGUBETI</u>						
N 215040 002					NP	Feb 13, 2027
<u>ACYCLOVIR - ACYCLOVIR</u>						
A 212361 001					CGT	Jun 12, 2024
<u>ADAGRASIB - KRAZATI</u>						
N 216340 001	10689377	May 17, 2037	DS DP U-3490			
	10689377	May 17, 2037	DS DP U-3953			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALECTINIB HYDROCHLORIDE - ALECENSA</u>						
N 208434 001					I-947 ODE-477	Apr 18, 2027 Apr 18, 2031
<u>ALPELISIB - PIORAY</u>						
N 212526 001	8227462	Apr 29, 2033	DS DP U-3809		I-937	Jan 18, 2027
<u>ALPELISIB - PIORAY</u>						
N 212526 002	8227462	Apr 29, 2033	DS DP U-3809		I-937	Jan 18, 2027
<u>ALPELISIB - PIORAY</u>						
N 212526 003	8227462	Apr 29, 2033	DS DP U-3809		I-937	Jan 18, 2027
<u>ALPELISIB - VIJOICE</u>						
N 218466 001	8227462 8476268	Apr 29, 2033 Sep 10, 2029	DS DP DS DP			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 001	11903908	Jun 17, 2034	U-3822			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 002	11903908	Jun 17, 2034	U-3822			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 001	11890261	Feb 15, 2038	U-2497			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 002	11890261	Feb 15, 2038	U-2497			
<u>AMIKACIN SULFATE - ARIKAYCE KIT</u>						
N 207356 001	12016873	May 15, 2035	U-2414			
<u>AMLODIPINE BENZOATE - KATERZIA</u>						
N 211340 001	11918685 11918685 >A> 12053461	Oct 06, 2037 Oct 06, 2037 Oct 06, 2037	U-3447 U-3448 DP			
<u>AMLODIPINE BESYLATE - NORLIOVA</u>						
N 214439 001	12005141 12005141	Feb 24, 2041 Feb 24, 2041	DP U-3309 DP U-3310			
<u>AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN - TALICIA</u>						
N 213004 001	11878011 11931463	May 27, 2042 Feb 12, 2034	U-3816 DP U-3866			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 001	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 002	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 003	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 004	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 005	9839619	Jun 28, 2032	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 006	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 001	11896562	Mar 10, 2037	U-3299			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 002	11896562	Mar 10, 2037	U-3299			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 003	11896562	Mar 10, 2037	U-3299			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 004	11896562	Mar 10, 2037	U-3299			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 001	11963952	Jan 30, 2040	U-3901			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 002	11963952	Jan 30, 2040	U-3901			
<u>APREMILAST - OTEZLA</u>						
N 205437 001	10092541	May 29, 2034	U-2403		I-884	Dec 20, 2024
	10092541	May 29, 2034	U-2659		M-299	Jul 20, 2026
	10092541*PED	Nov 29, 2034			NPP	Apr 25, 2027
	7427638	Feb 16, 2028	DS DP		ODE-248	Jul 19, 2026
	7427638*PED	Aug 16, 2028			PED	Jan 19, 2027
	9872854	May 29, 2034	U-2232		PED	Jan 20, 2027
	9872854	May 29, 2034	U-2233		PED	Oct 25, 2027
	9872854*PED	Nov 29, 2034				
<u>APREMILAST - OTEZLA</u>						
N 205437 002	10092541	May 29, 2034	U-2403		I-884	Dec 20, 2024
	10092541	May 29, 2034	U-2659		M-299	Jul 20, 2026
	10092541*PED	Nov 29, 2034			NPP	Apr 25, 2027
	7427638	Feb 16, 2028	DS DP		ODE-248	Jul 19, 2026
	7427638*PED	Aug 16, 2028			PED	Jan 19, 2027
	9872854	May 29, 2034	U-2232		PED	Jan 20, 2027
	9872854	May 29, 2034	U-2233		PED	Oct 25, 2027
	9872854*PED	Nov 29, 2034				
<u>APREMILAST - OTEZLA</u>						
N 205437 003	10092541	May 29, 2034	U-2403		I-884	Dec 20, 2024
	10092541	May 29, 2034	U-2659		M-299	Jul 20, 2026
	10092541*PED	Nov 29, 2034			NPP	Apr 25, 2027
	7427638	Feb 16, 2028	DS DP		ODE-248	Jul 19, 2026
	7427638*PED	Aug 16, 2028			PED	Jan 19, 2027
	9872854	May 29, 2034	U-2232		PED	Jan 20, 2027
	9872854	May 29, 2034	U-2233		PED	Oct 25, 2027
	9872854*PED	Nov 29, 2034				
<u>APREPITANT - APONVIE</u>						
N 216457 001	11878074	Sep 18, 2035	U-3787			
<u>APROCITENTAN - TRYVIO</u>						
N 217686 001	10919881	Feb 26, 2038	DS DP		NCE	Mar 22, 2029
	11174247	Nov 06, 2037	U-3879			
	11680058	Jul 26, 2038	U-3878			
	11787782	Mar 02, 2038	U-3877			
	8324232	Sep 21, 2029	DS DP U-3878			
<u>ARIPIPRAZOLE - ABILIFY ASIMTUFLI</u>						
N 217006 001	12016927	Apr 23, 2033	DP U-3245			
	12016927	Apr 23, 2033	DP U-543			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE - ABILIFY ASIMTUFIN</u>						
N 217006 001	12016927	Apr 23, 2033	DP U-3245			
	12016927	Apr 23, 2033	DP U-543			
<u>ARIPRAZOLE - ABILIFY ASIMTUFIN</u>						
N 217006 002	12016927	Apr 23, 2033	DP U-3245			
	12016927	Apr 23, 2033	DP U-543			
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 003	11407735	May 14, 2040	DS		NCE	Oct 29, 2026
	8829195	May 13, 2033	DS U-1374		ODE*	Oct 29, 2028
<u>ATORVASTATIN CALCIUM - ATORVALIO</u>						
N 213260 001	11925704	Jun 07, 2037	DP U-3853			
<u>ATROPINE SULFATE - ATROPINE SULFATE</u>						
A 217791 001					CGT	Dec 04, 2024
<u>AVACOPAN - TAVNEOS</u>						
N 214487 001	11951214	Nov 27, 2039	DP			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 001	11964980	Apr 10, 2040	DS DP			
	11999744	Apr 10, 2040	U-3168			
>A>	12060354	Mar 08, 2042	U-2726			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 002	11964980	Apr 10, 2040	DS DP			
	11999744	Apr 10, 2040	U-3168			
>A>	12060354	Mar 08, 2042	U-2726			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 003	11964980	Apr 10, 2040	DS DP			
>A>	12060354	Mar 08, 2042	U-2726			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 004	11964980	Apr 10, 2040	DS DP			
	11999744	Apr 10, 2040	U-3168			
	11999744	Apr 10, 2040	U-3506			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 005	11964980	Apr 10, 2040	DS DP			
	11999744	Apr 10, 2040	U-3168			
<u>AVATROMBOPAG MALEATE - DOPTELET</u>						
N 210238 001	7638536	Jul 28, 2027	DS DP			
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	7112592	Jan 07, 2026	DS DP U-2244		NPP	Jan 26, 2027
	7112592	Jan 07, 2026	DS DP U-2508			
	7112592	Jan 07, 2026	DS DP U-282			
	7112592	Jan 07, 2026	DS DP U-3818			
<u>AXITINIB - INLYTA</u>						
N 202324 001	10570202	Feb 03, 2035	U-2844			
	10570202*PED	Aug 03, 2035				
	10869924	Jan 12, 2037	U-3044			
	10869924*PED	Jul 12, 2037				
	6534524	Apr 29, 2025	DS DP			
	6534524*PED	Oct 29, 2025				
	8791140	Dec 14, 2030	DS			
	8791140*PED	Jun 14, 2031				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AXITINIB - INLYTA</u>						
N 202324 002	10570202	Feb 03, 2035	U-2844			
	10570202*PED	Aug 03, 2035				
	10869924	Jan 12, 2037	U-3044			
	10869924*PED	Jul 12, 2037				
	6534524	Apr 29, 2025	DS DP			
	6534524*PED	Oct 29, 2025				
	8791140	Dec 14, 2030	DS			
	8791140*PED	Jun 14, 2031				
<u>AZACITIDINE - ONUREG</u>						
N 214120 001 >A>	12053482	May 14, 2029	U-2950			
<u>AZACITIDINE - ONUREG</u>						
N 214120 002 >A>	12053482	May 14, 2029	U-2950			
<u>BACLOFEN - LYVISPAH</u>						
N 215422 001	11850225	Sep 29, 2041	DP U-3488			
	11850225	Sep 29, 2041	DP U-3489			
	11931328	Jul 29, 2039	DP			
<u>BACLOFEN - LYVISPAH</u>						
N 215422 002	11850225	Sep 29, 2041	DP U-3488			
	11850225	Sep 29, 2041	DP U-3489			
	11931328	Jul 29, 2039	DP			
<u>BACLOFEN - LYVISPAH</u>						
N 215422 003	11850225	Sep 29, 2041	DP U-3488			
	11850225	Sep 29, 2041	DP U-3489			
	11931328	Jul 29, 2039	DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 001	11925648	Apr 21, 2041	DP			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 001	8158616	May 31, 2032	DS DP			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 002	8158616	May 31, 2032	DS DP			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 003	8158616	May 31, 2032	DS DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 001	11865247	Jan 26, 2038	DP			
	11896759	Jan 26, 2038	DP			
	11957832	May 05, 2041	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 002	11865247	Jan 26, 2038	DP			
	11896759	Jan 26, 2038	DP			
	11957832	May 05, 2041	DP			
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 001					M-306	Jun 21, 2027
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 002					M-306	Jun 21, 2027
<u>BELZUTIFAN - WELIREG</u>						
N 215383 001	RE49948	Sep 05, 2034	DS DP U-3201		I-931	Dec 14, 2026
	RE49948	Sep 05, 2034	DS DP U-3780			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BEMPEDOIC ACID - NEXLETOI</u>						
N 211616 001	11744816	Mar 14, 2036	U-3883		I-943	Mar 22, 2027
	11926584	Jun 19, 2040	U-3873		I-944	Mar 22, 2027
	7335799	Dec 03, 2030	DS			
<u>BEMPEDOIC ACID; EZETIMIBE - NEXLIZET</u>						
N 211617 001	10912751	Mar 14, 2036	U-3224		I-943	Mar 22, 2027
	10912751	Mar 14, 2036	U-3884		I-945	Mar 22, 2027
	11744816	Mar 14, 2036	U-3692			
	11744816	Mar 14, 2036	U-3883			
	11926584	Jun 19, 2040	U-3873			
	7335799	Dec 03, 2030	DS			
<u>BENDAMUSTINE HYDROCHLORIDE - BELRAPZO</u>						
N 205580 001	11872214	Jan 28, 2031	DP			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	11872214	Jan 28, 2031	DP			
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 001	>A> 11795176	Jan 13, 2042	DS	U-713		
	>A> 9763953	May 16, 2027		U-713		
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 002	>A> 11795176	Jan 13, 2042	DS	U-713		
	>A> 9763953	May 16, 2027		U-713		
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 003	>A> 11795176	Jan 13, 2042	DS	U-713		
	>A> 9763953	May 16, 2027		U-713		
<u>BENZOYL PEROXIDE - EPSOLAY</u>						
N 214510 001	11865100	Feb 19, 2040	U-3357			
	11877997	Feb 19, 2040	U-3356			
	11986456	Feb 19, 2040	U-3947			
<u>BENZOYL PEROXIDE; TRETINOIN - TWYNEO</u>						
N 214902 001	>A> 12053546	Jun 29, 2032	DP			
<u>BERDAZIMER SODIUM - ZELSUVMI</u>						
N 217424 001	10258564	Nov 22, 2034	U-3797		NCE	Jan 05, 2029
	10258564	Nov 22, 2034	U-3798			
	10258564	Nov 22, 2034	U-3799			
	10265334	Jul 03, 2032	DP			
	10322081	Jul 10, 2035	U-3793			
	10322081	Jul 10, 2035	U-3794			
	10322081	Jul 10, 2035	U-3795			
	10322081	Jul 10, 2035	U-3796			
	10376538	Aug 20, 2030	DP			
	10736839	Jul 10, 2035	U-3790			
	10736839	Jul 10, 2035	U-3791			
	10736839	Jul 10, 2035	U-3792			
	11040006	Jul 10, 2035	DP	U-3789		
	11285098	Feb 28, 2034	DP			
	11723858	Jul 10, 2035	DP	U-3788		
	8282967	May 30, 2026	DS			
	8956658	May 30, 2026	DS			
	9289442	Jul 03, 2032	DP	U-3803		
	9526738	Sep 03, 2031	DP			
	9737561	Aug 20, 2030	U-3802			
	9855211	Feb 27, 2034	DP	U-3800		
	9855211	Feb 27, 2034	DP	U-3801		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251	001				I-942 M-305 ODE-468	Feb 23, 2027 Apr 24, 2027 Feb 23, 2031
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251	002	7390791	Apr 17, 2025	DS DP	I-942	Feb 23, 2027
		7390791*PED	Oct 17, 2025		ODE-468	Feb 23, 2031
		8754065	Aug 15, 2032	DS DP U-257		
		8754065*PED	Feb 15, 2033			
		9296769	Aug 15, 2032	DS DP U-257		
		9296769*PED	Feb 15, 2033			
<u>BINIMETINIB - MEKTOVI</u>						
N 210498	001	7777050	Mar 13, 2025	DS DP		
<u>BIRCH TRITERPENES - FILSUEVZ</u>						
N 215064	001	11083733	Jan 04, 2039	DP	NCE	Dec 18, 2028
		11266660	Jan 04, 2039	U-3811	ODE-460	Dec 18, 2030
		8828444	Jun 21, 2025	DP		
		9352041	Nov 24, 2030	U-3811		
		9827214	Nov 24, 2030	U-3811		
<u>BIVALIRUDIN - ANGIOMAX RTU</u>						
N 211215	001	11903993	May 20, 2039	U-3817		
		11918622	May 20, 2039	U-3817		
		11992514	May 20, 2039	DP		
<u>BORTEZOMIB - BORTEZOMIB</u>						
N 215331	001	12005069	Sep 23, 2042	DP		
<u>BORTEZOMIB - BORTEZOMIB</u>						
N 215331	002	12005069	Sep 23, 2042	DP		
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422	001	10307419	Oct 12, 2032	DP	I-913	May 10, 2026
		10307419*PED	Apr 12, 2033		M-14	May 08, 2027
		7888362	Apr 12, 2026	DS	Y PED	Nov 10, 2026
		7888362*PED	Oct 12, 2026		PED	Nov 08, 2027
		8349840	Apr 12, 2026	DP U-1529		
		8349840*PED	Oct 12, 2026			
		8618109	Apr 12, 2026	U-3281		
		8618109	Apr 12, 2026	U-543		
		8618109*PED	Oct 12, 2026			
		9839637	Apr 12, 2026	DP U-1529		
		9839637	Apr 12, 2026	DP U-3281		
		9839637	Apr 12, 2026	DP U-543		
		9839637*PED	Oct 12, 2026			
		RE48059	Dec 23, 2028	DS		
		RE48059*PED	Jun 23, 2029			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422	002	10307419	Oct 12, 2032	DP	I-913	May 10, 2026
		10307419*PED	Apr 12, 2033		M-14	May 08, 2027
		7888362	Apr 12, 2026	DS	Y PED	Nov 10, 2026
		7888362*PED	Oct 12, 2026		PED	Nov 08, 2027
		8349840	Apr 12, 2026	DP U-1529		
		8349840*PED	Oct 12, 2026			
		8618109	Apr 12, 2026	U-3281		
		8618109	Apr 12, 2026	U-543		
		8618109*PED	Oct 12, 2026			
		9839637	Apr 12, 2026	DP U-1529		
		9839637	Apr 12, 2026	DP U-3281		
		9839637	Apr 12, 2026	DP U-543		
		9839637*PED	Oct 12, 2026			
		RE48059	Dec 23, 2028	DS		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 002	RE48059*PED	Jun 23, 2029				
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 003	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	10307419*PED	Apr 12, 2033			M-14	May 08, 2027
	7888362	Apr 12, 2026	DS	Y	PED	Nov 10, 2026
	7888362*PED	Oct 12, 2026			PED	Nov 08, 2027
	8349840	Apr 12, 2026	DP U-1529			
	8349840*PED	Oct 12, 2026				
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 004	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	10307419*PED	Apr 12, 2033			M-14	May 08, 2027
	7888362	Apr 12, 2026	DS	Y	PED	Nov 10, 2026
	7888362*PED	Oct 12, 2026			PED	Nov 08, 2027
	8349840	Apr 12, 2026	DP U-1529			
	8349840*PED	Oct 12, 2026				
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 005	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	10307419*PED	Apr 12, 2033			M-14	May 08, 2027
	7888362	Apr 12, 2026	DS	Y	PED	Nov 10, 2026
	7888362*PED	Oct 12, 2026			PED	Nov 08, 2027
	8349840	Apr 12, 2026	DP U-1529			
	8349840*PED	Oct 12, 2026				
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 006	7888362	Apr 12, 2026	DS	Y	I-913	May 10, 2026
	7888362*PED	Oct 12, 2026			M-14	May 08, 2027
	8349840	Apr 12, 2026	DP U-1529		PED	Nov 10, 2026
	8349840*PED	Oct 12, 2026			PED	Nov 08, 2027
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 006	7888362	Apr 12, 2026	DS	Y	I-913	May 10, 2026
	7888362*PED	Oct 12, 2026			M-14	May 08, 2027
	8349840	Apr 12, 2026	DP U-1529		PED	Nov 10, 2026
	8349840*PED	Oct 12, 2026			PED	Nov 08, 2027
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
<u>BRIMONIDINE TARTRATE - LUMIFY PRESERVATIVE FREE</u>						
N 218424 001	11596600	Jul 27, 2029	U-2222			
	8293742	Jul 14, 2030	U-2222			
	9259425	Jul 14, 2030	U-2222			
<u>BROMFENAC SODIUM - BROMFENAC SODIUM</u>						
A 206027 001					PC	Jul 06, 2024
<u>BUDESONIDE - EOHILIA</u>						
N 213976 001	10293052	Nov 22, 2028	DP		NP	Feb 09, 2027
	11197822	Nov 09, 2026	DP		ODE-466	Feb 09, 2031
	11260064	Jan 10, 2039	DP			
	11357859	Nov 12, 2028	U-3820			
	11413296	Nov 09, 2026	DP			
	11564934	Jan 10, 2039	U-3820			
	8324192	Aug 03, 2029	U-3820			
	8497258	Nov 09, 2026	U-3820			
	8679545	Nov 09, 2026	DP			
	8975243	Nov 09, 2026	U-3820			
	9050368	Aug 01, 2029	DP			
	9119863	Nov 09, 2026	U-3820			
<u>BUDESONIDE - TARPEYO</u>						
N 215935 001	11896719	Jan 23, 2043	U-3810		ODE-464	Dec 20, 2030
	8491932	May 07, 2029	DP U-3269			
	8491932	May 07, 2029	DP U-3781			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001	11918565	Feb 02, 2043	U-3841		I-929	Nov 09, 2026
	11925706	Jan 22, 2041	DP U-3380			
	11931459	Mar 17, 2042	U-3839			
	11931459	Mar 17, 2042	U-3840			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002	11918565	Feb 02, 2043	U-3841		I-929	Nov 09, 2026
	11925706	Jan 22, 2041	DP U-3380			
	11931459	Mar 17, 2042	U-3839			
	11931459	Mar 17, 2042	U-3840			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 001					I-933	Jan 23, 2027
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 002					I-933	Jan 23, 2027
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 003					I-933	Jan 23, 2027

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 004					I-933	Jan 23, 2027
<u>BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY</u>						
N 215430 001	11883373	Jan 23, 2043	U-3419			
	11896563	Dec 01, 2041	U-3419			
	11925636	Jan 20, 2043	U-3419			
	11969421	Nov 05, 2034	U-3419			
	11986444	Feb 15, 2043	U-3419			
	12036191	Feb 15, 2043	U-3419			
	12042473	Feb 23, 2043	U-3419			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	11998542	Jul 02, 2034	U-1583			
	>A> 12048769	Nov 08, 2027	U-1585			
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	11154509	Apr 25, 2028	U-3815			
	9498486	Apr 25, 2028	U-3814			
<u>CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV</u>						
N 212690 001	11986446	Mar 15, 2033	U-3017		ODE-361	Jul 21, 2027
	11986446	Mar 15, 2033	U-3324		PED	Jan 21, 2028
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	11865102	Apr 26, 2039	DS DP U-2781			
	11865102	Apr 26, 2039	DS DP U-3236			
	11865102	Apr 26, 2039	DS DP U-3277			
	11963937	Jun 17, 2035	U-2780			
	11963937	Jun 17, 2035	U-2781			
<u>CANTHARIDIN - YCANTH</u>						
N 212905 001					NCE	Jul 21, 2028
<u>CAPMATINIB HYDROCHLORIDE - TABRECTA</u>						
N 213591 001	>A> 7767675	Nov 19, 2032	DS DP			
<u>CAPMATINIB HYDROCHLORIDE - TABRECTA</u>						
N 213591 002	>A> 7767675	Nov 19, 2032	DS DP			
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 001	>A> 10098845	Oct 07, 2034	DP U-219		>A> NP	Aug 07, 2027
	>A> 10292935	Oct 07, 2034	DP U-219			
	>A> 10688058	Oct 07, 2034	DP U-219			
	>A> 10973769	Oct 07, 2034	DP U-219			
	>A> 10987313	Oct 07, 2034	DP U-219			
	>A> 11357733	Oct 07, 2034	DP			
	>A> 11622941	Oct 07, 2034	DP			
	>A> 11666538	Oct 07, 2034	DP U-219			
	>A> 11986449	Dec 21, 2041	U-219			
	>A> 12064521	Oct 07, 2034	DP			
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 002	>A> 10098845	Oct 07, 2034	DP U-219		>A> NP	Aug 07, 2027
	>A> 10292935	Oct 07, 2034	DP U-219			
	>A> 10688058	Oct 07, 2034	DP U-219			
	>A> 10973769	Oct 07, 2034	DP U-219			
	>A> 10987313	Oct 07, 2034	DP U-219			
	>A> 11357733	Oct 07, 2034	DP			
	>A> 11622941	Oct 07, 2034	DP			
	>A> 11666538	Oct 07, 2034	DP U-219			
	>A> 11986449	Dec 21, 2041	U-219			
	>A> 12064521	Oct 07, 2034	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 003	>A> 10098845	Oct 07, 2034	DP U-219		>A> NP	Aug 07, 2027
	>A> 10292935	Oct 07, 2034	DP U-219			
	>A> 10688058	Oct 07, 2034	DP U-219			
	>A> 10973769	Oct 07, 2034	DP U-219			
	>A> 10987313	Oct 07, 2034	DP U-219			
	>A> 11357733	Oct 07, 2034	DP			
	>A> 11622941	Oct 07, 2034	DP			
	>A> 11666538	Oct 07, 2034	DP U-219			
	>A> 11986449	Dec 21, 2041	U-219			
	>A> 12064521	Oct 07, 2034	DP			
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 004	>A> 10098845	Oct 07, 2034	DP U-219		>A> NP	Aug 07, 2027
	>A> 10292935	Oct 07, 2034	DP U-219			
	>A> 10688058	Oct 07, 2034	DP U-219			
	>A> 10973769	Oct 07, 2034	DP U-219			
	>A> 10987313	Oct 07, 2034	DP U-219			
	>A> 11357733	Oct 07, 2034	DP			
	>A> 11622941	Oct 07, 2034	DP			
	>A> 11666538	Oct 07, 2034	DP U-219			
	>A> 11986449	Dec 21, 2041	U-219			
	>A> 12064521	Oct 07, 2034	DP			
<u>CEDAZURIDINE; DECITABINE - INQOVI</u>						
N 212576 001	11963971	Feb 24, 2041	DP			
<u>CEFEPIME HYDROCHLORIDE; ENMETAZOBACTAM - EXBLIFEP</u>						
N 216165 001	11124526	Nov 07, 2034	U-3852		NCE	Feb 22, 2029
	7687488	Dec 03, 2027	DS DP U-3851		GAIN	Feb 22, 2034
<u>CEFTOBIPROLE MEDOCARIL SODIUM - ZEVTERA</u>						
N 218275 001					NCE GAIN	Apr 03, 2029 Apr 03, 2034
<u>CILASTATIN SODIUM; IMIPENEM; RELEBACTAM - RECARBRIO</u>						
N 212819 001	8487093	Mar 21, 2033	DS DP U-2586			
	8487093	Mar 21, 2033	DS DP U-2587			
	8487093	Mar 21, 2033	DS DP U-2840			
<u>CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE - PHEXXI</u>						
N 208352 001	11992472	Mar 15, 2033	U-1			
<u>CLASCOTERONE - WINLEVI</u>						
N 213433 001	11938141	Jul 24, 2028	DP			
	8865690	Jul 24, 2025	U-2942			
	9211295	May 31, 2025	DP			
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
N 218158 001	10588913	May 09, 2036	DP		NP	Mar 04, 2027
	11376262	May 09, 2036	DP U-19			
<u>CLONIDINE HYDROCHLORIDE - ONYDA XR</u>						
N 217645 001	11918689	Jul 28, 2041	DP U-3944			
	8062667	Mar 29, 2029	DP			
<u>COLCHICINE - LODOCO</u>						
N 215727 001	10130585	May 09, 2034	U-3642			
	10206891	Nov 01, 2033	U-3641			
	10265281	Nov 01, 2033	U-3639			
	10842762	Nov 01, 2033	U-3640			
	11026899	Nov 01, 2033	U-3639			
	11026900	Nov 01, 2033	U-3639			
	11026901	Nov 01, 2033	U-3638			
	11944594	Nov 01, 2033	U-3864			
	11944595	Nov 01, 2033	U-3867			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>COLCHICINE - LODOCO</u>						
N 215727 001	11944595	Nov 01, 2033	U-3868			
	9744144	Nov 01, 2033	U-3643			
<u>COPPER - PARAGARD T 380A</u>						
N 018680 001					D-193	Jun 28, 2027
<u>CORTICOTROPIN - ACTHAR GEL (AUTOINJECTOR)</u>						
N 008372 003	11752199	Feb 25, 2041	U-3686			
	11752199	Feb 25, 2041	U-3687			
	11752199	Feb 25, 2041	U-3688			
<u>CORTICOTROPIN - ACTHAR GEL (AUTOINJECTOR)</u>						
N 008372 004	11752199	Feb 25, 2041	U-3686			
	11752199	Feb 25, 2041	U-3687			
	11752199	Feb 25, 2041	U-3688			
<u>CORTICOTROPIN - PURIFIED CORTROPHIN GEL</u>						
N 008975 002	11975047	Oct 27, 2043	U-3904			
	11975047	Oct 27, 2043	U-3905			
	11975047	Oct 27, 2043	U-3906			
	11975047	Oct 27, 2043	U-3907			
	11975047	Oct 27, 2043	U-3908			
	11975047	Oct 27, 2043	U-3909			
	11975047	Oct 27, 2043	U-3910			
	11975047	Oct 27, 2043	U-3911			
	11975047	Oct 27, 2043	U-3912			
	11975047	Oct 27, 2043	U-3913			
	11975047	Oct 27, 2043	U-3914			
	11975047	Oct 27, 2043	U-3915			
	11975047	Oct 27, 2043	U-3916			
	11975047	Oct 27, 2043	U-3917			
	11975047	Oct 27, 2043	U-3918			
	11975047	Oct 27, 2043	U-3919			
	11975047	Oct 27, 2043	U-3920			
	11975047	Oct 27, 2043	U-3921			
	11975047	Oct 27, 2043	U-3922			
	11975047	Oct 27, 2043	U-3923			
	11975047	Oct 27, 2043	U-3924			
	11975047	Oct 27, 2043	U-3925			
	11975047	Oct 27, 2043	U-3926			
<u>CUPRIC CHLORIDE - CUPRIC CHLORIDE</u>						
A 216113 001					CGT	Dec 21, 2024
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - TRALEMENT</u>						
N 209376 001	11975022	Jul 01, 2041	U-3899			
	11998565	Jul 01, 2041	DP			
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - TRALEMENT</u>						
N 209376 002	11975022	Jul 01, 2041	U-3899			
	11998565	Jul 01, 2041	DP			
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - MULTRYS</u>						
N 209376 003	11975022	Jul 01, 2041	U-3900			
	11998565	Jul 01, 2041	DP			
<u>CYCLOSPORINE - RESTASIS MULTIDOSE</u>						
N 050790 002	8629111	Aug 27, 2024	DP		Y	
	8633162	Aug 27, 2024	U-1479		Y	
	8642556	Aug 27, 2024	DP		Y	
	8648048	Aug 27, 2024	U-1483		Y	
	8685930	Aug 27, 2024	DP		Y	
	9248191	Aug 27, 2024	U-1479		Y	

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CYCLOSPORINE - CEQUA</u>						
N 210913 001	11951153	Feb 28, 2037	U-1483			
<u>CYSTEINE HYDROCHLORIDE - ELCYS</u>						
N 210660 001	11969439	Jan 15, 2039	U-2752			
<u>CYSTEINE HYDROCHLORIDE - NOURESS</u>						
N 212535 001	11642370	Jan 15, 2039	DP			
	11648262	Jan 15, 2039	DP			
	11679125	Jan 15, 2039	DP			
	11684636	Jan 15, 2039	DP			
	11826383	Jan 15, 2039	DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001					I-908 ODE-428 PED PED	Mar 16, 2026 Mar 16, 2030 Sep 16, 2026 Sep 16, 2030
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002					I-908 ODE-428 PED PED	Mar 16, 2026 Mar 16, 2030 Sep 16, 2026 Sep 16, 2030
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 217514 001	11504333	Jun 29, 2038	DP		NP	Mar 16, 2026
	11504333*PED	Dec 29, 2038			ODE-428	Mar 16, 2030
	7994185	Jan 20, 2030	DS DP		PED	Sep 16, 2026
	7994185*PED	Jul 20, 2030			PED	Sep 16, 2030
	8415345	Jan 20, 2030	DS DP			
	8415345*PED	Jul 20, 2030				
	8703781	Oct 15, 2030	DS DP	U-3565		
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025		U-3565		
	8835443*PED	Dec 10, 2025				
<u>DANICOPAN - VOYDEYA</u>						
N 218037 001	9796741	Feb 25, 2035	DS	U-3933	NCE ODE-476	Mar 29, 2029 Mar 29, 2031
<u>DANICOPAN - VOYDEYA</u>						
N 218037 002	9796741	Feb 25, 2035	DS	U-3933	NCE ODE-476	Mar 29, 2029 Mar 29, 2031
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001	6515117	Oct 04, 2025	DS DP	U-2139	M-298	May 08, 2026
	6515117	Oct 04, 2025	DS DP	U-493	NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Nov 08, 2026
	7456254	Jun 30, 2025		U-2139	PED	Dec 12, 2027
	7456254*PED	Dec 30, 2025				
	7851502	Aug 19, 2028	DP			
	7851502*PED	Feb 19, 2029				
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8221786	Mar 21, 2028	DP			
	8221786*PED	Sep 21, 2028				
	8329648	Aug 18, 2026		U-2139		
	8329648	Aug 18, 2026		U-2212		
	8329648	Aug 18, 2026		U-2213		
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028		U-2139		
	8361972	Mar 21, 2028		U-493		
	8361972*PED	Sep 21, 2028				
	8431685	Apr 13, 2025		U-2139		
	8431685*PED	Oct 13, 2025				



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001	8461105	Apr 13, 2025	U-2139			
	8461105*PED	Oct 13, 2025				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	8716251	Mar 21, 2028	DP			
	8716251*PED	Sep 21, 2028				
	8721615	Jan 18, 2030	DP	Y		
	8721615*PED	Jul 18, 2030				
	8906851	Aug 18, 2026	U-2139			
	8906851*PED	Feb 18, 2027				
	9238076	Apr 15, 2024	U-2139			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002	10973836	Mar 09, 2040	U-3127		M-298	May 08, 2026
	10973836*PED	Sep 09, 2040			NPP	Jun 12, 2027
	11826376	Jul 18, 2039	U-3766		PED	Nov 08, 2026
	11826376*PED	Jan 18, 2040			PED	Dec 12, 2027
	11903955	Mar 09, 2040	U-3825			
	11903955*PED	Sep 09, 2040				
	6515117	Oct 04, 2025	DS DP U-2139			
	6515117	Oct 04, 2025	DS DP U-493			
	6515117*PED	Apr 04, 2026				
	7456254	Jun 30, 2025	U-2139			
	7456254*PED	Dec 30, 2025				
	7851502	Aug 19, 2028	DP			
	7851502*PED	Feb 19, 2029				
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8221786	Mar 21, 2028	DP			
	8221786*PED	Sep 21, 2028				
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028	U-2139			
	8361972	Mar 21, 2028	U-493			
	8361972*PED	Sep 21, 2028				
	8431685	Apr 13, 2025	U-2139			
	8431685*PED	Oct 13, 2025				
	8461105	Apr 13, 2025	U-2139			
	8461105*PED	Oct 13, 2025				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	8716251	Mar 21, 2028	DP			
	8716251*PED	Sep 21, 2028				
	8721615	Jan 18, 2030	DP	Y		
	8721615*PED	Jul 18, 2030				
	8906851	Aug 18, 2026	U-2139			
	8906851*PED	Feb 18, 2027				
	9238076	Apr 15, 2024	U-2139			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 001	6515117	Oct 04, 2025	DS DP U-493		NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Dec 12, 2027
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 002	6515117	Oct 04, 2025	DS DP U-493		NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Dec 12, 2027
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 003	6515117	Oct 04, 2025	DS DP U-493		NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Dec 12, 2027
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 004	6515117	Oct 04, 2025	DS DP U-493		NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Dec 12, 2027
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 005	6515117	Oct 04, 2025	DS DP U-493		NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Dec 12, 2027
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
<u>DAPTOMYCIN - DAPTOMYCIN</u>						
N 217415 001	>A> 12053502	Aug 28, 2038	U-3981			
<u>DAPTOMYCIN - DAPTOMYCIN</u>						
N 217415 002	>A> 12053502	Aug 28, 2038	U-3981			
<u>DASATINIB - PHYRAGO</u>						
N 216099 001					>A> M-307	Dec 05, 2026
<u>DASATINIB - PHYRAGO</u>						
N 216099 002					>A> M-307	Dec 05, 2026
<u>DASATINIB - PHYRAGO</u>						
N 216099 003					>A> M-307	Dec 05, 2026

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DASATINIB - PHYRAGO</u>						
N 216099	004				>A> M-307	Dec 05, 2026
<u>DASATINIB - PHYRAGO</u>						
N 216099	005				>A> M-307	Dec 05, 2026
<u>DASATINIB - PHYRAGO</u>						
N 216099	006				>A> M-307	Dec 05, 2026
<u>DELAFLOXACIN MEGLUMINE - BAXDELA</u>						
N 208611	001	12036219	Jun 02, 2034	U-3967		
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517	001	11963995	May 21, 2029	U-2327		
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517	002	11963995	May 21, 2029	U-2327		
<u>DEURUXOLITINIB PHOSPHATE - LEQSELVI</u>						
N 217900	001	>A> 10561659	May 04, 2037	U-3976		
		>A> 11919907	May 21, 2041	DP U-3976		
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082	001	>A> 12016858	Mar 07, 2036	U-1995		
		>A> 12016858	Mar 07, 2036	U-3055		
		>A> 12016858*PED	Sep 07, 2036			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082	002	>A> 12016858	Mar 07, 2036	U-1995		
		>A> 12016858	Mar 07, 2036	U-3055		
		>A> 12016858*PED	Sep 07, 2036			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082	003	>A> 12016858	Mar 07, 2036	U-1995		
		>A> 12016858	Mar 07, 2036	U-3055		
		>A> 12016858*PED	Sep 07, 2036			
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354	001	>A> 12016858	Mar 07, 2036	U-1995		
		>A> 12016858	Mar 07, 2036	U-3055		
		>A> 12016858*PED	Sep 07, 2036			
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354	002	>A> 12016858	Mar 07, 2036	U-1995		
		>A> 12016858	Mar 07, 2036	U-3055		
		>A> 12016858*PED	Sep 07, 2036			
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354	003	>A> 12016858	Mar 07, 2036	U-1995		
		>A> 12016858	Mar 07, 2036	U-3055		
		>A> 12016858*PED	Sep 07, 2036			
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354	004	>A> 10959996	Mar 07, 2036	U-3055		
		>A> 10959996*PED	Sep 07, 2036			
		>A> 11179386	Mar 15, 2038	DP U-1995		
		>A> 11179386	Mar 15, 2038	DP U-3055		
		>A> 11179386*PED	Sep 15, 2038			
		11311488	Jun 10, 2041	DP U-1995		
		11311488	Jun 10, 2041	DP U-3055		
		>A> 11357772	Mar 07, 2036	U-1995		
		>A> 11357772	Mar 07, 2036	U-3055		
		>A> 11357772*PED	Sep 07, 2036			
		>A> 11446291	Mar 07, 2036	U-1995		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 004	>A> 11446291*PED	Sep 07, 2036				
	>A> 11564917	Mar 07, 2036	U-1995			
	>A> 11564917*PED	Sep 07, 2036				
	>A> 11648244	Mar 07, 2036	U-1995			
	>A> 11648244*PED	Sep 07, 2036				
	>A> 11813232	Mar 15, 2038	DP			
	>A> 11813232*PED	Sep 15, 2038				
	>A> 12016858	Mar 07, 2036	U-1995			
	>A> 12016858	Mar 07, 2036	U-3055			
	>A> 12016858*PED	Sep 07, 2036				
	>A> 8524733	Apr 03, 2031	DS DP			
	>A> 8524733*PED	Oct 03, 2031				
	>A> 9550780	Sep 18, 2033	DS DP U-1995			
	>A> 9550780	Sep 18, 2033	DS DP U-3055			
	>A> 9550780*PED	Mar 18, 2034				
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 005	>A> 10959996	Mar 07, 2036	U-3055			
	>A> 10959996*PED	Sep 07, 2036				
	>A> 11179386	Mar 15, 2038	DP U-1995			
	>A> 11179386	Mar 15, 2038	DP U-3055			
	>A> 11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	>A> 11357772	Mar 07, 2036	U-1995			
	>A> 11357772	Mar 07, 2036	U-3055			
	>A> 11357772*PED	Sep 07, 2036				
	>A> 11446291	Mar 07, 2036	U-1995			
	>A> 11446291*PED	Sep 07, 2036				
	>A> 11564917	Mar 07, 2036	U-1995			
	>A> 11564917*PED	Sep 07, 2036				
	>A> 11648244	Mar 07, 2036	U-1995			
	>A> 11648244*PED	Sep 07, 2036				
	>A> 11813232	Mar 15, 2038	DP			
	>A> 11813232*PED	Sep 15, 2038				
	>A> 12016858	Mar 07, 2036	U-1995			
	>A> 12016858	Mar 07, 2036	U-3055			
	>A> 12016858*PED	Sep 07, 2036				
	>A> 8524733	Apr 03, 2031	DS DP			
	>A> 8524733*PED	Oct 03, 2031				
	>A> 9550780	Sep 18, 2033	DS DP U-1995			
	>A> 9550780	Sep 18, 2033	DS DP U-3055			
	>A> 9550780*PED	Mar 18, 2034				
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 006	>A> 10959996	Mar 07, 2036	U-3055			
	>A> 10959996*PED	Sep 07, 2036				
	>A> 11179386	Mar 15, 2038	DP U-1995			
	>A> 11179386	Mar 15, 2038	DP U-3055			
	>A> 11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	>A> 11357772	Mar 07, 2036	U-1995			
	>A> 11357772	Mar 07, 2036	U-3055			
	>A> 11357772*PED	Sep 07, 2036				
	>A> 11446291	Mar 07, 2036	U-1995			
	>A> 11446291*PED	Sep 07, 2036				
	>A> 11564917	Mar 07, 2036	U-1995			
	>A> 11564917*PED	Sep 07, 2036				
	>A> 11648244	Mar 07, 2036	U-1995			
	>A> 11648244*PED	Sep 07, 2036				
	>A> 11813232	Mar 15, 2038	DP			
	>A> 11813232*PED	Sep 15, 2038				
	>A> 12016858	Mar 07, 2036	U-1995			
	>A> 12016858	Mar 07, 2036	U-3055			
	>A> 12016858*PED	Sep 07, 2036				
	>A> 8524733	Apr 03, 2031	DS DP			
	>A> 8524733*PED	Oct 03, 2031				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 006	>A> 9550780	Sep 18, 2033	DS DP U-1995			
	>A> 9550780	Sep 18, 2033	DS DP U-3055			
	>A> 9550780*PED	Mar 18, 2034				
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 007	>A> 10959996	Mar 07, 2036			U-3055	
	>A> 10959996*PED	Sep 07, 2036				
	>A> 11179386	Mar 15, 2038	DP U-1995			
	>A> 11179386	Mar 15, 2038	DP U-3055			
	>A> 11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	>A> 11357772	Mar 07, 2036			U-1995	
	>A> 11357772	Mar 07, 2036			U-3055	
	>A> 11357772*PED	Sep 07, 2036				
	>A> 11446291	Mar 07, 2036			U-1995	
	>A> 11446291*PED	Sep 07, 2036				
	>A> 11564917	Mar 07, 2036			U-1995	
	>A> 11564917*PED	Sep 07, 2036				
	>A> 11648244	Mar 07, 2036			U-1995	
	>A> 11648244*PED	Sep 07, 2036				
	>A> 11813232	Mar 15, 2038	DP			
	>A> 11813232*PED	Sep 15, 2038				
	>A> 12016858	Mar 07, 2036			U-1995	
	>A> 12016858	Mar 07, 2036			U-3055	
	>A> 12016858*PED	Sep 07, 2036				
	>A> 8524733	Apr 03, 2031	DS DP			
	>A> 8524733*PED	Oct 03, 2031				
	>A> 9550780	Sep 18, 2033	DS DP U-1995			
	>A> 9550780	Sep 18, 2033	DS DP U-3055			
	>A> 9550780*PED	Mar 18, 2034				
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 008	>A> 10959996	Mar 07, 2036			U-3055	
	>A> 10959996*PED	Sep 07, 2036				
	>A> 11179386	Mar 15, 2038	DP U-1995			
	>A> 11179386	Mar 15, 2038	DP U-3055			
	>A> 11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	>A> 11357772	Mar 07, 2036			U-1995	
	>A> 11357772	Mar 07, 2036			U-3055	
	>A> 11357772*PED	Sep 07, 2036				
	>A> 11446291	Mar 07, 2036			U-1995	
	>A> 11446291*PED	Sep 07, 2036				
	>A> 11564917	Mar 07, 2036			U-1995	
	>A> 11564917*PED	Sep 07, 2036				
	>A> 11648244	Mar 07, 2036			U-1995	
	>A> 11648244*PED	Sep 07, 2036				
	>A> 11813232	Mar 15, 2038	DP			
	>A> 11813232*PED	Sep 15, 2038				
	>A> 12016858	Mar 07, 2036			U-1995	
	>A> 12016858	Mar 07, 2036			U-3055	
	>A> 12016858*PED	Sep 07, 2036				
	>A> 8524733	Apr 03, 2031	DS DP			
	>A> 8524733*PED	Oct 03, 2031				
	>A> 9550780	Sep 18, 2033	DS DP U-1995			
	>A> 9550780	Sep 18, 2033	DS DP U-3055			
	>A> 9550780*PED	Mar 18, 2034				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</u>						
N 215390 001	11890272	Jul 17, 2040			U-3756	
	11890272	Jul 17, 2040			U-3935	
	11998528	Jan 12, 2043			U-3935	
	11998529	Jul 17, 2040			U-3935	

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</u>						
N 215390 002	11890272	Jul 17, 2040	U-3756			
	11890272	Jul 17, 2040	U-3935			
	11998528	Jan 12, 2043	U-3935			
	11998529	Jul 17, 2040	U-3935			
<u>DIAZEPAM - LIBERVANT</u>						
N 218623 001	11273131	Jun 18, 2038	DP		NP	Apr 26, 2027
<u>DIAZEPAM - LIBERVANT</u>						
N 218623 002	11273131	Jun 18, 2038	DP		NP	Apr 26, 2027
<u>DIAZEPAM - LIBERVANT</u>						
N 218623 003	11273131	Jun 18, 2038	DP		NP	Apr 26, 2027
<u>DIAZEPAM - LIBERVANT</u>						
N 218623 004	11273131	Jun 18, 2038	DP		NP	Apr 26, 2027
<u>DIAZEPAM - LIBERVANT</u>						
N 218623 005	11273131	Jun 18, 2038	DP		NP	Apr 26, 2027
<u>DOLUTEGRAVIR SODIUM; LAMIVUDINE - DOVATO</u>						
N 211994 001					NPP	Apr 05, 2027
<u>DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE - JULUCA</u>						
N 210192 001	12011506	Sep 05, 2038	DP			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 001	8168209	Nov 22, 2025	DP		Y	
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641		Y	
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641		Y	
	8283379*PED	May 22, 2026				
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 002	8168209	Nov 22, 2025	DP		Y	
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641		Y	
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641		Y	
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP		Y	
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-1641		Y	
	8362085*PED	May 22, 2026				
	8598233	Nov 22, 2025	DP		Y	
	8598233*PED	May 22, 2026				
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 004	8168209	Nov 22, 2025	DP		Y	
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641		Y	
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641		Y	
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP		Y	
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-1641		Y	
	8362085*PED	May 22, 2026				
	8598233	Nov 22, 2025	DP		Y	
	8598233*PED	May 22, 2026				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DROSPIRENONE - SLYND</u>						
N 211367 001	11951213	Jun 28, 2031	U-2553			
<u>DROSPIRENONE - DROSPIRENONE</u>						
N 216285 001	11951213	Jun 28, 2031	U-2553			
<u>DROSPIRENONE; ESTETROL - NEXTSTELLIS</u>						
N 214154 001	11957694	Jun 17, 2036	DP			
	11964055	Jun 17, 2036	DP			
<u>EDARAVONE - RADICAVA ORS</u>						
N 215446 001	11957660	Nov 01, 2039	DP		ODE-144	May 12, 2029
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 001					M-14	Oct 18, 2026
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 002					M-14	Oct 18, 2026
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 003					M-14	Oct 18, 2026
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	11872218	Jan 03, 2028	U-1969			
<u>EFLORNITHINE HYDROCHLORIDE - IWILFIN</u>						
N 215500 001					NP ODE-462	Dec 13, 2026 Dec 13, 2030
<u>ELAFIBRANOR - IOIRVO</u>						
N 218860 001	11185519	Mar 30, 2037	U-3955		NCE	Jun 10, 2029
	11331292	Mar 30, 2037	U-1854		ODE-486	Jun 10, 2031
	11850223	Mar 30, 2037	U-1854			
	11857523	Mar 30, 2037	U-3955			
	7632870	Sep 09, 2024	DP			
	7943661	Sep 09, 2024	DS DP			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 001	7419983	Jul 06, 2029	DS DP U-2360			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 002	7419983	Jul 06, 2029	DS DP U-2360			
<u>ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE; ELAGOLIX SODIUM - ORIAHNN (COPACKAGED)</u>						
N 213388 001	7419983	Jul 06, 2029	DS DP			
<u>ELTROMBOPAG CHOLINE - ALVAIZ</u>						
N 216774 001	11072586	Nov 05, 2038	DS DP U-3936			
	11072586	Nov 05, 2038	DS DP U-3937			
	11072586	Nov 05, 2038	DS DP U-3938			
<u>ELTROMBOPAG CHOLINE - ALVAIZ</u>						
N 216774 002	11072586	Nov 05, 2038	DS DP U-3936			
	11072586	Nov 05, 2038	DS DP U-3937			
	11072586	Nov 05, 2038	DS DP U-3938			
<u>ELTROMBOPAG CHOLINE - ALVAIZ</u>						
N 216774 003	11072586	Nov 05, 2038	DS DP U-3936			
	11072586	Nov 05, 2038	DS DP U-3937			
	11072586	Nov 05, 2038	DS DP U-3938			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG CHOLINE - ALVAIZ</u>						
N 216774 004	11072586	Nov 05, 2038	DS DP U-3936			
	11072586	Nov 05, 2038	DS DP U-3937			
	11072586	Nov 05, 2038	DS DP U-3938			
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 002					ODE-457	Jan 07, 2029
<u>ENSIFENTRINE - OHTUVAYRE</u>						
N 217389 001	10945950	Sep 15, 2035	DP		NCE	Jun 26, 2029
	9062047	Aug 21, 2031	DS U-3962			
	9956171	Sep 15, 2035	DP U-3962			
<u>EPHEDRINE SULFATE - EPHEDRINE SULFATE</u>						
N 213994 002	12029710	Jan 22, 2040	U-3963			
<u>EPINEPHRINE - NEFFY</u>						
N 214697 001	>A> 10576156	Feb 06, 2038	DP			
	>A> 10682414	Feb 06, 2039	U-3979			
	>A> 11173209	Feb 06, 2038	U-3979			
	>A> 11191838	Feb 06, 2039	DP U-3979			
	>A> 11717571	Feb 06, 2039	U-3979			
	>A> 11744895	Feb 06, 2039	U-3979			
	>A> 11918655	Feb 06, 2039	DP U-3979			
<u>EPLONTERSEN SODIUM - WAINUA (AUTOINJECTOR)</u>						
N 217388 001	10683499	Aug 25, 2034	DS DP U-2378		NCE	Dec 21, 2028
	8101743	Apr 01, 2025	DS DP		ODE-461	Dec 21, 2030
	9127276	May 01, 2034	DS			
	9181549	May 01, 2034	DS			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 001	10478494	Aug 13, 2036	U-3902		I-930	Jan 19, 2027
	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
	10898482	Feb 09, 2036	DP U-3805			
	10898482	Feb 09, 2036	DP U-3806			
	10898482	Feb 09, 2036	DP U-3807			
	11077106	Feb 02, 2038	U-3196			
	11077106	Feb 02, 2038	U-3808			
	11684620	Feb 09, 2036	U-3805			
	11684620	Feb 09, 2036	U-3806			
	11684620	Feb 09, 2036	U-3807			
	>A> 12037644	Oct 18, 2035	U-3972			
	9464071	Apr 28, 2031	U-3805			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 002	10478494	Aug 13, 2036	U-3902		I-930	Jan 19, 2027
	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
	10898482	Feb 09, 2036	DP U-3805			
	10898482	Feb 09, 2036	DP U-3806			
	10898482	Feb 09, 2036	DP U-3807			
	11077106	Feb 02, 2038	U-3196			
	11077106	Feb 02, 2038	U-3808			
	11684620	Feb 09, 2036	U-3805			
	11684620	Feb 09, 2036	U-3806			
	11684620	Feb 09, 2036	U-3807			
	>A> 12037644	Oct 18, 2035	U-3972			
	9464071	Apr 28, 2031	U-3805			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 003	10478494	Aug 13, 2036	U-3902		I-930	Jan 19, 2027
	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
	10898482	Feb 09, 2036	DP U-3805			
	10898482	Feb 09, 2036	DP U-3806			
	10898482	Feb 09, 2036	DP U-3807			
	11077106	Feb 02, 2038	U-3196			
	11077106	Feb 02, 2038	U-3808			
	11684620	Feb 09, 2036	U-3805			
	11684620	Feb 09, 2036	U-3806			
	11684620	Feb 09, 2036	U-3807			
>A>	12037644	Oct 18, 2035	U-3972			
	9464071	Apr 28, 2031	U-3805			
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	11883526	Feb 18, 2040	U-3812			
	11883526	Feb 18, 2040	U-3813			
<u>ESTRADIOL - ESTRADIOL</u>						
A 216160 001					CGT	Oct 23, 2024
<u>ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE</u>						
N 214846 001	11957684	Sep 29, 2037	U-3129			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 001	11865179	Nov 21, 2032	DS DP			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 002	11865179	Nov 21, 2032	DS DP			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 001	11959486	Jun 27, 2034	DP U-2014			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 002	11959486	Jun 27, 2034	DP U-2014			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 003	11959486	Jun 27, 2034	DP U-2014			
<u>ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA</u>						
N 209627 001	11850251	Jun 21, 2039	U-3785			
<u>ETRASIMOD ARGININE - VELSIPITY</u>						
N 216956 001	11884626	Jun 21, 2036	U-3731			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	7612109	Feb 05, 2025	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 002	7612109	Feb 05, 2025	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 003	7612109	Feb 05, 2025	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 004	7612109	Feb 05, 2025	DS DP			
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171 001	11851504	Mar 25, 2029	DS DP			
	12030962	Mar 25, 2029	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171 001	11851504	Mar 25, 2029	DS DP			
	12030962	Mar 25, 2029	DS DP			
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171 002	11851504	Mar 25, 2029	DS DP			
	12030962	Mar 25, 2029	DS DP			
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171 003	11851504	Mar 25, 2029	DS DP			
	12030962	Mar 25, 2029	DS DP			
<u>FERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001					NPP PED	Jul 01, 2027 Jan 01, 2028
<u>FIDAXOMICIN - DIFICID</u>						
N 213138 001	8586551*PED	Jan 15, 2024				
<u>FINERENONE - KERENDIA</u>						
N 215341 001	RE49826	Jul 29, 2035	DS			
<u>FINERENONE - KERENDIA</u>						
N 215341 002	RE49826	Jul 29, 2035	DS			
<u>FLOTUFOLASTAT F-18 GALLIUM - POSLUMA</u>						
N 216023 001	12036290	Nov 27, 2041	DP U-3614			
	12036290	Nov 27, 2041	DP U-3615			
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054 001	11980674	Apr 23, 2042	U-2450			
<u>FLUOROMETHOLONE - FLUOROMETHOLONE</u>						
A 216348 001					CGT	Jul 07, 2024
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 001	7500444	Feb 26, 2026	DP	Y		
	7500444*PED	Aug 26, 2026				
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 002	7500444	Feb 26, 2026	DP	Y		
	7500444*PED	Aug 26, 2026				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 004	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 005	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 006	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 007	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 008	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001					I-940	Mar 15, 2027
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 004	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 005	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 006	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FOSAPREPITANT DIMEGLUMINE - FOCINVEZ</u>						
N 216686 001	>A> 12042504	Jan 11, 2039	DP			
<u>FOSTEMSAVIR TROMETHAMINE - RUKOBIA</u>						
N 212950 001	8168615	Jul 13, 2029	DP			
<u>FRUQUINTINIB - FRUZAOLA</u>						
N 217564 001				>A> NCE		Nov 08, 2028
<u>FRUQUINTINIB - FRUZAOLA</u>						
N 217564 002				>A> NCE		Nov 08, 2028
<u>GILTERITINIB FUMARATE - XOSPATA</u>						
N 211349 001	11938130	Jul 01, 2036	DP			
	11938131	Jul 01, 2036	DP			
	11938132	Jul 01, 2036	DP			
	11938133	Jul 01, 2036	DP			
	11944620	Jul 01, 2036	DP			
	8969336	Nov 28, 2032	DS DP			
<u>GIVINOSTAT HYDROCHLORIDE - DUVYZAT</u>						
N 217865 001	10688047	Oct 28, 2036	DP U-3885		NCE	Mar 21, 2029
	7329689	Jan 15, 2025	DS DP		ODE-473	Mar 21, 2031
	9421184	Feb 03, 2032	U-3885			
	9867799	Feb 03, 2032	U-3885			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GIVINOSTAT HYDROCHLORIDE - DUVYZAT</u>						
N 217865 001	10688047	Oct 28, 2036	DP U-3885		NCE	Mar 21, 2029
	7329689	Jan 15, 2025	DS DP		ODE-473	Mar 21, 2031
	9421184	Feb 03, 2032	U-3885			
	9867799	Feb 03, 2032	U-3885			
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656 001	11891372	Apr 13, 2036	U-3254			
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656 002	11891372	Apr 13, 2036	U-3254			
<u>GLYCEROL PHENYL BUTYRATE - RAVICTI</u>						
N 203284 001	8404215	Mar 09, 2032	U-1383	Y		
	9254278	Sep 22, 2030	U-1816			
	9326966	Sep 22, 2030	U-1816			
<u>GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE - PREVDUO</u>						
N 216903 001	11938217	Oct 25, 2038	DP			
<u>GOLODIRSEN - VYONDYS 53</u>						
N 211970 001	RE47691	Jun 28, 2028	DP			
<u>HALOBETASOL PROPIONATE - HALOBETASOL PROPIONATE</u>						
A 215266 001					PC	Jun 24, 2024
<u>HALOBETASOL PROPIONATE - BRYHALI</u>						
N 209355 001	11957753	Nov 02, 2031	DP			
	11986527	Nov 02, 2031	U-2625			
<u>HALOBETASOL PROPIONATE; TAZAROTENE - DUOBRII</u>						
N 209354 001	11957753	Nov 02, 2031	DP			
	11986527	Nov 02, 2031	U-2625			
<u>HEPARIN SODIUM; TAUROLIDINE - DEFENCATH</u>						
N 214520 001					NCE GAIN	Nov 15, 2028 Nov 15, 2033
<u>HEPARIN SODIUM; TAUROLIDINE - DEFENCATH</u>						
N 214520 002					NCE GAIN	Nov 15, 2028 Nov 15, 2033
<u>HYDROMORPHONE HYDROCHLORIDE - HYDROMORPHONE HYDROCHLORIDE</u>						
A 216899 002					PC	Nov 11, 2024
<u>HYDROMORPHONE HYDROCHLORIDE - HYDROMORPHONE HYDROCHLORIDE</u>						
A 216899 003					PC	Dec 02, 2024
<u>HYDROXYUREA - XROMI</u>						
N 216593 001					NP ODE-470	Apr 04, 2027 Apr 04, 2031
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8754090	Jun 03, 2031	U-1456	Y	M-14	Aug 24, 2025
	8754090*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	8754090	Jun 03, 2031	U-1456	Y	M-14	Aug 24, 2025
	8754090*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	8754090	Jun 03, 2031	U-1456	Y	M-14	Aug 24, 2025
	8754090*PED	Dec 03, 2031				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	8754090	Jun 03, 2031	U-1456	Y	M-14	Aug 24, 2025
	8754090*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	8754090	Jun 03, 2031	U-1456	Y	M-14	Aug 24, 2025
	8754090*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	8754090	Jun 03, 2031	U-1456	Y	M-14	Aug 24, 2025
	8754090*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004					M-14	Aug 24, 2025
<u>IBRUTINIB - IMBRUVICA</u>						
N 217003 001	10004746	Jun 03, 2031	U-3846			
	10004746	Jun 03, 2031	U-3847			
	10004746	Jun 03, 2031	U-3848			
	10004746	Jun 03, 2031	U-3849			
	10016435	Jun 03, 2031	U-3845			
	10463668	Oct 24, 2034	U-2970			
	10478439	Jun 03, 2031	U-2666			
	10478439	Jun 03, 2031	U-2970			
	10478439	Jun 03, 2031	U-3422			
	10478439	Jun 03, 2031	U-3842			
	10478439	Jun 03, 2031	U-3843			
	10478439	Jun 03, 2031	U-3844			
	10478439	Jun 03, 2031	U-3845			
	10478439*PED	Dec 03, 2031				
	10695350	Oct 24, 2034	U-2970			
	10751342	Jun 03, 2031	U-2666			
	10751342	Jun 03, 2031	U-3842			
	10751342	Jun 03, 2031	U-3843			
	10751342	Jun 03, 2031	U-3844			
	11672803	Jun 03, 2031	U-2666			
	11672803	Jun 03, 2031	U-3842			
	11672803	Jun 03, 2031	U-3843			
	11672803	Jun 03, 2031	U-3844			
	8476284	Dec 28, 2026	U-3843			
	8476284	Dec 28, 2026	U-3844			
	8476284	Dec 28, 2026	U-3845			
	8497277	Dec 28, 2026	U-2666			
	8497277	Dec 28, 2026	U-2970			
	8497277	Dec 28, 2026	U-3422			
	8497277	Dec 28, 2026	U-3842			
	8497277	Dec 28, 2026	U-3843			
	8497277	Dec 28, 2026	U-3844			
	8497277	Dec 28, 2026	U-3845			
	8497277*PED	Jun 28, 2027				
	8563563	Apr 26, 2027	U-2666			
	8563563	Apr 26, 2027	U-3842			
	8563563	Apr 26, 2027	U-3843			
	8563563	Apr 26, 2027	U-3844			
	8563563	Apr 26, 2027	U-3845			
	8703780	Dec 28, 2026	U-2666			
	8703780	Dec 28, 2026	U-3842			
	8952015	Dec 28, 2026	U-2666			
	8952015	Dec 28, 2026	U-3842			
	8952015	Dec 28, 2026	U-3843			
	8952015	Dec 28, 2026	U-3844			
	8952015	Dec 28, 2026	U-3845			
	8999999	Jun 03, 2031	U-2666			
	8999999	Jun 03, 2031	U-3842			
	8999999	Jun 03, 2031	U-3843			
	8999999	Jun 03, 2031	U-3844			
	9125889	Jun 03, 2031	U-3845			
	9795604	Oct 24, 2034	U-2970			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 217003 001	9795604	Oct 24, 2034	U-3422			
	9795604*PED	Apr 24, 2035				
	9801881	Jun 03, 2031	U-3846			
	9801881	Jun 03, 2031	U-3847			
	9801883	Jun 03, 2031	U-2666			
	9801883	Jun 03, 2031	U-3842			
	9801883	Jun 03, 2031	U-3843			
	9801883	Jun 03, 2031	U-3844			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 001					NPP	May 11, 2026
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002					NPP	May 11, 2026
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 003					NPP	May 11, 2026
<u>ILOPERIDONE - FANAPT</u>						
N 022192 001					I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192 002					I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192 003					I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192 004					I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192 005					I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192 006					I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192 007					I-939	Apr 02, 2027
<u>ILOPROST - AURLUMYN</u>						
N 217933 001					NP ODE-465	Feb 13, 2027 Feb 13, 2031
<u>IMETELSTAT SODIUM - RYTELO</u>						
N 217779 001	7494982	Dec 27, 2025	DS DP		ODE-482	Jun 06, 2031
	9375485	Mar 15, 2033	U-3956			
	9388415	Sep 09, 2024	U-3956			
	9388416	Sep 09, 2024	U-3956			
<u>IMETELSTAT SODIUM - RYTELO</u>						
N 217779 002	7494982	Dec 27, 2025	DS DP		ODE-482	Jun 06, 2031
	9375485	Mar 15, 2033	U-3956			
	9388415	Sep 09, 2024	U-3956			
	9388416	Sep 09, 2024	U-3956			
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 001	11850245	Apr 30, 2030	U-1455			
	11850245	Apr 30, 2030	U-172			
<u>INDOMETHACIN - INDOMETHACIN</u>						
A 217883 001					CGT	Jul 10, 2024

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IPTACOPAN HYDROCHLORIDE - FABHALTA</u>						
N 218276 001	>A> 10093663	Jul 14, 2034	U-3980		>A> I-949	Aug 07, 2027
	>A> 11723901	Aug 30, 2038	U-3980		NCE	Dec 05, 2028
	11951101	Jul 15, 2041	U-3895		ODE-456	Dec 05, 2030
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001	11344552	Aug 19, 2036	U-3824		I-932	Feb 13, 2027
	>A> 12059497	Oct 15, 2036	DP		ODE-463	Feb 13, 2031
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500 001					NPP	Dec 08, 2026
					ODE-454	Dec 08, 2030
					ODE-458	Dec 08, 2030
					PED	Jun 08, 2027
					PED	Jun 08, 2031
					PED	Jun 08, 2031
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500 002					NPP	Dec 08, 2026
					ODE-454	Dec 08, 2030
					ODE-458	Dec 08, 2030
					PED	Jun 08, 2027
					PED	Jun 08, 2031
					PED	Jun 08, 2031
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207501 001					NPP	Dec 08, 2026
					ODE-453	Dec 08, 2030
					ODE-459	Dec 08, 2030
					PED	Jun 08, 2027
					PED	Jun 08, 2031
					PED	Jun 08, 2031
<u>IVABRADINE HYDROCHLORIDE - IVABRADINE HYDROCHLORIDE</u>						
A 214051 001					>A> PC	Jan 15, 2025
<u>IVABRADINE HYDROCHLORIDE - IVABRADINE HYDROCHLORIDE</u>						
A 214051 002					>A> PC	Jan 15, 2025
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	11951212	Apr 14, 2035	DP U-3894			
<u>LACOSAMIDE - MOTPOLY XR</u>						
N 216185 001	11337943	Jun 05, 2040	DP U-3660			
	11337943	Jun 05, 2040	DP U-3954			
	>A> 11883374	Jun 05, 2040	DP U-3660			
	>A> 11883374	Jun 05, 2040	DP U-3954			
	>A> 12042474	Jun 05, 2040	DP U-3660			
	>A> 12042474	Jun 05, 2040	DP U-3954			
<u>LACOSAMIDE - MOTPOLY XR</u>						
N 216185 002	11337943	Jun 05, 2040	DP U-3660			
	11337943	Jun 05, 2040	DP U-3954			
	>A> 11883374	Jun 05, 2040	DP U-3660			
	>A> 11883374	Jun 05, 2040	DP U-3954			
	>A> 12042474	Jun 05, 2040	DP U-3660			
	>A> 12042474	Jun 05, 2040	DP U-3954			
<u>LACOSAMIDE - MOTPOLY XR</u>						
N 216185 003	11337943	Jun 05, 2040	DP U-3660			
	11337943	Jun 05, 2040	DP U-3954			
	>A> 11883374	Jun 05, 2040	DP U-3660			
	>A> 11883374	Jun 05, 2040	DP U-3954			
	>A> 12042474	Jun 05, 2040	DP U-3660			
	>A> 12042474	Jun 05, 2040	DP U-3954			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LACOSAMIDE - MOTPOLY XR</u>						
N 216185 003	11337943	Jun 05, 2040	DP U-3660			
	11337943	Jun 05, 2040	DP U-3954			
	>A> 11883374	Jun 05, 2040	DP U-3660			
	>A> 11883374	Jun 05, 2040	DP U-3954			
	>A> 12042474	Jun 05, 2040	DP U-3660			
	>A> 12042474	Jun 05, 2040	DP U-3954			
<u>LANSOPRAZOLE - LANSOPRAZOLE</u>						
N 208025 001	11986554	Apr 21, 2036	DP			
<u>LATANOPROST - IYUZEH</u>						
N 216472 001	8637054	Jul 08, 2031	DP U-446			
<u>LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN</u>						
N 208259 001	11020385	Mar 14, 2034	U-1524			
<u>LATANOPROSTENE BUNOD - VYZULTA</u>						
N 207795 001	8058467	Feb 21, 2029	DS U-2144			
<u>LEMBOREXANT - DAYVIGO</u>						
N 212028 001	10702529	Oct 21, 2035	DP			
	11026944	Oct 21, 2035	DP			
<u>LEMBOREXANT - DAYVIGO</u>						
N 212028 002	10702529	Oct 21, 2035	DP			
	11026944	Oct 21, 2035	DP			
<u>LENACAPAVIR SODIUM - SUNLENCA</u>						
N 215973 001	11944611	Jun 04, 2041	U-3507			
<u>LENACAPAVIR SODIUM - SUNLENCA</u>						
N 215974 001	11944611	Jun 04, 2041	DS DP U-3507			
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	10259791	Aug 26, 2035	DS		I-868	Aug 10, 2024
	10259791*PED	Feb 26, 2036			M-14	Apr 03, 2027
	10407393	Aug 26, 2035	DS		M-269	Jul 21, 2024
	10407393*PED	Feb 26, 2036			M-272	Dec 19, 2024
	11090386	Feb 23, 2036	U-3519		ODE-196	Aug 15, 2025
	11090386*PED	Aug 23, 2036			PED	Feb 15, 2026
	11186547	Aug 26, 2035	DS		PED	Oct 03, 2027
	11186547*PED	Feb 26, 2036				
	7253286	Oct 24, 2025	DS DP			
	7253286*PED	Apr 24, 2026				
	7612208	Sep 19, 2026	DS DP			
	7612208*PED	Mar 19, 2027				
	9006256	Jul 27, 2027	U-1695			
	9006256*PED	Jan 27, 2028				
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	10259791	Aug 26, 2035	DS		I-868	Aug 10, 2024
	10259791*PED	Feb 26, 2036			M-14	Apr 03, 2027
	10407393	Aug 26, 2035	DS		M-269	Jul 21, 2024
	10407393*PED	Feb 26, 2036			M-272	Dec 19, 2024
	11090386	Feb 23, 2036	U-3519		ODE-196	Aug 15, 2025
	11090386*PED	Aug 23, 2036			PED	Feb 15, 2026
	11186547	Aug 26, 2035	DS		PED	Oct 03, 2027
	11186547*PED	Feb 26, 2036				
	7253286	Oct 24, 2025	DS DP			
	7253286*PED	Apr 24, 2026				
	7612208	Sep 19, 2026	DS DP			
	7612208*PED	Mar 19, 2027				
	9006256	Jul 27, 2027	U-1695			
	9006256*PED	Jan 27, 2028				



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	10259791	Aug 26, 2035	DS		I-868	Aug 10, 2024
	10259791*PED	Feb 26, 2036			M-14	Apr 03, 2027
	10407393	Aug 26, 2035	DS		M-269	Jul 21, 2024
	10407393*PED	Feb 26, 2036			M-272	Dec 19, 2024
	11090386	Feb 23, 2036		U-3519	ODE-196	Aug 15, 2025
	11090386*PED	Aug 23, 2036			PED	Feb 15, 2026
	11186547	Aug 26, 2035	DS		PED	Oct 03, 2027
	11186547*PED	Feb 26, 2036				
	7253286	Oct 24, 2025	DS DP			
	7253286*PED	Apr 24, 2026				
	7612208	Sep 19, 2026	DS DP			
	7612208*PED	Mar 19, 2027				
	9006256	Jul 27, 2027		U-1695		
	9006256*PED	Jan 27, 2028				
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 001	RE46791	Jan 18, 2029	DS DP			
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 002	RE46791	Jan 18, 2029	DS DP			
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 001	RE46791	Jan 18, 2029	DS DP			
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 002	RE46791	Jan 18, 2029	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021343 001	11931559	Dec 22, 2041	DS			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021379 001	11931559	Dec 22, 2041	DS			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021488 001	11931559	Dec 22, 2041	DS			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021731 001	11931559	Dec 22, 2041	DS			
<u>LEUPROLIDE ACETATE - FENSOLVI KIT</u>						
N 213150 001	11931559	Dec 22, 2041	DS			
<u>LEVOKETOCONAZOLE - RECORLEV</u>						
N 214133 001	11903940	Mar 02, 2040		U-3821		
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 001					M-304	Mar 24, 2026
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 002					M-304	Mar 24, 2026
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 003					M-304	Mar 24, 2026
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 004					M-304	Mar 24, 2026
<u>LEVONORGESTREL - MIRENA</u>						
N 021225 001	11850182	Sep 14, 2029	DP U-3819			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVONORGESTREL - SKYLA</u>						
N 203159 001	11850182	Sep 14, 2029	DP U-3819			
<u>LEVONORGESTREL - LILETTA</u>						
N 206229 001	12004992	Oct 06, 2033	DS			
<u>LEVONORGESTREL - KYLEENA</u>						
N 208224 001	11850182	Sep 14, 2029	DP U-3819			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	11911388	Apr 10, 2030	U-3854			
<u>LOFEXIDINE HYDROCHLORIDE - LOFEXIDINE HYDROCHLORIDE</u>						
A 218613 001				>A> CGT		Feb 24, 2025
<u>LOTEPREDNOL ETABONATE - INVELTYS</u>						
N 210565 001	11872318	May 03, 2033	DP			
<u>LOTEPREDNOL ETABONATE - EYSUVIS</u>						
N 210933 001	11872318	May 03, 2033	DP			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 001	11980617	Oct 27, 2039	U-3940			
	>A> 12070459	Aug 30, 2039	DP U-3362			
	>A> 12070459	Aug 30, 2039	DP U-3363			
	8598119	Dec 28, 2029	U-543	Y		
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 002	11980617	Oct 27, 2039	U-3940			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 003	11980617	Oct 27, 2039	U-3940			
<u>LUTETIUM LU 177 DOTATATE - LUTATHERA</u>						
N 208700 001	10596276	Jul 25, 2038	DP		NPP	Apr 23, 2027
	10596276*PED	Jan 25, 2039			ODE-166	Jan 26, 2025
	10596278	Jul 25, 2038	DP		ODE-479	Apr 23, 2031
	10596278*PED	Jan 25, 2039			PED	Jul 26, 2025
	11904027	Jul 25, 2038	DP		PED	Oct 23, 2027
	11904027*PED	Jan 25, 2039			PED	Oct 23, 2031
<u>LUTETIUM LU-177 VIPIVOTIDE TETRAJETAN - PLUVICTO</u>						
N 215833 001	11951190	Nov 12, 2035	U-3345			
<u>MACITENTAN; TADALAFIL - OPSYNVI</u>						
N 218490 001	10946015	Sep 11, 2026	DP U-3881		NP	Mar 22, 2027
	7094781	Dec 05, 2025	DS DP		ODE-475	Mar 22, 2031
	8268847	Apr 18, 2029	DP U-3882			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MACITENTAN; TADALAFIL - OPSYNVI</u>						
N 218490 001	10946015	Sep 11, 2026	DP U-3881		NP	Mar 22, 2027
	7094781	Dec 05, 2025	DS DP		ODE-475	Mar 22, 2031
	8268847	Apr 18, 2029	DP U-3882			
<u>MACITENTAN; TADALAFIL - OPSYNVI</u>						
N 218490 002	10946015	Sep 11, 2026	DP U-3881		NP	Mar 22, 2027
	7094781	Dec 05, 2025	DS DP		ODE-475	Mar 22, 2031
	8268847	Apr 18, 2029	DP U-3882			
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 214662 001	>A> 10512657	Oct 26, 2032	U-3850		I-938	Mar 13, 2027
	>A> 11229647	Feb 12, 2040	U-3290		ODE-471	Mar 13, 2031
	>A> 11229647	Feb 12, 2040	U-3974			
	>A> 11229661	Oct 26, 2032	U-3850			
	>A> 11260053	May 26, 2031	U-3290			
	>A> 11260053	May 26, 2031	U-3974			
	>A> 11376251	Oct 26, 2032	U-3290			
	>A> 11376251	Oct 26, 2032	U-3974			
	>A> 11497745	Feb 12, 2040	U-3290			
	>A> 11497745	Feb 12, 2040	U-3974			
	>A> 11918578	Feb 12, 2040	U-3290			
	>A> 11918578	Feb 12, 2040	U-3974			
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 214662 002	>A> 10512657	Oct 26, 2032	U-3973		>A> NCE	Sep 29, 2026
	>A> 11229661	Oct 26, 2032	U-3973			
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 001	>A> RE50050	Jun 19, 2034	DS DP			
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 002	>A> RE50050	Jun 19, 2034	DS DP			
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 003	>A> RE50050	Jun 19, 2034	DS DP			
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 004	>A> RE50050	Jun 19, 2034	DS DP			
<u>MAVORIXAFOR - XOLREMDI</u>						
N 218709 001	10548889	Dec 11, 2038	DP		NCE	Apr 26, 2029
	10610527	Dec 22, 2036	U-3932		ODE-480	Apr 26, 2031
	10953003	Dec 14, 2036	DP			
	11045461	Dec 11, 2038	DP			
	11219621	Dec 22, 2036	U-3932			
<u>METAXALONE - METAXALONE</u>						
N 022503 001	11918559	Jul 29, 2039	DP			
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400 001	11969503	Jan 02, 2033	DP			
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630 001					M-303	Jan 08, 2027
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630 002					M-303	Jan 08, 2027
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	11911518	Mar 23, 2032	U-2357			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	11911518	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	11911518	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	11911518	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	11911518	Mar 23, 2032	U-2357			
<u>MIFEPRISTONE - MIFEPRISTONE</u>						
A 211436 001					PC	Jul 17, 2024
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	11969435	Jun 19, 2037	U-1643			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	11903938	Aug 17, 2038	DS U-2371			
	12042488	May 30, 2038	DS			
	12042489	May 30, 2038	DS U-2371			
	12042490	May 30, 2038	U-2371			
	RE48608	Oct 20, 2031	U-2371			
<u>MINOCYCLINE HYDROCHLORIDE - MINOCIN</u>						
N 050444 001	11944634	Oct 16, 2032	DP			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	>A> 12059409	Sep 28, 2029	DP			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	>A> 12059409	Sep 28, 2029	DP			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 001	11878049	Jul 31, 2041	U-3782			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 002	11878049	Jul 31, 2041	U-3782			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 003	11878049	Jul 31, 2041	U-3782			
<u>MOMELOTINIB DIHYDROCHLORIDE - OJJAARA</u>						
N 216873 001	11963962	Dec 02, 2040	U-3928			
<u>MOMELOTINIB DIHYDROCHLORIDE - OJJAARA</u>						
N 216873 002	11963962	Dec 02, 2040	U-3928			
<u>MOMELOTINIB DIHYDROCHLORIDE - OJJAARA</u>						
N 216873 003	11963962	Dec 02, 2040	U-3928			
<u>MONOMETHYL FUMARATE - BAFIERTAM</u>						
N 210296 001	11903918	Feb 27, 2035	U-1384			
<u>MYCOPHENOLATE MOFETIL - MYHIBBIN</u>						
N 216482 001	11931455	Aug 16, 2039	DP U-1752			
<u>NALMEFENE HYDROCHLORIDE - ZURNAI (AUTOINJECTOR)</u>						
N 218590 001	>A> 10279131	Jul 31, 2031	DP			
	>A> 10357609	Aug 21, 2031	DP			
	>A> 10478560	Jan 24, 2026	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NALMEFENE HYDROCHLORIDE - ZURNAI (AUTOINJECTOR)</u>						
N 218590 001	>A> 10881798	Feb 11, 2034	DP			
	>A> 10905827	Aug 21, 2031	DP			
	>A> 11185642	Aug 28, 2031	DP			
	>A> 11191908	Oct 18, 2035	DP			
	>A> 11446440	Aug 21, 2031	DP			
	>A> 11446441	Jan 24, 2026	DP			
	>A> 11813435	Feb 25, 2035	DP			
	>A> 11857547	Nov 05, 2039	DP			
	>A> 11865112	Nov 05, 2039	DP	U-3630		
	>A> 8021335	Oct 04, 2026	DP			
	>A> 8496619	Aug 21, 2031	DP			
	>A> 8562564	Jan 24, 2026	DP			
	>A> 9180259	Jan 24, 2026	DP			
	>A> 9364610	Aug 21, 2031	DP			
	>A> 9364611	Aug 21, 2031	DP			
	>A> 9446195	Aug 21, 2031	DP			
	>A> 9533102	Jan 24, 2026	DP			
	>A> 9629959	Jan 24, 2026	DP			
<u>NALOXONE HYDROCHLORIDE - KLOXXADO</u>						
N 212045 001					NP	Apr 29, 2024
<u>NALOXONE HYDROCHLORIDE - REZENOPY</u>						
N 215487 001					NP	Apr 19, 2027
<u>NALOXONE HYDROCHLORIDE - RIVIVE</u>						
N 217722 001	11806428	May 11, 2032	DP			
<u>NETARSUDIL MESYLATE - RHOPRESSA</u>						
N 208254 001	11020385	Mar 14, 2034		U-1524		
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	>A> 12042494	Nov 18, 2030	DP	U-3522		
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 001	11872211	May 19, 2043		U-3754	NCE	Nov 27, 2028
	11884634	Aug 09, 2039	DP		ODE-452	Nov 27, 2030
	11884635	Aug 09, 2039	DP			
	11905255	Aug 09, 2039	DP			
	11925619	May 19, 2043		U-3754		
	11925620	May 19, 2043		U-3754		
	11938116	May 19, 2043		U-3754		
	11951096	May 19, 2043		U-3754		
	11957662	May 19, 2043		U-3754		
	12011434	May 19, 2043		U-3754		
	12011435	May 19, 2043		U-3754		
	12036207	May 19, 2043		U-3754		
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 002	10590087	Aug 09, 2039	DS		NCE	Nov 27, 2028
	10710966	Aug 09, 2039	DS	U-3754	ODE*	Nov 27, 2030
	10941118	Aug 09, 2039	DS	U-3754		
	11504354	Jul 08, 2042		DP		
	11612588	Jul 08, 2042		DP	U-3754	
	11807611	Sep 08, 2042		DP	U-3754	
	11820748	Aug 09, 2039		DP		
	11844780	Sep 08, 2042		DP	U-3754	
	11845732	Aug 09, 2039	DS	U-3754		
	11872211	May 19, 2043		U-3754		
	11884634	Aug 09, 2039		DP		
	11884635	Aug 09, 2039		DP		
	11905255	Aug 09, 2039		DP		
	11925619	May 19, 2043		U-3754		
	11925620	May 19, 2043		U-3754		
	11938116	May 19, 2043		U-3754		
	11951096	May 19, 2043		U-3754		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 002	11957662	May 19, 2043	U-3754			
	12011434	May 19, 2043	U-3754			
	12011435	May 19, 2043	U-3754			
	12036207	May 19, 2043	U-3754			
	7342118	Aug 18, 2025	DS			
	7795447	Aug 18, 2025	DS			
	7951958	Mar 11, 2025	DS			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 003	10590087	Aug 09, 2039	DS		NCE	Nov 27, 2028
	10710966	Aug 09, 2039	DS U-3754		ODE*	Nov 27, 2030
	10941118	Aug 09, 2039	DS U-3754			
	11504354	Jul 08, 2042	DP			
	11612588	Jul 08, 2042	DP U-3754			
	11807611	Sep 08, 2042	DP U-3754			
	11820748	Aug 09, 2039	DP			
	11844780	Sep 08, 2042	DP U-3754			
	11845732	Aug 09, 2039	DS U-3754			
	11872211	May 19, 2043	U-3754			
	11884634	Aug 09, 2039	DP			
	11884635	Aug 09, 2039	DP			
	11905255	Aug 09, 2039	DP			
	11925619	May 19, 2043	U-3754			
	11925620	May 19, 2043	U-3754			
	11938116	May 19, 2043	U-3754			
	11951096	May 19, 2043	U-3754			
	11957662	May 19, 2043	U-3754			
	12011434	May 19, 2043	U-3754			
	12011435	May 19, 2043	U-3754			
	12036207	May 19, 2043	U-3754			
	7342118	Aug 18, 2025	DS			
	7795447	Aug 18, 2025	DS			
	7951958	Mar 11, 2025	DS			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003	11931377	Jun 03, 2029	DS DP U-3903			
	11931377*PED	Dec 03, 2029				
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 004	11931377	Jun 03, 2029	DS DP U-3903			
<u>NITROGLYCERIN - NITROGLYCERIN</u>						
A 216103 001					CGT	Aug 21, 2024
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531 001	12013403	Mar 04, 2036	U-1941			
	12013403	Mar 04, 2036	U-1942			
	12013403	Mar 04, 2036	U-1943			
	12013403	Mar 04, 2036	U-1944			
	12013403	Mar 04, 2036	U-2093			
	12013403	Mar 04, 2036	U-2094			
	8361977	Dec 23, 2030	DS DP			
<u>OCTREOTIDE ACETATE - MYCAPSSA</u>						
N 208232 001	11857595	Feb 03, 2036	U-3784		ODE-474	Jun 26, 2027
	11890316	Dec 28, 2040	U-3232			
	11969471	Sep 17, 2029	DP			
	11986529	Sep 17, 2029	U-2857			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 001	11951111	Nov 12, 2041	U-3886			
	11951111	Nov 12, 2041	U-3887			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 002	11951111	Nov 12, 2041	U-3886			
	11951111	Nov 12, 2041	U-3887			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 003	11951111	Nov 12, 2041	U-3886			
	11951111	Nov 12, 2041	U-3887			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 004	11951111	Nov 12, 2041	U-3886			
	11951111	Nov 12, 2041	U-3887			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	11970530	Oct 25, 2041	U-3929			
	11970530	Oct 25, 2041	U-3930			
	11970530	Oct 25, 2041	U-3931			
	11975001	Oct 07, 2029	DP			
>A>	12048695	Oct 07, 2029	DP			
	7449464	Sep 08, 2027	DS DP			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	11970530	Oct 25, 2041	U-3929			
	11970530	Oct 25, 2041	U-3930			
	11970530	Oct 25, 2041	U-3931			
	11975001	Oct 07, 2029	DP			
>A>	12048695	Oct 07, 2029	DP			
	7449464	Sep 08, 2027	DS DP			
<u>OLICERIDINE - OLINVYK</u>						
N 210730 001	11931350	Mar 23, 2032	DS	U-2986		
<u>OLICERIDINE - OLINVYK</u>						
N 210730 002	11931350	Mar 23, 2032	DS	U-2986		
<u>OLICERIDINE - OLINVYK</u>						
N 210730 003	11931350	Mar 23, 2032	DS	U-2986		
<u>OLIVE OIL; SOYBEAN OIL - CLINOLIPID 20%</u>						
N 204508 001					NPP	Apr 24, 2027
<u>OLUTASIDENIB - REZLIDHIA</u>						
N 215814 001	>A> 12053463	May 16, 2039	DS DP			
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209816 001	7553828	Jun 02, 2025	DS			
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209817 001	7553828	Jun 02, 2025	DS			
<u>OMAVELOXOLONE - SKYCLARYS</u>						
N 216718 001	11919838	Apr 20, 2029	U-3862			
	11919838	Apr 20, 2029	U-3863			
<u>OMEPRAZOLE; SODIUM BICARBONATE - KONVOMEF</u>						
N 213593 001	11911473	Jul 16, 2039	U-623			
	11911473	Jul 16, 2039	U-624			
	12042539	Jul 16, 2039	DP			
<u>OPICAPONE - ONGENTYS</u>						
N 212489 001	10583130	Mar 31, 2030	U-3869			
	8168793	Apr 02, 2029	DS DP	U-3869		
	8524746	Jul 14, 2029	U-3869			
	9550759	Jul 26, 2026	U-3870			
	9550759	Jul 26, 2026	U-3871			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OPICAPONE - ONGENTYS</u>						
N 212489 001	9550759	Jul 26, 2026				
	9630955	Dec 12, 2032	DS DP			
	9745290	Oct 10, 2027	DP			
<u>OPICAPONE - ONGENTYS</u>						
N 212489 002	10583130	Mar 31, 2030				
	8168793	Apr 02, 2029	DS DP			
	8524746	Jul 14, 2029				
	9550759	Jul 26, 2026				
	9550759	Jul 26, 2026				
	9550759	Jul 26, 2026				
	9630955	Dec 12, 2032	DS DP			
	9745290	Oct 10, 2027	DP			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	10183020	Jan 02, 2035	DP		I-941	Feb 16, 2027
	10183020	Jan 02, 2035	DP			
	10183020	Jan 02, 2035	DP			
	10183020	Jan 02, 2035	DP			
	8946235	Aug 08, 2032	DS DP			
	8946235	Aug 08, 2032	DS DP			
	8946235	Aug 08, 2032	DS DP			
	8946235	Aug 08, 2032	DS DP			
	9732058	Jul 25, 2032	DS DP			
	9732058	Jul 25, 2032	DS DP			
	9732058	Jul 25, 2032	DS DP			
	9732058	Jul 25, 2032	DS DP			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	10183020	Jan 02, 2035	DP		I-941	Feb 16, 2027
	10183020	Jan 02, 2035	DP			
	10183020	Jan 02, 2035	DP			
	10183020	Jan 02, 2035	DP			
	8946235	Aug 08, 2032	DS DP			
	8946235	Aug 08, 2032	DS DP			
	8946235	Aug 08, 2032	DS DP			
	8946235	Aug 08, 2032	DS DP			
	9732058	Jul 25, 2032	DS DP			
	9732058	Jul 25, 2032	DS DP			
	9732058	Jul 25, 2032	DS DP			
	9732058	Jul 25, 2032	DS DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	11896599	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	11896599	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	11896599	Apr 13, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	11964056	Aug 24, 2027	DP			
	>A> 12060361	Mar 30, 2025	DP			U-1556
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	11964056	Aug 24, 2027	DP			
	>A> 12060361	Mar 30, 2025	DP			U-1556
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	11964056	Aug 24, 2027	DP			
	>A> 12060361	Mar 30, 2025	DP			U-1556



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	11964056	Aug 24, 2027	DP			
	>A> 12060361	Mar 30, 2025	DP U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	11964056	Aug 24, 2027	DP			
	>A> 12060361	Mar 30, 2025	DP U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	11964056	Aug 24, 2027	DP			
	>A> 12060361	Mar 30, 2025	DP U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	11964056	Aug 24, 2027	DP			
	>A> 12060361	Mar 30, 2025	DP U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 200534 001					M-14	Jul 21, 2024
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 200535 001					M-14	Jul 21, 2024
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 200535 002					M-14	Jul 21, 2024
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 201194 001					M-14	Jul 21, 2024
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 001	10239846	Nov 15, 2030	U-3740			
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 002	10239846	Nov 15, 2030	U-3740			
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 003	10239846	Nov 15, 2030	U-3740			
<u>PALIPERIDONE PALMITATE - ERZOFRI</u>						
N 216352 001	11666573	Sep 24, 2039	U-3968			
	11666573	Sep 24, 2039	U-3969			
<u>PALIPERIDONE PALMITATE - ERZOFRI</u>						
N 216352 002	11666573	Sep 24, 2039	U-3968			
	11666573	Sep 24, 2039	U-3969			
<u>PALIPERIDONE PALMITATE - ERZOFRI</u>						
N 216352 003	11666573	Sep 24, 2039	U-3968			
	11666573	Sep 24, 2039	U-3969			
<u>PALIPERIDONE PALMITATE - ERZOFRI</u>						
N 216352 004	11666573	Sep 24, 2039	U-3968			
	11666573	Sep 24, 2039	U-3969			
<u>PALIPERIDONE PALMITATE - ERZOFRI</u>						
N 216352 005	11666573	Sep 24, 2039	U-3968			
	11666573	Sep 24, 2039	U-3969			
<u>PALIPERIDONE PALMITATE - ERZOFRI</u>						
N 216352 006	11666573	Sep 24, 2039	U-3968			
	11666573	Sep 24, 2039	U-3969			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALOPEGTERIPARATIDE - YORVIPATH</u>						
N 216490 001					>A> ODE-492	Aug 09, 2031
<u>PALOPEGTERIPARATIDE - YORVIPATH</u>						
N 216490 002					>A> ODE-492	Aug 09, 2031
<u>PALOPEGTERIPARATIDE - YORVIPATH</u>						
N 216490 003					>A> ODE-492	Aug 09, 2031
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 001	12023312	Aug 31, 2031	U-3966			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 002	12023312	Aug 31, 2031	U-3966			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 003	12023312	Aug 31, 2031	U-3966			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 004	12023312	Aug 31, 2031	U-3966			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 005	12023312	Aug 31, 2031	U-3966			
<u>PATISIRAN SODIUM - ONPATRO</u>						
N 210922 001					M-270	Jan 13, 2026
<u>PEGCETACOPLAN - EMPAVELI</u>						
N 215014 001	11844841	Dec 09, 2038	DP U-3172			
	11844841	Dec 09, 2038	DP U-3173			
	11844841	Dec 09, 2038	DP U-3174			
<u>PEGCETACOPLAN - SYFOVRE</u>						
N 217171 001	11903994	Feb 22, 2037	U-3826			
	11903994	Feb 22, 2037	U-3827			
	11903994	Feb 22, 2037	U-3828			
<u>PEGULICIANINE ACETATE - LUMISIGHT</u>						
N 214511 001	10285759	Dec 08, 2031	U-3890		NCE	Apr 17, 2029
	9032965	Dec 08, 2031	U-3890			
	9155471	Oct 12, 2031	U-3890			
	9532835	Dec 08, 2031	U-3890			
	9763577	Sep 14, 2034	DS DP U-3890			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	11857646	Mar 16, 2037			U-665	
	11925695	Mar 16, 2037			U-665	
<u>PERFLUTREN - DEFINITY RT</u>						
N 021064 002	11857646	Mar 16, 2037			U-665	
	11925695	Mar 16, 2037			U-665	
<u>PHENTOLAMINE MESYLATE - RYZUMVI</u>						
N 217064 001	10278918	Jan 31, 2034			DP	
	10772829	Jan 31, 2034			DP	
	11090261	Jan 31, 2034			DP	
	11400077	Oct 25, 2039			U-3804	
	11844858	Jan 31, 2034			DP	
	9795560	Jan 31, 2034			DP	
<u>PHENYLEPHRINE HYDROCHLORIDE; TROPICAMIDE - MYDCOMBI</u>						
N 215352 001	11839487	Jul 15, 2031			U-3685	
<u>PIFLUFOLASTAT F-18 - PYLARIFY</u>						
N 214793 001	11851407	Jun 09, 2037	DS DP		U-3130	
<u>PILOCARPINE HYDROCHLORIDE - OLOSI</u>						
N 217836 001	11974986	Aug 18, 2037			U-3741	
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 001					ODE-451	Dec 01, 2030

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PIRTOBRUTINIB - JAYPIRCA</u> N 216059 002					ODE-451	Dec 01, 2030
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u> N 211150 001					>A> NPP >A> ODE-489	Jun 21, 2027 Jun 21, 2031
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u> N 211150 002					>A> NPP >A> ODE-489	Jun 21, 2027 Jun 21, 2031
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u> N 203469 001					I-934 ODE-472	Mar 19, 2027 Mar 19, 2031
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u> N 203469 002					I-934 ODE-472	Mar 19, 2027 Mar 19, 2031
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u> N 203469 003					I-934 ODE-472	Mar 19, 2027 Mar 19, 2031
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u> N 203469 004					I-934 ODE-472	Mar 19, 2027 Mar 19, 2031
<u>PONESIMOD - PONVORY</u> N 213498 001	11951097	Oct 10, 2042	U-3891			
<u>PONESIMOD - PONVORY</u> N 213498 002	11951097	Oct 10, 2042	U-3891			
<u>PONESIMOD - PONVORY</u> N 213498 003	11951097	Oct 10, 2042	U-3891			
<u>PONESIMOD - PONVORY</u> N 213498 004	11951097	Oct 10, 2042	U-3891			
<u>PONESIMOD - PONVORY</u> N 213498 005	11951097	Oct 10, 2042	U-3891			
<u>PONESIMOD - PONVORY</u> N 213498 006	11951097	Oct 10, 2042	U-3891			
<u>PONESIMOD - PONVORY</u> N 213498 007	11951097	Oct 10, 2042	U-3891			
<u>PONESIMOD - PONVORY</u> N 213498 008	11951097	Oct 10, 2042	U-3891			
<u>PONESIMOD - PONVORY</u> N 213498 009	11951097	Oct 10, 2042	U-3891			
<u>PONESIMOD - PONVORY</u> N 213498 010	11951097	Oct 10, 2042	U-3891			
<u>PRALSETINIB - GAVRETO</u> N 213721 001	11872192 11963958	Apr 03, 2039 Apr 03, 2039	U-2952 U-2828			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>REMDESIVIR - VEKLURY</u>						
N 214787 001	10065958	Sep 16, 2031	DS		D-183	Jan 21, 2025
	10065958*PED	Mar 16, 2032			M-301	Jul 13, 2026
	10675296	Jul 10, 2038	DP		NCE	Oct 22, 2025
	10675296*PED	Jan 10, 2039			NPP	Apr 25, 2025
	10695361	Sep 16, 2036		U-3831	PED	Jul 21, 2025
	10695361	Sep 16, 2036		U-3832	PED	Oct 25, 2025
	10695361*PED	Mar 16, 2037			PED	Apr 22, 2026
	11007208	Sep 16, 2036		U-3831	PED	Jan 13, 2027
	11007208	Sep 16, 2036		U-3832		
	11007208*PED	Mar 16, 2037				
	11266681	Jul 10, 2038		U-3831		
	11266681	Jul 10, 2038		U-3832		
	11266681*PED	Jan 10, 2039				
	11382926	Sep 16, 2036		U-3831		
	11382926	Sep 16, 2036		U-3832		
	11382926*PED	Mar 16, 2037				
	11491169	May 28, 2041		U-3835		
	11491169	May 28, 2041		U-3836		
	11491169*PED	Nov 28, 2041				
	11492353	Dec 08, 2031	DS			
	11492353*PED	Jun 08, 2032				
	11903953	May 28, 2041		U-3835		
	11903953	May 28, 2041		U-3836		
	11903953*PED	Nov 28, 2041				
	11975012	May 28, 2041		U-3835		
	11975012	May 28, 2041		U-3836		
	11975012*PED	Nov 28, 2041				
	11975017	Jul 10, 2038	DP			
	11975017*PED	Jan 10, 2039				
	8008264	Sep 06, 2029	DS DP			
	8008264*PED	Mar 06, 2030				
	8318682	Apr 22, 2029	DS DP			
	8318682*PED	Oct 22, 2029				
	9724360	Oct 29, 2035	DS DP			
	9724360*PED	Apr 29, 2036				
	9949994	Oct 29, 2035	DS			
	9949994*PED	Apr 29, 2036				
	RE46762	Apr 22, 2029	DS DP			
	RE46762*PED	Oct 22, 2029				
<u>REMDESIVIR - VEKLURY</u>						
N 214787 002	10065958	Sep 16, 2031	DS		D-183	Jan 21, 2025
	10065958*PED	Mar 16, 2032			M-301	Jul 13, 2026
	10695361	Sep 16, 2036		U-3829	NCE	Oct 22, 2025
	10695361	Sep 16, 2036		U-3830	NPP	Apr 25, 2025
	10695361*PED	Mar 16, 2037			PED	Jul 21, 2025
	11007208	Sep 16, 2036		U-3829	PED	Oct 25, 2025
	11007208	Sep 16, 2036		U-3830	PED	Apr 22, 2026
	11007208*PED	Mar 16, 2037			PED	Jan 13, 2027
	11382926	Sep 16, 2036		U-3829		
	11382926	Sep 16, 2036		U-3830		
	11382926*PED	Mar 16, 2037				
	11491169	May 28, 2041		U-3833		
	11491169	May 28, 2041		U-3834		
	11491169*PED	Nov 28, 2041				
	11492353	Dec 08, 2031	DS			
	11492353*PED	Jun 08, 2032				
	11903953	May 28, 2041		U-3833		
	11903953	May 28, 2041		U-3834		
	11903953*PED	Nov 28, 2041				
	11975012	May 28, 2041		U-3833		
	11975012	May 28, 2041		U-3834		
	11975012*PED	Nov 28, 2041				
	8008264	Sep 06, 2029	DS DP			
	8008264*PED	Mar 06, 2030				
	8318682	Apr 22, 2029	DS DP			
	8318682*PED	Oct 22, 2029				
	9724360	Oct 29, 2035	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>REMDESIVIR - VEKLURY</u>						
N 214787 002	9724360*PED	Apr 29, 2036				
	9949994	Oct 29, 2035	DS			
	9949994*PED	Apr 29, 2036				
	RE46762	Apr 22, 2029	DS DP			
	RE46762*PED	Oct 22, 2029				
<u>REMIMAZOLAM BESYLATE - BYFAVO</u>						
N 212295 001	9827251	Jan 13, 2034	U-2968			
<u>REPOTRECTINIB - AUGTYRO</u>						
N 218213 001	11452725	Jul 24, 2036	U-3755		NCE	Nov 15, 2028
	11452725	Jul 24, 2036	U-3961		ODE-455	Nov 15, 2030
					ODE-483	Jun 13, 2031
					ODE-488	Jun 13, 2031
<u>REPOTRECTINIB - AUGTYRO</u>						
N 218213 002	10294242	Jul 05, 2036	DS		NCE	Nov 15, 2028
	11452725	Jul 24, 2036	U-3755		ODE*	Nov 15, 2030
	11452725	Jul 24, 2036	U-3961		ODE-488	Jun 13, 2031
	9714258	Jan 23, 2035	DS DP			
<u>RESMETIROM - REZDIFFRA</u>						
N 217785 001	10376517	Sep 17, 2033	U-3861		NCE	Mar 14, 2029
	11564926	Sep 17, 2033	DS DP U-3861			
	11986481	Sep 17, 2033	U-3861			
	7452882	Sep 12, 2026	DS DP			
	9266861	Sep 17, 2033	DS DP			
<u>RESMETIROM - REZDIFFRA</u>						
N 217785 002	10376517	Sep 17, 2033	U-3861		NCE	Mar 14, 2029
	11564926	Sep 17, 2033	DS DP U-3861			
	11986481	Sep 17, 2033	U-3861			
	7452882	Sep 12, 2026	DS DP			
	9266861	Sep 17, 2033	DS DP			
<u>RESMETIROM - REZDIFFRA</u>						
N 217785 003	10376517	Sep 17, 2033	U-3861		NCE	Mar 14, 2029
	11564926	Sep 17, 2033	DS DP U-3861			
	11986481	Sep 17, 2033	U-3861			
	7452882	Sep 12, 2026	DS DP			
	9266861	Sep 17, 2033	DS DP			
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001	12048692	Aug 29, 2039	U-2440			
	>A> 7288657	Oct 31, 2028	DS			
<u>RIBOCICLIB SUCCINATE - KISOALI</u>						
N 209092 001	>A> 8962630	Dec 09, 2029	U-1981			
	>A> 8962630	Dec 09, 2029	U-2355			
	>A> 8962630	Dec 09, 2029	U-2356			
	>A> 8962630	Dec 09, 2029	U-3265			
	>A> 8962630	Dec 09, 2029	U-3266			
	>A> 8962630	Dec 09, 2029	U-3975			
	>A> 9416136	Aug 20, 2029	U-1981			
	>A> 9416136	Aug 20, 2029	U-2355			
	>A> 9416136	Aug 20, 2029	U-2356			
	>A> 9416136	Aug 20, 2029	U-3265			
	>A> 9416136	Aug 20, 2029	U-3266			
	>A> 9416136	Aug 20, 2029	U-3975			
	>A> 9868739	Nov 09, 2031	U-1981			
	>A> 9868739	Nov 09, 2031	U-2355			
	>A> 9868739	Nov 09, 2031	U-2356			
	>A> 9868739	Nov 09, 2031	U-3265			
	>A> 9868739	Nov 09, 2031	U-3266			
	>A> 9868739	Nov 09, 2031	U-3975			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIBOCICLIB SUCCINATE - KISOALI</u>						
N 209092 001	>A> 8962630	Dec 09, 2029	U-1981			
	>A> 8962630	Dec 09, 2029	U-2355			
	>A> 8962630	Dec 09, 2029	U-2356			
	>A> 8962630	Dec 09, 2029	U-3265			
	>A> 8962630	Dec 09, 2029	U-3266			
	>A> 8962630	Dec 09, 2029	U-3975			
	>A> 9416136	Aug 20, 2029	U-1981			
	>A> 9416136	Aug 20, 2029	U-2355			
	>A> 9416136	Aug 20, 2029	U-2356			
	>A> 9416136	Aug 20, 2029	U-3265			
	>A> 9416136	Aug 20, 2029	U-3266			
	>A> 9416136	Aug 20, 2029	U-3975			
	>A> 9868739	Nov 09, 2031	U-1981			
	>A> 9868739	Nov 09, 2031	U-2355			
	>A> 9868739	Nov 09, 2031	U-2356			
	>A> 9868739	Nov 09, 2031	U-3265			
	>A> 9868739	Nov 09, 2031	U-3266			
	>A> 9868739	Nov 09, 2031	U-3975			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001	7125879	Apr 21, 2025	DS DP U-1153			
	7125879	Apr 21, 2025	DS DP U-1307			
	7125879	Apr 21, 2025	DS DP U-1740			
	7125879	Apr 21, 2025	DS DP U-3353			
	7125879	Apr 21, 2025	DS DP U-3874			
	7125879*PED	Oct 21, 2025				
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT PED</u>						
N 219016 001	11065198	Oct 23, 2037	DP			
	7125879	Apr 21, 2025	DS DP U-3874			
<u>RIPRETINIB - QINLOCK</u>						
N 213973 001	11896585	Dec 30, 2040	DP			
	11903933	Dec 30, 2040	DP			
	11911370	Dec 30, 2040	DP			
	11918564	Dec 30, 2040	DP			
	11969414	Feb 08, 2041	U-3897			
	11969415	Dec 30, 2040	U-3219			
	12023325	Aug 12, 2040	U-3960			
	12023326	Aug 12, 2040	U-3959			
	12023327	Aug 12, 2040	U-3958			
	12023328	Dec 30, 2040	U-3957			
	>A> 12059410	Aug 12, 2040	U-3153			
	>A> 12059411	Aug 12, 2040	U-3971			
	>A> 12064422	Dec 30, 2040	U-3219			
<u>RISDIPLAM - EVRYSDI</u>						
N 213535 001	11938136	Nov 08, 2036	DP			
<u>RISPERIDONE - RISVAN</u>						
N 214835 001	10058504	May 31, 2031	DP		NP	Mar 29, 2027
	10085936	May 31, 2031	DP			
	10182982	May 31, 2031	U-3943			
	10195138	May 31, 2031	U-3943			
	10335366	May 31, 2031	DP			
	10463607	May 31, 2031	DP			
	10881605	May 31, 2031	DP			
	11007139	May 31, 2031	U-3942			
	11173110	May 31, 2031	U-3941			
	11241377	May 31, 2031	U-3939			
	11752092	May 31, 2031	U-3941			
	11752093	May 31, 2031	DP			
	11752094	May 31, 2031	U-3942			
	11759416	May 31, 2031	U-3939			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RISPERIDONE - RISVAN</u>						
N 214835 002	10058504	May 31, 2031	DP		NP	Mar 29, 2027
	10085936	May 31, 2031	DP			
	10182982	May 31, 2031	U-3943			
	10195138	May 31, 2031	U-3943			
	10335366	May 31, 2031	DP			
	10463607	May 31, 2031	DP			
	10881605	May 31, 2031	DP			
	11007139	May 31, 2031	U-3942			
	11173110	May 31, 2031	U-3941			
	11241377	May 31, 2031	U-3939			
	11752092	May 31, 2031	U-3941			
	11752093	May 31, 2031	DP			
	11752094	May 31, 2031	U-3942			
	11759416	May 31, 2031	U-3939			
<u>RIVAROXABAN - XARELTO</u>						
N 215859 001	7157456	Aug 28, 2024	DS DP			
	7157456*PED	Feb 28, 2025				
<u>ROFLUMILAST - ZORYVE</u>						
N 215985 001	11992480	Jun 07, 2037	U-3748			
	12005051	Jun 07, 2037	U-3748			
	12005052	Jun 07, 2037	DP			
	12011437	Jun 07, 2037	DP			
	12016848	Jun 07, 2037	DP			
	>A> 12042487	Jun 07, 2037	DP			
<u>ROFLUMILAST - ZORYVE</u>						
N 215985 002	>A> 10940142	Jun 07, 2037	DP		NS	Jul 09, 2027
	>A> 11129818	Aug 25, 2037	U-3970			
	>A> 11793796	Jun 07, 2037	DP			
	>A> 11819496	Jun 07, 2037	U-3970			
	>A> 11992480	Jun 07, 2037	U-3970			
	>A> 12005051	Jun 07, 2037	U-3970			
	>A> 12005052	Jun 07, 2037	DP			
	>A> 12011437	Jun 07, 2037	DP			
	>A> 12016848	Jun 07, 2037	DP			
	>A> 12042487	Jun 07, 2037	DP			
	>A> 9884050	Jun 07, 2037	DP			
	>A> 9907788	Jun 07, 2037	U-3970			
<u>ROFLUMILAST - ZORYVE</u>						
N 217242 001	11992480	Jun 07, 2037	U-3773		NP	Dec 15, 2026
	12005051	Jun 07, 2037	U-3773			
	12005052	Jun 07, 2037	DP			
	12011437	Jun 07, 2037	DP			
	12016848	Jun 07, 2037	DP			
	>A> 12042487	Jun 07, 2037	DP			
<u>SACUBITRIL; VALSARTAN - ENTRESTO SPRINKLE</u>						
N 218591 001	10722471	Feb 02, 2037	DP U-3896			
	8101659	Jan 15, 2025	DP			
	8877938	May 27, 2027	DS DP			
	9388134	Nov 08, 2026	U-1723			
<u>SACUBITRIL; VALSARTAN - ENTRESTO SPRINKLE</u>						
N 218591 002	10722471	Feb 02, 2037	DP U-3896			
	8101659	Jan 15, 2025	DP			
	8877938	May 27, 2027	DS DP			
	9388134	Nov 08, 2026	U-1723			
<u>SELADELPAR LYSINE - LIVDELZI</u>						
N 217899 001	>A> 10272058	Mar 19, 2035	U-1854		>A> NCE	Aug 14, 2029
	>A> 11406611	Mar 19, 2035	U-1854			
	>A> 11596614	Mar 19, 2035	U-1854			
	>A> 7301050	Aug 02, 2025	DS DP			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELADELPAR LYSINE - LIVDELZI</u>						
N 217899 001	>A> 7709682	Sep 13, 2026	DS			
	>A> 9486428	Mar 19, 2035	U-1854			
<u>SELENIOS ACID - SELENIOS ACID</u>						
N 209379 001	11998565	Jul 01, 2041	DP			
<u>SELENIOS ACID - SELENIOS ACID</u>						
N 209379 002	11998565	Jul 01, 2041	DP			
<u>SELENIOS ACID - SELENIOS ACID</u>						
N 209379 003	11998565	Jul 01, 2041	DP			
<u>SELPERCATINIB - RETEVMO</u>						
N 213246 001	10137124	Oct 10, 2037	U-2826		NPP	May 29, 2027
	10137124	Oct 10, 2037	U-2827		ODE-484	May 29, 2031
	10137124	Oct 10, 2037	U-2828		ODE-485	May 29, 2031
	10137124	Oct 10, 2037	U-3450		ODE-487	May 29, 2031
	10137124	Oct 10, 2037	U-3451			
	10137124	Oct 10, 2037	U-3452			
	10137124	Oct 10, 2037	U-3453			
	10137124	Oct 10, 2037	U-3949			
	10137124	Oct 10, 2037	U-3950			
	10137124	Oct 10, 2037	U-3951			
	10172851	Oct 10, 2037	U-2826			
	10172851	Oct 10, 2037	U-2827			
	10172851	Oct 10, 2037	U-2828			
	10172851	Oct 10, 2037	U-3450			
	10172851	Oct 10, 2037	U-3451			
	10172851	Oct 10, 2037	U-3452			
	10172851	Oct 10, 2037	U-3453			
	10172851	Oct 10, 2037	U-3949			
	10172851	Oct 10, 2037	U-3950			
	10172851	Oct 10, 2037	U-3951			
	10584124	Oct 10, 2038	DS U-2826			
	10584124	Oct 10, 2038	DS U-2827			
	10584124	Oct 10, 2038	DS U-2828			
	10584124	Oct 10, 2038	DS U-3450			
	10584124	Oct 10, 2038	DS U-3451			
	10584124	Oct 10, 2038	DS U-3452			
	10584124	Oct 10, 2038	DS U-3453			
	10584124	Oct 10, 2038	DS U-3949			
	10584124	Oct 10, 2038	DS U-3950			
	10584124	Oct 10, 2038	DS U-3951			
	10786489	Oct 10, 2038	DP U-2971			
	10786489	Oct 10, 2038	DP U-2972			
	10786489	Oct 10, 2038	DP U-2973			
	10786489	Oct 10, 2038	DP U-2974			
	10786489	Oct 10, 2038	DP U-2975			
	10786489	Oct 10, 2038	DP U-2976			
	10786489	Oct 10, 2038	DP U-2977			
	10786489	Oct 10, 2038	DP U-3450			
	10786489	Oct 10, 2038	DP U-3451			
	10786489	Oct 10, 2038	DP U-3452			
	10786489	Oct 10, 2038	DP U-3453			
	10786489	Oct 10, 2038	DP U-3949			
	10786489	Oct 10, 2038	DP U-3950			
	10786489	Oct 10, 2038	DP U-3951			
<u>SELPERCATINIB - RETEVMO</u>						
N 213246 002	10137124	Oct 10, 2037	U-2826		NPP	May 29, 2027
	10137124	Oct 10, 2037	U-2827		ODE-484	May 29, 2031
	10137124	Oct 10, 2037	U-2828		ODE-485	May 29, 2031
	10137124	Oct 10, 2037	U-3450		ODE-487	May 29, 2031
	10137124	Oct 10, 2037	U-3451			
	10137124	Oct 10, 2037	U-3452			
	10137124	Oct 10, 2037	U-3453			
	10137124	Oct 10, 2037	U-3949			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELPERCATINIB - RETEVMQ</u>						
N 213246 002	10137124	Oct 10, 2037	U-3950			
	10137124	Oct 10, 2037	U-3951			
	10172851	Oct 10, 2037	U-2826			
	10172851	Oct 10, 2037	U-2827			
	10172851	Oct 10, 2037	U-2828			
	10172851	Oct 10, 2037	U-3450			
	10172851	Oct 10, 2037	U-3949			
	10172851	Oct 10, 2037	U-3950			
	10172851	Oct 10, 2037	U-3951			
	10584124	Oct 10, 2038	DS U-2826			
	10584124	Oct 10, 2038	DS U-2827			
	10584124	Oct 10, 2038	DS U-2828			
	10584124	Oct 10, 2038	DS U-3450			
	10584124	Oct 10, 2038	DS U-3451			
	10584124	Oct 10, 2038	DS U-3452			
	10584124	Oct 10, 2038	DS U-3453			
	10584124	Oct 10, 2038	DS U-3949			
	10584124	Oct 10, 2038	DS U-3950			
	10584124	Oct 10, 2038	DS U-3951			
	10786489	Oct 10, 2038	DP U-2971			
	10786489	Oct 10, 2038	DP U-2972			
	10786489	Oct 10, 2038	DP U-2973			
	10786489	Oct 10, 2038	DP U-2974			
	10786489	Oct 10, 2038	DP U-2975			
	10786489	Oct 10, 2038	DP U-2976			
	10786489	Oct 10, 2038	DP U-2977			
	10786489	Oct 10, 2038	DP U-3450			
	10786489	Oct 10, 2038	DP U-3451			
	10786489	Oct 10, 2038	DP U-3452			
	10786489	Oct 10, 2038	DP U-3453			
	10786489	Oct 10, 2038	DP U-3949			
	10786489	Oct 10, 2038	DP U-3950			
	10786489	Oct 10, 2038	DP U-3951			
<u>SELPERCATINIB - RETEVMQ</u>						
N 218160 001	10112942	Oct 10, 2037	DS DP		NCE	May 08, 2025
	10137124	Oct 10, 2037	U-3450			
	10137124	Oct 10, 2037	U-3949			
	10137124	Oct 10, 2037	U-3950			
	10137124	Oct 10, 2037	U-3951			
	10172851	Oct 10, 2037	U-3450			
	10172851	Oct 10, 2037	U-3949			
	10172851	Oct 10, 2037	U-3950			
	10172851	Oct 10, 2037	U-3951			
<u>SELPERCATINIB - RETEVMQ</u>						
N 218160 002	10112942	Oct 10, 2037	DS DP		NCE	May 08, 2025
	10137124	Oct 10, 2037	U-3450			
	10137124	Oct 10, 2037	U-3949			
	10137124	Oct 10, 2037	U-3950			
	10137124	Oct 10, 2037	U-3951			
	10172851	Oct 10, 2037	U-3450			
	10172851	Oct 10, 2037	U-3949			
	10172851	Oct 10, 2037	U-3950			
	10172851	Oct 10, 2037	U-3951			
<u>SELPERCATINIB - RETEVMQ</u>						
N 218160 003	10112942	Oct 10, 2037	DS DP		NCE	May 08, 2025
	10137124	Oct 10, 2037	U-3450			
	10137124	Oct 10, 2037	U-3949			
	10137124	Oct 10, 2037	U-3950			
	10137124	Oct 10, 2037	U-3951			
	10172851	Oct 10, 2037	U-3450			
	10172851	Oct 10, 2037	U-3949			
	10172851	Oct 10, 2037	U-3950			
	10172851	Oct 10, 2037	U-3951			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 004	10112942	Oct 10, 2037	DS DP		NCE	May 08, 2025
	10137124	Oct 10, 2037	U-3450			
	10137124	Oct 10, 2037	U-3949			
	10137124	Oct 10, 2037	U-3950			
	10137124	Oct 10, 2037	U-3951			
	10172851	Oct 10, 2037	U-3450			
	10172851	Oct 10, 2037	U-3949			
	10172851	Oct 10, 2037	U-3950			
	10172851	Oct 10, 2037	U-3951			
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 001	7425637	Mar 13, 2025	DS			
	8178693	Mar 13, 2025	DS DP			
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 002	7425637	Mar 13, 2025	DS			
	8178693	Mar 13, 2025	DS DP			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 001					I-935	Mar 08, 2027
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 002					I-935	Mar 08, 2027
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 003					I-935	Mar 08, 2027
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 004					I-935	Mar 08, 2027
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 005	12029779	Oct 10, 2038	U-3162		I-935	Mar 08, 2027
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 021845 001					ODE-469	Jan 31, 2030
<u>SILDENAFIL CITRATE - LIOREV</u>						
N 214952 001	12005062	Dec 24, 2038	DP U-3582			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 001	11944602	Jul 24, 2036	U-3889			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 002	11944602	Jul 24, 2036	U-3889			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 003	11944602	Jul 24, 2036	U-3889			
<u>SIROLIMUS - FYARRO</u>						
N 213312 001	>A> 12061183	Mar 05, 2036	DP			
<u>SODIUM ACETATE - SODIUM ACETATE</u>						
A 216920 001					CGT	Nov 16, 2024
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	11986446	Mar 15, 2033	U-3324			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 001	11896572	Jul 21, 2037	DP			
	11986451	Jul 21, 2037	U-3934			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 002	11896572	Jul 21, 2037	DP			
	11986451	Jul 21, 2037	U-3934			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 003	11896572	Jul 21, 2037	DP			
	11986451	Jul 21, 2037	U-3934			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 004	11896572	Jul 21, 2037	DP			
	11986451	Jul 21, 2037	U-3934			
<u>SODIUM THIOSULFATE - PEDMARK</u>						
N 212937 001	11964018	Jul 01, 2039	U-3898			
	11992530	Jul 01, 2039	U-3948			
	11998604	Jul 01, 2039	U-3952			
<u>SOPFIRONIUM BROMIDE - SOFDRA</u>						
N 217347 001					NCE	Jun 20, 2029
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 001	11857528	Mar 19, 2040	U-3521			
	11865098	Jun 01, 2038	U-2548			
	11872203	Dec 30, 2042	U-3693			
	11872204	Dec 30, 2042	U-3693			
	11969404	Mar 19, 2040	U-3892			
	11986454	Mar 19, 2040	U-3775			
	11986455	Mar 19, 2040	U-3521			
	11998639	Sep 05, 2037	DP U-2548			
	12005036	Dec 30, 2042	U-3693			
	>A> 12036194	Dec 30, 2042	U-3693			
	>A> 12064411	Dec 30, 2042	U-3693			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 002	11857528	Mar 19, 2040	U-3521			
	11865098	Jun 01, 2038	U-2548			
	11872203	Dec 30, 2042	U-3693			
	11872204	Dec 30, 2042	U-3693			
	11969404	Mar 19, 2040	U-3892			
	11986454	Mar 19, 2040	U-3775			
	11986455	Mar 19, 2040	U-3521			
	11998639	Sep 05, 2037	DP U-2548			
	12005036	Dec 30, 2042	U-3693			
	>A> 12036194	Dec 30, 2042	U-3693			
	>A> 12064411	Dec 30, 2042	U-3693			
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 003	10519146	May 21, 2038	DS DP		NCE	May 28, 2026
	11236091	May 20, 2040	DS DP U-3306		ODE*	May 28, 2028
	11426404	Sep 15, 2040	U-3306			
	11827635	May 20, 2040	DS DP U-3306			
<u>SUFENTANIL CITRATE - DSUVIA</u>						
N 209128 001	12033733	Mar 16, 2030	DP			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 001	11980623	May 29, 2033	DP			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 002	11980623	May 29, 2033	DP			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 003	11980623	May 29, 2033	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 004	11980623	May 29, 2033	DP			
<u>TADALAFIL - TADLIO</u>						
N 214522 001	11975006	Dec 24, 2038	DP U-3397			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 001	10189837	Oct 20, 2031	DS DP		I-920	Jun 20, 2026
	10780088	Jul 27, 2029		U-3651		
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029		U-2437		
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 002	10189837	Oct 20, 2031	DS DP		I-920	Jun 20, 2026
	10780088	Jul 27, 2029		U-3651		
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029		U-2437		
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 003	10189837	Oct 20, 2031	DS DP			
	10780088	Jul 27, 2029		U-3651		
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029		U-2437		
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 004	10189837	Oct 20, 2031	DS DP		I-920	Jun 20, 2026
	10780088	Jul 27, 2029		U-3651		
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029		U-2437		
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 005	10189837	Oct 20, 2031	DS DP			
	10780088	Jul 27, 2029		U-3651		
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029		U-2437		
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 006	10189837	Oct 20, 2031	DS DP			
	10780088	Jul 27, 2029		U-3651		
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029		U-2437		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304 001					NPP PED	Jul 03, 2026 Jan 03, 2027
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304 002					NPP PED	Jul 03, 2026 Jan 03, 2027
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304 003					NPP PED	Jul 03, 2026 Jan 03, 2027

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА</u>						
N 022304 003					NPP PED	Jul 03, 2026 Jan 03, 2027
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 001	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
	11344512*PED	Oct 21, 2028				
	8536130	Sep 22, 2028	U-1276			
	8536130*PED	Mar 22, 2029				
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 002	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
	11344512*PED	Oct 21, 2028				
	8536130	Sep 22, 2028	U-1276			
	8536130*PED	Mar 22, 2029				
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 003	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
	11344512*PED	Oct 21, 2028				
	8536130	Sep 22, 2028	U-1276			
	8536130*PED	Mar 22, 2029				
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 004	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
	11344512*PED	Oct 21, 2028				
	8536130	Sep 22, 2028	U-1276			
	8536130*PED	Mar 22, 2029				
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 005	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
	11344512*PED	Oct 21, 2028				
	8536130	Sep 22, 2028	U-1276			
	8536130*PED	Mar 22, 2029				
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА</u>						
N 203794 001					NPP PED	Jul 03, 2026 Jan 03, 2027
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	11826339	Jan 25, 2033	U-3342			
	11826339	Jan 25, 2033	U-3343			
	11918556	Apr 07, 2033	U-3342			
	11918556	Apr 07, 2033	U-3343			
	11918557	Jan 25, 2033	U-3003			
	11918557	Jan 25, 2033	U-3865			
	12049457	Feb 12, 2035	DS DP			
<u>TASIMELTEON - HETLIOZ LO</u>						
N 214517 001	11826339	Jan 25, 2033	U-3342			
	11918556	Apr 07, 2033	U-3342			
	11918557	Jan 25, 2033	U-3003			
	12049457	Feb 12, 2035	DS DP			
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723 001	10155002	Sep 12, 2031	U-2736			
	10420775	Sep 12, 2031	U-2736			
	10420775	Sep 12, 2031	U-2852			
	10420775	Sep 12, 2031	U-2853			
	11052093	Apr 13, 2032	DS DP U-2736			
	11052093	Apr 13, 2032	DS DP U-2852			
	11052093	Apr 13, 2032	DS DP U-2853			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723 001	11491163	Apr 11, 2033	U-2736			
	11491163	Apr 11, 2033	U-2852			
	11491163	Apr 11, 2033	U-2853			
	8765732	Sep 12, 2031	U-2852			
	8765732	Sep 12, 2031	U-2853			
	9090562	Sep 12, 2031	DS DP			
	9549931	Sep 12, 2031	U-2736			
	9549931	Sep 12, 2031	U-2852			
	9549931	Sep 12, 2031	U-2853			
	9855275	Sep 12, 2031	U-2736			
<u>TECOVIRIMAT - TPOXX</u>						
N 208627 001	11890270	Aug 08, 2032	U-2346			
<u>TENAPANOR HYDROCHLORIDE - IBSRELA</u>						
N 211801 001	12016856	Dec 30, 2029	DS DP			
<u>TENAPANOR HYDROCHLORIDE - XPHOZAH</u>						
N 213931 001	12016856	Dec 30, 2029	DS DP			
<u>TENAPANOR HYDROCHLORIDE - XPHOZAH</u>						
N 213931 002	12016856	Dec 30, 2029	DS DP			
<u>TENAPANOR HYDROCHLORIDE - XPHOZAH</u>						
N 213931 003	12016856	Dec 30, 2029	DS DP			
<u>TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY</u>						
N 208464 001	8754065	Aug 15, 2032	DS DP U-1275			
	8754065	Aug 15, 2032	DS DP U-3880			
	8754065	Aug 15, 2032	DS DP U-999			
	8754065*PED	Feb 15, 2033				
	9296769	Aug 15, 2032	DS DP U-1275			
	9296769	Aug 15, 2032	DS DP U-3880			
	9296769	Aug 15, 2032	DS DP U-999			
	9296769*PED	Feb 15, 2033				
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 001	11844804	Jun 04, 2033	U-2418			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 002	11844804	Jun 04, 2033	U-2418			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 003	11844804	Jun 04, 2033	U-2418			
<u>TESTOSTERONE UNDECANOATE - TLANDO</u>						
N 208088 001	12011503	Oct 16, 2040	DP U-3964			
	12011503	Oct 16, 2040	DP U-3965			
<u>THIOTEPA - TEPYLUTE</u>						
N 216984 001	11975013	Aug 16, 2041	DP			
<u>TIRBANIBULIN - KLISYRI</u>						
N 213189 001					D-192	Jun 07, 2027
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 007	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 008	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 009	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 010	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 011	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 012	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 001	11918623	Jun 14, 2039				
			U-3855			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 002	11918623	Jun 14, 2039				
			U-3855			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 003	11918623	Jun 14, 2039				
			U-3855			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 004	11918623	Jun 14, 2039				
			U-3855			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 005	11918623	Jun 14, 2039				
			U-3855			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 006	11918623	Jun 14, 2039				
			U-3855			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 007	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	11918623	Jun 14, 2039	U-3855			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 008	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	11918623	Jun 14, 2039	U-3855			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 009	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	11918623	Jun 14, 2039	U-3855			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 010	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	11918623	Jun 14, 2039	U-3855			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 011	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	11918623	Jun 14, 2039	U-3855			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 012	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	11918623	Jun 14, 2039	U-3855			
	9474780	Jan 05, 2036	DS DP			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 012	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	11918623	Jun 14, 2039	U-3855			
	9474780	Jan 05, 2036	DS DP			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 001	6821987	Apr 26, 2025	DS DP U-3100			
	7166722	Nov 16, 2024	DS DP			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 002	6821987	Apr 26, 2025	DS DP U-3100			
	7166722	Nov 16, 2024	DS DP			
<u>TOPIRAMATE - EPRONTIA</u>						
N 214679 001	11911362	Aug 21, 2040	DP U-3413			
	11911362	Aug 21, 2040	DP U-3414			
	11911362	Aug 21, 2040	DP U-3415			
<u>TOVORAFENIB - OJEMDA</u>						
N 217700 001	10426782	Jun 23, 2035	DP		NCE	Apr 23, 2029
	8293752	Aug 04, 2031	DS DP		ODE-478	Apr 23, 2031
<u>TOVORAFENIB - OJEMDA</u>						
N 218033 001	10426782	Jun 23, 2035	DP		NCE	Apr 23, 2029
	8293752	Aug 04, 2031	DS DP		ODE-478	Apr 23, 2031
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001					>A> I-908	Mar 16, 2026
					>A> ODE-428	Mar 16, 2030
					>A> PED	Sep 16, 2026
					>A> PED	Sep 16, 2030
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002					>A> I-908	Mar 16, 2026
					>A> ODE-428	Mar 16, 2030
					>A> PED	Sep 16, 2026
					>A> PED	Sep 16, 2030
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003					>A> I-908	Mar 16, 2026
					>A> ODE-428	Mar 16, 2030
					>A> PED	Sep 16, 2026
					>A> PED	Sep 16, 2030
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 217513 001	>A> 7378423	May 29, 2027	DS DP		>A> NP	Mar 16, 2026
	>A> 7378423*PED	Nov 29, 2027			>A> ODE-428	Mar 16, 2030
	>A> 8703781	Oct 15, 2030	DS DP U-3564		>A> PED	Sep 16, 2026
	>A> 8703781*PED	Apr 15, 2031			>A> PED	Sep 16, 2030
	>A> 8835443	Jun 10, 2025	U-3564			
	>A> 8835443*PED	Dec 10, 2025				
<u>TRAVOPROST - IDOSE TR</u>						
N 218010 001					NP	Dec 13, 2026
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	11826327	Feb 03, 2042	U-3749			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 001	11826327	Feb 03, 2042	U-3749		>A> NP	May 23, 2025
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 002	11826327	Feb 03, 2042	U-3749		>A> NP	May 23, 2025

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 003	11826327	Feb 03, 2042	U-3749		>A> NP	May 23, 2025
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 004	11826327	Feb 03, 2042	U-3749		>A> NP	May 23, 2025
<u>TRILACICLIB DIHYDROCHLORIDE - COSELA</u>						
N 214200 001	>A> 11040042	Oct 25, 2031	DP			
<u>TROFINETIDE - DAYBUE</u>						
N 217026 001	>A> 11827600	Jul 12, 2042	DS DP U-3556			
<u>TUCATINIB - TUKYSA</u>						
N 213411 001	11207324	Apr 27, 2038	U-3783			
	11666572	Apr 27, 2038	U-3783			
	>A> 12048698	Apr 27, 2038	U-3783			
<u>TUCATINIB - TUKYSA</u>						
N 213411 002	11207324	Apr 27, 2038	U-3783			
	11666572	Apr 27, 2038	U-3783			
	>A> 12048698	Apr 27, 2038	U-3783			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 001	11857542	Dec 22, 2041	U-3786			
	11925709	Jan 30, 2035	DP			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 002	11925709	Jan 30, 2035	DP			
<u>UPADACITINIB - RINVOO</u>						
N 211675 001	11365198	Oct 17, 2036	U-3275		I-946	Apr 26, 2027
	11365198	Oct 17, 2036	U-3946		NPP	Apr 26, 2027
	11512092	Oct 17, 2036	U-3275		ODE-481	Apr 26, 2031
	11512092	Oct 17, 2036	U-3371			
	11512092	Oct 17, 2036	U-3487			
	11512092	Oct 17, 2036	U-3946			
	11773106	Oct 17, 2036	U-3275			
	11773106	Oct 17, 2036	U-3371			
	11773106	Oct 17, 2036	U-3487			
	11773106	Oct 17, 2036	U-3946			
	11976077	Oct 17, 2036	U-3298			
	11993605	Oct 17, 2036	U-3275			
	11993605	Oct 17, 2036	U-3946			
	11993606	Oct 17, 2036	U-3487			
	8962629	Jan 15, 2031	DS U-3255			
	8962629	Jan 15, 2031	DS U-3275			
	8962629	Jan 15, 2031	DS U-3341			
	8962629	Jan 15, 2031	DS U-3371			
	8962629	Jan 15, 2031	DS U-3624			
	8962629	Jan 15, 2031	DS U-3945			
	8962629	Jan 15, 2031	DS U-3946			
	RE47221	Aug 16, 2033	DS			
<u>UPADACITINIB - RINVOO</u>						
N 211675 002	RE47221	Aug 16, 2033	DS		I-946	Apr 26, 2027
					NPP	Apr 26, 2027
					ODE-481	Apr 26, 2031
<u>UPADACITINIB - RINVOO</u>						
N 211675 003	RE47221	Aug 16, 2033	DS		I-946	Apr 26, 2027
					NPP	Apr 26, 2027
					ODE-481	Apr 26, 2031

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>UPADACITINIB - RINVOO LQ</u>						
N 218347 001	10981923	Oct 17, 2036	DS		NCE	Aug 16, 2024
	11186584	Oct 17, 2036	DS		NP	Apr 26, 2027
	11661425	Oct 17, 2036	DS		ODE-481	Apr 26, 2031
	11680069	Oct 17, 2036	DS			
	11718627	Oct 17, 2036	DS			
	11773105	Oct 17, 2036	DS			
	8962629	Jan 15, 2031	DS	U-3945		
	8962629	Jan 15, 2031	DS	U-3946		
	9951080	Oct 17, 2036	DS			
	RE47221	Aug 16, 2033	DS			
<u>VADADUSTAT - VAFSEO</u>						
N 215192 001	10149842	Nov 14, 2034	DS DP		NCE	Mar 27, 2029
	11065237	Nov 14, 2034	DS DP	U-3876		
	11324734	Mar 31, 2036	DP			
	11844756	Mar 31, 2036		U-3876		
	11857543	Jun 09, 2034		U-3876		
	7811595	Mar 13, 2028	DS DP			
	8323671	Apr 03, 2028		U-3876		
	8343952	Aug 14, 2027	DS DP			
	8598210	Jun 26, 2027	DS DP			
	8940773	Jun 26, 2027		U-3876		
	9701636	Nov 14, 2034	DS DP			
	9987262	Nov 14, 2034		U-3876		
	RE47437	Jun 26, 2027	DS DP			
<u>VADADUSTAT - VAFSEO</u>						
N 215192 002	10149842	Nov 14, 2034	DS DP		NCE	Mar 27, 2029
	11065237	Nov 14, 2034	DS DP	U-3876		
	11324734	Mar 31, 2036	DP			
	11844756	Mar 31, 2036		U-3876		
	11857543	Jun 09, 2034		U-3876		
	7811595	Mar 13, 2028	DS DP			
	8323671	Apr 03, 2028		U-3876		
	8343952	Aug 14, 2027	DS DP			
	8598210	Jun 26, 2027	DS DP			
	8940773	Jun 26, 2027		U-3876		
	9701636	Nov 14, 2034	DS DP			
	9987262	Nov 14, 2034		U-3876		
	RE47437	Jun 26, 2027	DS DP			
<u>VADADUSTAT - VAFSEO</u>						
N 215192 003	10149842	Nov 14, 2034	DS DP		NCE	Mar 27, 2029
	11065237	Nov 14, 2034	DS DP	U-3876		
	11324734	Mar 31, 2036	DP			
	11844756	Mar 31, 2036		U-3876		
	11857543	Jun 09, 2034		U-3876		
	7811595	Mar 13, 2028	DS DP			
	8323671	Apr 03, 2028		U-3876		
	8343952	Aug 14, 2027	DS DP			
	8598210	Jun 26, 2027	DS DP			
	8940773	Jun 26, 2027		U-3876		
	9701636	Nov 14, 2034	DS DP			
	9987262	Nov 14, 2034		U-3876		
	RE47437	Jun 26, 2027	DS DP			
<u>VALBENAZINE TOSYLATE - INGREZZA SPRINKLE</u>						
N 218390 001	10065952	Oct 28, 2036	DS DP	U-1995	I-925	Aug 18, 2026
	10065952	Oct 28, 2036	DS DP	U-3055		
	10844058	Oct 28, 2036	DS DP	U-1995		
	10844058	Oct 28, 2036	DS DP	U-3055		
	10851103	Oct 28, 2036	DS DP	U-1995		
	10851103	Oct 28, 2036	DS DP	U-3055		
	10851104	Oct 28, 2036	DS	U-1995		
	10851104	Oct 28, 2036	DS	U-3055		
	10857137	Oct 10, 2037		U-1995		
	10857148	Oct 10, 2037		U-1995		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VALBENAZINE TOSYLATE - INGREZZA SPRINKLE</u>						
N 218390 001	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10874648	Oct 10, 2037	U-3055			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3055			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040	U-1995			
	10952997	Oct 10, 2037	U-1995			
	10993941	Oct 10, 2037	U-1995			
	11026931	Aug 14, 2039	U-1995			
	11026939	Sep 18, 2038	DP U-1995			
	11026939	Sep 18, 2038	DP U-3055			
	11040029	Oct 10, 2037	U-1995			
	11311532	Sep 18, 2038	DP U-1995			
	11311532	Sep 18, 2038	DP U-3055			
	11439629	Oct 10, 2037	U-3055			
	11654142	Nov 14, 2038	U-3055			
	8039627	Apr 11, 2031	DS DP			
	8357697	Nov 08, 2027	U-1995			
	8357697	Nov 08, 2027	U-3055			
<u>VALBENAZINE TOSYLATE - INGREZZA SPRINKLE</u>						
N 218390 002	10065952	Oct 28, 2036	DS DP U-1995		I-925	Aug 18, 2026
	10065952	Oct 28, 2036	DS DP U-3055			
	10844058	Oct 28, 2036	DS DP U-1995			
	10844058	Oct 28, 2036	DS DP U-3055			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-3055			
	10851104	Oct 28, 2036	DS U-1995			
	10851104	Oct 28, 2036	DS U-3055			
	10857137	Oct 10, 2037	U-1995			
	10857148	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10874648	Oct 10, 2037	U-3055			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3055			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040	U-1995			
	10952997	Oct 10, 2037	U-1995			
	10993941	Oct 10, 2037	U-1995			
	11026931	Aug 14, 2039	U-1995			
	11026939	Sep 18, 2038	DP U-1995			
	11026939	Sep 18, 2038	DP U-3055			
	11040029	Oct 10, 2037	U-1995			
	11311532	Sep 18, 2038	DP U-1995			
	11311532	Sep 18, 2038	DP U-3055			
	11439629	Oct 10, 2037	U-3055			
	11654142	Nov 14, 2038	U-3055			
	8039627	Apr 11, 2031	DS DP			
	8357697	Nov 08, 2027	U-1995			
	8357697	Nov 08, 2027	U-3055			
<u>VALBENAZINE TOSYLATE - INGREZZA SPRINKLE</u>						
N 218390 003	10065952	Oct 28, 2036	DS DP U-1995		I-925	Aug 18, 2026
	10065952	Oct 28, 2036	DS DP U-3055			
	10844058	Oct 28, 2036	DS DP U-1995			
	10844058	Oct 28, 2036	DS DP U-3055			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-3055			
	10851104	Oct 28, 2036	DS U-1995			
	10851104	Oct 28, 2036	DS U-3055			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VALBENAZINE TOSYLATE - INGREZZA SPRINKLE</u>						
N 218390 003	10857137	Oct 10, 2037	U-1995			
	10857148	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10874648	Oct 10, 2037	U-3055			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3055			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040	U-1995			
	10952997	Oct 10, 2037	U-1995			
	10993941	Oct 10, 2037	U-1995			
	11026931	Aug 14, 2039	U-1995			
	11026939	Sep 18, 2038	DP U-1995			
	11026939	Sep 18, 2038	DP U-3055			
	11040029	Oct 10, 2037	U-1995			
	11311532	Sep 18, 2038	DP U-1995			
	11311532	Sep 18, 2038	DP U-3055			
	11439629	Oct 10, 2037	U-3055			
	11654142	Nov 14, 2038	U-3055			
	8039627	Apr 11, 2031	DS DP			
	8357697	Nov 08, 2027	U-1995			
	8357697	Nov 08, 2027	U-3055			
<u>VAMOROLONE - AGAMREE</u>						
N 215239 001	11690853	Mar 07, 2033	U-3747			
<u>VARENICLINE TARTRATE - TYRVAYA</u>						
N 213978 001	11903941	Oct 19, 2035	U-1900			
	11903942	Oct 19, 2035	DP			
	11903943	Oct 19, 2035	U-1900			
	11911380	Oct 19, 2035	U-1900			
<u>VIGABATRIN - VIGAFYDE</u>						
N 217684 001	12016857	Aug 16, 2039	DP			
<u>VONOPRAZAN FUMARATE - VOQUEZNA</u>						
N 215151 001					>A> I-948	Jul 17, 2027
<u>VORASIDENIB - VORANIGO</u>						
N 218784 001	>A> 10172864	Jul 11, 2034	DS DP		>A> NCE	Aug 06, 2029
	>A> 11345677	Jan 16, 2039	DS DP U-3978		>A> ODE-491	Aug 06, 2031
	>A> 11844758	Dec 04, 2035	U-3977			
	>A> 9579324	Jul 11, 2034	DS			
<u>VORASIDENIB - VORANIGO</u>						
N 218784 002	>A> 10172864	Jul 11, 2034	DS DP		>A> NCE	Aug 06, 2029
	>A> 11345677	Jan 16, 2039	DS DP U-3978		>A> ODE-491	Aug 06, 2031
	>A> 11844758	Dec 04, 2035	U-3977			
	>A> 9579324	Jul 11, 2034	DS			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 001	10646550	Aug 01, 2036	DP U-3927			
	11590204	Aug 01, 2036	DP U-3927			
	11911446	Aug 01, 2036	U-3927			
	8198242	Jun 11, 2030	DS DP U-3927			
	RE48267	May 20, 2030	U-3927			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 002	10646550	Aug 01, 2036	DP U-3927			
	11590204	Aug 01, 2036	DP U-3927			
	11911446	Aug 01, 2036	U-3927			
	8198242	Jun 11, 2030	DS DP U-3927			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 002	RE48267	May 20, 2030	U-3927			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 003	10646550	Aug 01, 2036	DP U-3927			
	11590204	Aug 01, 2036	DP U-3927			
	11911446	Aug 01, 2036	U-3927			
	8198242	Jun 11, 2030	DS DP U-3927			
	RE48267	May 20, 2030	U-3927			
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 001	11944612	Dec 02, 2036	U-3893			
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 002	11944612	Dec 02, 2036	U-3893			
<u>VOXELOTOR - OXBRYTA</u>						
N 216157 001	11944612	Dec 02, 2036	U-3893			
<u>VUTRISIRAN SODIUM - AMVUTTRA</u>						
N 215515 001	>A> 12049628	Jul 28, 2036	DS DP U-3396			
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	10570139	Apr 22, 2034	U-1745		I-936	Mar 07, 2027
	10570139	Apr 22, 2034	U-2145		ODE-467	Mar 07, 2031
	10570139	Apr 22, 2034	U-2537			
	10570139	Apr 22, 2034	U-2666			
	10570139	Apr 22, 2034	U-3063			
	10570139	Apr 22, 2034	U-3486			
	10570139	Apr 22, 2034	U-3860			
	11142528	Apr 22, 2034	DP U-1745			
	11142528	Apr 22, 2034	DP U-2145			
	11142528	Apr 22, 2034	DP U-2537			
	11142528	Apr 22, 2034	DP U-2666			
	11142528	Apr 22, 2034	DP U-3063			
	11142528	Apr 22, 2034	DP U-3486			
	11142528	Apr 22, 2034	DP U-3860			
	11701357	Jun 24, 2039	U-3860			
	11786531	Jan 19, 2043	U-3715			
	11786531	Jan 19, 2043	U-3716			
	11786531	Jan 19, 2043	U-3717			
	11786531	Jan 19, 2043	U-3718			
	11786531	Jan 19, 2043	U-3719			
	11786531	Jan 19, 2043	U-3720			
	11786531	Jan 19, 2043	U-3875			
	11851437	Aug 15, 2037	DS DP			
	11884674	Aug 15, 2037	U-1745			
	11884674	Aug 15, 2037	U-2145			
	11884674	Aug 15, 2037	U-2537			
	11884674	Aug 15, 2037	U-2666			
	11884674	Aug 15, 2037	U-3063			
	11884674	Aug 15, 2037	U-3486			
	11884674	Aug 15, 2037	U-3860			
	11896596	Jan 19, 2043	U-3715			
	11896596	Jan 19, 2043	U-3716			
	11896596	Jan 19, 2043	U-3717			
	11896596	Jan 19, 2043	U-3718			
	11896596	Jan 19, 2043	U-3719			
	11896596	Jan 19, 2043	U-3720			
	11896596	Jan 19, 2043	U-3875			
	11911386	Jan 19, 2043	U-3715			
	11911386	Jan 19, 2043	U-3716			
	11911386	Jan 19, 2043	U-3717			
	11911386	Jan 19, 2043	U-3718			
	11911386	Jan 19, 2043	U-3719			
	11911386	Jan 19, 2043	U-3720			
	11911386	Jan 19, 2043	U-3875			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	11970500	Aug 15, 2037	U-1745			
	11970500	Aug 15, 2037	U-2145			
	11970500	Aug 15, 2037	U-2537			
	11970500	Aug 15, 2037	U-2666			
	11970500	Aug 15, 2037	U-3063			
	11970500	Aug 15, 2037	U-3486			
	11970500	Aug 15, 2037	U-3860			
	9447106	Apr 22, 2034	DS DP U-1745			
	9447106	Apr 22, 2034	DS DP U-2145			
	9447106	Apr 22, 2034	DS DP U-2537			
	9447106	Apr 22, 2034	DS DP U-2666			
	9447106	Apr 22, 2034	DS DP U-3063			
	9447106	Apr 22, 2034	DS DP U-3486			
	9447106	Apr 22, 2034	DS DP U-3860			
<u>ZILUCOPLAN SODIUM - ZILBRYSO</u>						
N 216834 001	11965040	Jun 12, 2035	DP			
<u>ZILUCOPLAN SODIUM - ZILBRYSO</u>						
N 216834 002	11965040	Jun 12, 2035	DP			
<u>ZILUCOPLAN SODIUM - ZILBRYSO</u>						
N 216834 003	11965040	Jun 12, 2035	DP			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 001	11884696	Dec 24, 2037	U-2552			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 002	11884696	Dec 24, 2037	U-2552			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 003	11884696	Dec 24, 2037	U-2552			

## PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 44<sup>TH</sup> Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at [http://www.accessdata.fda.gov/scripts/cder/ob/results\\_patent.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm)

The current complete list of exclusivity terms is available at [http://www.accessdata.fda.gov/scripts/cder/ob/results\\_exclusivity.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm)